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Abstract 
 
 
The increasing worldwide incidence of obesity presents a significant economic burden on healthcare 
resources. The recent obesity epidemic may be attributed to the increasing availability of high fat 
and high sugar foods in our modern environment. These foods are energy dense, and are thus 
processed by the mesocorticolimbic system as rewarding substrates. The increased hedonic 
experience encoded by the activation of the mesocorticolimbic system during consumption of these 
energy dense foods may result in overconsumption. This may result in non-homeostatic energy 
intake, precipitating obesity.  
 
Melanocortins are neuropeptides which signal anorectically to reduce food intake and increase 
energy expenditure. Preliminary data within our group found that intra-ventral tegmental area (VTA) 
melanocortin administration reduced acute food intake in ad libitum fed rats. The work described in 
this thesis has determined that this effect is mediated via the melanocortin 4 receptor (MC4R), and 
is dependent on both nutritional status and diurnal phase. Furthermore, melanocortins were found 
to reduce acute food seeking behaviour in mice. Intra-VTA administration of melanocortins resulted 
in the increased activation of neurons in both the VTA and downstream mesocorticolimbic areas, 
including the nucleus accumbens shell, amygdala, lateral septal nuclei, ventral pallidum (VP) and the 
prefrontal cortex. Finally, the restoration of MC4R signalling in specific regions of the 
mesocorticolimbic system of MC4R null mice was used to investigate the role of MC4R in reward and 
energy homeostasis. Restoring MC4R signalling in the VP decreased chronic food intake but had no 
effect on body weight. General activity was decreased in these mice, suggesting melanocortin 
signalling in the VP plays a role in activity and energy expenditure.  
 
These findings suggest that melanocortin signalling in the mesocorticolimbic system may serve to 
maintain energy homeostasis and thus prevent the development of obesity. Further work is required 
to characterise the specific neuronal circuits responsible.  
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1.1 Obesity  
 
 
Obesity is characterised by increased adipose tissue deposition caused by a metabolic imbalance 
between energy intake and energy expenditure. Energy intake which exceeds metabolic 
requirement is stored as lipid in adipose tissue depots around the body. Obesity is defined as having 
a body mass index (BMI) equal to or greater than 30, and is calculated by dividing body weight in 
kilograms (kg) by height squared in metres (World Health Organization 2008). Obesity is associated 
with an increased risk of cardiovascular disease, diabetes, musculoskeletal disorders and specific 
cancers (World Health Organisation 2013). Worldwide obesity prevalence has nearly doubled since 
1980. It was estimated in 2008 that 1.4 billion adults were overweight, with 500 million of these 
being obese (World Health Organisation 2013). By 2050, the projected costs to the United Kingdom 
(UK) National Health Service for treating obesity related disease has been estimated to reach £10 
billion per year (Department of Health 2007). It is clear that obesity represents a significant 
economic problem, and that the prevention and treatment of obesity is a major healthcare priority.  
 
Anti-obesity therapies have experienced varying success. Current obesity treatment in the UK 
includes bariatric surgery, pharmacotherapy and advice on implementing lifestyle changes. Lifestyle 
changes, such as dietary alterations and prescribed exercise regimes often experience low 
adherence rates and remain largely ineffective in treating obesity. Bariatric surgery, involving either 
gastric banding or gastric bypass, remains the most effective treatment, achieving long term 
sustained weight loss, amelioration of diabetes and improvements in cardiovascular function 
(Sjöström, Lindroos et al. 2004). However, this approach in treating obesity is only available for the 
morbidly obese (BMI ≥ 40 kgm-2) and is associated with increased risk of death from surgical 
complications (O’Rourke, Andrus et al. 2006). Existing prescription pharmacotherapy treatment in 
the UK is currently limited to Orlistat, a lipase inhibitor which prevents the breakdown and thus the 
absorption of dietary fat (Zhi, Melia et al. 1995). The weight loss effects of Orlistat are modest; a 5-
10% reduction in total body weight is common after 1 – 4 years of daily treatment (Rucker, Padwal 
et al. 2007). However, due to the unpleasant gastrointestinal side effects associated with the use of 
lipase inhibitors, there is a lack of adherence to such treatments, further reducing their efficacy. 
There is thus an obvious requirement for an anti-obesity treatment which is cost-effective, 
efficacious and safe.  
 
27 
 
Obesity is often a multifactorial disease. A sedentary lifestyle, excessive intake of high calorie foods 
and genetic predisposition all contribute to the development of obesity. Although monogenic causes 
of obesity remain rare, there is considerable evidence to suggest that most obesity is polygenic 
(Swarbrick and Vaisse 2003, Mutch and Clément 2006). Polygenic mutations may render individuals 
more susceptible to environmental cues which promote an imbalance between energy expenditure 
and energy intake (Llewellyn, Trzaskowski et al. 2014). Thus, environmental factors play a key role in 
determining obesity prevalence.  
 
 
1.2 Homeostatic and hedonic control of food intake  
 
 
Food intake is regulated by neuronal signalling within distinct and diffuse areas of the brain. Nutrient 
intake is a basic requirement shared by all animals, and thus the brain areas which regulate food 
intake are highly conserved across species. Nutrient utilisation is essential for growth, development 
and survival in order that living organisms are able to successfully reproduce and continue to 
survive. Effective nutrient intake has been attributed to the divergence of the genus Homo erectus, 
ancestors of modern day Homo sapiens, 1.8 million years ago (Leonard, Snodgrass et al. 2011). 
Increased consumption of animal fats encouraged encephalisation of the brain, illustrating the 
importance of nutrition in establishing and ensuring evolutionary success of a species. Given the 
importance of food intake in survival, it is not surprising that food intake is a complex process 
governed by signalling within a number of brain areas.  
 
The hypothalamus is a key brain area where peripheral neural and endocrine signals are integrated 
with central nervous system (CNS) signals to regulate functions such as reproduction, growth and 
energy homeostasis. Endocrine factors, or hormones, are released from peripheral tissues into the 
circulation in response to fluctuations in the internal environment of the organism, and act as 
messengers to maintain or restore internal homeostasis. The hypothalamus is in close proximity to 
the median eminence, a region with a semi-permeable blood-brain-barrier (BBB) that facilitates 
communication between the periphery and the CNS (Pardridge 1986). Circulating hormones are able 
to move via active transport across the median eminence and into hypothalamic brain regions to 
influence neuronal signalling. These neuronal pathways extend throughout hypothalamic and extra-
hypothalamic brain areas, and can eventually result in the modulation of higher brain functions and 
behaviour, and of descending peripheral nervous system (PNS) neuronal pathways. The activation of 
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these pathways will result in an integrated biological response aimed at restoring homeostasis in 
response to the initially sensed fluctuations in the internal environment.  
 
Feeding behaviour is a biological response determined in part by hypothalamic signalling, with the 
overall aim of preserving energy homeostasis. This may be chronic regulation of body weight or 
acute regulation of food intake.  However, feeding behaviour is also regulated by non-homeostatic 
signalling, or hedonic signalling. The brain areas involved in hedonic signalling are located within the 
mesocorticolimbic system, a collative term for brain areas responsible for the experience of reward 
and pleasure. It is well established that hypothalamic nuclei project extensively to extra-
hypothalamic areas of the brain, including areas of the mesocorticolimbic system (Lemaire, Nezzar 
et al. 2013, Oh, Harris et al. 2014), suggesting an anatomical substrate for the integration of 
homeostatic and hedonic regulatory mechanisms in the control of energy homeostasis.  
 
Signalling within the mesocorticolimbic system is necessary for food intake. The existence of a brain 
system which evokes feelings of pleasure, or hedonia, suggest it exists to motivate and reinforce 
behaviour. Given the importance of feeding behaviour to survival, it is not surprising that other 
extra-hypothalamic brain systems are also employed to ensure effective food intake. The 
mesocorticolimbic system is key to providing a motivational drive to execute behaviour which will 
benefit the organism, and for providing a reward experience to reinforce future behaviour. This 
brain system is evolutionarily important in times of food scarcity, providing a motivational drive to 
seek and ingest food. Feelings of hedonia ensure food ingestion is a pleasurable experience, 
increasing the likelihood of the organism repeating the behaviour in the future.  
 
Dysfunction in mesocorticolimbic signalling may cause inappropriate behaviour execution, overriding 
homeostatic signalling mechanisms. Severe and prolonged perturbations in energy intake may result 
in obesity, or conversely, in anorexia. The high incidence of body weight disorders implies a 
significant contribution of hedonic signalling to energy intake regulation. If energy intake was solely 
controlled by hypothalamic homeostatic mechanisms, organisms would be expected to remain at an 
optimal body weight and rarely fluctuate away from this norm (Saper, Chou et al. 2002). The rapid 
worldwide increase in obesity rates over the past fifty years (Crimmins, Preston et al. 2011) suggests 
an evolutionary genetic change in our energy homeostasis mechanisms is unlikely. The rapid 
increase in obesity rates has emerged due to the industrialisation of the sourcing, manufacture, and 
distribution of food stuffs. The increasing availability of affordable processed high fat and high sugar 
foods within the western diet is an important environmental change which has precipitated an 
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obesity pandemic. The mesocorticolimbic system is sensitive to environmental changes and is 
constantly processing and predicting cues which may lead to effective nutrient intake.  
 
Caloric density of food is directly proportional to its reward value. Thus, when ingested, the 
mesocorticolimbic system is appropriately activated according to the value of the reward. Increased 
caloric density increases the value of a food reward and provides an increased perceived experience 
of hedonia, feeding back to the organism a sense of pleasure and fulfilment. This in turn increases 
the future likelihood that the organism will undertake food seeking behaviour in order to fulfil the 
motivational requirement to feel hedonia. The mesocorticolimbic system may thus be detrimental in 
the context of abundant high reward food stuffs, increasing the incidence of non-homeostatic food 
intake and instigating obesity. Thus, energy intake regulation is determined by the convergence of 
homeostatic and hedonic signalling mechanisms, and is heavily influenced by environmental context.  
 
 
1.3 Hypothalamic control of food intake 
 
 
1.3.1 The adipostat mechanism 
 
The hypothalamus controls energy intake and expenditure with the aim of maintaining energy 
homeostasis. Circulating humoral factors are able to access the hypothalamus via the median 
eminence, relaying information from the periphery. The adipostat mechanism describes homeostatic 
regulatory elements which control body adiposity. The hormone leptin is thought to be the key 
signalling molecule of this system. Leptin is an adipokine, synthesised and released from white 
adipose tissue (WAT). The cloning and discovery of leptin (Zhang, Proenca et al. 1994) led to the 
assumption that a negative feedback loop exists between the periphery and the hypothalamus 
which is able to detect leptin as an indicator of chronic and, to some degree, acute nutritional status. 
Leptin knock-out (KO) mice, termed ob/ob mice, exhibit increased adiposity and increased food 
intake, and this phenotype can be rescued with administration of exogenous leptin (Pelleymounter, 
Cullen et al. 1995). Administration of leptin to normal weight animals also reduces food intake and 
body weight. The leptin receptor, LepR, is highly expressed in hypothalamic areas (Tartaglia, 
Dembski et al. 1995), mediating central sensitivity to circulating leptin levels. Leptin reflects chronic 
energy status, circulating in direct proportion to total WAT mass. There is also evidence that leptin 
falls following a fast of 12 hours (Kolaczynski, Considine et al. 1996), and is subsequently released in 
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response to acute food intake (Kolaczynski, Ohannesian et al. 1996) suggesting it can also regulate 
acute nutritional status.  
 
However, despite obese humans and mice exhibiting high levels of circulating leptin, they still 
remain obese (Maffei, Halaas et al. 1995, Considine, Sinha et al. 1996). The hypothalamus becomes 
desensitised to constantly high circulating levels of leptin, resulting in a decreased ability to reduce 
food intake ans increase energy expenditure, but maintains the ability to detect present WAT levels. 
It is perhaps likely that the adipostat mechanism is more important in increasing food intake and 
body weight in times of chronic nutritional deficit, rather than in times of nutritional abundance and 
over-feeding. The adipostat remains a critical element in the control of energy homeostasis but is 
unlikely to be the sole target in effectively treating obesity.  
 
1.3.2 The arcuate nucleus  
 
The hypothalamus is located on the ventral aspect of the brain and bordered by the optic chiasm at 
the rostral limit and the mammillary bodies at the caudal limit. The median eminence forms the 
inferior border of the hypothalamus. The hypothalamus contains several nuclei which have distinct 
roles in maintaining internal homeostasis. The arcuate nucleus (Arc) is a hypothalamic area situated 
in close proximity to the median eminence, facilitating the detection of peripheral circulating factors. 
There are two primary populations of neurons in the Arc involved in the regulation of energy 
homeostasis. One population of neurons expresses the anorectic peptide pre-cursor molecule pro-
opiomelanocortin (POMC) (Elias, Lee et al. 1998) and another population of neurons co-expresses 
the orexigenic peptides neuropeptide Y (NPY) and agouti-related protein (AgRP) (Hahn, Breininger et 
al. 1998) (Figure 1.1). NPY/AgRP neuronal activation causes the local release of NPY which binds to 
the NPY receptor, Y1R (Csiffáry, Görcs et al. 1990) which is expressed on and inhibits the activity of 
POMC neurons (Broberger, Landry et al. 1997). In addition, NPY/AgRP neurons also exert an 
inhibitory control over POMC neurons via local release of the inhibitory neurotransmitter γ-
aminobutyric acid (GABA).  
 
Within POMC neurons, the precursor molecule POMC undergoes tissue specific cleavage into the 
melanocortin peptides which signal anorectically through melanocortin receptors 3 and 4 
(MC3R/MC4R) (see section 1.8 for a detailed review of the central melanocortin system). MC3R is  
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Figure 1.1 NPY/AgRP and POMC neuronal populations in the arcuate nucleus of the hypothalamus. 
Abbreviations: µ-OR, mu-opiod receptor; AgRP, agouti-related protein; GABA, γ-amminobutyric acid; 
GSHR, growth hormone secretagogue receptor; LepR, leptin receptor; MC3R, melanocortin receptor 
3; NPY, neuropeptide Y; Y1R, neuropeptide receptor Y1; Y2R, neuropeptide receptor Y2R. Taken 
from ‘Anatomy  and regulation of the central melanocortin system’ (Cone 2005).  
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expressed in the Arc on both NPY/AgRP and POMC neurons (Jégou, Boutelet et al. 2000, Mounien, 
Bizet et al. 2005) where it plays a role in inhibition of NPY/AgRP signalling and in POMC neuronal 
feedback.  
 
Receptors for a number of humoral signalling factors are located on these two populations of Arc 
neurons. LepR is expressed on both POMC and NPY/AgRP expressing neurons (Mercer, Hoggard et 
al. 1996, Cheung, Clifton et al. 1997). Leptin signals anorectically by inhibiting the activation of 
NPY/AgRP neurons and by stimulating activation of POMC neurons. Ghrelin is an orexigenic peptide 
released from the stomach and pancreas in response to fasting. The ghrelin receptor, growth 
hormone secretagogue receptor (GHSR) is expressed on NPY/AgRP neurons (Dickson and Luckman 
1997, Cowley, Smith et al. 2003). GHSR KO mice have reduced body weight but food intake remains 
unaffected, suggesting ghrelin is likely involved in the regulation of energy expenditure (Sun, Wang 
et al. 2004). However, the effects on body weight have been suggested to be as a result of perturbed 
growth hormone (GH) signalling, as both GH and ghrelin signal through GHSR (Howard, Feighner et 
al. 1996). However, GHSR KO mice are resistant to the effects of a high-fat diet, suggesting ghrelin is 
required in the development of dietary induced obesity (Zigman, Nakano et al. 2005). Insulin, a 
peptide with a well characterised role in the control of peripheral glucose sensitivity and utilisation 
also signals centrally within the Arc. Insulin receptors are expressed on both NPY/AgRP and POMC 
neuronal populations. Insulin stimulates activation of POMC neurons, and inhibits activation of 
NPY/AgRP neurons, promoting anorectic signalling within the Arc to reduce food intake and increase 
energy expenditure.  
 
NPY/AgRP neurons project to other hypothalamic and extra-hypothalamic nuclei involved in energy 
intake and expenditure. These include projections within the Arc, to the paraventricular nucleus 
(PVN) and lateral (LH) areas of the hypothalamus, and projections to regions within the 
mesocorticolimbic system (Broberger, Johansen et al. 1998). Arc POMC neurons project to the PVN 
and LH, to regions of the mesocorticolimbic system and to brainstem areas including the nucleus 
tractus solitarius (NTS) (Koylu, Couceyro et al. 1998, Bagnol, Lu et al. 1999, King and Hentges 2011).  
The expression of multiple feeding peptide receptors in the Arc suggests a high level of crosstalk in 
hypothalamic signalling. Additionally, genetic models of dysfunctional hypothalamic signalling 
provide evidence of redundancy in the control of energy homeostasis within the Arc. 
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1.3.3 The paraventricular nucleus  
 
The PVN is located within the immediate dorsal vicinity of the third ventricle and has extensive 
reciprocal neuronal connections with other hypothalamic and extra-hypothalamic nuclei. The PVN 
contains magnocellular neurons that project to the posterior pituitary where they release arginine 
vasopressin (AVP) and oxytocin into the circulation (Swanson and Kuypers 1980, Van Den Pol 1982) 
to regulate  diuresis in body fluid retention, and processes including lactation and social behaviour 
(Lee, Macbeth et al. 2009). The PVN also contains parvocellular neurons which signal within the PVN 
and project to regions including the median eminence, brainstem areas and other hypothalamic 
nuclei. These parvocellular neurons express hypothalamic releasing factors including corticotropin 
releasing hormone (CRH) and thyrotropin releasing hormone (TRH). CRH is important in the 
regulation of the hypothalamic-pituitary-adrenal (HPA) stress axis, whilst TRH is involved in the 
hypothalamic-pituitary-thyroid axis in the control of body growth (Zoeller, Tan et al. 2007, Ulrich-Lai 
and Herman 2009). The PVN also sends neuronal projections to areas of the mesocorticolimbic 
system, the midbrain, brainstem and preganglionic neurons of sympathetic and parasympathetic 
divisions of the PNS (Saper, Loewy et al. 1976, Swanson 1977, Geerling, Shin et al. 2010). The PVN 
receives neuronal projections from other hypothalamic areas, including the Arc, LH and the 
dorsomedial nucleus (DMN) (Ter Horst and Luiten 1987, Moga and Saper 1994). The PVN also 
receives projections from extra-hypothalamic areas including the brainstem and the 
mesocorticolimbic system (Staiger and Wouterlood 1990, Moga and Saper 1994).  
 
The role of the PVN in energy homeostasis has been investigated using brain lesioning experiments 
in rats. Bilateral lesioning of the PVN causes the development of hyperphagia but not the profound 
weight gain observed in rats which receive lesioning of the ventromedial nucleus (VMN) of the 
hypothalamus (Fukushima, Tokunaga et al. 1987). As both POMC and NPY/AgRP Arc neuronal 
populations project to the PVN, it has been hypothesised that magnocellular and parvocellular 
neurons act downstream of Arc signalling in the control of many homeostatic processes, including 
energy intake and expenditure (Baker and Herkenham 1995, Bell, Bhatnagar et al. 2000, Fekete, 
Legradi et al. 2000). Indeed, MC4R is highly expressed in the PVN and is co-expressed with AVP and 
oxytocin (Siljee, Unmehopa et al. 2013). Administration of the α-melanocyte stimulating hormone 
(α-MSH) analogue [Nle4,ᴅ-Phe7]-α-MSH (NDP-MSH) into the PVN acutely decreases food intake in 
rats (Giraudo, Billington et al. 1998, Kim, Grace et al. 2002). Conversely, administration of NPY into 
the PVN increases acute food intake (Stanley and Leibowitz 1985, Stanley, Small et al. 2001). In 
addition, direct administration of TRH and CRH into the PVN causes hypophagia and increases 
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energy expenditure in rats (Arase, York et al. 1988, Krahn, Gosnell et al. 1988), further 
demonstrating the role of PVN parvocellular neurons in exerting negative control over energy intake.  
 
1.3.4 The ventromedial nucleus and dorsomedial nucleus 
 
The VMN and DMN are located superiorly and lateral to the Arc, the DMN being located most 
superiorly. The VMN sends neuronal projections to surrounding hypothalamic areas, the brainstem 
and mesocorticolimbic areas (Saper, Swanson et al. 1976), the majority of which are reciprocal 
projections (Fahrbach, Morrell et al. 1989). In the 1950s, the VMN was believed to be involved in 
satiety as bilateral lesioning of the VMN in rats and cats caused hyperphagia and obesity (Anand and 
Brobeck 1951). However, lesioning studies cannot establish whether there are individual anorectic 
and orexigenic pathways situated within a brain region, and the original results may have partly 
reflected accidental lesioning of adjacent PVN areas (Gold 1973). There is in fact evidence of an 
anorectic role for the VMN. Brain-derived neurotrophic factor (BDNF) is a signalling factor required 
for growth and development of the nervous system, which also has a well characterised anorectic 
role in energy homeostasis. Chronic intracerebroventricular (ICV) administration of BDNF attenuates 
weight gain (Lapchak and Hefti 1992) and reduces food intake in rats (Pelleymounter, Cullen et al. 
1995). BDNF is expressed at high levels in the VMN (Kawamoto, Nakamura et al. 1996) and 
expression levels are increased by fasting (Xu, Goulding et al. 2003) and decreased following 
peripheral glucose administration (Unger, Calderon et al. 2007). Administration of BDNF into the 
VMN decreases food intake and increase energy expenditure (Wang, Bomberg et al. 2007), and 
chronic administration into the VMN attenuates high fat diet (HFD) induced obesity (Godar, Dai et al. 
2011).  
 
The DMN is located dorsally with regards to the VMN and projects reciprocally to the PVN, LH, VMN 
and to brainstem areas (Berk and Finkelstein 1981, Ter Horst and Luiten 1986). Lesioning of the DMN 
causes hypophagia and reduces body weight in rats (Bernardis 1970), suggesting the DMN may drive 
feeding. NPY is highly expressed within the rat brain DMN postnatally, but rapidly declines during 
the progression into adulthood (Grove, Brogan et al. 2001), perhaps reflecting the increased energy 
intake requirement during periods of rapid growth and development. Increased levels of NPY can be 
detected in the DMN of obese mice (Guan, Yu et al. 1998) and knockdown of NPY in the DMN 
prevents hyperphagia and weight gain in a spontaneous genetic model of rodent obesity (Yang, Scott 
et al. 2009). This suggests NPY signalling within the DMN plays a role in ensuring energy intake and 
excessive signalling may contribute to the development of obesity.  
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1.3.5 The lateral hypothalamus 
 
The LH is located laterally with regards to the VMN and DMN. In the 1950s,  bilateral LH lesions were 
shown to cause hypophagia and reduced body weight in rats (Anand and Brobeck 1951), suggesting 
it acts as a ‘feeding centre’. The LH receives projections from the PVN, DMN and VMN (Saper, 
Swanson et al. 1976, Ter Horst and Luiten 1986) and reciprocally projects extensively to the 
thalamus, mesocorticolimbic areas and the brainstem (Shen 1983). There are two distinct 
populations of neurons in the LH which express either melanin-concentrating hormone (MCH) or the 
orexins (Skofitsch, Jacobowitz et al. 1985, de Lecea, Kilduff et al. 1998, Sakurai, Amemiya et al. 
1998).  
 
MCH is cleaved from a precursor molecule, prepro-MCH, and it signals through MCH-R1 and MCH-R2 
receptors (Saito, Nothacker et al. 1999), which are widely expressed throughout the brain (Saito, 
Cheng et al. 2001). ICV administration of MCH stimulates food intake in rats and MCH expression is 
increased with fasting in both lean and obese animals (Qu, Ludwig et al. 1996). MCH KO mice are 
hypophagic and lean (Shimada, Tritos et al. 1998) and despite low leptin levels they do not increase 
their food intake, suggesting MCH is essential for the hyperphagic response to leptin in times of 
decreased adiposity. LepR is expressed within the LH on GABAergic neurons, and intra-LH 
administration of leptin is able to decrease food intake via activation of these inhibitory neurons 
(Leinninger, Jo et al. 2009).  More recently, it has been shown that GABAergic neurons extending 
from the bed nucleus of the stria terminalis (BNST) of the extended amygdala synapse on LH 
glutamatergic neurons and inhibit their activity, resulting in the promotion of feeding behaviour 
(Jennings, Rizzi et al. 2013).  
 
The orexins are also cleaved from a precursor molecule, prepro-orexin, (Sakurai, Amemiya et al. 
1998) which undergoes further processing to produce orexin-A and orexin-B. The orexins bind to the 
orexin receptors, OX1R and OX2R, which are expressed within the PVN, VMN, cortex, 
mesocorticolimbic areas, thalamus and brainstem (Trivedi, Yu et al. 1998). Orexin-B has a 10-fold 
higher affinity for OX2R than for OX1R, whilst Orexin-A binds to OX1R and OX2R with equal affinity 
(Sakurai, Amemiya et al. 1998). ICV administration of orexins stimulates feeding and prepro-orexin 
expression is increased with fasting (Sakurai, Amemiya et al. 1998). Orexins are also important in 
arousal; orexin KO mice exhibit a syndrome similar to narcolepsy in humans (Chemelli, Willie et al. 
1999). Thus, orexins may signal orexigenically within the LH by influencing arousal state to promote 
energy intake. 
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1.4 Extra-hypothalamic control of food intake  
 
 
In addition to hypothalamic circuitry, food intake is also governed by extra-hypothalamic signalling. 
The brainstem is crucial to the regulation of food intake; decerebrate rats which have the neural 
connections between the forebrain and brainstem severed are still able to eat and become satiated 
(Grill and Norgren 1978, Grill 1980). The brainstem has a role in autonomic control of cardiovascular, 
respiratory, gustatory and circadian processes and is a site of passage for spinal tracts which relays 
sensory and motor information from the periphery to the central nervous system. The brainstem 
consists of the midbrain, pons and medulla, each containing distinct nuclei involved in food intake. A 
key set of brainstem nuclei in the control of food intake are known collectively as the NTS. The NTS is 
located within the caudal brainstem and is the primary nucleus which receives information from the 
periphery via gustatory afferents. These afferent nerve fibres are located within the vagus nerve 
which terminates within the NTS. Vagal nerve fibres transmit information regarding gut distention, 
chemical composition of food, water content and pH (Schwartz 2000), and this information can 
subsequently modulate food intake. Vagotomised rats exhibit hypophagia and decreased body 
weight (Snowdon and Epstein 1970). Several endocrine factors released from the gastrointestinal 
(GI) system can signal through vagal afferents, including ghrelin and cholecystokinin (CCK) (Smith, 
Jerome et al. 1981, Date, Murakami et al. 2002), demonstrating the importance of vagal-brainstem 
signalling in the control of food intake.  
 
The NTS also receives information from afferent hypothalamic projections arising in the PVN, DMN, 
Arc and LH, and afferent projections from mesocorticolimbic areas (van der Kooy, Koda et al. 1984). 
Additionally, cranial nerves VII (facial) and IX (glossopharyngeal) provide sensory input to the NTS 
from the tongue (Katz, Nicolelis et al. 2000). The NTS is also sensitive to circulating factors within the 
blood due to its close proximity with the area postrema (AP). The AP is similar in architecture to the 
median eminence; it has a semi-permeable BBB which allows circulating factors access to AP 
neurons. These neurons signal directly to the NTS, conveying information regarding the current 
peripheral state. Lesioning the AP in rats results in hypophagia and decreased body weight (Hyde 
and Miselis 1983), suggesting its role in sensing peripheral endocrine factors is important in the 
control of food intake.  
 
A key neuronal population within the NTS involved in food intake are POMC expressing neurons, the 
only other POMC producing neurons in the brain distinct from the Arc population (Joseph, Pilcher et 
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al. 1983, Bronstein, Schafer et al. 1992). The expression of MC4R in the NTS and dorsal motor 
nucleus of the vagus (DMV) suggests melanocortin signalling in the brainstem is involved in food 
intake. Indeed, administration of a melanocortin agonist into the fourth ventricle, which is situated 
adjacent to the NTS, decreases food intake in rats (Grill, Ginsberg et al. 1998). Furthermore, LepR is 
expressed within the NTS and administration of leptin into the NTS causes a decrease in food intake 
(Elmquist, Bjorbaek et al. 1998, Grill, Schwartz et al. 2002).   
 
The parabrachial nucleus (PBN) of the dorsal pons receives innervation from the NTS and sends 
efferent projections to components of the mesocorticolimbic system (Norgren and Leonard 1971). It 
is believed to play a role in modulating conditioned taste aversion (CTA), a learning and memory 
process that pairs specific tastes with malaise, so that future aversive events are avoided 
(Yamamoto, Fujimoto et al. 1995). This is particularly important in rodents because they are unable 
to initiate emesis. In both rodents and humans, the PBN has been postulated to play a role in 
relaying hedonic information regarding nutrient content between the NTS and the 
mesocorticolimbic system (Soderpalm and Berridge 2000). Furthermore, a specific circuit extending 
from the PBN to the central amygdala containing calcitonin-gene related peptide neurons has been 
characterised which is able to suppress feeding during aversive conditions when it is unfavourable to 
feed (Carter, Soden et al. 2013).  
 
The complexity of crosstalk between signalling factors and neuronal populations in the brainstem 
reflects the variety and number of processes the brainstem regulates. The widespread projection 
profile of each group of nuclei demonstrates the importance of whole brain neuronal convergence in 
the control of food intake via the brainstem.  
 
 
1.5 The mesocorticolimbic system  
 
 
Another extra-hypothalamic system involved in the control of food intake is the mesocorticolimbic 
system.  The hypothalamus projects extensively to areas of the mesocorticolimbic system (Barone, 
Wayner et al. 1981, Silverman, Hoffman et al. 1981, Duva, Tomkins et al. 2005), and 
mesocorticolimbic signalling is required for food intake as it plays a vital role in ensuring food intake 
behaviour is executed (Saper, Chou et al. 2002).   
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1.5.1    Dopamine 
 
The mesocorticolimbic system consists of a number of widespread midbrain and forebrain areas 
which collectively play a role in hedonic signalling, memory formation and decision making. An 
important neurotransmitter in mesocorticolimbic system signalling is dopamine. Dopamine was first 
characterised in the 1950s as a neurotransmitter from the effects of central dopamine deficiency in 
movement disorders (Carlsson, Lindqvist et al. 1957, Carlsson, Lindqvist et al. 1958, Bernheimer and 
Hornykiewicz 1965) before it was postulated to be involved in reward and hedonia (Wise 1982). 
Dopamine is a catecholamine and is a precursor molecule in the synthesis of other catecholamines, 
adrenaline and noradrenaline. Dopamine is synthesised from L-phenylalanine in a subset of neurons 
in the brain and by the adrenal medulla. In the periphery, dopamine regulates various physiological 
functions by acting as a paracrine signal (Siragy, Felder et al. 1989, Mezey, Eisenhofer et al. 1996). 
Central dopaminergic signalling is vital in the planning and execution of motor control, lactation, 
stress, sexual arousal, learning, memory, motivation, reward and hedonia (Beaulieu and Gainetdinov 
2011).  
 
The ability of dopamine to elicit feelings of pleasure, or hedonia, through mesocorticolimbic 
signalling is vital in goal directed behaviour. Hedonia is the experience of pleasure, thus the term 
hedonia is often used interchangeably with pleasure in the literature (Berridge and Kringelbach 
2011). Reward is the experience of hedonia after the fulfilment of a goal. Natural rewards such food, 
water and sexual activity (Kelley and Berridge 2002) are able to drive goal directed behaviour, and 
are thus vital to survival.  
 
1.5.2 Dopamine receptors  
 
Dopamine binds to the five dopamine receptors, termed D1 – D5, to exert its effects. Dopamine 
receptor binding was first characterised in the rat retina where dopamine administration was proven 
to cause an increase in adenylyl cyclase activity (Brown and Makman 1972). Soon after, it was 
discovered that dopamine receptor activation could either increase or decrease adenylyl cyclase 
activity (Cools and Van Rossum 1976), suggesting the action of two distinct dopamine receptor 
subtypes. Following these observations, dopamine receptors were first cloned in 1988 (Bunzow, Van 
Tol et al. 1988), and revealed to be guanine protein coupled receptors (GPCRs) with an extracellular 
binding domain. Dopamine binds to the receptor which undergoes a conformational change 
resulting in dissociation of the associated G-protein subunits. The Gα subunit is then able to 
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stimulate or inhibit the activity of adenylyl cyclase, which participates in the formation of cyclic 
adenosine monophosphate (cAMP), which in turn is able to phosphorylate proteins within targeted 
signal transduction pathways, causing specific cellular functions to occur. Dopamine receptor Gα 
proteins can be stimulatory (Gs) or inhibitory (Gi), the designation referring to the inhibition or 
stimulation of adenylyl cyclase activity. Dopamine receptor subtypes are thus divided into the 
stimulatory D1-like type (D1 and D5) and the inhibitory D2-like type (D2, D3 and D4).  
 
D1 and D2 receptors are most abundantly and widely expressed within the CNS; they are detectable 
in all brain areas receiving dopaminergic projections (Meador-Woodruff, Mansour et al. 1991, Levey, 
Hersch et al. 1993). Differential expression levels of D1 and D2 have been characterised in the 
amygdala, hippocampus and pituitary, but only D2 is expressed in midbrain areas (Meador-
Woodruff, Mansour et al. 1991). D3 has a more restricted expression pattern, limited to the nucleus 
accumbens (NAcb) and  the caudate and putamen (CPu) (Landwehrmeyer, Mengod et al. 1993). The 
expression of D4 is limited to the frontal and parietal cortices, thalamus, striatum and hippocampus 
(Ariano, Wang et al. 1997), whilst D5 expression is limited to the thalamus, hypothalamus and 
hippocampus (Meador-Woodruff, Mansour et al. 1992). D4 is the receptor with the highest affinity 
for dopamine, with an affinity approximately 10-fold higher than D2 and D3. D1 and D5 have the 
lowest affinity for dopamine (Vallone, Picetti et al. 2000).  
 
Dopamine receptors may be located both presynaptically and postsynaptically. Presynaptic 
receptors are located on the presynaptic membrane where they play a role in negative feedback 
signalling at the synapse. The release of a neurotransmitter from the presynaptic membrane into the 
synaptic cleft will expose that neurotransmitter to receptors located on both the presynaptic and 
postsynaptic membranes. Typically, binding and activation of a presynaptic receptor will inhibit 
further neurotransmitter release from that neuron, providing a negative feedback loop. This allows 
the neuron to self-regulate further neurotransmitter release, preventing depletion. Presynaptic 
activity is termed neuromodulation and is an important process usually observed in the formation of 
memory and learned behaviour, which is primarily driven by dopamine signalling (Marder 2012).  
 
1.5.3 Dopaminergic pathways  
 
Less than 1% of neurons in the CNS are dopaminergic, (Björklund and Dunnett 2007), and there are 
nine established regions of dopaminergic cell bodies, designated A8 – A16  (Fuxe 1965, Marín, 
Herrero et al. 2005). There are also eight established dopaminergic pathways, along which 
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dopaminergic neurons project from areas A8 – A16 to other areas of the brain (Figure 1.2). 
Collectively, the regions A8 – A10 comprise the largest population of dopaminergic cell bodies within 
the CNS.  
 
There are four major dopaminergic pathways, each involved in a specific physiological response. The 
tuberoinfundibular pathway arises from neurons in the A12 and A14 regions in the Arc and projects 
to the pituitary gland where it controls prolactin secretion. The nigrostriatal pathway arises from 
neurons in the A8 and A9 regions, the substantia nigra (SN), and projects to the striatum. This 
pathway is vital in the initiation and execution of motor function and involves signalling within the 
basal ganglia. The two other major dopaminergic projections are known separately as the 
mesolimbic and mesocortical pathways, but are often considered together as the mesocorticolimbic 
system due to their closely related functions. The mesolimbic pathway projects from the A10 region 
of neurons, known as the ventral tegmental area (VTA), and extends to several midbrain and 
forebrain areas involved in hedonic signalling. The mesocortical pathway also projects from the A10 
region of neurons, the VTA, and projects primarily to frontal cortical areas also involved in hedonic 
signalling. Henceforth, the anatomy and function of the mesolimbic and mesocortical pathways will 
be considered together as the mesocorticolimbic system.  
 
1.5.4 The nucleus accumbens 
 
The anatomical origin of dopaminergic mesocorticolimbic signalling is the VTA. The VTA immediately 
projects and synapses within another midbrain structure, the NAcb. The NAcb is located lateral to 
the septum and dorsal to the CPu of the basal ganglia. Anatomically, the NAcb is considered part of 
the ventral striatum. The NAcb is anatomically divided into two regions, the ventromedial region, 
known as the shell, and the dorsolateral region, known as the core. The NAcb shell (NAcbSh) and the 
core (NAcbC) display different projection profiles, hence the function of each are considered 
separately. The NAcbSh projects to the amygdala, ventral pallidum (VP), LH, periaqueductal gray 
(PAG), VTA and the SN. The NAcbC projections are less widespread, with projections to the VTA, SN 
and the VP. Both the NAcbSh and NAcbC receive projections from the VTA, medial prefrontal cortex 
(mPFC), amygdala, hippocampus and the thalamus (Heimer, Zahm et al. 1991).  
 
The role of the NAcb was initially highlighted by the observation that rats will self-administer 
amphetamines into the NAcb when given the opportunity (Hoebel, Monaco et al. 1983), suggesting 
that dopaminergic signalling within the NAcb is pleasurable, or hedonic. Amphetamines inhibit the 
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Figure 1.2 Schematic diagram of a sagittal section of the rodent brain representing the location of 
dopaminergic nuclei A8 – A16. Abbreviations: A8, retrorubral area; A9, substantia nigra; A10, 
ventral tegmental area; A11, posterior hypothalamus; A12, arcuate nucleus; A13, zona incerta; A14, 
periventricular hypothalamus;  A15, supraoptic nucleus; A16, olfactory bulb. Adapted from Björklund 
et al (Björklund and Dunnett 2007).  
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dopamine transporter (DAT), located on the presynaptic membrane. DAT is responsible for the re-
uptake of synaptic dopamine after presynaptic release, preventing further neuronal transmission. 
Inhibiting DAT increases the exposure time of dopamine at the postsynaptic membrane where it is 
able to bind and stimulate further neuronal transmission. Thus, dopaminergic neuronal activation 
induces feelings of hedonia via signalling within the NAcb. It has since been proven that this effect 
involves activation of D2 receptors and is mediated through the NAcbSh and not the NAcbC (Rodd-
Henricks, McKinzie et al. 2002).  
 
The roles of the NAcbSh and NAcbC in reward are complex. Inhibiting activation of the NAcbC 
decreases the response of rodents to a stimulus which is paired with a predictive reward, such as a 
lightbulb flash with the delivery of sucrose into drinking water (Ambroggi, Ghazizadeh et al. 2011). 
Inactivation of the NAcbSh increases the response to a stimulus which is not paired with a predictive 
reward. This supports previous findings (Ikemoto and Panksepp 1999, Cardinal, Pennicott et al. 2001, 
Di Chiara 2002) which support a role for the NAcbSh in negatively regulating behavioural response to 
stimuli which do not lead to reward, and for the NAcbC in promoting a behavioural response to 
stimuli which predict reward.  
 
Dopamine signalling within the NAcb in reward demonstrates the versatility of dopamine as a 
neurotransmitter. There are two categories of external stimuli which are able to elicit a behavioural 
response, termed appetitive and aversive (Barberini, Morrison et al. 2012). Appetitive stimuli are 
positively desired, whilst aversive stimuli are negative and promote avoidance. For example, food 
consumption is considered appetitive, whereas consumption of toxins is aversive. The NAcb is an 
area where signalling encoding appetitive and aversive stimuli converges and is processed to 
produce a behavioural output. For example, when rats are presented with an appetitive (sucrose) 
following an aversive (quinine) stimulus, and vice versa, dopaminergic neuronal firing patterns in the 
NAcb reverses (Setlow, Schoenbaum et al. 2003, Badrinarayan, Wescott et al. 2012).  
 
The opposing actions of dopamine in the NAcb demonstrate the ability of one neurotransmitter to 
signal differentially according to the stimulus. The NAcb should not be considered simply as an area 
which transmits feelings of hedonia and reward, but a structure which is able to differentially 
modulate neuronal output according to the stimulus.  
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1.5.5 The amygdala 
 
The amygdala is an almond shaped group of nuclei located within the temporal lobe in the forebrain. 
It is subdivided into nuclei according to their location, termed the basolateral (BLA), central (CeA) 
and medial (MeA) amygdala. The amygdala forms extensive reciprocal projections with many areas 
of the cortex and the hippocampus (McDonald 1992, PitkÄNen, Pikkarainen et al. 2000). The 
hippocampus is a structure vital in the formation, storage and recollection of memory (Bird and 
Burgess 2008). The amygdala also forms reciprocal projections with the thalamus, hypothalamus, 
VTA, prefrontal cortex (PFC) and brainstem (Sah, Faber et al. 2003), and has a well characterised role 
in fear and anxiety (Davis 1992, Pape and Pare 2010).  
 
Lesioning of the amygdala removes the ability of rodents and primates to associate reward value 
with a stimulus they have previously been exposed to. Primates exhibit irregular food preferences 
after lesioning (Murray, Gaffan et al. 1996), and rats lose their conditioned aversive response to a 
lightbulb flash stimulus and the absence of food (Hatfield, Han et al. 1996). The extensive 
communication between the amygdala and hippocampus suggests a role for the amygdala in 
comparing stimulus memory with the current stimulus. Through hippocampal interaction, the 
amygdala is thought to provide memory of how rewarding a past stimulus was. This aids future 
behavioural decision, allowing the organism to decide whether the risk of achieving the goal is worth 
the reward (Baxter and Murray 2002).  
 
1.5.6 The ventral pallidum  
 
The VP is located within the basal ganglia of the striatum, adjacent to the globus pallidus (GP). The 
GP is an important effector nucleus involved in the inhibition of voluntary motor control. The VP was 
first identified as a major projection target for the NAcb (Heimer and Wilson 1975), but it also has 
reciprocal projections with the frontal cortex, VTA, amygdala, LH and brainstem (Haber, 
Groenewegen et al. 1985, Zahm, Williams et al. 1996). The location of the VP within the striatum and 
the established projections from the NAcb to the VP suggested that the VP was involved in providing 
motivation for executing voluntary motor control (Mogenson, Jones et al. 1980). Indeed, intra-VP 
administration of opioids in rats increases motor activity and increases intracranial self-stimulation 
(ICSS), suggesting VP opioid signalling is able to modulate motor activity and is perceived as hedonic 
(Johnson, Stellar et al. 1993).  
 
44 
 
Lesioning of the GP and VP in rats causes complete ablation of feeding behaviour (Morgane 1961) 
and development of aversive behavioural responses to appetitive stimuli such as sucrose (Cromwell 
and Berridge 1993). This behavioural response may be termed anhedonia, a state where appetitive 
stimuli are unable to elicit an appropriate behavioural response. Anhedonia has also been 
characterised in humans with lesions of the GP and VP (Miller, Vorel et al. 2006). Thus, the VP 
appears to have a role in controlling feeding behaviour and reward processing. The VP has been 
described as a final limbic pathway which transmits and enhances signalling from the NAcb to affect 
reward directed motor control through the basal ganglia (Smith, Tindell et al. 2009).  
 
1.5.7 The septal nuclei   
 
The septal nuclei are located dorsally to the corpus callosum and anteriorly to the septum 
pellucidum within the forebrain. The septal nuclei are divided into two sub regions: the lateral septal 
nuclei (LS) and the medial septal nuclei. Together, the septal nuclei largely form reciprocal 
projections with the hippocampus, hypothalamus, brainstem, NAcb, VTA and the mPFC (Meibach 
and Siegel 1977, Staiger and Wouterlood 1990, Risold and Swanson 1997). 
 
In one of the first ICSS experiments in rats, repeated self-stimulation of the septal nuclei was 
observed, demonstrating that activation of the septal nuclei produce feelings of hedonia (Olds and 
Milner 1954). Lesioning of the septal nuclei in rats causes increased lever-pressing in return for a 
food reward after a stimulus, suggesting the loss of septal signalling resulted in a hypersensitivity for 
rewarding stimuli (Lorens and Kondo 1969). This suggests the septal nuclei may be inhibitory in 
mediating reward and may signal to desensitise the response to rewarding stimuli. The septal nuclei 
have more recently been identified as an important relay centre in the neuronal circuit from the 
hippocampus to the VTA (Luo, Tahsili-Fahadan et al. 2011). Inactivating this neuronal pathway 
caused rats to lose preference for a stimulus which indicated administration of cocaine, an 
amphetamine which induces hedonia. Collectively, this suggests the septal nuclei are involved in 
regulating the behavioural response to a stimulus, though this is likely aided by widespread afferent 
input from other mesocorticolimbic areas.  
 
1.5.8 The prefrontal cortex   
 
The cerebral cortex is the external neuronal structure which constitutes the surface of the cerebrum. 
The structure of the cortex is organised into six anatomical layers, each receiving specific neuronal 
45 
 
input from forebrain, midbrain and hindbrain structures (Shipp 2007, Greig, Woodworth et al. 2013), 
and can be divided into functionally separate areas across the cerebrum. The primary cortical area 
involved in mesocorticolimbic signalling is the PFC, located rostrally of the forebrain. The PFC is 
subdivided into two key areas, the orbitofrontal cortex (OFC) and the mPFC. The mPFC is further 
subdivided into prelimbic (PRL), infralimbic (IL) and anterior cingulate (ACC) cortices. Each area of 
the mPFC forms extensive reciprocal projections with cortical and subcortical brain areas (Sesack, 
Deutch et al. 1989, Hoover and Vertes 2007). The OFC also forms extensive reciprocal projections 
with cortical and subcortical brain areas (Morecraft, Geula et al. 1992). All PFC areas show extensive 
communication with the thalamus, a structure which acts as a relay centre for sensory and motor 
information between subcortical structures and the cortex (Komura, Tamura et al. 2001, Guillery and 
Sherman 2002).  
 
The cortex is primarily responsible for executive function, such as cognition and decision making 
(Rushworth, Noonan et al. 2011). Because the cortex is a superficial brain structure, it has been 
extensively studied using non-invasive bio-imaging methods. Functional magnetic resonance imaging 
(fMRI) detects and measures a blood oxygen level-dependent (BOLD) signal which represents 
increased metabolic demand within the brain. BOLD is usually indicative of increased neuronal 
activation and can thus be used as a tool to assess brain function. When human volunteers are asked 
to make a gambling choice in return for a monetary reward, an increased BOLD signal is detected in 
the ACC during the decision phase (Rogers, Ramnani et al. 2004). During the outcome rewarding 
phase, increased BOLD signalling was detected in the OFC. Another study using the same reward 
paradigm detected increased signalling within the mPFC and the OFC during receipt of a monetary 
reward (Carlson, Foti et al. 2011). Taken together, these findings illustrate that PFC signalling is 
involved in both reward directed decision making and the immediate rewarding phase.  
 
1.5.9 γ-aminobutyric acid and glutamate  
 
Electrophysiological recordings from dopaminergic neurons indicate they have three states of 
activation. Neurons may be inactive and quiescent, firing tonically, or firing in phasic bursts (Grace 
and Bunney 1983). The firing behaviour of the neuron encodes the information that is being 
transmitted, and this behaviour is sensitive to excitatory and inhibitory inputs that change the 
electrochemical properties of that neuron. Thus, the majority of neurons within the 
mesocorticolimbic system either co-release GABA or glutamate or synapse with GABA or glutamate 
46 
 
expressing neurons (Lindefors 1993, Nair-Roberts, Chatelain-Badie et al. 2008, Yamaguchi, Wang et 
al. 2011).   
 
Glutamate is an amino acid and is the most abundantly expressed excitatory neurotransmitter 
within the CNS. There are two categories of glutamate receptors, ionotropic and metabotropic. 
Ionotropic receptors are ligand-gated ion channels which allow non-selective cation flux into the 
neuron upon glutamate binding. The influx of cations into the neuron causes an excitatory 
postsynaptic potential (EPSP) to be generated. An increasing number of EPSP events increase the 
likelihood that an action potential will be generated. There are four types of ionotropic glutamate 
receptors: the N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR), kainate and delta receptor types (Hollmann, O'Shea-
Greenfield et al. 1989, Keinanen, Wisden et al. 1990, Yamazaki, Araki et al. 1992). Metabotropic 
glutamate receptors (mGluR) are GPCRs which are coupled to either Gi, Gs or Gq. Gq is a G-protein 
which signals in a calcium (Ca2+) dependent intracellular signalling pathway. mGluR are able to 
induce either an EPSP or an inhibitory postsynaptic potential (IPSP) in the target neuron. Increasing 
IPSP events decrease the likelihood that an action potential will be generated.   
 
Glutamate receptors may be presynaptic or postsynaptic (Pinheiro and Mulle 2008). Glutamate 
receptor expression is widespread and concentrated in areas of the mesocorticolimbic system, in 
particular the cortex and midbrain (Headley and Grillner 1990, Monyer, Burnashev et al. 1994). 
Glutamate is co-expressed with dopamine in neurons of the mesocorticolimbic system (Sulzer, Joyce 
et al. 1998), and stimulation of dopaminergic neurons in the NAcb causes the release of glutamate 
and induction of EPSPs in the postsynaptic neuron (Stuber, Hnasko et al. 2010, Tecuapetla, Patel et 
al. 2010). Thus, glutamate is the primary excitatory neurotransmitter within the mesocorticolimbic 
system which signals to increase dopaminergic neuronal activity.  
 
GABA is a metabolite of glutamate and is the primary inhibitory neurotransmitter within the 
mesocorticolimbic system. There are two types of GABA receptors, ionotropic (GABAA) and 
metabotropic (GABAB). GABAA are ligand-gated ion channels which upon opening cause the influx of 
chloride ions (Cl-) into the cell, reducing the membrane potential. GABAB receptors are primarily 
coupled to Gi which inhibits the formation of adenylyl cyclase within the cell. GABA receptor 
activation results in the formation of IPSPs in the target neuron, reducing the likelihood than an 
action potential is able to be generated.   
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GABA receptors may also be presynaptic or postsynaptic (Matthews, Ayoub et al. 1994). GABA 
receptor expression is widespread across areas of the mesocorticolimbic system (Wisden, Laurie et 
al. 1992, Calver, Medhurst et al. 2000). GABA receptors are expressed on dopaminergic neurons in 
the midbrain (Okada, Matsushita et al. 2004) and it is well established that GABAergic neurons 
project within the striatum to inhibit the release of dopamine (Tepper and Lee 2007). The majority 
of dopaminergic neurons receive tonic GABAergic input (Grace and Bunney 1985). If GABAergic input 
is removed, dopaminergic neurons are disinhibited and fire in higher frequency bursts (Lobb, Wilson 
et al. 2010).  It has also been demonstrated more recently that some dopaminergic neurons are able 
to release GABA which inhibits firing in the target neuron (Tritsch, Ding et al. 2012).  
 
The extensive projections and reciprocal communication within the mesocorticolimbic system 
suggest a great deal of complexity in dopaminergic signalling. The widespread expression of GABA 
and glutamate receptors, both presynaptic and postsynaptic, further adds to this signalling 
complexity. Tonic and phasic firing activity of dopaminergic neurons in the mesocorticolimbic system 
may be affected by glutamatergic and GABAergic signalling, but dopaminergic neurons may also co-
release these neurotransmitters to affect neuronal activation. Along with presynaptic receptor 
activity, the interaction of GABA and glutamate with dopamine aids neuromodulation of synaptic 
activity. Neuromodulation allows neurons to become plastic, a process vital in neuronal circuits 
which govern executive functions such as behaviour, memory and learning.  
 
 
1.6 The ventral tegmental area  
 
 
1.6.1 Structure and neuronal subtypes 
 
The VTA was first recognised in 1925 by Chiao Tsai who studied the morphology of Nissl stained 
sections of the midbrain of the opossum (Tsai 1925), and was thus designated the VTA of Tsai. Tsai 
distinguished there were two morphologically different groups of nuclei within the midbrain, now 
termed the A9 (SN) and A10 (VTA) dopaminergic regions. The VTA is located in the ventral midbrain, 
medial to the SN. The cell bodies of dopaminergic neurons which signal within the mesocorticolimbic 
system are located within the VTA, thus the VTA is the upstream origin of dopaminergic signalling 
within this system.  
 
48 
 
The VTA is comprised of four distinct nuclei which display different projection profiles and neuronal 
compositions. The parabrachial pigmented nucleus (PBP) is located ventrally within the VTA and 
makes up approximately half of the total volume. It contains the highest percentage of dopaminergic 
neurons within the VTA. The second largest nucleus in the VTA is the paranigral nucleus (PN) which 
makes up approximately a fifth of the volume of the VTA and also contains a high percentage of 
dopaminergic neurons. The third largest nucleus is the parafasciculus retroflexus (PFR) which forms 
~18% of the volume of the VTA, but contains a low percentage of dopaminergic neurons. The 
smallest nucleus in volume is the ventral tegmental tail (VTT), located caudally within the VTA. It 
forms ~10% of the volume of the VTA and has the lowest percentage of dopaminergic neurons 
(Halliday and Tork 1986, Oades and Halliday 1987). In total, the VTA comprises ~60% dopaminergic 
neurons, ~30% GABAergic neurons and ~2 – 3% glutamatergic neurons (Bayer and Pickel 1991, Hur 
and Zaborszky 2005). VTA dopaminergic neurons synapse on and receive innervation from both 
GABA and glutamate neuronal populations (Chuhma, Zhang et al. 2004, Omelchenko and Sesack 
2009). In addition, numerous receptors for other centrally active peptides and neurotransmitters 
have been detected in the VTA, including GHSR (Zigman, Jones et al. 2006), LepR (Hommel, Trinko et 
al. 2006), nicotinic acetylcholine receptors (Azam, Winzer-Serhan et al. 2002) and 5-
hydroxytryptamine (serotonin) receptors (Cornea-Hebert, Riad et al. 1999).  
 
1.6.2 Efferent and afferent projections  
 
The VTA receives extensive afferent input from many areas of the brain. The first VTA neuronal 
tracing studies undertaken (Phillipson 1979) revealed that the VTA receives input from both 
ascending and descending pathways, from the brainstem and forebrain respectively. More recent 
retrograde tracing studies (Geisler and Zahm 2005) have revealed that the VTA receives projections 
from distinct nuclei, but that these projections are arranged into a single formation passing through 
the core of the brain to the VTA. This is believed to provide easy access for all brain areas to 
communicate rapidly with VTA projecting neurons. The VTA is most densely innervated by 
descending projections from the PFC, LS, NAcbSh, VP, lateral habenula (LHb), lateral preoptic area 
(LPO) and the LH (Figure 1.3). Ascending projections which innervate the VTA come from the PAG, 
pons and the dorsal raphe nuclei, which produces serotonin.  
 
The primary efferent projections from the VTA extend to the NAcb and consist of ~80% 
dopaminergic neurons (Fallon 1981, Swanson 1982, Albanese and Minciacchi 1983, Klitenick, Deutch 
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et al. 1992). Other dopaminergic and non-dopaminergic efferent targets of the VTA include the PFC, 
LS, VP, amygdala, hippocampus, and the locus coeruleus and the parabrachial nucleus (PBN) of the 
brainstem. The proportion of these projecting neurons that are dopaminergic ranges between ~1 
and ~60%, with the remaining neurons being either GABAergic or glutamatergic.  
 
1.6.3 Role in reward and motivation  
 
The primary function of the VTA is to detect rewarding stimuli and to transmit that information to 
other mesocorticolimbic areas in order to produce an appropriate behavioural response. The VTA 
receives afferent input encoding information regarding the stimuli from ascending and descending 
neuronal pathways and projects extensively to forebrain, midbrain and hindbrain areas to affect 
motivational and reward processing. It is important to consider the VTA as a multi-unit structure 
with many subset populations of neurons with different projection targets. This has been 
characterised by measuring dopamine release in specific projection targets of the VTA after intra-
VTA administration of various agents; intra-VTA administration of orexin increases dopamine release 
in the PFC but not in the NAcb (Vittoz and Berridge 2006), whereas intra-VTA administration of an 
opioid receptor agonist decreases dopamine release in the PFC but not in the NAcb (Margolis, Lock 
et al. 2006). Thus, the VTA does not signal stereotypically nor activate the same projection targets 
each time a stimulus is encountered. 
 
A reward is defined as a stimulus which is able to induce behaviour aimed towards attaining further 
reward. Achieving a reward produces feelings of hedonia which help increase the likelihood that 
future appetitive behaviour will occur in the presence of cues which predict the reward. This is 
termed positive reinforcement (Fields, Hjelmstad et al. 2007). The VTA plays a vital role in processing 
primary reward and in ensuring behavioural positive reinforcement of that reward.  
 
The role of the VTA in reward was first demonstrated whereby electrical stimulation of the VTA 
induced acute feeding behaviour (Waldbillig 1975), suggesting that VTA neuronal activation is able 
to motivate attainment of a natural reward. Additionally, rodents will repeatedly self-administer 
rewarding substances such as opioids (Bozarth and Wise 1981), ethanol (Gatto, McBride et al. 1994) 
and cocaine (Roberts and Koob 1982) into the VTA, and ablation of dopaminergic signalling in the 
VTA prevents this self-administrative behaviour (Roberts and Koob 1982, Rodd, Melendez et al. 
2004). 
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Figure 1.3 Schematic diagram illustrating afferent projections of the ventral tegmental area (VTA) 
and reciprocal interconnecting projections of key mesocorticolimbic nuclei. Abbreviations: LH, 
lateral hypothalamus; LHb, lateral habenula; LPO, lateral preoptic area; LS, lateral septum; NAcb, 
nucleus accumbens; PFC, prefrontal cortex; VTA, ventral tegmental area. Adapted from Geisler et al 
(Geisler and Zahm 2005). 
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VTA dopamine neurons are either silent, firing tonically or firing phasically (Grace and Bunney 1983). 
A dopaminergic neuron action potential is typically wider, has a slower firing rate and a slower 
axonal conductance velocity compared to GABAergic and glutamatergic neuron action potentials. 
VTA dopamine neurons also exhibit intermittent rapid firing activity, and thus can be identified easily 
in vivo and in vitro using electrophysiology (Ungless and Grace 2012).  Upon receipt of an 
unexpected reward, VTA dopamine neurons fire increasingly phasically (Schultz, Apicella et al. 1993, 
Bayer and Glimcher 2005). Burst firing of dopamine neurons is dependent on excitatory 
glutamatergic input, and glutamate receptor agonists have been shown to greatly increase 
dopaminergic neuronal activity (Johnson, Seutin et al. 1992, Chergui, Charlety et al. 1993). The 
intensity of neuronal firing is directly proportional to the magnitude of the reward, the amount or 
calorie content of food (Tobler, Fiorillo et al. 2005). Phasic VTA dopaminergic neuron firing decreases 
with repeated exposure to a stimulus predicting reward (Ljungberg, Apicella et al. 1992, Schultz, 
Apicella et al. 1993). If a reward is withheld or delayed, VTA dopaminergic neurons alter their firing 
pattern to denote this (Hollerman and Schultz 1998). Thus, neuron firing rate encodes information 
about how the current reward compares with that of the expected reward, and the firing rate is 
adjusted accordingly to transmit this information via dopamine release at target sites. This is 
described as the reward-prediction error function of the VTA (Schultz, Dayan et al. 1997).  
 
The VTA is therefore responsible for reproducing behavioural responses such as conditioned place 
preference (CPP), where rodents have been trained to pair a stimulus with reward in a certain 
location, and will return to that location in anticipation of receiving that reward again. Mice which 
have perturbed VTA dopaminergic signalling lose their ability to perform CPP (Zweifel, Argilli et al. 
2008). CPP is a useful tool in assessing the function of the VTA and is often used in conjunction with 
self-administration studies to assess the effects of various agents in VTA reward signalling (Prus, 
James et al. 2009).  
 
1.6.4 Role in addiction 
 
The mesocorticolimbic system is a target for substances of abuse as they induce hedonia by affecting 
dopaminergic signalling similarly to natural rewards. Experiencing hedonia as part of reward is a 
necessary process in reinforcing behaviour which is essential to organism survival. Addiction is 
defined as a state where compulsive behaviour is repeatedly undertaken to attain a reward despite 
an awareness of the negative consequences such as health decline, financial deficit and/or loss of 
social interaction (Hyman, Malenka et al. 2006). Dysfunctional reward signalling is often the basis for 
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the development of addiction, and both natural and abusive substances can either precipitate or 
worsen addictive behaviour. 
 
The pathophysiology underlying addiction is complex and not well understood. Cellular mechanisms 
involved in addiction and tolerance such as receptor sensitisation underlie changes in synaptic 
plasticity. The VTA demonstrates synaptic plasticity, which results in changes to neuronal firing 
frequencies following repeated presentation of a reward (Ljungberg, Apicella et al. 1992, Schultz, 
Apicella et al. 1993). Pathological changes in VTA synaptic plasticity are thus believed to be involved 
in the development of addiction (Hyman, Malenka et al. 2006). This is supported by the observation 
that intra-VTA administration of glutamate antagonists prevents central sensitisation to nicotine, 
cocaine and morphine (Shoaib and Stolerman 1992, Harris and Aston-Jones 2003, Harris, Wimmer et 
al. 2004). Concurrent with these findings, VTA neurons from rats administered cocaine show 
increased glutamate receptor synaptic currents (Ungless, Whistler et al. 2001) and the expression of 
glutamate receptors increases in the VTA after repeated administration of cocaine, morphine and 
alcohol (Ortiz, Fitzgerald et al. 1995, Fitzgerald, Ortiz et al. 1996, Lu, Grimm et al. 2003).  
 
GABAergic signalling is also implicated in the development of addiction. Opiates and 
benzodiazepines inhibit GABAergic activation, causing disinhibition of dopamine neurons and thus 
an increase in their activity (Macdonald and Barker 1978, Johnson and North 1992). Chronic 
exposure to these drugs of abuse sensitises GABAergic neurons so that they reduce their inhibitory 
input to the VTA, subsequently increasing dopaminergic neuronal activity and facilitating compulsive 
behaviours (Miller, Greenblatt et al. 1988, Mathon, Lesscher et al. 2005).   
 
These findings confirm the involvement of GABA and glutamate signalling in VTA synaptic plasticity 
in the development of sensitisation. These VTA signalling mechanism may underlie the development 
of addiction.  
 
The vastly complex signalling network within the mesocorticolimbic system is reflective of our 
enriched stimulatory environment and the diversity of interactions each individual may encounter. 
No two humans are alike in their perception and reaction to stimuli, making interpretation of how 
addiction and compulsive behaviour arises from the VTA difficult. Nevertheless, understanding the 
physiological basis of how the mesocorticolimbic system signals in pathological reward seeking and 
consumption behaviour will undoubtedly require an understanding of the role of the VTA.   
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1.7 Hedonic signalling in food intake   
 
 
1.7.1 ‘Wanting’ and ‘liking’  
 
The components of reward can be categorised into two separate aspects, ‘wanting’ and ‘liking’ 
(Berridge, Robinson et al. 2009). Incentive salience is described as the process of wanting, and 
represents the motivational aspect of reward driven behaviour. Incentive salience can be triggered 
even when the reward has not been experienced or liked before. If a reward has been experienced 
before, incentive salience plays a role in behavioural conditioning. Behavioural conditioning is the 
emergence of repeated goal-seeking behaviour driven by previous encounter of a reward. In 
incentive salient processing, neuronal input into the VTA comes directly from afferents encoding the 
nature of the stimulus. Thus, dopamine signalling is heavily implicated in wanting (Berridge 2007). 
Incentive salience is mediated furthermore by communication between other sub-cortical structures 
within the mesocorticolimbic system, including the amygdala, NAcb, VP and the LS (Daw, Niv et al. 
2005). It is also well characterised that food deprivation can increase incentive salience, likely 
through the actions of orexigenic peptides within the mesocorticolimbic system (Berridge, Ho et al. 
2010).  
 
Conversely, liking is the hedonic experience generated after the stimulus has been received and 
processed by the subcortical structures involved in incentive salience. Liking primarily involves 
cortical structures including the OFC, mPFC and the insular cortex (Berridge, Robinson et al. 2009). 
Dopamine signalling is also implicated in liking, but large glutamatergic projections from the pre-
frontal cortex to the VTA are vital in contextual association of hedonic feelings with pleasurable 
stimuli. Thus, wanting a foodstuff and liking during food consumption are important paradigms 
integral to food seeking and ingestive behaviour.  
 
Dissociation of wanting from liking increases the likelihood of compulsive addictive behaviour. If 
wanting a reward exceeds liking a reward, cravings for that reward may be observed (Goldstein, 
Woicik et al. 2010). This is often described in the development of addiction, and the subsequent 
changes in synaptic plasticity within the VTA and related mesocorticolimbic areas underlie the 
molecular basis of craving. Food cravings are defined as an intense desire to consume a specific 
food, usually a high energy foodstuff, and they have been likened to drug cravings (Pelchat 2002). 
Despite the World Health Organisation not recognising food as an addictive substance, consumption 
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of food activates the same anatomical pathways and causes similar synaptic rearrangements as 
drugs of abuse do. However, significant efforts have been made recently by a multinational 
organisation investigating the neurobiology of food intake, addiction and stress (NeuroFAST) to 
recognise and classify food addiction as a mental disorder (Mercer and Bird 2012). Reward signalling 
in the control of food intake is a diffuse, atypical process, dependent upon a number of variable 
factors which include (but are not limited to) the type of stimulus, environmental context and 
memory. This does not necessarily mean that over-eating is the same as compulsive drug taking, but 
parallels may be drawn between the two. 
 
1.7.2 Dopamine in food intake 
 
Electrical stimulation of the VTA induces feeding behaviour in rats (Trojniar and Staszewska 1994, 
Maliszewska-Scislo and Trojniar 1999). Dopamine release occurs in areas of the mesocorticolimbic 
system innervated by the VTA after consumption of food (Hernandez and Hoebel 1988, Hajnal, 
Smith et al. 2004). This suggests food is perceived as rewarding and that feelings of hedonia are 
elicited upon food consumption. Six-hydroxydopamine (6-OHDA) is a toxin which is transported into 
dopaminergic neurons by DAT where it induces mitochondrial apoptosis and neuronal death. 
Specific destruction of VTA dopaminergic neurons by intra-VTA injection of 6-OHDA induces aphagia 
in rats (Ungerstedt 1971), demonstrating that VTA dopaminergic signalling is critical in food intake.  
 
1.7.3 Non-homeostatic food intake and obesity   
 
It has been suggested that overeating may reflect dysfunction in dopaminergic circuits within the 
mesocorticolimbic system. D2 receptors are enriched within the PFC and are believed to play a role in 
inhibitory control in decision making (Klein, Neumann et al. 2007). Mutations in D2 have been 
reported in individuals with substance abuse problems (Noble 1998), suggesting D2 is important in 
the control of impulsive reward seeking behaviour. Indeed, D2 receptor availability within the 
midbrain (Volkow, Wang et al. 2003) and the PFC (Volkow, Wang et al. 2008) is reduced in obese 
individuals, suggesting a loss of inhibitory control over dopaminergic signalling within these brain 
areas. In rodents, both obesity-prone and diet induced obese (DIO) rats exhibit reduced D2 
expression throughout the mesocorticolimbic system (Geiger, Behr et al. 2008, Geiger, Haburcak et 
al. 2009). Additionally, peripheral administration of a D2 antagonist increases food intake and weight 
gain in rats (Clifton, Rusk et al. 1991), likely due to the inhibition of D2-mediated dopamine release. 
Thus, aberrant dopamine signalling via D2 may cause impulsive overeating and eventual obesity.  
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Palatability of food is important in reward. Organoleptic properties such as the smell, visual 
appearance and mouth-feel of food are involved in palatability, and the integration of these signals 
takes place in the prefrontal cortex (de Araujo and Simon 2009). Palatable foods generally have a 
high energy value and have been shown to induce hyperphagia in both rodents and humans despite 
satiety (Naim, Brand et al. 1985, Prentice 1998). This suggests palatable foods are able to drive 
increased consumption, and this is thought to be due to the perception by the mesocorticolimbic 
system that they are more rewarding owing to their high energy content. In humans, food 
preference varies from person to person. Generally, both rodents and humans will show preference 
for a high fat or high sugar foodstuff versus a low fat or low sugar foodstuff (Young 1940, 
Drewnowski and Greenwood 1983). Dietary variety also induces hyperphagia in rodents and humans 
(Rolls, Rowe et al. 1981, Rolls, Van Duijvenvoorde et al. 1983, Martire, Holmes et al. 2013), believed 
to be due to a requirement to fulfil a sensory specific satiation, concerning mouth-feel, smell and 
taste (Raynor and Epstein 2001).  
 
After a period of fasting, normal weight individuals show increased activation of the hypothalamus, 
striatum, VTA and NAcb upon presentation of high calorie foodstuffs (Page, Seo et al. 2011). Post-
prandially, neuronal activation within the PFC is increased. In obese individuals, PFC activation is 
reduced in comparison to normal weight individuals. Given the role of the PFC in transmitting 
reward and decision-making, it appears the obese brain may be blunted to the rewarding effects of 
food, leading to ineffective decision making in food seeking behaviour. This in turn may cause 
overeating as the hedonic drive to consume food is increased in order to fulfil the reward deficit.  
 
The response of the mesocorticolimbic system in mediating reward in food intake is dependent on 
many factors, one being current nutritional status. The hypothalamus is thought to be an important 
site of action for feeding hormones such as leptin and ghrelin which are released peripherally and 
travel within the circulation to the hypothalamus. A number of centrally expressed feeding 
neuropeptides, such as the melanocortins, are responsive to peripheral feeding hormones and signal 
within the hypothalamus to affect energy homeostasis. However, central and peripheral feeding 
hormones can also target and influence neuronal signalling within extra-hypothalamic brain areas in 
order to control food intake, including the mesocorticolimbic system.  
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1.8 The melanocortin signalling system  
 
 
1.8.1 Pro-opiomelanocortin and the melanocortins 
 
The melanocortins are a class of peptide hormones which are generated by cleavage of the 
precursor molecule POMC. Human POMC consists of 241 amino acid residues and is cleaved by the 
tissue specific enzymes pro-hormone convertase 1 and 2 (PC1 and PC2) into the melanocortins. In 
humans, the melanocortins comprise α, β, γ-melanocyte stimulating hormone (α-MSH, β-MSH and γ-
MSH) and adrenocorticotropin (ACTH) (Figure 1.4). In rodents, β-MSH does not exist as γ-lipotropin 
lacks the cleavage site required for PC2 processing. Tissue specific cleavage of POMC allows for 
tightly controlled expression of specific melanocortins in discrete areas of the brain and periphery. 
POMC is discretely expressed centrally within the Arc and the NTS, and peripherally expressed in the 
anterior and intermediate pituitary, skin cells and cells of the immune system (Civelli, Birnberg et al. 
1982, Bronstein, Schafer et al. 1992, Mechanick, Levin et al. 1992, Schauer, Trautinger et al. 1994). 
Arc POMC neurons project most densely to the PVN, the periventricular nucleus and the perifornical 
area of the hypothalamus, but also project to the LH, supraoptic nucleus (SON), amygdala, BST, 
raphe nuclei, VTA and PAG (King and Hentges 2011) (Figure 1.5). Arc POMC neurons also project to 
the PBN, the reticular nucleus (RET) and the NTS of the brainstem (Jacobowitz and O'Donohue 1978, 
Watson, Akil et al. 1978, Joseph and Michael 1988).   
 
Also found within many melanocortin-expressing areas of the brain and periphery are the 
endogenous melanocortin receptor antagonists, agouti and AgRP. Agouti and AgRP are structurally 
similar, consisting of 131 amino acid residues and both containing the Arg-Phe-Phe sequence which 
confers antagonistic activity at MC1R, MC2R and MC4R of the melanocortin receptors (Haskell-
Luevano, Cone et al. 2001). Agouti was first hypothesised to play a role in mammalian coat 
colouration in the 1950s (Silvers and Russell 1955) whereas AgRP was not characterised until 1997 
(Ollmann, Wilson et al. 1997).  Agouti is mainly expressed peripherally, in dermal papillae cells where 
it antagonises melanocortin receptor signalling to prevent pigmentation (Lu, Willard et al. 1994). 
Centrally, AgRP is co-expressed within NPY containing neurons of the Arc, and has been reported to 
be expressed in the subthalamic nucleus of the basal ganglia, and the hippocampus (Shutter, 
Graham et al. 1997, Bai, Sozen et al. 2005). Peripherally, AgRP is expressed within the adrenal cortex 
of the kidney, the testes and dorsal root ganglia (Shutter, Graham et al. 1997).  
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Figure 1.4 Schematic diagram showing processing of pro-opiomelanocortin (POMC) into the 
melanocortins and related peptides. Abbreviations: α-MSH, α-melanocyte stimulating hormone; β-
MSH, β-melanocyte stimulating hormone; γ-MSH, γ-melanocyte stimulating hormone; ACTH, 
adrenocorticotropin; PC1, pro-hormone convertase 1; PC2, pro-hormone convertase 2. Grey shading 
indicates peptides containing the essential melanocortin binding sequence Arg-Phe-Phe.  
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1.8.2 Melanocortin receptors 
 
The melanocortins share a homologous sequence of four amino acids, His-Phe-Arg-Trp, which is 
essential for ligand binding activity at the melanocortin receptors (Hruby, Wilkes et al. 1987, 
Castrucci, Hadley et al. 1989). The melanocortin receptors were first cloned in the 1990s and consist 
of MC1R – MC5R (Mountjoy, Robbins et al. 1992, Roselli-Rehfuss, Mountjoy et al. 1993).  
 
Melanocortin receptors are GPCRs and may be coupled to the adenylyl cyclase stimulatory pathway 
G-protein, Gs, or the phospholipase C-mediated pathway G-protein, Gq (Konda, Gantz et al. 1994).  
All the melanocortin receptors exhibit constitutive signalling activity in the absence of a ligand, and 
agouti and AgRP can act as inverse agonists of the melanocortin receptors (Swords, Noon et al. 2004, 
Garcin, Le Gallic et al. 2009, Tao, Huang et al. 2010).  It has also recently been shown that 
hypothalamic neuronal firing can be regulated by α-MSH or AgRP binding to MC4R and coupling to 
the inwardly rectifying sodium channel Kir7.1, independently of Gs (Ghamari-Langroudi, Digby et al. 
2015). Melanocortin receptors have also been shown to form heterodimer and homodimer 
formations in the cell membrane (Mandrika, Petrovska et al. 2005) in a process essential for normal 
receptor functioning (Biebermann, Krude et al. 2003).  
 
Melanocortins are structurally similar and are able to bind to all five melanocortin receptors with 
differing affinities (Yang 2011). All the melanocortins are able to bind to MC1R with differing 
affinities. MC2R is selective for ACTH, thus ACTH has the highest affinity for this receptor. γ-MSH has 
the highest affinity for MC3R, but MC3R is equally selective for both γ-MSH and ACTH. MC4R is most 
selective for α-MSH and ACTH, but also binds β-MSH and γ-MSH. MC5R is most selective for α-MSH 
and ACTH, but may also bind β-MSH. γ-MSH does not bind to MC5R (Tatro 1996). 
 
More recently, melanocortin receptors have been shown to interact with melanocortin receptor 
accessory protein 1 and 2 (MRAP1 and MRAP2) (Sebag and Hinkle 2007). MRAPs are molecular 
chaperone proteins which assist trafficking of the receptor to the cell membrane, ligand binding and 
downstream signalling, thus they play a vital role in ensuring melanocortin receptor function. 
MRAP1 is essential for MC2R function (Sebag and Hinkle 2009) and MRAP2 has been shown to 
regulate developmental control of growth via MC4R (Sebag, Zhang et al. 2013). MRAP2 mutations 
have also been implicated in mammalian obesity (Asai, Ramachandrappa et al. 2013).  
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Figure 1.5 Sagittal section of the rodent brain illustrating key neuronal projections of the central 
melanocortin system. Abbreviations: AgRP, agouti-related protein; AP, area postrema; ARC, arcuate 
nucleus; BST, bed nucleus of the stria terminalis; CCK, cholecystokinin; CEA, central amygdala; CNS, 
central nervous system; DMV, dorsal motor nucleus of the vagus; LH, lateral hypothalamus; LPB, 
lateral parabrachial nucleus; ME, median eminence; NTS, nucleus tractus solitarius; PVN, 
paraventricular nucleus; POMC, pro-opiomelanocortin; RET, reticular nucleus. Taken from Cone 
(Cone 2005).  
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1.8.3 Melanocortin receptor expression 
 
MC1R is mainly expressed within the periphery in melanocytes (De Luca, Siegrist et al. 1993) and 
immune cells including mast cells (Artuc, Grutzkau et al. 1999), neutrophils (Bohm, Brzoska et al. 
1999) and leukocytes (Andersen, Hagglund et al. 2005). Thus, MC1R is primarily involved in skin 
pigmentation and immune response. MC2R is expressed within the adrenal cortex (Xia and Wikberg 
1996), anterior pituitary (Morris, Kola et al. 2003) and melanocytes (Slominski, Ermak et al. 1996). 
The expression of MC2R reflects its role in HPA axis signalling and involvement in skin pigmentation.  
 
MC3R and MC4R are the most highly expressed melanocortin receptors within the CNS. MC3R is 
most highly expressed within the Arc, VMN and medial preoptic area (MPO) and is moderately 
expressed within the LS, thalamus, VTA, PAG, NAcbSh, amygdala and the dorsal raphe nuclei (Gantz, 
Konda et al. 1993, Roselli-Rehfuss, Mountjoy et al. 1993). In the Arc, MC3R is expressed in ~44% of 
AgRP/NPY containing neurons and ~31% of POMC containing neurons (Jégou, Boutelet et al. 2000, 
Mounien, Bizet et al. 2005). MC3R is believed to be expressed presynaptically in the Arc to 
negatively regulate melanocortin signalling within the Arc (Cowley, Smart et al. 2001). MC3R is 
expressed at extremely low levels in the periphery.  
 
MC4R expression is highest within the PVN, SON, VMN, DMN, LH, LS, thalamus, CPu and the BNST. 
MC4R is also highly expressed within the DMV of the brainstem. Moderate MC4R expression has 
also been observed in the medial amygdala, VP, insular and cingulate cortices, hippocampus and 
thalamus (Gantz, Miwa et al. 1993, Mountjoy, Mortrud et al. 1994, Kishi, Aschkenasi et al. 2003, Liu, 
Kishi et al. 2003). The peripheral expression of MC4R is widespread; it has been detected in the 
heart, lung, kidney and testes (Mountjoy, Jenny Wu et al. 2003).  
 
MC5R is highly expressed within the periphery, but can be detected at very low levels in diffuse 
areas within the hypothalamus, hippocampus, cortex and brainstem (Griffon, Mignon et al. 1994). In 
the periphery, MC5R has been detected within the adrenal cortex, stomach, lung, spleen and 
sebaceous glands (Labbe, Desarnaud et al. 1994).  
 
1.8.4 Peripheral effects of melanocortins  
 
Melanocortins are involved in a variety of physiological processes, reflected by their widespread 
expression. The first established physiological role of melanocortins was in the control of amphibian 
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pigmentation via the pituitary (Allen 1916, Smith 1916). Since then, it has been established that 
melanocortins play a role in a variety of physiological systems, including energy homeostasis (Butler 
2006), stress (Dores 2009), inflammation (Catania, Lonati et al. 2010) and skin pigmentation 
(Shadiack, Sharma et al. 2007).  
 
ACTH is synthesised within corticotrophic cells of the anterior pituitary, where it is released into the 
circulation in response to CRH. PC2 expression in the anterior pituitary is extremely low, preventing 
further cleavage to α-MSH. ACTH stimulates the release of glucocorticoids from the adrenal cortex of 
the kidney. Gamma-MSH is also synthesised within the anterior pituitary and released alongside 
ACTH in response to CRH release (Pedersen, Ling et al. 1982).  
 
Alpha-MSH, γ-MSH and ACTH are synthesised within and released from melanocytes in the skin, 
where they signal in a paracrine fashion to affect pigmentation (Hunt, Todd et al. 1994, Hunt, Kyne 
et al. 1995, Wakamatsu, Graham et al. 1997, Spencer and Schallreuter 2009). In addition, α-MSH 
affects skin pigmentation in mammals via release from melanotrophic cells of the intermediate 
pituitary, where PC2 expression is high. 
 
Within the immune system, all the melanocortins have been shown to inhibit nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) (Manna and Aggarwal 1998, Muceniece, Zvejniece 
et al. 2005, Getting, Lam et al. 2006). NF-κB is a transcription factor involved in immune response, 
and thus there is interest in melanocortins as anti-inflammatory agents (Catania, Lonati et al. 2010).  
 
1.8.5 Central effects of melanocortins  
 
Melanocortin signalling within the brain has been implicated in many physiological and behavioural 
outputs. The first reports regarding the effects of central melanocortin administration observed that 
ACTH and α-MSH induced stretching, yawning and grooming in cats and dogs (Ferrari 1958). It has 
since been shown that these behaviours are mediated through MC3R and MC4R (Adan, Cone et al. 
1994, Jansone, Bergstrom et al. 2004), and are most likely a response to reduce stress-related 
arousal (Adan 2000). ICV administration of the non-selective MC3R/MC4R agonist Ac-Nle4-c[Asp4,ᴅ-
Phe,Lys10]-α-MSH(4-10)-NH2 (Melanotan II) has been shown to induce anxiety related behaviour in 
rats, and MC4R specific blockade reduced the incidence of these behaviours (Chaki, Ogawa et al. 
2003). Additionally, stimulating the stress response by restraining rodents for one hour causes 
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upregulation of POMC messenger ribonucleic acid (mRNA) in the Arc, suggesting the involvement of 
melanocortins in the stress and anxiety response (Larsen and Mau 1994).  
 
ICV administration of ACTH and α-MSH has also been shown to induce penile erections in male rats 
(Argiolas, Melis et al. 2000). Furthermore, copulatory behaviour is increased in mice after injection 
of an MC4R specific agonist, and this behaviour is diminished in MC4R KO mice (Van der Ploeg, 
Martin et al. 2002). This suggests melanocortins are involved in sexual arousal, a finding which is 
reflected in the increased sexual arousal observed following peripheral melanocortin administration 
in humans (Wessells, Levine et al. 2000).  
 
ICV administration of α-MSH or the non-selective MC3R/MC4R agonist NDP-MSH reduces fever 
induced temperature, demonstrating the anti-pyretic signalling properties of melanocortins 
(Holdeman and Lipton 1985). ICV administration of α-MSH also reduces local inflammation induced 
by interleukin-1 injection (Macaluso, McCoy et al. 1994). ICV administration of melanocortins has 
also been shown to induce hyperalgesia in rodents (Bertolini, Poggioli et al. 1979, Sandman and 
Kastin 1981), suggesting a role in pain signalling pathways. Indeed, MC4R is expressed within the 
PAG and the DMV (Liu, Kishi et al. 2003), areas both known to be involved in pain perception.  
 
Intravenous (IV) and ICV administration of γ-MSH in mice increases mean arterial blood pressure 
(MAP) (Ni, Butler et al. 2006). ICV, but not IV, administration of α-MSH increases MAP in mice. 
However, ICV pre-treatment with a sodium channel blocker completely abolished any effect on MAP 
after peripheral and ICV administration of α-MSH or γ-MSH. This suggests blood pressure may be 
affected by melanocortin signalling through both peripheral MC3R and hypothalamic MC3R and 
MC4R expressing neurons containing sodium channels. As the hypothalamus projects extensively to 
the brainstem, the central effects of melanocortins on blood pressure are likely mediated by 
sympathetic outflow via the brainstem.  
 
1.8.6 The role of the melanocortin system in food intake and energy expenditure 
 
The melanocortins are crucial to the regulation of energy homeostasis. Within the hypothalamus, a 
major site of homeostatic control of energy intake, α-MSH is synthesised by and released from 
POMC containing neurons of the Arc. These POMC neurons project widely to hypothalamic and 
extra-hypothalamic areas where they locally release α-MSH. Another key population of POMC 
containing neurons are located within the NTS, and also project widely throughout the brain. The 
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discrete but widespread expression of MC3R and MC4R throughout the brain, generally maps to this 
projection field of central POMC neurons. Together, these populations of POMC neurons regulate 
physiological responses to control food intake and energy expenditure. Optogenetic stimulation of 
POMC neurons within the Arc causes transient POMC neuronal activation, resulting in decreased 
acute food intake (Aponte, Atasoy et al. 2011), corroborating existing evidence that these neurons 
are involved in the anorectic response to energy intake (Giraudo, Billington et al. 1998, Kim, Grace et 
al. 2002).  
 
POMC KO mice were first generated in 1999, and were found to be obese, hyperphagic, to have 
increased longitudinal growth and adrenal insufficiency (Yaswen, Diehl et al. 1999) and yellow skin 
pigmentation, a result of chronic loss of agonistic action at MC1R receptors. Thus, it appears POMC 
is essential for food intake and body weight regulation, and for normal functioning of the HPA axis. 
 
Recessive yellow (e/e) is a frameshift mutation which renders MC1R unable to activate adenylyl 
cyclase (Robbins, Nadeau et al. 1993). Recessive yellow mice have yellow pigmentation, altered pain 
sensation and a perturbed inflammatory response but no obvious effects on body weight, adiposity 
or food intake (Ollmann, Lamoreux et al. 1998), suggesting MC1R is not involved in energy 
homeostasis.  
 
MC2R KO causes neonatal lethality in 75% of mice. Surviving mice have adrenal insufficiency, 
unaltered longitudinal length, but decreased fat mass (Chida, Nakagawa et al. 2007). This suggests 
that MC2R is involved in the regulation of energy expenditure. The defective HPA axis is thought to 
result in impaired gluconeogenesis, which is subsequently responsible for the decrease in fat mass 
(Chida, Nakagawa et al. 2007) and it appears unlikely that MC2R directly regulates body weight.  
 
MC3R KO mice have increased adipose tissue mass and reduced longitudinal growth. Surprisingly, 
they are also hypophagic, suggesting that the increased adiposity reflects an increased feed 
efficiency (Chen, Marsh et al. 2000). Additionally, MC4R KO mice are obese, hyperphagic, 
insulinemic, exhibit decreased energy expenditure, have increased longitudinal growth and have a 
normal HPA axis (Huszar, Lynch et al. 1997). Additionally, obesity severity is increased in double 
MC3R and MC4R KO mice (Chen, Marsh et al. 2000). Collectively, these data suggests MC3R is more 
important in energy expenditure than food intake, and that MC4R may be important in both.  
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MC5R KO mice do not exhibit any alterations in energy homeostasis, although they are unable to 
thermoregulate effectively due to the loss of sebaceous lipid production for coat water repellence 
(Chen, Kelly et al. 1997). Interestingly, AgRP KO mice do not exhibit any alterations in energy 
homeostasis, and POMC and melanocortin levels also remain unaltered in these mice (Qian, Chen et 
al. 2002). However, lethal yellow (Ay) is a spontaneous mutation in rodents arising in the agouti 
protein, causing ectopic overexpression of agouti throughout the brain and periphery. Homozygous 
Ay alleles are embryonic lethal, but mice with heterozygous Ay alleles survive, possess yellow skin and 
fur pigmentation, and become obese, hyperphagic, insulinemic and (Klebig, Wilkinson et al. 1995). 
Agouti antagonises all the melanocortin receptors, thus ectopic brain expression results in a 
phenotype similar to the POMC KO mouse. Overexpression of AgRP also results in a phenotype 
identical to the Ay mouse but without the change in pigmentation (Ollmann, Wilson et al. 1997).  
 
MC3R and MC4R thus appear to play vital roles in energy homeostasis and would appear to be 
putative targets in the regulation of food intake. It would also be expected that ablation of all 
melanocortin signalling would result in a more severe obese phenotype than the individual 
melanocortin receptor KO mice body weight phenotypes. However, the Ay mouse and POMC KO 
phenotypes do not reflect this. It is likely that the absence of other signalling peptides derived from 
POMC but unrelated to the melanocortins may have opposing effects on energy homeostasis, 
resulting in the different phenotypes observed.  
 
Additionally, presynaptic MC3R signalling has been shown to negatively regulate POMC neuronal 
activation within the Arc in response to increased melanocortin release (Cowley, Smart et al. 2001). 
It has been suggested that the loss of presynaptic MC3R signalling within the Arc leads to an increase 
in melanocortin signalling, resulting in a phenotype which is not obese. Thus, the hypothesis remains 
that MC3R and MC4R are the key melanocortin receptors through which energy homeostasis is 
regulated.  
 
1.8.7 Significance of melanocortin signalling in human obesity  
 
The involvement of melanocortins in human obesity was confirmed by the identification of 
individuals with POMC deficiency. Genetic sequencing of two children who exhibited obesity, 
hyperphagia, red-hair and fair skin pigmentation and adrenal insufficiency (Krude, Biebermann et al. 
1998) revealed both carried different mutations in the POMC gene which resulted in either 
premature truncation of the POMC protein or in a frameshift mutation of the POMC gene which 
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prevented translation. Both mutations render the product of the POMC gene null, preventing further 
cleavage into functional POMC products. As a result, α-MSH and ACTH levels were undetectable in 
the serum of these patients. Thus, humans affected by mutations in POMC which render the protein 
null, have a similar phenotype to that of the POMC KO mouse (Yaswen, Diehl et al. 1999). 
Additionally, humans with mutations in PC1 are unable to undergo cleavage of POMC and thus 
exhibit obesity and adrenal insufficiency (O'Rahilly, Gray et al. 1995, Jackson, O’Rahilly et al. 1999).  
 
Shortly after the discovery that mutations in human POMC cause obesity, it was reported that 
dominantly inherited frameshift mutations in the MC4R gene in humans may be associated with a 
monogenic form of obesity (Vaisse, Clement et al. 1998, Yeo, Farooqi et al. 1998). A subset of these 
patients are also tall, which perhaps reflects the increased longitudinal length in the MC4R KO 
mouse. None of the affected patients exhibited adrenal insufficiency, confirming that MC4R is not 
important in the HPA axis. Further investigations showed recessive mutations in MC4R may also be 
associated with early onset obesity (Farooqi, Yeo et al. 2000). Binge eating, defined as a the 
consumption of a large amount of food despite satiation, is also increased in humans with 
characterised MC4R mutations (Branson, Potoczna et al. 2003). To date, around 80 mutations in the 
MC4R gene associated with early onset obesity have been characterised (Fani, Bak et al. 2014). 
Approximately 80% of these mutations result in the intracellular retention of MC4R whereby the 
receptor is unable to insert into the cell membrane, resulting in a defective signalling pathway 
(Lubrano-Berthelier, Durand et al. 2003).  
 
Haploinsufficiency of MC4R is implicated in 5% of all cases of severe early onset human obesity 
(Farooqi, Keogh et al. 2003, Larsen, Echwald et al. 2005). Thus, mutations in the MC4R gene remain 
the most common monogenic cause of obesity, although incidence is rare within the general 
population.   
 
1.8.8 Current melanocortin therapy in obesity treatment  
 
The melanocortins appear potentially useful in the treatment of overeating and obesity, given their 
role in reducing food intake and increasing energy expenditure via MC3R and MC4R. However, there 
are currently no melanocortin based therapeutics licensed for the treatment of metabolic 
dysfunction. This is mainly due to a lack of efficacy, undesirable side effects and tissue bioavailability 
(Fani, Bak et al. 2014).  
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Pre-clinical research has reported weight loss in both humans and rodents after melanocortin 
treatment (McMinn, Wilkinson et al. 2000, Fehm, Smolnik et al. 2001, Pierroz, Ziotopoulou et al. 
2002). Peptides generated to contain the His-Phe-Arg-Trp sequence which confers activity at the 
melanocortin receptors have been shown to reduce acute food intake in rats after ICV 
administration (Ye, MacNeil et al. 2005). Additionally, acute (Hansen, Schioth et al. 2005) and 
chronic (da Silva, Kuo et al. 2006) ICV administration of Melanotan II in DIO rats was able to reduce 
food intake and body weight respectively. However, Melanotan II also increased MAP in rats (da 
Silva, Kuo et al. 2006). This proves the efficacy of an MC3R/MC4R agonist in reducing dietary obesity 
but also their role in increasing blood pressure. In humans, 7 day administration of an MC4R agonist 
to obese individuals with loss-of-function mutations in MC4R caused increased systolic blood 
pressure, despite these individuals initially having lower blood pressure than weight matched 
controls (Greenfield, Miller et al. 2009). The side effect of increased blood pressure is problematic, 
especially considering the cardiovascular risk already associated with being overweight or obese 
(World Health Organisation 2013).  
 
As with any centrally targeted drug, passage across the BBB into the brain is necessary and can be 
problematic. Additionally, oral bioavailability is important when considering administration of any 
therapy in humans. If a drug is able to be administered orally and absorbed through the GI tract into 
the circulation, this reduces the need for intravenous cannulation and infusion which require 
medical assistance. The first report of a synthetic melanocortin peptide repeatedly administered 
orally and detected centrally in rats and mice was shown to cause an acute decrease in food intake 
and chronic weight loss (Hess, Linde et al. 2008). Achieving increased bioavailability was a result of 
backbone cyclisation of the peptide, which uses a series of covalent interactions to ensure structural 
stability within the serum. However, no further investigations with these peptides have been 
reported, suggesting a lack of success in the subsequent pre-clinical investigations.  
 
Another promising investigation showing decreased food intake and body weight in mice with 
chronic administration of another melanocortin peptide similarly reduced food intake and body 
weight in DIO rats (He, Ye et al. 2010, He, Ye et al. 2010). However, this agent did not decrease body 
weight in obese humans (Krishna, Gumbiner et al. 2009). More recently, a partial MC4R agonist 
peptide was shown to reduce body weight in DIO rodents without the undesirable penile erection 
side effect that many previous peptides have reported (Hong, Bakshi et al. 2011). This suggests the 
emergence of a class of peptides which are able to selectively activate MC4R-dependent pathways 
involved in energy homeostasis. This is corroborated by a study reporting chronic administration of 
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an MC4R specific agonist is able to ameliorate obesity and improve glucose tolerance in DIO Rhesus 
macaque monkeys (Kievit, Halem et al. 2013). This study reported no increase in diastolic blood 
pressure or heart rate as a result of melanocortin treatment, again suggesting the ability of a peptide 
to selectively activate MC4R-dependent pathways. However, to date no melanocortin related 
peptide has achieved success in advanced human trials in the treatment of obesity.  
 
Another focus area of melanocortin therapy in obesity treatment is MRAP2 signalling. Given the role 
of MRAP2 in ensuring MC4R competency (Sebag, Zhang et al. 2013) and the association of MRAP2 
mutations with mammalian obesity (Asai, Ramachandrappa et al. 2013), they represent a significant 
therapeutic target. Functional rescue of mutated MC4R by pharmacological chaperones has been 
demonstrated in vitro (René, Le Gouill et al. 2010) but has yet to be tested in vivo. Although MRAP2 
mutations are associated with a high percentage of mammalian obesity caused by dysfunctional 
MC4R signalling, it remains that this pharmacological approach may only be effective in those with a 
specific subset of MRAP2 trafficking mutations. Nevertheless, the results from these studies are 
eagerly awaited.  
 
The therapeutic benefits offered by melanocortin treatment are potentially vast. Thus, there is 
increasing focus on the development of safe and efficacious melanocortin pharmaceuticals to treat a 
range of diseases including stroke (Holloway, Smith et al. 2011), arthritis (Getting, Kaneva et al. 
2009), skin cancer (Abdel-Malek 2010) and sexual dysfunction (Shadiack, Sharma et al. 2007).  
The emergence of peptides able to selectively activate target MC4R-dependent signalling pathways, 
such as those involved in energy homeostasis, show future promise in the treatment of overeating 
and obesity.  
 
 
 
 
 
 
 
 
 
 
 
68 
 
1.9 Aims of this thesis  
 
 
Non-homeostatic food intake is a major contributing factor in the development of obesity. Food 
intake is controlled by both homeostatic and non-homeostatic signalling pathways with the brain. 
Melanocortin signalling within the hypothalamus in the control of food intake and energy 
expenditure is relatively well understood. However, the role of melanocortins in the 
mesocorticolimbic system in the control of food intake remains unclear. In the following chapters 
within this thesis I have investigated the role of acute and chronic manipulation of melanocortin 
signalling within distinct areas of the mesocorticolimbic system in the control of energy homeostasis 
in rodents.  
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Chapter 2: Investigating the acute 
feeding effects of melanocortins in the 
ventral tegmental area   
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2.1 Introduction  
 
 
2.1.1 Food intake patterns in rodents 
 
Rodents are nocturnal animals; they are most active and aroused during the dark phase. When 
rodents are housed under a 12 hour light phase/12 hour dark phase regime they will consume 
around 70% of their total daily food intake during the dark phase (Ellacott, Morton et al. 2010). 
Rodents consume food in distinct bouts, or meals. The average 24 hour food intake for a rat is 
approximately 10–15 kilocalories/gram (kcal/g) of body weight, and for a wildtype (WT) mouse is 
approximately 10–12kcal/g of body weight. Rodents will consume the majority of their dark phase 
food intake within the first two hours at the onset of the phase as they begin to awaken. Thus, 
measuring rodent food intake in a physiologically ad libitum fed state is usually undertaken at the 
onset of the dark phase. Similarly, measuring rodent food intake in a physiologically fasted state is 
undertaken at the onset of the light phase, whereby access to food is removed for the duration of 
the dark phase when the majority of food consumption would usually occur. Rodents are unable to 
perceive red light due to their dichromatic vision, thus their food intake may be monitored during 
the dark phase under red lighting without disturbing them. Post-prandial rodent feeding behaviour is 
stereotypical; rats and mice will groom then rest or sleep immediately after food intake. This is 
described as the behavioural satiety sequence (Ellacott, Morton et al. 2010).   
 
2.1.2 Feeding peptides in the mesocorticolimbic system  
 
Physiologically, it is important we become acutely sensitised to food when hungry to ensure 
successful food intake. Feeding signals can also hijack the mesocorticolimbic system to drive hedonic 
food seeking and food intake. The hypothalamus is the primary target for feeding hormones to exert 
their effects, and thus communication between the hypothalamus and extra-hypothalamic brain 
areas is vital in mediating the whole brain response to food. POMC containing neurons originating 
within the Arc project to the amygdala, VTA and PAG of the mesocorticolimbic system (Koylu, 
Couceyro et al. 1998, King and Hentges 2011). Additionally, AgRP containing neurons project 
strongly to the amygdala, and NPY containing neuronal projections from the Arc have been 
characterised within the PFC, NAcb, striatum and the LS (Broberger, Johansen et al. 1998). Orexin 
containing neurons arising within the LH are known to project to the VTA, amygdala and the 
striatum (Shen 1983). Many of these hypothalamic areas also receive reciprocal GABAergic or 
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glutamatergic projections from the mesocorticolimbic system (Barone, Wayner et al. 1981, 
Silverman, Hoffman et al. 1981, Duva, Tomkins et al. 2005), suggesting the existence of  a feedback 
circuit whereby output from the hypothalamus can be altered according to input from the 
mesocorticolimbic system.  
 
The observation that receptors for feeding hormones and neuropeptides are expressed within 
mesocorticolimbic areas suggests that they can influence reward signalling to increase the likelihood 
that we either consume or refuse food. Additionally, feeding hormone signalling within the 
mesocorticolimbic system has been implicated in the reward response to drugs of abuse (Hsu, Taylor 
et al. 2005, Richardson and Aston-Jones 2012, Skibicka 2013), suggesting they are able to mediate 
the reward response to other stimuli beside food.   
 
2.1.2.1 Ghrelin 
 
The role of ghrelin in the control of food intake via the mesocorticolimbic system is reasonably well 
studied. GHSR is expressed on dopaminergic neurons within the VTA (Guan, Yu et al. 1997, Abizaid, 
Liu et al. 2006) and intra-VTA administration of ghrelin in rats has been shown to cause an acute 
increase in palatable food intake, but not standard chow (Egecioglu, Jerlhag et al. 2010). Intra-VTA 
administration of ghrelin also causes a subsequent increase in NAcb dopamine levels (Jerlhag, 
Egecioglu et al. 2007). In addition, GHSR KO mice exhibit reduced intake of palatable food, and 
unchanged dopamine levels within the NAcb after ingestion of palatable food. Intra-VTA 
administration of a GHSR antagonist in fasted rats also decreases food seeking behaviour (Skibicka, 
Hansson et al. 2011). Intra-NAcb pre-treatment with either a D1 or D2 receptor antagonist blocks food 
seeking behaviour elicited by intra-VTA ghrelin administration (Skibicka, Shirazi et al. 2013). Finally, 
ghrelin has also been shown to increase VTA dopaminergic neuronal activity in rats upon receipt of a 
palatable sugar pellet reward (Cone, McCutcheon et al. 2014). Collectively, these findings suggest 
ghrelin signalling within the VTA influencing dopamine release in the NAcb is important in mediating 
the incentive value of palatable foodstuffs.  
 
2.1.2.2 Leptin 
 
LepR is expressed on dopaminergic neurons within the VTA (Figlewicz, Evans et al. 2003) and intra-
VTA administration of leptin reduces acute food intake in ad libitum fed rats (Hommel, Trinko et al. 
2006). Additionally, leptin administration reduces the excitability of VTA dopamine neurons and RNA 
72 
 
interference (RNAi) knockdown of LepR in the VTA increases food intake and preference for 
palatable food. However, the feeding effects of intra-VTA administration of leptin are attenuated in 
proportion with increasing body weight in DIO rats (Bruijnzeel, Qi et al. 2013), suggesting the central 
leptin resistance that develops in obesity in response to chronically elevated levels of leptin also 
develops within extra-hypothalamic brain areas. Thus, leptin resistance in the VTA may influence the 
non-homeostatic regulation of food intake in obesity. Recently, leptin has been shown to suppress 
excitatory input onto VTA dopaminergic neurons, suggesting LepR-mediated presynaptic inhibition 
of glutamate neurons (Thompson and Borgland 2013). Thus, leptin appears to reduce food intake by 
inhibiting dopaminergic neuronal excitability within the VTA and obesity may attenuate this action 
by promoting central leptin resistance.  
 
2.1.2.3 Orexins 
 
The VTA and NAcb receive orexin-containing projections from the LH (Nakamura, Uramura et al. 
2000) that synapse on either dopaminergic or GABAergic neurons (Balcita-Pedicino and Sesack 
2007). OX2R receptor expression has been detected within the VTA and NAcb (Marcus, Aschkenasi 
et al. 2001) and OX1R receptor expression has been detected in the VTA (Lu, Bagnol et al. 2000). 
Intra-VTA administration of orexin-A or orexin-B increases the excitability of VTA dopaminergic 
neurons by stimulating glutamatergic input (Borgland, Storm et al. 2008), and also increases cocaine 
self-administration in rats (Espana, Melchior et al. 2011). Additionally, either intra-VTA 
administration or peripheral administration of an OX1R receptor antagonist reduces self-
administration of cocaine in rats (Espana, Oleson et al. 2010). Intra-VTA administration of an OX1R 
antagonist also reduces HFD pellet consumption, and decreases c-Fos expression within the VTA in 
these animals (Valdivia, Patrone et al. 2014). c-Fos is an early onset transcription factor which is 
expressed immediately after neuronal activation and can be identified post-mortem to identify areas 
of increased neuronal activity (Hoffman, Smith et al. 1993). These observations suggest orexins 
enhance the effects of rewarding stimuli and may be potential targets for the treatment of 
addiction.  
 
2.1.2.4 Glucagon-like peptide 1 
 
Glucagon-like peptide 1 (GLP-1) is primarily released from intestinal L-cells and plays a role in 
glucose homeostasis and satiety (Holst 2007). GLP-1 receptors are expressed within the VTA 
(Merchenthaler, Lane et al. 1999) and intra-VTA administration of exendin-4 (EX4), a GLP-1 
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analogue, acutely decreases consumption of both palatable and normal chow (Alhadeff, Rupprecht 
et al. 2012) (Dickson, Shirazi et al. 2012). Administration of EX4 to VTA dopaminergic neurons 
increased AMPAR-mediated currents, suggesting GLP-1 mediates its effects by increasing 
glutamatergic input onto VTA dopaminergic neurons (Mietlicki-Baase, Ortinski et al. 2013). This 
appears to contradict evidence that increased dopaminergic activity contributes to increased 
hedonic feeding, but one possible explanation is that the increased dopaminergic activity represents 
increased inhibitory D2 presynaptic activity. This may dampen dopaminergic hedonic signalling, 
reducing the motivation to consume food. It may also be possible that increased dopamine signalling 
adequately fulfils incentive salience, reducing the requirement to further consume more food. 
Further study is required to elucidate the effects of GLP-1 on mesocorticolimbic signalling.  
 
2.1.2.5 Insulin 
 
Insulin receptors are expressed on VTA dopaminergic neurons (Figlewicz, Evans et al. 2003) and 
intra-VTA administration of insulin acutely decreases palatable sucrose intake (Figlewicz, Bennett et 
al. 2008). Chronic ICV infusion of insulin increases DAT expression within the VTA (Figlewicz, Szot et 
al. 1994), and increased DAT expression is also observed in the VTA of obese hyperinsulinaemic rats  
(Figlewicz, Patterson et al. 1998). In another study, intra-VTA insulin administration dose-
dependently decreased dopamine levels within the VTA (Mebel, Wong et al. 2012), and this effect 
was blocked by intra-VTA pre-treatment with a DAT inhibitor. This suggests insulin is able to inhibit 
dopamine signalling by reducing the amount of time dopamine is available within the synaptic cleft. 
Recently, it has been demonstrated that insulin is able to inhibit excitatory glutamatergic input onto 
VTA dopaminergic neurons, a process which also requires endocannabinoid mediated presynaptic 
signalling (Labouebe, Liu et al. 2013).  
 
Crosstalk between hypothalamic and non-hypothalamic areas is vital in ensuring effective nutrient 
intake. Despite the strong homeostatic drive to preserve energy homeostasis provided by 
hypothalamic signalling, hedonic drive is required in order to motivate and reinforce food seeking 
behaviour and ingestion. Factors that regulate feeding may thus target the mesocorticolimbic 
system in order to affect different facets of food intake in a non-stereotypical fashion. It appears 
ghrelin, leptin, the orexins, GLP-1 and insulin affect different properties of dopamine signalling in 
order to influence food intake. The role of other feeding hormones and neuropeptides in 
mesocorticolimbic signalling are less well characterised, but increasing evidence suggests amylin 
(Mietlicki-Baase, Ortinski et al. 2013), neurotensin (Opland, Sutton et al. 2013) and the 
74 
 
melanocortins (Lerma-Cabrera, Carvajal et al. 2012, Roseberry 2013) may also play a role in hedonic 
feeding.  
 
2.1.3 Acute feeding effects of melanocortins via the hypothalamus 
 
The effects of specific components of the melanocortin system on appetite following administration 
into the hypothalamus have been extensively studied.  ICV administration of α-MSH or ACTH causes 
an acute decrease in food intake in both fed and fasted rats (Poggioli, Vergoni et al. 1986). This acute 
anorectic effect of melanocortins has also been confirmed in mice and rabbits (Bertolini, Poggioli et 
al. 1988). Administration of α-MSH into the Arc, PVN, LH, DMN and MPO in rats also decreases acute 
food intake, whilst intra-PVN, DMN and MPO administration of AgRP causes a delayed increase in 
food intake after 8 hours (Kim, Rossi et al. 2000). ICV administration of the MC3R/MC4R agonist 
Melanotan II inhibits feeding in four models of hyperphagia including fasted WT mice, heterozygous 
Ay mice, ob/ob mice and mice pre-treated with NPY (Fan, Boston et al. 1997). Co-ICV administration 
of the MC3R/MC4R antagonist Ac-[Nle4,Asp5,ᴅ-2-Nal7,Lys10]-cyclo-α-MSH(4-10) (SHU9119) prevented 
the anorectic effect of Melanotan II in all four hyperphagic models, and ICV administration of 
SHU9119 alone caused an increase in acute food intake in all four hyperphagic models after both 
fasting and feeding. Additionally, acute and chronic food intake is increased in fed and fasted rats 
after ICV administration of the specific MC4R antagonists Ac-Cys-Nle-Arg-His-ᴅ-Nal-Arg-Trp-Gly-Cys-
NH2 (HS024) (Kask, Mutulis et al. 1998), Ac-Cys-Glu-His-ᴅ-2-Nal-Arg-Trp-Gly-Cys-Pro-Pro-Lys-Asp-NH2 
(HS014) (Kask, Rago et al. 1998, Vergoni, Bertolini et al. 1998) and Ac-Cys-Glu-His-diCl-ᴅ-Phe-Arg-
Trp-Gly-Cys-Pro-Pro-Lys-Asp-NH2 (HS028) (Skuladottir, Jonsson et al. 1999).  
 
γ-MSH is more selective for MC3R than MC4R (Schiöth, Muceniece et al. 1995) and it has been 
demonstrated that ICV administration does not reduce food intake in rats (Abbott, Rossi et al. 2000), 
suggesting hypothalamic MC3R does not play a role in acute food intake. However, ICV 
administration of γ-MSH is able to reduce acute food intake in chicks (Smith, Kohart et al. 2009) 
reflecting species variation concerning the role of γ-MSH. Furthermore, ICV administration of β-MSH, 
which binds to central MC3R and MC4R receptors, has been shown to reduce acute food intake in 
rats (Abbott, Rossi et al. 2000), despite the absence of endogenous β-MSH in rodents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
Typically, the anorectic effects of melanocortins are observed up to six hours post-administration 
(Poggioli, Vergoni et al. 1986, Bertolini, Poggioli et al. 1988). This suggests that other acute 
behaviours elicited by melanocortin administration such as grooming, stretching and yawning 
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(Ferrari 1958) are not inhibitory on feeding behaviour, as they are only observed immediately after 
administration and are not prolonged. However, stress is an important inhibitory factor in food 
intake, and immobilisation-induced stress in rats results in a 50% decrease in food intake (Vergoni, 
Bertolini et al. 1999). This effect is blocked by ICV administration of HS014, suggesting MC4R is also 
important in the effects of stress on food intake.  
 
Collectively, these observations suggest the feeding effects of melanocortins are primarily mediated 
through MC4R in hypothalamic areas. The tonic inhibitory anorectic tone established by endogenous 
melanocortin signalling within the hypothalamus may be enhanced or inhibited by MC4R agonists 
and antagonists, respectively, to significantly affect acute food intake.   
 
2.1.4 POMC and melanocortin receptor 3 and 4 expression in the mesocorticolimbic system  
 
POMC protein expression has been reported in the VTA, PAG, amygdala, LS and the hippocampus as 
a result of POMC hypothalamic projections to these mesocorticolimbic areas (Bagnol, Lu et al. 1999, 
Leriche, Cote-Velez et al. 2007, King and Hentges 2011, Padilla, Reef et al. 2012). Melanocortin 
receptor expression in the mesocorticolimbic system has been widely reported, with MC4R 
expression being more widespread than the expression of MC3R. High MC3R mRNA expression 
levels have been detected in the VTA, raphe nuclei, LS and moderate expression levels have been 
identified in the amygdala and PAG (Robbins, Nadeau et al. 1993). High MC4R mRNA expression 
levels have been characterised in the CPu, NAcbC, NAcbSh, LS, MeA, CeA and PAG, and moderate 
levels of MC4R expression have been characterised in the PRL, IL and VP. However, only low 
expression levels of MC4R mRNA have been reported for the VTA by some groups (Mountjoy, 
Mortrud et al. 1994, Kishi, Aschkenasi et al. 2003). Conversely, autoradiography detection of MC4R 
mRNA has previously described high expression in the VTA, and also for the NAcb, the septal nuclei 
and the PAG (Alvaro, Tatro et al. 1996). More recently, an MC4R-green fluorescent protein (GFP) 
expressing mouse model has shown MC4R protein expression in the insular cortex, NAcbSh, CPu, VP, 
LS, hippocampus, MeA, CeA, PAG and the raphe nuclei (Liu, Kishi et al. 2003) which aligns closely 
with mRNA expression profiles from previous MC4R expression studies (Roselli-Rehfuss, Mountjoy et 
al. 1993, Mountjoy, Mortrud et al. 1994, Kishi, Aschkenasi et al. 2003). However, this study and 
others (Lippert, Ellacott et al. 2014) have reported no expression of GFP in the VTA in this mouse 
model, suggesting MC4R is not expressed there. Expression levels of MC4R mRNA and MC4R protein 
in the VTA clearly varies between reports, perhaps reflecting the sensitivity of each detection 
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method. Collectively, these data suggest the presence of a diffuse melanocortin signalling system in 
the mesocorticolimbic system.  
 
2.1.5 Acute feeding effects of melanocortins via the mesocorticolimbic system 
 
The acute effects of intra-VTA melanocortin administration on food intake has been confirmed in our 
research laboratory, whereby intra-VTA administration of NDP-MSH is able to reduce food intake in 
ad libitum fed rats within the 0-1 hour time point post-administration, but not in fasted rats (Figure 
2.1; K. A. Banks (2011) MRes thesis, Investigative Medicine, Imperial College London). This suggests 
that in the fed state, the VTA becomes acutely sensitised to the anorectic effects of melanocortins 
and is able to signal to reduce food intake via MC3R and/or MC4R. The neuronal pathways and 
neuronal phenotypes which mediate this anorectic effect of melanocortins via the VTA remain 
unknown.   
 
Intra-VTA administration of the specific MC4R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-
NH2 has also been shown to reduce food intake and ethanol consumption in ad libitum fed rats for 
up to 4 hours post-administration (Lerma-Cabrera, Carvajal et al. 2012). Intra-VTA administration of 
the specific MC4R antagonist HS014 was also shown to increase ethanol consumption and food 
intake in ad libitum fed rats. Another study confirmed similar feeding effects after intra-VTA 
administration of Melanotan II, a non-selective MC3R/MC4R agonist to ad libitum fed rats 
(Roseberry 2013). Acute food intake was reduced up to 24 hours post injection, whereas intra-VTA 
administration of SHU9119 to ad libitum fed rats caused an increase in food intake 24 hours post-
administration. Intra-VTA Melanotan II administration was not effective at reducing food intake in 
fasted rats, suggesting the VTA is more sensitive to the anorectic effects of melanocortins in a fed 
state. Chronic antagonism of MC4R with daily administration of SHU9119 for 5 days caused an 
increase in body weight and cumulative food intake, demonstrating that chronic perturbation of the 
melanocortin tone via the VTA is sufficient to promote an obesogenic phenotype. Additionally, intra-
VTA administration of Melanotan II to rats has been shown to decrease acute consumption of 1, 2 
and 10% weight/volume (w/v) sucrose and 0.2% w/v saccharin solutions (Yen and Roseberry 2014), 
reinforcing that the anorectic effect of melanocortins via the VTA is able to regulate consumption of 
multiple rewarding substances. Together, these report the initial observations of intra-VTA 
melanocortin signalling on food intake and suggest MC4R plays an important role in VTA reward 
signalling. These studies also suggest that the neuronal circuits which mediate reward during  
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Fig 2.1 The effect of intra-VTA administration of NDP-MSH, a non-specific MC3R/MC4R agonist on 
food intake in fasted rats in the early light phase and ad libitum fed rats in the early dark phase. 
Adult male Wistar rats received intra-VTA administration of 0.3, 0.1, 0.03 or 0.01nmol NDP-MSH at 
the onset of the early dark or light phase. Food intake is expressed as mean grams of RM1 chow ± 
SEM at A) 0 - 1 hours post administration during the onset of the early light phase in fasted rats and 
at B) 0 - 1 hours post administration during the onset of the early dark phase in ad libitum fed rats. 
(n=9-10) *p<0.05, **p<0.01. (K. A. Banks (2011) MRes thesis). 
 
A 
B 
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consumption of drugs of abuse, such as ethanol, and food, are not distinct, and that reward is 
mediated through the same neuronal pathways and the same neural substrates.  
 
Administration of the MC4R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 into the NAcb 
decreases food intake after 2 hours post-administration, and intra-NAcb administration of the MC4R 
antagonist HS014 increases food intake within the 2-4 hour time point post-administration in ad 
libitum fed rats (Lerma-Cabrera, Carvajal et al. 2012). A small increase in food intake is also observed 
after administration of AgRP into the central amygdala in ad libitum fed rats (Kim, Rossi et al. 2000). 
Together, this suggests that the feeding effects of intra-VTA administration of melanocortins may 
possibly be mediated via downstream areas. 
 
ICV administration of AgRP removes preference for a sucrose reward, but has no effect on 
preference for a high fat reward in rats (Davis, Choi et al. 2011). This is at odds with the observation 
that ICV administration of AgRP in rats promotes operant responding to stimuli which has been 
paired with peanut oil, but not sucrose (Tracy, Clegg et al. 2008). Furthermore, ICV administration of 
AgRP to rats fed on a high fat diet increased motivational behaviour to attain a sucrose reward, 
suggesting melanocortin signalling physiologically inhibits food seeking behaviour and that diet may 
influence this system (Figlewicz, Jay et al. 2013).  
 
Together, these findings suggest that antagonism of the melanocortin system modulates specific 
food seeking behaviour differentially according to the type of reward presented and may be affected 
by background diet.  
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2.1.6 Hypothesis  
 
I hypothesise that melanocortin signalling within the VTA plays a role in the regulation of acute food 
intake and food seeking behaviour and that this is mediated through MC4R.  
 
2.1.7 Aims 
 
To determine the effects of melanocortin signalling and the role of MC4R within the VTA in the 
regulation of acute food intake and feeding behaviour, I will investigate:- 
 
- The effects of diurnal variation on melanocortin signalling in the VTA in the control of acute 
food intake in fasted and ad libitum fed male Wistar rats.  
- The effect of intra-VTA administration of an MC4R specific agonist, N-[(3R)-1,2,3,4-
tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-
triazol-1ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ), on food intake in fasted and ad 
libitum fed male Wistar rats.  
- The effect of intra-VTA administration of an MC3R/MC4R specific agonist, NDP-MSH, on 
food intake in fasted and ad libitum fed male C57BL/6J mice. 
- The effect of intra-VTA administration of NDP-MSH on general and food-seeking behaviour 
in fasted and ad libitum fed male C57BL/6J mice. 
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2.2 Methods 
 
 
2.2.1 Materials 
 
[Nle4,ᴅ-Phe7]-α-MSH (NDP-MSH) was purchased from Bachem, Switzerland. N-[(3R)-1,2,3,4-
tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-
1ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ) was purchased from Tocris Bioscence, USA. 
  
2.2.2 Animals  
 
Adult male Wistar rats (220 – 250g) were purchased from Charles River (Kent, UK). Rats were group 
housed pre-surgery in individually ventilated cages under controlled temperatures  (21-23°C) and a 
12 hour light/dark cycle with ad libitum access to Rat and Mouse 1 diet (RM1) (Special Diet Service, 
Essex, UK) and water. All rats post-surgery were singly housed and maintained in individually 
ventilated cages under the same conditions.  
 
Adult male C57BL/6J mice (20 – 25g) were purchased from Harlan (Derby, UK). Mice were group 
housed pre-surgery in individually ventilated cages under controlled temperatures  (21-23°C) and a 
12 hour light/dark cycle with ad libitum access to RM1 and water. All mice post-surgery were singly 
housed and maintained in individually ventilated cages under the same conditions. 
 
All animal procedures undertaken were approved by the British Home Office and carried out under 
the British Home Office Animals (Scientific Procedures) Act 1986 (Project licence 70/7236).  
 
2.2.3 Verification of intra-VTA cannula placement in rats and mice 
 
2.2.3.1 Intra-VTA ink injections in rats  
 
Adult male Wistar rats (n=2) were terminally anaesthetised by intraperitoneal (IP) administration of 
150mg/kg sodium pentobarbital (Merial Animal Health Ltd, UK) until loss of the pedal reflex was 
observed. Rats were positioned on a stereotaxic frame (Model 900, David Kopf Instruments, USA) 
with non-rupture ear bars and the incisor bar positioned 3mm below the interaural line. A 2cm 
longitudinal incision was made on the dorsal cranial surface and the periosteum was cleared to 
expose the cranium. Bregma and the sagittal suture (Figure 2.2) were identified to guide stereotaxic 
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co-ordinate positioning as previously determined from ‘The Rat Brain in Stereotaxic co-ordinates’ 
(Paxinos and Watson 2006). The PBP of the VTA was targeted as it constitutes the largest volume of 
the VTA and the largest proportion of dopaminergic neurons. Co-ordinates targeting the VTA were 
calculated as 6mm caudal from bregma, 0.5mm lateral from bregma and 8.5mm ventral from the 
surface of the brain. A unilateral hole with a diameter of 0.7mm was drilled in the right cranial 
surface using a stereotaxically mounted electric drill above the right PBP. A stainless steel 24 gauge 
cannula (Plastics One, USA) was positioned over the drilled hole using a stereotaxically mounted 
clamp which acted as a guide cannula for a stainless steel 28 gauge injector which was inserted to 
project 1mm beyond the tip of the guide cannula. An electrical infusion pump (Model A55-1111, 
Harvard Apparatus, USA) was calibrated to deliver a flow rate of 120µl/hr via the injector. The guide 
cannula and injector were inserted into the drilled hole to a depth of 8.5mm and 1µl 1:40 
volume/volume (v/v) Indian ink (Stephens, UK) in 0.01M phosphate buffered saline (Appendix 1) was 
delivered over 30 seconds. The guide cannula and injector remained in situ for a further 5 minutes 
before removal to minimise injector backflow.  
 
2.2.3.2 Intra-VTA ink injections in mice 
 
Adult male C57BL/6J mice (n=3) were terminally anaesthetised by IP administration of 120mg/kg 
sodium pentobarbital until loss of the pedal reflex was observed. Mice were positioned on a 
stereotaxic frame (Model 900, David Kopf Instruments, USA) with non-rupture ear bars and the 
incisor bar positioned 2mm below the interaural line. A 1.5cm longitudinal incision was made on the 
dorsal cranial surface and the periosteum was cleared to expose the cranium. Bregma and the 
sagittal suture (Figure 2.2) were identified to guide stereotaxic co-ordinate positioning as previously 
determined from ‘The Mouse Brain in Stereotaxic co-ordinates’ (Franklin and Paxinos 2007). Co-
ordinates targeting the PBP of the VTA were calculated as 3.2mm caudal from bregma, 0.5mm 
lateral from bregma and 4.8mm ventral from the surface of the brain. A unilateral hole with a 
diameter of 0.7mm was drilled in the right cranium surface using a stereotaxically mounted electric  
drill above the right PBP. A stainless steel 28 gauge cannula (Plastics One, USA) was positioned over 
the drilled hole using a stereotaxically mounted clamp which acted as a guide cannula for a stainless 
steel 32 gauge injector which was inserted to project 1mm. An electrical infusion pump (Model A55-
1111, Harvard Apparatus, USA) was calibrated to deliver a flow rate of 120µl/hr via the injector. The 
guide cannula and injector were inserted into the drilled hole to a depth of 4.8mm and 1µl of  
1:40 v/v Indian ink in 0.01M PBS was delivered over 30 seconds. The guide cannula and injector 
remained in situ for a further 5 minutes before removal to minimise injector backflow. 
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Figure 2.2 A) Dorsal aspect of the adult Wistar rat cranium describing the suture reference 
markings used in stereotaxic localisation. Picture taken from ‘The Rat Brain in Stereotaxic Co-
ordinates’ (Paxinos and Watson 2006). B) The dorsal aspect of the adult mouse cranium describing 
the suture reference markings used in stereotaxic localisation. Picture taken from ‘The Mouse Brain 
in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007).  
 
 
 
B  
A  
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After ink injection, rat and mouse brains were dissected out and rapidly frozen in isopentane (VWR, 
UK) over dry ice before mounting on 20mm cork discs (ThermoScientific, UK) using optical cutting 
temperature (OCT) mounting media (VWR, UK). Brains were then sliced at -20°C on a cryostat 
(Model OTF 5040, Bright Instruments, UK) to 20µm thickness before mounting onto polylysine 
coated microscope slides (VWR, UK) and stained using Cresyl violet solution.  
 
2.2.3.3 Cresyl violet staining of ink injected rat and mouse brains 
 
Materials 
 
Cresyl violet solution (Appendix 1) 
Ethanol absolute (VWR, UK) 
Xylene (VWR, UK) 
DPX mountant (VWR, UK) 
 
Method  
 
Slides containing rat and mouse brain tissue slices were dried overnight at room temperature (RTP). 
The slides were first cleared in xylene for 5 minutes, removed and placed back in xylene for a further 
5 minutes. The slides were then fixed in 100% ethanol for 5 minutes, removed and placed back in 
100% ethanol for a further 5 minutes. Slides were then placed in 95% ethanol:5% glass distilled 
water (GDW) for 5 minutes then 70% ethanol:30% GDW for 5 minutes before washing in GDW for 5 
seconds and staining in Cresyl violet solution for 20 minutes. Slides were then washed in GDW for 2 
minutes before undergoing the previous washes in reverse order for the same durations. Slides were 
removed from xylene and glass coverslips (VWR, UK) applied immediately using DPX mountant 
before leaving to dry overnight. Slides were observed under a light microscope (Nikon, Eclipse 50i) 
and co-ordinates which resulted in ink spread 0.2mm outside the boundary of the PBP of the VTA 
were discounted.  
 
2.2.4 Intra-VTA cannulation in rats  
 
Rats were anaesthetised with 2l/min O2 and 4% isofluorane within an anaesthetic induction chamber 
until loss of the pedal reflex was observed. Fur covering the dorsal cranial area caudal from the eyes 
was removed using fur clippers. Prophylactic antibiotics (Appendix 2) were administered IP to 
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prevent post-operative bacterial infection. Rats were positioned on a stereotaxic frame (Model 900, 
David Kopf Instruments, USA) with non-rupture ear bars and the incisor bar positioned 2mm below 
the interaural line. A rat anaesthetic mask (Model 906, David Kopf Instruments, USA) was adjusted 
to fit the frame and initially delivered 1.5l/min O2 and 4% isofluorane. Isofluorane percentage was 
adjusted to deliver an appropriate depth of anaesthesia according to observation of rat respiratory 
rate and pedal reflex throughout the procedure. Buprenorphine (Appendix 2) was administered 
subcutaneously (SC) to provide immediate post-surgical anaesthesia. Lacrilube (Allergan, UK) was 
applied to the eyes to prevent keratitis and the cranial area was swabbed with 1:10 v/v iodine 
(Ecolabs Ltd, UK) and sterile water (B.Braun, UK) to promote sterility. A 2.5cm longitudinal incision 
was made on the dorsal cranial surface and the periosteum was cleared to expose the cranium. 
Bregma and the sagittal suture (Figure 2.2) were identified to guide calculation of the required 
stereotaxic co-ordinates determined from ink injection studies (6mm caudal from bregma and 
0.5mm lateral from bregma). A unilateral hole with a diameter of 0.7mm was drilled in the right the 
cranial surface using a stereotaxically mounted electric drill above the right PBP. Three 0.1mm 
indentations were made in the cranial surface using a hand drill (Department of Medical 
Engineering, Imperial College London, UK), one rostral and right of bregma and two caudal right and 
left of bregma. Three stainless steel screws (Antrin Miniature Specialities, USA) were partially 
inserted into the indented cranial surface with a 0.2mm dorsal projection. A stainless steel 24 gauge 
cannula projecting 8.5mm ventrally (Plastics One, USA) was positioned over the drilled hole using a 
stereotaxically mounted clamp and inserted to the required depth. The cannula remained in situ as 
dental cement (Associated Dental Products Ltd, UK) was applied to the cranial surface and projecting 
screws to secure the cannula in place. Fifteen minutes were allowed for the cement to dry before 
removal of the clamp and insertion of a 28 gauge 8.5mm stainless steel dummy cannula (Plastics 
One, USA) to prevent debris entering the cannula post-surgery. Rats were placed in a warming 
chamber to recover post-surgery at 32°C, and 5ml of warmed 0.9% sodium chloride solution was 
administered IP to counteract dehydration. Rats were housed individually and given access to liquid 
RM1 diet for 24 hours post-surgery.   
 
2.2.5 Intra-VTA cannulation in mice  
 
Mice were anaesthetised with 2l/min O2 and 4% isofluorane within an anaesthetic induction 
chamber until loss of the pedal reflex was observed. Fur covering the dorsal cranial area caudal from 
the eyes was removed using fur clippers. Prophylactic antibiotics (Appendix 2) were administered IP 
to prevent post-operative bacterial infection and carprofen (Appendix 2) was administered SC to 
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provide long-term analgesia. Mice were supported on an insulated platform and positioned on a 
stereotaxic frame (Model 900, David Kopf Instruments, USA) with non-rupture ear bars and the 
incisor bar positioned 2mm below the interaural line. A mouse anaesthetic mask (Model 907, David 
Kopf Instruments, USA) was adjusted to fit the frame and initially delivered 1l/min O2 and 2.5% 
isofluorane. Isofluorane percentage was adjusted to deliver an appropriate depth of anaesthesia 
according to observation of mouse respiratory rate and pedal reflex throughout the procedure. 
Lacrilube (Allergan, UK) was applied to the eyes and the cranial area was swabbed with 1:10 v/v 
iodine and sterile water. A 1cm longitudinal incision was made on the dorsal cranial surface and the 
periosteum was cleared to expose the cranium. Bregma and the sagittal suture (Figure 2.2) were 
identified to guide calculation of the required stereotaxic co-ordinates determined from ink injection 
studies (3.2mm caudal from bregma and 0.5mm lateral from bregma). A unilateral hole with a 
diameter of 0.7mm was drilled in to the right the cranial surface using a stereotaxically mounted 
electric drill above the right PBP. Four 0.05mm indentations were made in the cranial surface using a 
scalpel, one rostral of bregma, two right and left of bregma and one caudal of bregma. Four stainless 
steel screws were partially inserted into the indented cranial surface with a 0.1mm dorsal projection. 
A stainless steel 28 gauge cannula projecting 4.8mm ventrally was positioned over the drilled hole 
using a stereotaxically mounted clamp and inserted to the required depth. The cannula remained in 
situ as dental cement was applied to the cranial surface and projecting screws to secure the cannula 
in place. Ten minutes were allowed for the cement to dry before removal of the clamp and insertion 
of a 4.8mm stainless steel dummy cannula. Mice were placed in a warming chamber to recover post-
surgery at 32°C, and buprenorphine was administered SC upon visible improvement of breathing 
rate. 0.2ml of warmed 0.9% sodium chloride solution was administered IP to counteract 
dehydration. Mice were housed individually and given access to liquid RM1 diet for 24 hours post-
surgery.   
 
2.2.6 Feeding study acclimatisation and intra-VTA injection 
 
Rats and mice were allowed 7 days to recover post-cannulation surgery and were handled and 
restrained daily for 5 minutes to become acclimatised to the injection procedure. Each rodent 
received three sham injection procedures prior to feeding studies whereby an unloaded injector 
attached to an electrical infusion pump was inserted into the indwelling cannula and switched on for 
acclimatisation to the noise and vibrations produced by the pump.   
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For rats, the injector was attached to an electrical infusion pump (Model A55-1111, Harvard 
Apparatus, USA) and was calibrated to deliver a flow rate of 120µl/hr via the injector. The infusion 
pump used a closed water system via a polythene tube (Plastics One, USA) and a 10µl Hamilton 
syringe (Fisher Scientific, UK), which was separated from the injectable treatment by an air bubble. 
Peptides or saline vehicle were delivered to conscious partially restrained rats in a volume of 1µl via 
a 28 gauge stainless steel injector projecting 1mm ventrally via the indwelling 24 gauge cannula. The 
injector was left in situ for a further 30 seconds post-administration to minimise backflow before 
removal, and replacement of the dummy cannula.  
 
For mice, the injector was attached to an electrical infusion pump (Model A55-1111, Harvard 
Apparatus, USA) and was calibrated to deliver a flow rate of 12µl/hr via the injector. Peptides or 
saline vehicle were delivered to conscious fully restrained mice in a volume of 0.5µl via a 32 gauge 
stainless steel injector projecting 1mm ventrally via the indwelling 28 gauge cannula.  
 
Experimental treatment groups were injected by a designated individual to minimise variation in 
procedure and to avoid cross-contamination of treatments. A minimum of 72 hours was allowed for 
a washout period between feeding studies for both rats and mice. Outliers were classed as animals 
whose total food intake between the 0–1 hour or 0–24 hour interval was higher or lower than two 
standard deviations away from the total mean food intake for that treatment group. Outliers were 
subsequently excluded from further analysis within each study.  
 
2.2.7 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted rats in the early dark phase 
 
As described in section 2.1.5, the acute anorectic effect of intra-VTA administration of NDP-MSH in 
fasted rats has been previously established. Intra-VTA administration of NDP-MSH in fasted rats did 
not significantly decrease food intake. The anorectic response to intra-VTA NDP-MSH in fasted rats 
has previously been observed at the onset of the early light phase. Thus, in order to assess the effect 
of diurnal variation on VTA melanocortin signalling, rats were fasted during the light phase and the 
feeding response to intra-VTA melanocortins was observed at the onset of the dark phase. In 
previous feeding studies, 0.03nmol NDP-MSH was established as the lowest effective dose which 
elicited a reduction in food intake when administered at the onset of the dark phase in ad libitum 
fed rats, and thus a dose of 0.03nmol NDP-MSH was used in this study.  
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Rats were randomised into treatment groups by body weight, fasted during the light phase (09:00 – 
19:00) and intra-VTA injected with vehicle control saline or 0.03nmol NDP-MSH (n=9-11) at the onset 
of the early dark phase (19:00 – 20:00). Rats were immediately returned to their cages following 
intra-VTA administration with access to a pre-weighed amount of RM1 diet and access to water. 
Food weight was measured at 1, 2, 4, 8 and 24 hours post intra-VTA administration, and body weight 
was measured at 24 hours post intra-VTA administration.  
 
2.2.8 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed rats in the early light phase 
 
As discussed in section 2.1.5, the acute anorectic effect of intra-VTA administration of NDP-MSH in 
ad libitum fed rats has been previously established, in ad libitum fed rats injected at the onset of the 
early dark phase. However, in previous studies, intra-VTA administration of NDP-MSH did not reduce 
food intake as potently in overnight fasted rats injected in the early light phase. To assess whether 
the changes in the rats’ responsiveness reflected their nutritional state or the diurnal phase, rats 
were allowed free access to food during the dark phase and the feeding response to intra-VTA 
melanocortins was observed at the onset of the light phase.  
 
Rats fed ad libitum during the dark phase (19:00 – 09:00) were randomised into treatment groups by 
body weight and received an intra-VTA injection of saline or 0.03nmol NDP-MSH (a dose previously 
shown to reduce food intake in ad libitum fed rats in the early dark phase, but not in fasted rats in 
the early light phase) (n=9-11) at the onset of the early light phase (9:00 – 10:00). Rats were 
immediately returned to their cages following injection with access to a pre-weighed amount of RM1 
diet and access to water. Food weight was measured at 1, 2, 4, 8 and 24 hours post intra-VTA 
administration and body weight was measured at 24 hours post intra-VTA administration.  
 
2.2.9 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in fasted 
rats in the early light phase 
 
To investigate whether the anorectic effects of melanocortins on food intake via the VTA in ad 
libitum fed rats were mediated via MC4R, I examined the effects of intra-VTA administration of a 
selective MC4R agonist. Previous central administration of THIQ demonstrated efficacy at rodent 
MC4R with a half maximal effective concentration (EC50) of 0.3nmol (Van der Ploeg, Martin et al. 
2002), and thus 0.3nmol THIQ was selected for administration in this study. 
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Rats fasted during the dark phase (19:00 – 9:00) were randomised into treatment groups by body 
weight and received an intra-VTA injection of saline or 0.3nmol THIQ (n=9-11) at the onset of the 
early light phase (9:00 – 10:00). Rats were immediately returned to their cages following intra-VTA 
administration with access to a pre-weighed amount of RM1 diet and access to water. Food weight 
was measured at 1, 2, 4, 8 and 24 hours post intra-VTA administration and body weight was 
measured at 24 hours post intra-VTA administration.  
 
2.2.10 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in ad 
libitum fed rats in the early dark phase 
 
To determine whether the anorectic effects of THIQ were dependent on nutritional state, rats fed ad 
libitum during the light phase (9:00 – 19:00) were randomised into treatment groups by body weight 
and received intra-VTA administration of saline or 0.3nmol THIQ (n=9-11) at the onset of the early 
dark phase (19:00 – 20:00). Rats were immediately returned to their cages following intra-VTA 
administration with access to a pre-weighed amount of RM1 diet and access to water. Food weight 
was measured at 1, 2, 4, 8 and 24 hours post intra-VTA administration and body weight was 
measured at 24 hours post intra-VTA administration.  
 
2.2.11 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed mice in the early dark phase  
 
The effect of intra-VTA administration of NDP-MSH on food intake was initially characterised in 
fasted and ad libitum fed rats. To determine the relevance of these findings in mice, I investigated 
whether they too showed differential feeding responses to intra-VTA melanocortins dependent on 
nutritional state.  
 
Mice fasted during the light phase (9:00 – 19:00) were randomised into treatment groups by body 
weight and received an intra-VTA injection of saline or 0.02nmol NDP-MSH (n=6) at the onset of the 
early dark phase (19:00 – 20:00). Mice were immediately returned to their cages following injection 
with access to a pre-weighed amount of RM1 diet and access to water. Food weight was measured 
at 1, 2, 4, 8 and 24 hours post intra-VTA administration and body weight was measured at 24 hours 
post intra-VTA administration.  
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2.2.12 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted mice in the early light phase  
 
To determine whether the anorectic effects of an MC4R agonist in mice were dependent on 
nutritional state, mice fasted during the dark phase (19:00 – 9:00) were randomised into treatment 
groups by body weight and received an intra-VTA injection of 0.02nmol NDP-MSH or saline (n=6) at 
the onset of the early light phase (9:00 – 10:00). Mice were immediately returned to their cages 
following injection with access to a pre-weighed amount of RM1 diet and access to water. Food 
weight was measured at 1, 2, 4, 8 and 24 hours post intra-VTA administration and body weight was 
measured at 24 hours post intra-VTA administration.  
 
2.2.13 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on behaviour 
in ad libitum fed mice in the early dark phase  
 
To determine if the feeding effects of intra-VTA NDP-MSH in mice were secondary to alterations in 
behaviour, acute behaviour was monitored following intra-VTA NDP-MSH administration using an 
adapted observational protocol (Rogers, Fisher et al. 1997, Scott, Kimura et al. 2005, McGavigan, 
O'Hara et al. 2015).  
 
Mice fed ad libitum during the light phase (9:00 – 19:00) were randomised into treatment groups by 
body weight and received an intra-VTA injection of saline or 0.02nmol NDP-MSH (n=6) at the onset 
of the early dark phase (19:00 – 20:00). Mice were immediately returned to their cages following 
intra-VTA administration with access to RM1 diet and water. Behaviour was monitored for 1 hour in 
5 minute intervals by two observers blinded to the treatment groups. The beginning of each 5 
minute interval was divided into three five second intervals and the behaviour of the mouse was 
observed on each 5 second interval. Mouse behaviour was categorised as feeding, drinking, 
locomotion, rearing, climbing, stationary, sleeping, bed-making, burrowing and grooming (Table 2.1).  
 
2.2.14 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
seeking behaviour in ad libitum fed mice in the early dark phase  
 
To determine the specific effect of intra-VTA NDP-MSH on feeding behaviour in mice, breakpoint to 
commence seeking and total duration spent seeking a palatable foodstuff was observed after intra- 
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Table 2.1 Definition of rodent behaviour in the home cage environment observed following intra-
VTA NDP-MSH administration. Adapted from McGavigan et al 2015. (McGavigan, O’Hara et al. 
2015).  
 
 
 
 
 
 
 
 
 
 
Behaviour Definition 
Feeding 
Feeding from food hopper or feeding from food 
held in paws 
Drinking Licking at water spout 
Locomotion Moving around the cage with all four legs moving 
Rearing 
Front paws raised off the ground and rear paws 
touching the ground 
Climbing 
Front paws raised against side of the cage, cage 
furniture or suspended from cage lid 
Stationary No paws moving 
Sleeping Visibly asleep 
Bed-making Moving bedding with paws 
Burrowing Scratching flooring material with paws 
Grooming Scratching, biting or licking itself 
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VTA administration of NDP-MSH using an adapted observational protocol (Egecioglu, Jerlhag et al. 
2010).  
 
Mice were acclimatised to an open field chamber three times for 10 minutes in the week preceding 
the food seeking behavioural experiment. Mice were also acclimatised to an open 1ml eppendorf 
tube filled with peanut butter (Skippy Smooth Peanut Butter, Hormel Foods, USA) three times for 1 
hour preceding the week in which the food seeking behavioural experiment commenced.  
 
Mice fed ad libitum during the light phase (9:00 – 19:00) were randomised into treatment groups by 
body weight and received an intra-VTA injection of saline or 0.02nmol NDP-MSH (n=6) at the onset 
of the early dark phase (19:00 – 20:00). Immediately after intra-VTA NDP-MSH administration, mice 
were consistently placed in the same quadrant of the open field chamber and the peanut butter 
filled eppendorf consistently placed in an opposite quadrant at time zero. Breakpoint to initiate food 
seeking behaviour was defined as the time at which sniffing, licking or touching the eppendorf with 
the front paws commenced. Total time spent food seeking was defined as the total time recorded 
sniffing, licking or touching the eppendorf with the front paws in the 10 minutes following injection. 
Mice were returned to their cages following completion of the behavioural observation.  
 
2.2.15 Statistics 
 
 All food intake data is presented as mean ± standard error of the mean (SEM). General behavioural 
and food seeking behavioural observational data is presented as the median, inter-quartile and total 
range. Food intake data was analysed using an unpaired t-test (GraphPad Prism Version 5.01, 
GraphPad Software, CA, USA). General behavioural and food seeking behavioural observational data 
was analysed using a Mann-Whitney U test, or, if repeated values were observed, data was analysed 
using a Wilcoxon signed rank test (GraphPad Prism Version 5.01, GraphPad Software, CA, USA). In all 
data analyses P values were defined as the following: p<0.05, *, p<0.01, **, p<0.001, ***.  
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2.3 Results  
 
 
2.3.1 Verification of accurate intra-VTA ink injection for cannula placement in rats 
 
The accuracy of co-ordinates targeting the parabrachial pigmented nucleus (PBP) of the VTA was 
confirmed using intra-nuclear ink injection in rats. Ink staining was observed unilaterally in the right 
PBP in 100% of rats (n=2) with limited spread to surrounding brain areas. Ink staining was not 
observed in the Arc or ventricular system in 100% of rats (n=2). A representative bright field 
microphotograph is presented in Figure 2.3A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Verification of co-ordinates used for injection into the parabrachial pigmented nucleus 
(PBP) of the ventral tegmental area (VTA) in rats. Abbreviations: Arc, arcuate nucleus of the 
hypothalamus; PBP, parabrachial pigmented nucleus. Rats received a unilateral injection of 1µl 1:40 
v/v Indian ink in 0.01M PBS into the right PBP. PBP co-ordinates were located at 6mm caudal from 
bregma, 0.5mm lateral from bregma and 8.5mm ventral from the surface of the brain. Brain tissue 
was counterstained with Cresyl violet solution. A) Rat brain section located at 6mm caudal to 
bregma. B) Representative brain map located at 6mm caudal to bregma adapted from ‘The Rat Brain 
in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). C) Rat brain section located at 1.8mm 
caudal to bregma. D) Representative brain map located at 1.8mm caudal to bregma adapted from 
‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). Scale bar represents 
0.25mm.  
 
A B 
C D 
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2.3.2 Verification of accurate intra-VTA ink injection for cannula placement in mice 
 
The accuracy of co-ordinates targeting the PBP of the VTA was investigated using intra-nuclear ink 
injection in mice. Three sets of co-ordinates were attempted to locate the VTA as shown in Table 
2.2. 
 
Ink staining was observed in the right PBP of mice injected using co-ordinate sets 1 and 2 with 
moderate spread to surrounding brain areas. Ink staining was observed unilaterally in the right PBP 
in mice injected using co-ordinate set 3 (n=2) with limited spread to surrounding brain areas. Ink 
staining was not observed in the Arc or ventricular system of any mice injected (n=4). A 
representative bright field microphotograph is presented in Figure 2.4A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.4 Verification of accurate ink injection targeting the parabrachial pigmented nucleus (PBP) 
of the ventral tegmental area (VTA) in mice. Abbreviations: 3V, third ventricle; Aq, aqueduct;  Arc, 
arcuate nucleus of the hypothalamus; PBP, parabrachial pigmented nucleus of the ventral tegmental 
area. Mice received a unilateral injection of 0.5µl 1:40 v/v Indian ink in 0.01M PBS into the right PBP. 
PBP co-ordinates were located at 3.2mm caudal from bregma, 0.5mm lateral from bregma and 
4.8mm ventral from the surface of the brain. Brain tissue was counterstained with Cresyl violet 
solution. A) Mouse brain section located at 3.16mm caudal to bregma. B) Representative brain map 
located at 3.16mm caudal to bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ 
(Franklin and Paxinos 2007). C) Mouse brain section located at 2.18mm caudal to bregma. D) 
Representative brain map located at 2.18mm caudal to bregma adapted from ‘The Mouse Brain in 
Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.5mm. 
A B 
C D 
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Table 2.2 Co-ordinate sets tested for targeting the parabrachial pigmented nucleus (PBP) of the 
ventral tegmental area (VTA) in mice. Experimentally attempted co-ordinates detailing caudal-
rostral, lateral and dorso-ventral measurements in mm from bregma in C57BL/6J mice targeting the 
PBP of the VTA. The optimal co-ordinate set accurately targeting the PBP was 3.2mm caudal from 
bregma, 0.5mm lateral from bregma and 4.8mm ventral from the surface of the brain (n=4 in total).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attempted co-ordinates 
(bregma origin) 
Co-ordinate set 1 (mm) 
n=1 
Co-ordinate set 2 (mm) 
n=1 
Co-ordinate set 3 (mm) 
n=2 
Caudal-rostral -3.3 -3.2 -3.2 
Lateral ±0.5 ±0.5 ±0.5 
Dorso-ventral 4.0 4.5 4.8 
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2.3.3 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted rats in the early dark phase 
 
Intra-VTA administration of 0.03nmol NDP-MSH to fasted rats at the onset of the early dark phase 
significantly reduced food intake in the 0-1 hour time interval compared to saline control (saline: 
4.17 ± 0.23 vs. 0.03nmol NDP-MSH: 2.72 ± 0.34 p<0.01). Intra-VTA administration of 0.03nmol NDP-
MSH also significantly reduced food intake in the 1-2 hour time interval compared to saline control 
(saline: 3.10 ± 0.25 vs. 0.03nmol NDP-MSH: 1.62 ± 0.32 p<0.01) (Figure 2.5).  
 
There were no other significant differences in food intake between groups at any other time point at 
which it was measured.   
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Figure 2.5 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted rats in the early dark phase. Adult male Wistar rats fasted from 09:00 received an 
intra-VTA injection of saline or 0.03nmol NDP-MSH at the onset of the early dark phase. Food intake 
is expressed as mean grams of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 hours 
post administration. (n=9-11) **p<0.01 vs. saline.  
 
A B 
C D 
E F 
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2.3.4 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed rats in the early light phase 
 
Intra-VTA administration of 0.03nmol NDP-MSH to ad libitum fed rats at the onset of the early light 
phase significantly reduced food intake in the 0-1 hour time interval compared to intra-VTA 
administration of saline (saline: 1.06 ± 0.23 vs. 0.03nmol NDP-MSH: 0.39 ± 0.12 p<0.01) (Figure 2.6).   
 
There were no other significant differences in food intake between groups at any other time point at 
which it was measured.   
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Figure 2.6 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed rats in the early light phase. Adult male Wistar rats received an intra-VTA 
injection of saline or 0.03nmol NDP-MSH at the onset of the early light phase. Food intake is 
expressed as mean grams of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 hours 
post administration. (n=9-11) *p<0.05 vs. saline.  
A B 
C D 
E F 
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2.3.5 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in ad 
libitum fed rats in the early dark phase 
 
Intra-VTA administration of 0.3nmol THIQ to ad libitum fed rats at the onset of the early dark phase 
significantly reduced food intake in the 0-1 hour time interval compared to intra-VTA administration 
of saline (saline: 3.33 ± 0.22 vs. 0.03nmol NDP-MSH: 2.26 ± 0.40 p<0.05) (Figure 2.7).  
 
There were no other significant differences in food intake between groups at any other time point at 
which it was measured. 
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Figure 2.7 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in ad 
libitum fed rats in the early dark phase. Adult male Wistar rats received an intra-VTA injection of 
saline or 0.3nmol THIQ at the onset of the early dark phase. Food intake is expressed as mean grams 
of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 hours post administration. (n=9-11). 
*p<0.05 vs. saline. 
A B 
E F 
C D 
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2.3.6 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in fasted 
rats in the early light phase 
 
Intra-VTA administration of 0.3nmol THIQ to fasted rats at the onset of the early light phase did not 
result in any significant difference in food intake between groups at any time point at which it was 
measured (Figure 2.8).   
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Figure 2.8 The effect of intra-VTA administration of the MC4R agonist THIQ on food intake in 
fasted rats in the early light phase. Adult male Wistar rats fasted from 19:00 received an intra-VTA 
injection of saline or 0.3nmol THIQ at the onset of the early light phase. Food intake is expressed as 
mean grams of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 hours post 
administration. (n=9-11). 
A B 
C D 
E F 
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2.3.7 The effect of intra- VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted mice in the early light phase 
 
Intra-VTA administration of 0.02nmol NDP-MSH to fasted mice at the onset of the early light phase 
did not result in any significant difference in food intake between groups at any time point at which 
it was measured (Figure 2.9).   
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Figure 2.9 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in fasted mice in the early light phase. Adult male C57BL/6J mice fasted from 19:00 received 
an intra-VTA injectionion of saline or 0.02nmol NDP-MSH at the onset of the early light phase. Food 
intake is expressed as mean grams of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 
hours post administration. (n=6).  
A B 
C D 
E F 
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2.3.8 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed mice in the early dark phase 
 
Intra-VTA administration of 0.02nmol NDP-MSH to ad libitum fed mice at the onset of the early dark 
phase significantly reduced food intake in the 0-1 hour time interval compared to intra-VTA 
administration of saline (saline: 0.79 ± 0.33 vs. 0.02nmol NDP-MSH: 0.04 ± 0.01 p<0.05). Intra-VTA 
administration of 0.02nmol NDP-MSH also significantly reduced food intake in the 2-4 hour time 
interval (saline: 0.89 ± 0.04 vs. 0.02nmol NDP-MSH: 0.74 ± 0.02 p<0.05) and the 0-24 hour time 
interval (saline: 5.69 ± 0.40 vs. 0.02nmol NDP-MSH: 4.30 ± 0.18 p<0.05) compared to intra-VTA 
administration of saline (Figure 2.10).  
 
There were no other significant differences in food intake between groups at any other time point at 
which it was measured.   
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Figure 2.10 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
intake in ad libitum fed mice in the early dark phase. Adult male C57BL/6J mice received an intra-
VTA injection of saline or 0.02nmol NDP-MSH at the onset of the early light phase. Food intake is 
expressed as mean grams of RM1 chow ± SEM at A) 0-1, B) 1-2, C) 2-4, D) 8-24 and F) 0-24 hours 
post administration. (n=6). *p<0.05 vs. saline.  
A B 
C 
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2.3.9 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH  on behaviour 
in ad libitum fed mice in the early dark phase 
 
Intra-VTA administration of 0.02nmol NDP-MSH to ad libitum fed mice at the onset of the early dark 
phase did not result in any significant difference in general behaviour between groups during the 0-1 
hour time interval post-administration (Figure 2.11).  
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Figure 2.11 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on 
behaviour in ad libitum fed mice in the early dark phase. Abbreviations: ns, non significant. Adult 
male C57BL/6J mice received an intra-VTA injection of saline or 0.02nmol NDP-MSH at the onset of 
the early dark phase. Behaviour is expressed as the median and interquartile range of the number of 
behavioural observations between 0-1 hour post administration. (n=6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
2.3.10 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on food 
seeking behaviour in ad libitum fed mice in the early dark phase 
 
Intra-VTA administration of 0.02nmol NDP-MSH to ad libitum fed mice at the onset of the early dark 
phase significantly reduced food seeking duration in the 0-10 minute time interval post-
administration compared to intra-VTA administration of saline (saline: 170.5 (47.0-280.0) vs. 
0.02nmol NDP-MSH: 58.0 (14.0-111.0) p<0.05). Intra-VTA administration of 0.02nmol NDP-MSH to 
ad libitum fed mice at the onset of the early dark phase did not result in any significant difference in 
food seeking breakpoint between groups during the 0-10 minute time interval post-administration 
compared to intra-VTA administration of saline (Figure 2.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH  on food 
seeking behaviour in ad libitum fed mice in the early dark phase. Adult male C57BL/6J mice 
received an intra-VTA injection of saline or 0.02nmol NDP-MSH at the onset of the early dark phase. 
A) Food seeking duration and B) food seeking breakpoint is expressed as the median and 
interquartile range of the number of seconds observed between 0-10 minutes post administration. 
(n=6). *p<0.05 vs. saline, ns - *p=0.44. 
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2.4 Discussion  
 
 
The VTA has been characterised as a signalling target for many factors that influence feeding, 
including both neuropeptides and classical gut hormones. Effects on reward related behaviour may 
be observed after direct administration of these feeding peptides into the VTA and other related 
mesocorticolimbic areas (Davis, Choi et al. 2010, Pandit, la Fleur et al. 2013, Revitsky and Klein 
2013). It is likely that these profound effects on food seeking behaviour are mediated via the VTA 
and other downstream brain areas within the mesocorticolimbic system. The VTA also projects to 
the hypothalamus, which may reflect another possible pathway mediating these effects (Phillipson 
1979, Geisler and Zahm 2005).  
 
The initial observations describing the effects of intra-VTA melanocortin administration on food 
intake in rodents, both from our department (see Figure 2.1) and recently published by other groups 
(Lerma-Cabrera, Carvajal et al. 2012, Roseberry 2013, Yen and Roseberry 2014), have suggested a 
role for melanocortins in reward signalling via the VTA. Intra-VTA melanocortin administration has 
been shown to reduce acute food intake in ad libitum fed, but not fasted rats, suggesting a 
differential sensitivity to melanocortin signalling in these animals. Physiologically, it makes sense 
that animals should be sensitised to the anorectic effects of melanocortins when fed, and 
desensitised to the anorectic effects when fasted. If animals were sensitive to a reduction in food 
intake during a state of physiological fasting, this could promote a negative energy balance and may 
result in starvation at a detriment to the animal. These findings show that intra-VTA melanocortin 
administration may be effective in reducing food intake under conditions when it is unfavourable to 
eat, such as in a fed state. Over consumption of food leads to a positive energy balance whereby 
ingested calories exceed expended calories. This may eventually be stored as excess adipose tissue, 
resulting in the development of obesity. It appears that melanocortin signalling via the VTA acts to 
restore energy homeostasis by exerting an inhibitory tone over energy intake in periods of 
nutritional excess. This proves that the VTA of the mesocorticolimbic system is involved in anorectic 
melanocortin signalling in the control of food intake and is sensitive to current nutritional status.  
 
Awareness of baseline hunger state before conducting a feeding study is vital. The time of day 
chosen to observe food intake may change depending on whether an anorectic or orexigenic effect 
is expected. Previous investigations in ad libitum fed rats have been carried out at the onset of the 
dark phase, as rats will consume the majority of their daily food intake at the beginning of the dark 
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phase, and thus observing food intake at this time point is physiologically relevant. Rats are 
therefore most sensitive to anorectic signals at this period of the day. In these experiments, rats 
were provided with free access to food during the light phase preceding the experiment to fulfil a 
required fed state. When investigating food intake responses in fasted rats, rats were fasted during 
the dark phase which is usually the period of the day where they would usually be most active and 
aroused. Food intake was then observed at the onset of the light phase. This ensured that the rats 
were significantly fasted and thus more sensitive to orexigenic signals at this period of the day. 
However, feeding at different times of the day may be subject to diurnal variation beyond that of 
nutritional state. Diurnal variation exists to regulate various daily physiological processes in order to 
preserve homeostasis. Hypothalamic signalling is often under circadian control and hormone release 
fluctuates in a diurnal pattern. In order to investigate the effect of diurnal variation on the feeding 
effects of intra-VTA melanocortin signalling, rats were fasted during the light phase and acute food 
intake was measured at the onset of the dark phase; and rats were ad libitum fed during the dark 
phase and acute food intake was measured at the onset of the light phase. This provided a baseline 
whereby rats were subject to the same nutritional restrictions as the previous feeding studies but 
during a different diurnal phase, allowing for the assessment of the effects of diurnal variation on 
the feeding effects of intra-VTA melanocortin signalling.  
 
Intra-VTA administration of NDP-MSH to fasted rats at the onset of the dark phase resulted in a 50% 
reduction in food intake compared to saline injected controls during both the 0 – 1 hour and 1 – 2 
hour time intervals. Previous intra-VTA administration of NDP-MSH to fasted rats at the onset of the 
light phase did not affect food intake (Figure 2.1). This may reflect the arousal state of the animal, as 
rats are typically relatively inactive and consume a smaller proportion of their daily food intake 
during the light phase. Thus I hypothesised that rats may be may be more sensitive to the anorectic 
effects of intra-VTA melanocortin administration if ad libitum fed before administration in the early 
light phase. Additionally, rats will consume the majority of their food intake at the onset of the dark 
phase, increasing the likelihood that any anorectic effect on food intake will likely be detected 
during this acute time period. 
 
Intra-VTA administration of NDP-MSH to ad libitum fed rats at the onset of the light phase 
significantly reduced food intake during the 0 – 1 hour time interval. Previous intra-VTA 
administration of NDP-MSH to ad libitum fed rats at the onset of the dark phase also significantly 
reduced acute food intake (Figure 2.1). This suggests that satiated rats remain sensitive to intra-VTA 
melanocortin signalling irrespective of whether the study is conducted in the early light or dark 
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phase. For these ad libitum fed rats, food intake monitored during the 0 – 1 hour time point at the 
onset of the light phase was 50% less than the food intake monitored at the same time interval at 
the onset of the dark phase (Figure 2.1). This likely reflects the preference for rats to feed at the 
onset of the dark phase, despite both cohorts being satiated. However, it may also reflect a 
reduction in general activity during the light phase, when rats are less likely to demonstrate feeding 
behaviour.  
 
Together, these observations demonstrate the effect of diurnal signalling on melanocortin driven 
food intake via the VTA. In satiated rats, the nutritional status of the animal appears to override any 
change in feeding behaviour which would usually be governed by the diurnal phase. However, in 
fasted rats, food intake appears to be driven primarily by the diurnal phase and thus the arousal 
state of the animal. This is likely due to a diurnal variation in the sensitivity of VTA neurons and may   
reflect a change in dopaminergic neuronal firing rates. It is highly likely that melanocortins affect 
dopaminergic neuronal signalling within the VTA, as feeding is a reward driven behaviour requiring 
dopaminergic signalling to occur (Ungerstedt 1971, Trojniar and Staszewska 1994). Feeding effects 
via the VTA could be elicited either by direct activation of melanocortin receptors on dopaminergic 
neurons, or via melanocortin receptor activation on GABAergic or glutamatergic neurons which 
regulate dopaminergic neuronal firing. Dopaminergic neurons in rodents exhibit diurnal variation in 
their neuronal firing rates, becoming more sensitive to D2 receptor activation in the dark phase 
(Dominguez-Lopez, Howell et al. 2014). It is possible that differences in the firing rates of 
dopaminergic neurons in the light and dark phases may be partially responsible for the observed 
differences in food intake post intra-VTA melanocortin administration. In conclusion, these findings 
suggest that both diurnal phase and nutritional state are important in determining the effects of 
melanocortins in the VTA on food intake.  
 
Intra-VTA administration of THIQ, an MC4R specific agonist, in ad libitum fed rats significantly 
reduced food intake in the 0 – 1 hour time interval. This suggests that the anorectic effects of 
melanocortins in the VTA are mediated through MC4R. Despite the ambiguity regarding localisation 
of MC4R mRNA and protein in the VTA, this provides pharmacological evidence of an MC4R sensitive 
neuronal circuit which is able to reduce food intake in satiated rats via the VTA. The role of MC4R in 
reducing food intake via the hypothalamus is well characterised (Huszar, Lynch et al. 1997, Giraudo, 
Billington et al. 1998, Chen, Metzger et al. 2000, Balthasar, Dalgaard et al. 2005, Aponte, Atasoy et 
al. 2011), and these observations suggest that the anorectic effects of MC4R activation may also be 
mediated via the mesocorticolimbic system. This is corroborated by other findings which 
114 
 
demonstrate an intra-VTA MC4R specific agonist reduces food intake in ad libitum fed rats and an 
intra-VTA administration of an MC4R specific antagonist increases food intake (Lerma-Cabrera, 
Carvajal et al. 2012). However, the reduction in acute 0 – 1 hour food intake was as not as marked as 
with intra-VTA administration of NDP-MSH, a non-specific MC3R/MC4R agonist (Figure 2.1). This 
likely reflects the difference in potency between THIQ and NDP-MSH, or may represent an additive 
effect of MC3R signalling via the VTA. MC3R expression levels are high in the VTA (Roselli-Rehfuss, 
Mountjoy et al. 1993), but activation of MC3R is unlikely to affect food intake as MC3R KO mice are 
hypophagic (Chen, Marsh et al. 2000, Lippert, Ellacott et al. 2014), suggesting MC3R does not signal 
anorectically to reduce food intake. Thus, it is likely that the VTA signals via MC4R to reduce food 
intake in satiated rats.  
 
It was deemed important to establish the effect of intra-VTA melanocortin administration in mice to 
determine if the effects on food intake were species specific and thus only observable in rats. Intra-
VTA administration of NDP-MSH significantly reduced food intake in ad libitum fed but not fasted 
mice in the 0 – 1 hour time interval, reflecting the feeding effects observed in rats after intra-VTA 
melanocortin administration. Food intake was also reduced between the 2 – 4 hour and 0 – 24 hour 
time intervals suggesting a prolonged anorectic effect of intra-VTA melanocortin signalling, which 
was not observed in rats. The reduction in 0 – 1 hour time interval food intake in mice was also more 
profound than the reduction observed in rats, perhaps reflecting that the dose of NDP-MSH was not 
equivalent between the studies. It may also suggest an increased sensitivity of mice to the anorectic 
effect of melanocortin signalling in the VTA. It must also be considered that although rats require 
little restraint during intra-nuclear injection, mice require full restraint for the entirety of the 
procedure. This will inevitably result in an increased stress response in mice, perhaps altering VTA 
sensitivity. It has been established that MC4R signals within the amygdala in mediating the neuronal 
response to restraint-induced stress (Liu, Garza et al. 2013), and thus that melanocortin signalling 
within the mesocorticolimbic system is sensitive to stressor input, which may significantly affect 
behavioural response.  
 
Intra-VTA administration of α-MSH in rats has been shown to cause immediate grooming behaviour, 
which was attenuated by pre-treatment with the MC3R/MC4R antagonists, HS014 and HS964 (Klusa, 
Svirskis et al. 1998). It was important to establish in mice whether the anorectic effects of NDP-MSH 
via the VTA were secondary to an increased frequency of behaviours not related to feeding. There 
was no significant difference in any behaviour observed during the 0 -1 hour time interval post intra-
VTA administration of either NDP-MSH or saline. These same findings have also been confirmed in 
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rats after intra-VTA NDP-MSH administration, except that increased head down behaviour was 
observed in the NDP-MSH treatment group (K. E. Beale (2011) PhD thesis, Section of Investigative 
Medicine, Imperial College London). The behavioural profile of the mice reflected increased general 
activity in the dark phase, demonstrating expected diurnal variation in general behaviours during the 
dark phase. Higher grooming behaviour than expected was observed within both treatment groups, 
perhaps as a result of the restraint.  
 
NDP-MSH is an α-MSH analogue, which binds non-specifically to MC3R and MC4R. NDP-MSH has 
been described as being between 10 and 26 times more potent than α-MSH and has been shown to 
exhibit prolonged biological activity at both of these receptors (Sawyer, Sanfilippo et al. 1980). 
Although NDP-MSH is a useful pharmacological tool with which to investigate the role of 
melanocortin signalling within the VTA, it must be considered how physiological the effects of intra-
VTA NDP-MSH are when compared to endogenous α-MSH signalling. The increased potency and 
efficacy of NDP-MSH may be maximally activating circuits within the VTA to affect food intake in ad 
libitum fed animals, a response which may not be usually observed in the physiological ad libitum 
fed state. However, these findings demonstrate the presence of a circuit which is sensitive to 
melanocortin intervention and that may be targeted therapeutically to modulate food intake.   
 
It was also important to assess specific components of food-seeking behavioural effects of intra-VTA 
melanocortins. Intra-VTA administration of NDP-MSH significantly reduced food seeking duration in 
ad libitum fed mice by approximately 70%. This supports the previous findings which demonstrate 
that VTA melanocortin signalling reduces acute food intake. This appears to be as a result of reduced 
food seeking, although further investigations on ingested peanut butter meal size by periodically 
weighing the eppendorf would help fully characterise this anorectic effect. It must be considered 
that peanut butter is a highly palatable food stuff when comparing these results to the previous 
experiments which monitor acute chow intake. Peanut butter detection and ingestion cannot be 
considered equal to chow as the value of the reward encountered is encoded differently by the 
mesocorticolimbic system.   
 
These findings may reflect a hierarchical system in the control of food intake between the 
hypothalamus and the mesocorticolimbic system. Administration of melanocortins into the PVN has 
been shown to reduce food intake in both ad libitum fed and fasted rats, suggesting the 
hypothalamus is acutely sensitive to anorectic signals irrelevant of the current nutritional status of 
the animal. The VTA appears to be differentially sensitive to melanocortins according to current 
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nutritional status, perhaps as the result of a post-prandial fulfilment of hedonic requirement. If the 
‘wanting’ aspect of food intake has been fulfilled, the mesocorticolimbic system may signal to switch 
off feeding behaviour. It appears that melanocortin signalling within the mesocorticolimbic system is 
sensitive to hedonic input, but that these inputs are unable to override homeostatic hypothalamic 
signalling pathways which may promote over-feeding. Hypothalamic signalling systems do become 
differentially sensitive to anorectic and orexigenic signals with feeding and fasting, but the effect is 
rarely so profound. The observation that a similar dose of NDP-MSH into the hypothalamus is able to 
reduce food intake in fasted animals but not via the VTA suggests the mesocorticolimbic system is 
also sensitive to the current nutritional status of the animal. These studies also confirm that the 
anorectic effects of melanocortins are not species specific.  
 
Interestingly, intra-VTA administration of α-MSH has been shown to increase ethanol self-
administration in ad libitum fed rats (Shelkar, Kale et al. 2015), which contradicts the previous 
finding that intra-VTA administration of NDP-MSH decreased ethanol intake (Lerma-Cabrera, 
Carvajal et al. 2012). This may highlight specific signalling in sub regions within the VTA, as Shelkar et 
al targeted the posterior VTA rather than specific nuclei, such as the PBP. This may suggest that VTA 
sub regions signal differentially in reward, as demonstrated by their varied architecture and 
neuronal populations. This observation highlights that assessing the volume and diffusion of 
compounds administered to the VTA is important in interpreting the behavioural outcome. The 
initial ink injection studies in these experiments provide proof of accurate targeting of the PBP and 
give an indication of the spread of this volume of liquid in brain tissue.  
 
Further evidence supporting a physiological role for melanocortin signalling in the VTA is provided by 
the expression of prolylcarboxypeptidase (PRCP). PRCP is an enzyme which negatively regulates α-
MSH expression by removing the C-terminal amino acid of α-MSH, rendering it inactive. PRCP is 
expressed in neuronal efferent axon terminals which release α-MSH, and ICV administration of PRCP 
inhibitors has been shown to decrease food intake (Wallingford, Perroud et al. 2009). The expression 
of PRCP is high in the VTA, suggesting it may regulate local melanocortin processing (Jeong and 
Diano 2014). However, PRCP may also influence the processing of other peptides found within the 
VTA. 
 
As an outcome of these initial investigations, it is hoped that further intra-nuclear administration 
studies in mice will allow for observation of acute feeding behaviour in transgenic mouse models, for 
example the MC4R KO mouse model. This would give direct pharmacological evidence for the 
117 
 
presence or absence of functional MC4R receptors in the VTA. The results of intra-VTA THIQ 
administration in rats suggest MC4R is present, but it would be interesting to confirm these findings 
in WT mice in a similar experiment. Investigating the effects of intra-VTA administration of a PRCP 
inhibitor would also support the role of melanocortin signalling in the VTA. In order to further 
characterise the effects of melanocortin signalling on mesocorticolimbic system signalling, it may be 
interesting to cannulate the VTA and a downstream VTA target area, such as the amygdala. This 
would allow for intra-VTA administration of an MC4R agonist after pre-treatment with a 
dopaminergic receptor antagonist downstream. This could provide further information on how 
melanocortin signalling may be interacting with dopaminergic circuits of the mesocorticolimbic 
system. It would also be relevant to reproduce these experiments in both lean and obese rodents, to 
assess the effects of obesity on VTA melanocortin signalling. It is well known that obesity causes long 
term perturbations in both central dopaminergic and melanocortin signalling.  
 
Observing the behavioural effects upon exposure to a palatable versus a non-palatable diet after 
intra-VTA melanocortin administration would also complement the food-seeking studies described 
here. It may be that palatable foods are sufficient to override both homeostatic and hedonistic 
circuits, indicating a switch to non-homeostatic food intake. Therefore, it would be interesting to see 
if melanocortins affect palatability and food choice, or whether they signal anorectically irrelevant of 
these factors. In addition, it would be interesting to repeat the food-seeking behavioural 
experiments with standard chow pellets, which may indicate if melanocortins signal independently 
of the value of the food reward. As discussed previously, it would also be beneficial to monitor meal 
size ingested in individual bouts in the food-seeking protocol in order to fully characterise the effect 
of VTA melanocortin signalling on specific aspects of food intake. 
 
In conclusion, these observations confirm a role for melanocortin signalling via the VTA in the 
control of acute food intake in ad libitum fed rats and mice. Additionally, melanocortin signalling in 
the VTA appears to be mediated via MC4R, and is influenced by both nutritional status and the 
arousal state of the animal. Furthermore, melanocortin signalling in the VTA is sufficient to reduce 
acute food seeking behaviour. Thus, the acute physiological feeding effects of melanocortins via the 
VTA have been described in this chapter. However, the identity of the brain areas involved in this 
feeding response and neuronal circuits responsible downstream of the VTA remain unknown. In 
order to fully characterise the role of melanocortin signalling in the control of energy homeostasis, 
the specific neuronal circuits which mediate these effects must be distinguished. Thus, studies 
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investigating the acute effects of melanocortin signalling via the VTA on neuronal activation in the 
VTA itself and downstream mesocorticolimbic areas are described in Chapter 3.  
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Chapter 3: The effect of melanocortins 
on neuronal activation via the ventral 
tegmental area  
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3.1 Introduction  
 
 
Chapter 2 described experiments investigating the acute feeding and behavioural effects in rodents 
following intra-VTA administration of a MC3R/MC4R receptor agonist. NDP-MSH was able to reduce 
acute food intake in ad libitum fed rats, an effect which appears to be sensitive to both nutritional 
status and diurnal phase. The same anorectic response was also observed in mice following intra-
VTA administration of NDP-MSH. Intra-VTA melanocortin administration was also shown to affect 
food-seeking behaviour in mice. The neuronal basis responsible for these effects remains unknown. 
Investigating the effects of melanocortin administration on neuronal signalling may identify the 
specific brain areas involved in mesocorticolimbic melanocortin signalling in the reduction of food 
intake.  
 
3.1.1 Neuronal activation 
 
The CNS and PNS control biological functions in a precise and regulated manner. The CNS comprises 
the brain and spinal cord which contact the PNS through ganglionic interaction. The PNS comprises 
of all somatic, sympathetic, parasympathetic and enteric innervation of the periphery. The human 
brain contains around 86 billion neurons, each with multiple connections to multiple neurons within 
distinct circuits (Azevedo, Carvalho et al. 2009), and communication between these neuronal circuits 
is vital for the passage of information relating to physiological processes. Neuronal communication 
occurs at synapses, specialised regions where neuronal membranes come in close proximity to one 
another. The presynaptic membrane is commonly axonal, the post-synaptic membrane may be 
dendritic or somatic (Sjöström, Rancz et al. 2008).  
 
Neurotransmitters are compounds used to relay information between the presynaptic and 
postsynaptic membrane and they are usually bound within vesicles in the presynaptic neuron 
(Südhof and Rizo 2011). Similarly, neuropeptides are also compounds used to relay information 
between neurons and are released from presynaptic vesicles. Neurotransmitters are generated by 
local synthesis at the synapse, whereas neuropeptides are usually cleaved from a large precursor 
molecule in the soma of a neuron and transported to the synapse. Neuropeptides and 
neurotransmitters are packaged separately at the synapse and neuropeptides are released most 
commonly from presynaptic dendritic membranes, unlike neurotransmitters which are released 
most commonly from presynaptic axonal membranes (Ludwig and Leng 2006). Neuropeptides are 
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usually present at much lower concentrations in the neuron, at around the 3 to 10mM range, than 
neurotransmitters, which are typically in the 100mM range (Siegel and Agranoff 1999). Furthermore, 
neuropeptides are typically more efficacious than neurotransmitters. Neuropeptides are able to bind 
to their respective GPCRs in nanomolar to micromolar affinities, whereas neurotransmitters bind to 
their respective receptors, which may also be GPCRs, at micromolar to millimolar concentrations.  
 
The release of a presynaptic vesicle is dependent on the generation of an electrical event upstream 
in the neuronal circuit. Neurons are electrically excitable cells and they express membrane voltage 
gated ion channels making them sensitive to electrical input (Llinas 1988). The existence of ion 
channels allows electrically sensitive neuronal cells to fire, or depolarise (Figure 3.1). Depolarisation 
is the result of a positive feedback loop, where the opening of ion channels further increases the 
probability of more ion channels opening. Neuronal hyperpolarisation follows depolarisation, as the 
membrane potential decreases towards resting membrane potential. Action potentials thus 
propagate along the axon of a neuron in one direction only; they are prevented from reactivating 
refractory areas of the neuron which have recently fired by subsequent hyperpolarisation. 
 
As the propagation of action potentials reaches the bouton of the axon, they activate voltage gated 
calcium ion (Ca2+) channels in the membrane. The concentration gradient that exists between the 
interior and exterior of the neuron causes Ca2+ influx into the bouton. Ca2+ is then able to bind to Ca2+ 
responsive elements located on presynaptic vesicles and the presynaptic membrane, enabling 
vesicle fusion with the membrane and exocytosis of neurotransmitter into the synaptic cleft. The 
neurotransmitter diffuses across the synaptic cleft towards the postsynaptic membrane where it 
binds to its respective membrane receptor, inducing a conformational change and activating 
intracellular signalling pathways in the postsynaptic neuron. This results in further generation and 
propagation of action potentials along the postsynaptic neuron, continuing the process of neuronal 
activation. Thus, neurotransmitters are required to convert presynaptic electrical signals into 
chemical signals at the synapse, and then to enable reconversion of this chemical signal into an 
electrical signal in the postsynaptic neuron in order to transmit information.  
 
The frequency and duration of an action potential encodes information regarding the stimulus which 
triggered it. In response, the neuron employs the synapse in both passage and modulation of 
information being transmitted by altering the duration and intensity of neurotransmitter release. A 
further level of complexity is achieved by the categorisation of action potentials into inhibitory and  
excitatory, both altering the excitability of the neuron accordingly. This enables the communication 
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Figure 3.1 Schematic diagram illustrating phases of the action potential. The existence of voltage 
gated ion channels acts to create and maintain a membrane potential. Sodium ions (Na+) and 
potassium ions (K+) are the key ions responsible for setting the resting membrane potential of a 
neuron, usually at around -85 to -60 millivolts (mV). An action potential is an electrical event 
generated at the axon hillock by the influx of Na+ into the neuron. As Na+ enters the neuron (1), the 
potential gradient that exists between the interior and exterior of the neuron increases causing the 
efflux of K+ (2) through K+ channels as the cell begins to depolarise. This increases the membrane 
potential towards the threshold value for action potential generation, approximately -53mV for a 
typical neuron. If the threshold is exceeded, an action potential is generated and the neuron fully 
depolarises. Depolarisation reaches maximum velocity at around 0mV and continues to overshoot 
until it reaches around 40mV. This is followed by the closing of Na+ channels and the opening of K+ 
channels. The neuron begins to hyperpolarise and the membrane potential decreases until it 
surpasses resting membrane potential, at around -90mV. During this after-hyperpolarisation event, 
K+ channels close (3) and the resting membrane potential is restored. Taken from ‘Foundations of 
Physiological Psychology’ (Carlson 1992).  
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of complex signalling patterns such as those exhibited in the formation of memory and behaviour. 
 
3.1.2 Melanocortins and neuronal activation 
 
c-Fos protein is a transcription factor which is expressed in the nucleus early on following neuronal 
activation. It can be used as an indirect marker of neuronal activation, as upregulation of the 
expression of c-Fos mRNA or protein indicates a recent cellular activation event (Dragunow and Faull 
1989). Thus, mapping of c-Fos like immunoreactivity (cFLI) in the brain following a particular 
treatment or regime can be used to identify brain regions of interest.  
 
The effect of melanocortins on neuronal activation has been extensively studied using c-Fos. ICV 
administration of Melanotan II in fasted rats increases cFLI in the PVN, SON, CeA, AP and PBN in a 
dose dependent fashion (Thiele, Van Dijk et al. 1998). Additionally, ICV administration of Melanotan 
II to MC4R KO mice has been shown to increase cFLI in the PVN to that comparable of WT mice, but 
did not increase cFLI in the AP (Rowland, Schaub et al. 2010). Intraventricular administration of 
Melanotan II to MC3R KO mice conversely showed normal cFLI in the AP and reduced cFLI in the 
PVN.  
 
ICV administration of AgRP in rats increases c-Fos expression in the hypothalamus and reward nuclei 
(Hagan, Benoit et al. 2001). ICV administration of AgRP in rats has also been shown to increase c-Fos 
expression in the VTA and to increase dopamine release in the prefrontal cortex, a major efferent 
target for VTA dopamine neurons (Davis, Choi et al. 2011). Ablation of AgRP expressing neurons in 
the midbrain have also been shown to affect dopaminergic neuronal activation (Dietrich, Bober et al. 
2012) suggesting dopamine neurons in the VTA are sensitive to melanocortin input.  
 
It is likely that these findings indicate the activation of MC4R expressing neurons, as MC4R 
expression is high within each of these brain areas. It is important to consider that the pattern of 
neuronal activation may also indicate second order neurons which are activated in response to the 
primary activation of first order neurons which express the receptor of interest. The second order 
neurons may not necessarily express the receptor of interest, in this case MC4R, but they may be 
responsive to a neurotransmitter or neuropeptide released as a result of activation of MC4R on the 
first order neuron.  
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3.1.3 Melanocortins and dopaminergic neurons  
 
There is a growing body of evidence which suggests that melanocortin signalling in the 
mesocorticolimbic system is tightly linked to dopaminergic signalling. MC4R has been shown to co-
express with the dopaminergic receptor D1 in the NAcb and the PVN (Hsu, Taylor et al. 2005, Cui, 
Mason et al. 2012). ICV and intra-VTA administration of α-MSH has been shown to cause an increase 
in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC), a metabolite of dopamine, in the NAcb 
and CPu in rats (Torre and Celis 1986, Lindblom, Opmane et al. 2001). Pre-treatment with the MC4R 
antagonist Ac-Cys-Gly-ᴅ-Nal-Arg-Trp-Cys-NH2 (HS131) is able to block this effect, suggesting a role for 
MC4R in mediating dopaminergic transmission from the VTA to the NAcb. Interestingly, intra-VTA 
administration of β-MSH in rats also increases dopamine and DOPAC levels in the NAcb, however 
intra-VTA administration of γ-MSH decreases dopamine and DOPAC levels in the NAcb (Jansone, 
Bergstrom et al. 2004), suggesting differential signalling of VTA dopamine neurons in response to 
melanocortin activation.  
 
Melanocortins are heavily implicated in synaptic plasticity which is a key physiological process in 
behaviour formation. Synaptic changes are usually brought about by a change in AMPAR dynamics at 
the synapse (Caruso, Lagerstrom et al. 2014). This alters the sensitivity of the neuron in response to 
glutamate signalling, the primary excitatory neurotransmitter in the brain. This in turn can affect 
morphological features, such as dendritic branching, which give rise to long term potentiation (LTP) 
and long term depression which represent the molecular basis of memory and learned behaviours. 
Short-term plasticity may also occur after acute signalling, which is governed by the frequency of the 
action potentials received at the synapse. Melanocortin signalling in the NAcb has been shown to 
underlie the formation of behaviour associated with anhedonia (Lim, Huang et al. 2012). Chronic 
stress in mice was found to inhibit the excitatory output of D1-expressing dopaminergic neurons in 
the NAcb through AMPAR, via the activation of MC4R on those D1-expressing dopaminergic neurons. 
D1 usually signals to upregulate cAMP, and therefore generally signals to stimulate and increase the 
signalling effect of the neuron. Activation of MC4R on these neurons has been shown to inhibit 
dopaminergic signalling through D1, which perhaps explains the anhedonia observed following MC4R 
activation. Interestingly, MC4R activation has been shown to upregulate the expression of AMPAR at 
the synapse in hippocampal cells and increase the number of dendritic spines at the synapse, 
forming the basis of LTP (Shen, Fu et al. 2013). Therefore, it is clear that melanocortins can signal 
within the mesocorticolimbic system to both stimulate and inhibit the activation of particular 
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neurons resulting in both acute and chronic molecular changes which presumably give rise to 
changes in behaviour.  
 
3.1.4 Melanocortins and MC4R expression in the mesocorticolimbic system  
 
As discussed previously, the mesocorticolimbic system is a diffuse collection of brain areas which 
signal to one another in processing reward and affecting behaviour. It is likely that any neuropeptide 
which is hypothesised to affect reward signalling will activate neurons in a number of these distinct 
brain areas.   
 
The VTA represents the nuclei furthest upstream within the mesocorticolimbic system, as it contains 
the cell bodies of the dopaminergic neurons which signal within this system. Thus, it would be 
relevant to investigate neuronal activation within the VTA itself after intra-VTA melanocortin 
administration.  
 
The amygdala is a direct downstream target of the VTA, and an indirect target via the NAcb. MC4R 
expression is high in the amygdala (Gantz, Miwa et al. 1993, Mountjoy, Mortrud et al. 1994, Kishi, 
Aschkenasi et al. 2003, Liu, Kishi et al. 2003). AgRP administration to the central amygdala has been 
shown to increase food intake (Kim, Rossi et al. 2000) whilst Melanotan II caused a decrease in HFD 
intake (Boghossian, Park et al. 2010). Therefore, the amygdala may be a region in which 
melanocortin signalling can influence energy homeostasis, and is a possible downstream target for 
intra-VTA melanocortin signalling.  
 
The septal nuclei form reciprocal connections with many areas of the mesocorticolimbic system 
including the VTA and are responsible for regulating the behavioural response to a particular 
stimulus, specifically in reward paradigms. MC4R is expressed at moderate to high levels in the LS 
(Liu, Kishi et al. 2003, Siljee, Unmehopa et al. 2013), therefore it is likely that melanocortins may also 
activate neurons within the LS.  
 
The NAcb is a major effector target of the VTA and both the shell and core have a well characterised 
role in reward processing and reinforcement. Alpha-MSH protein has been reported to be expressed 
in the NAcb (Jacobowitz and O'Donohue 1978, Eskay, Giraud et al. 1979) and MC4R expression has 
been reported as moderate to high (Mountjoy, Mortrud et al. 1994, Alvaro, Tatro et al. 1996). 
Furthermore, melanocortin signalling within the NAcb has been shown to inhibit the rewarding 
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effects of drugs of abuse such as cocaine and ethanol (Hsu, Taylor et al. 2005, Lim, Huang et al. 2012) 
and ethanol, and of food intake (Lerma-Cabrera, Carvajal et al. 2012).  The NAcb is therefore an 
established target of melanocortin signalling, but it is unknown whether melanocortin signalling 
originating in the VTA is able to affect neuronal activation in the NAcb.  
 
The VP is a mesocorticolimbic area involved in final pathway processing from the nucleus accumbens 
and associated motivational areas to the striatum in order to execute behaviour. MC4R expression is 
moderate within the VP (Liu, Kishi et al. 2003). Blockade of GABAergic signalling within the VP, but 
not the NAcbSh, has been shown to increase food preference for a HFD (Covelo, Patel et al. 2014), 
therefore it is likely that the VP plays a role in mediating food reward. The expression of MC4R in the 
VP suggests that melanocortin signalling may be physiologically relevant in reward processing.  
 
The PFC is one of the final targets for neuronal circuits within the mesocorticolimbic system. The 
control of executive decision-making, which determines behaviour, is governed by signalling within 
this cortical region. The degree and the location of neuronal activation in the PFC is dependent on 
the likelihood that a reward will be encountered, and the size of the reward, as measured by 
fluorodeoxyglucose positron emission tomography (FDG-PET) (Rogers, Owen et al. 1999). FDG-PET 
investigation revealed that exposure to highly palatable foodstuffs selectively activates subdivisions 
of the PFC compared to unrelated or non-palatable foodstuffs (Wang, Volkow et al. 2004). MC4R is 
not expressed in any sub region of the PFC, but activation of VTA circuits via melanocortin signalling 
might result in PFC activation.  
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3.1.5 Hypothesis  
 
I hypothesise that melanocortin signalling within the VTA is able to activate downstream neuronal 
circuits in distinct areas of the mesocorticolimbic system.  
 
3.1.6 Aims 
 
To determine the effects of melanocortin signalling on neuronal activation within the VTA and in 
other areas of the mesocorticolimbic system, and to confirm that any effects observed have 
relevance in both rats and mice, I will investigate:- 
 
- The effect of intra-VTA administration of an MC4R/MC4R specific agonist, NDP-MSH, on cFLI 
in the mesocorticolimbic system of ad libitum fed male Wistar rats.  
- The effect of intra-VTA administration of an MC4R/MC4R specific agonist, NDP-MSH, on cFLI 
in the mesocorticolimbic system of ad libitum fed male C57BL/6J mice.  
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3.2 Methods 
 
 
3.2.1 Materials 
 
[Nle4,ᴅ-Phe7]-α-MSH (NDP-MSH) was purchased from Bachem, Switzerland. Primary polyclonal anti-
c-Fos rabbit antibody was purchased from Merck Millipore, Germany. Secondary biotinylated goat-
anti rabbit antibody was purchased from Vector Laboratories, Cambridgeshire, UK.  
 
3.2.2 Animals  
 
Adult male Wistar rats (220 – 250g) were purchased from Charles River (Kent, UK). Rats were group 
housed pre-surgery in individually ventilated cages under controlled temperatures (21-23°C) and a 
12 hour light/dark cycle with ad libitum access to RM1 (Special Diet Service, Essex, UK) and water. All 
rats post-surgery were singly housed and maintained in individually ventilated cages under the same 
conditions.  
 
Adult male C57BL/6J mice (20 – 25g) were purchased from Harlan (Derby, UK). Mice were housed 
pre-surgery in individually ventilated cages under controlled temperatures  (21-23°C) and a 12 hour 
light/dark cycle with ad libitum access to RM1 (Special Diet Service, Essex, UK) and water. All mice 
post-surgery were singly housed and maintained in individually ventilated cages under the same 
conditions. 
 
All animal procedures undertaken were approved by the British Home Office and carried out under 
the British Home Office Animals (Scientific Procedures) Act 1986 (Project licence 70/7236).  
 
3.2.3 Verification of accurate intra-VTA ink injection for cannula placement in rats and mice 
 
3.2.3.1 Intra-VTA ink injections in rats  
 
The location of intra-VTA cannula placement was optimised by prior intra-nuclear injection of 1µl 
1:40 v/v Indian ink in 0.01M PBS (Appendix 1) into the parabrachial pigmented nucleus (PBP) of the 
VTA as described in section 2.2.3.1. Cresyl violet staining of brain slices was carried out as described 
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in section 2.2.3.3. The location of the injection site was verified using ‘The Rat Brain in Stereotaxic 
co-ordinates’ (Paxinos and Watson 2006).  
 
3.2.3.2 Intra-VTA ink injections in mice 
 
The location of intra-VTA cannula placement was optimised by prior intra-nuclear injection of 0.5µl 
1:40 v/v Indian ink in 0.01M PBS (Appendix 1) into the PBP of the VTA as described in section 2.2.3.2. 
Cresyl violet staining of brain slices was carried out as described in section 2.2.3.3. The location of 
the injection site was verified using ‘The Mouse Brain in Stereotaxic co-ordinates’ (Franklin and 
Paxinos 2007). 
 
3.2.4 Intra-VTA cannulation in rats  
 
An indwelling cannula targeting the PBP of the VTA was implanted using co-ordinates optimised 
from ink injection studies. Co-ordinates targeting the PBP of the VTA were 6mm caudal from 
bregma, 0.5mm lateral of bregma and 8.5mm ventral from the surface of the brain. Intra-VTA 
cannulation surgery was carried out as described in section 2.2.4.  
 
3.2.5 Intra-VTA cannulation in mice  
 
An indwelling cannula targeting the PBP of the VTA was implanted using co-ordinates optimised 
from ink injection studies. Co-ordinates targeting the PBP of the VTA were 3.2mm caudal from 
bregma, 0.5mm lateral of bregma and 4.8mm ventral from the surface of the brain. Intra-VTA 
cannulation surgery was carried out as described in section 2.2.5.  
 
3.2.6 c-Fos study acclimatisation and intra-VTA administration  
 
Rats and mice were acclimatised to the intra-VTA injection procedure and underwent intra-VTA 
administration of substances as outlined in section 2.2.6. Rats were administered 1µl of either saline 
or NDP-MSH at a flow rate of 120µl/hr into the VTA, and mice were administered 0.5µl of either 
either saline or NDP-MSH at a flow rate of 12µl/hr. After injection, all animals were returned to their 
individual home cages with no access to food and free access to water for 90 minutes before 
undergoing transcardial perfusion.  
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To confirm that the c-Fos immunohistochemistry protocol being used was able to detect neuronal 
activation, a rat (n=1) and a mouse (n=1) were injected IP with 9% sodium chloride solution 
(hypertonic saline) to induce robust neuronal activation in the PVN of the hypothalamus. Hypertonic 
saline control animals were acclimatised to handling as outlined in section 2.2.6 and returned to 
their individual home cages with no access to food and free access to water for 90 minutes before 
undergoing transcardial perfusion. Brain sections from hypertonic saline injected animals underwent 
c-Fos immunohistochemistry alongside brain sections from experimental animals as positive controls 
for cFLI.   
 
3.2.7 Transcardial perfusion of rats  
 
Materials 
 
4% formaldehyde solution (Appendix 1) 
1 x PBS (Appendix 1) 
5000IU/ml heparin sodium (Pfizer, UK)  
40% sucrose solution (Appendix 1) 
Ethanol absolute (VWR, UK) 
Isopentane (VWR, UK) 
Anti-freeze (Appendix 1)  
 
Method 
 
Rats were terminally anaesthetised by IP administration of 150mg/kg sodium pentobarbital. 
Immediately after a loss of the pedal reflex was observed, rats were placed in a supine position and a 
horizontal 5cm incision made below the xiphoid process to expose the abdominal cavity. Two 
longitudinal 6cm incisions were made on the left and the right of the thorax perpendicular to the 
horizontal incision to expose the diaphragm. The abdominal aorta was visualised and clamped to 
focus perfusion circulation. An incision was made in the diaphragm to expose the heart and a blunt 
18 gauge needle inserted into the left ventricle at the apex of the heart. One x PBS containing 1:100 
v/v 5000IU/ml heparin sodium cooled to 4°C was flushed through the left ventricle and an incision 
made in the right atria to allow for circulated perfusate to drain. Each rat was perfused for 10 
minutes at a flow rate of 10ml/min before perfusion with 4% formaldehyde solution cooled to 4°C 
for 5 minutes at a flow rate of 10ml/min. Brains were immediately dissected out and stored at 4°C 
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for 24hrs in 4% formaldehyde solution for further fixation followed by 7 days in 40% sucrose solution 
at RTP to dehydrate the tissue.  
 
3.2.8 Transcardial perfusion of mice  
 
Mice were terminally anaesthetised by IP administration of 120mg/kg sodium pentobarbital. 
Immediately after a loss of the pedal reflex was observed, mice were fixed to a cork platform in the 
supine position and a horizontal 2cm incision made below the xiphoid process to expose the 
abdominal cavity. Two longitudinal 3cm incisions were made on the left and the right of the thorax 
perpendicular to the horizontal incision to expose the diaphragm. An incision was made in the 
diaphragm to expose the heart and a blunt 21 gauge needle inserted into the left ventricle at the 
apex of the heart. 1 x PBS containing 1:100 v/v 5000IU/ml heparin sodium cooled to 4°C was flushed 
through the left ventricle and an incision made in the right atria to allow for circulated perfusate to 
drain. Each mouse was perfused for 5 minutes at a flow rate of 10ml/min before perfusion with 4% 
formaldehyde solution cooled to 4°C for 5 minutes at a flow rate of 10ml/min. Brains were 
immediately dissected out and stored at 4°C for 24hrs in 4% formaldehyde solution for further 
fixation followed by 3 days in 40% sucrose solution at RTP to dehydrate the tissue.  
 
3.2.9 Preparation of rat and mouse brain tissue for c-Fos immunohistochemistry 
 
After tissue dehydration, rat and mouse brains were frozen rapidly in isopentane over dry ice and 
sliced to 40µm thickness on a sliding microtome (Model AS200 Shandon, Thermo Fisher Scientific, 
UK) before storage in anti-freeze at 20°C.  
 
3.2.10 c-Fos immunohistochemistry 
 
Materials 
 
1 x PBS (Appendix 1) 
Methanol (VWR, UK) 
30% H2O2 (hydrogen peroxide) (VWR, UK)  
Blocking solution (Appendix 1) 
Tween 20 (VWR, UK) 
Secondary antibody diluent solution (Appendix 1) 
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Vectastain Elite avidin-biotin-complex (ABC) solution (Appendix 1, Vector Laboratories, UK) 
50mg/ml 3,3′-diaminobenzidine (DAB) solution (Appendix 1) 
Ethanol absolute (VWR, UK) 
GDW 
Xylene (VWR, UK) 
DPX mountant (VWR, UK) 
 
Method 
 
Free floating brain sections were washed 3 x 5 minutes in 1 x PBS to remove residual anti-freeze. 
Sections were then placed in methanol consisting of 0.6% v/v hydrogen peroxide to block 
endogenous peroxidase activity for 15 minutes. Sections underwent a further 3 x 5 minute washes in 
1 x PBS before incubation in blocking solution for 2 hours at RTP to minimise non-specific binding.  
Sections were then incubated overnight in a 1:20000 v/v dilution of primary polyclonal anti-c-Fos 
rabbit antibody in blocking solution. The following day, sections were washed in 3 x 5 minutes in 1 x 
PBS containing 0.05% v/v Tween 20 before undergoing incubation in a 1:400 dilution v/v of 
secondary biotinylated goat-anti rabbit antibody in secondary antibody solution for 2 hours. After 1 
hour and 30 minutes of incubation time had elapsed, the avidin-biotin-complex (ABC) solution 
(Appendix 1) was prepared to allow formation of biotinylated horseradish peroxidase 
macromolecular complexes. Following secondary antibody incubation, sections were washed 3 x 5 
minutes in 1 x PBS containing 0.05% v/v Tween 20 before undergoing incubation in ABC solution for 
1 hour. Sections were washed 3 x 5 minutes in 1 x PBS containing 0.05% v/v Tween 20 before 
undergoing staining in 50mg/ml 3,3′-Diaminobenzidine (DAB) solution for approximately 3 minutes 
or until hypertonic saline control sections indicated sufficient staining. Sections were washed 2 x 5 
minutes in 1 x PBS and mounted onto polylysine coated microscope slides before leaving to dry for 
12 hours. The following day, slides were dehydrated by 1 x 30 second wash in 70% ethanol, 2 x 30 
second washes in 100% ethanol and 1 x 30 second wash in xylene. Slides were removed from xylene 
and glass coverslips applied immediately using DPX mountant before leaving to dry overnight.  
 
Slides were observed under a light microscope (Nikon, Eclipse 50i) and counted by an individual  
blinded to the treatment groups. Equal numbers of sections were matched from each treatment 
group by a range of rostral-caudal bregma measurements verified by ‘The Rat Brain in Stereotaxic 
co-ordinates’ (Paxinos and Watson 2006) for rats and ‘The Mouse Brain in Stereotaxic co-ordinates’ 
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(Franklin and Paxinos 2007) for mice (see Table 3.1 for co-ordinate ranges for each brain area). CFLI 
was counted bilaterally in all sections.  
 
3.2.11 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH  on c-Fos like 
immunoreactivity in brain areas regulating reward and energy homeostasis in ad libitum 
fed rats and ad libitum fed mice  
 
c-Fos is an early onset transcription factor which is usually expressed early after neuronal activation 
has occurred (Dragunow and Faull 1989). Thus, cFLI was used as a marker for neuronal activation to 
identify brain areas activated by intra-VTA administration of NDP-MSH.  
 
We had previously established the anorectic effect of intra-VTA administration of NDP-MSH in ad 
libitum fed rats, as described in section 2.1.5. The anorectic response to intra-VTA NDP-MSH was 
observed at the onset of the early dark phase as the majority of rodent food intake occurs during the 
dark phase. A reduction in food intake was observed after intra-VTA administration of NDP-MSH at 
the onset of the early dark phase as previously described (Figure 2.1). Thus, in order to assess the 
effect of intra-VTA administration of NDP-MSH on cFLI, rodents were ad libitum fed during the light 
phase and NDP-MSH was administered intra-VTA at the onset of the dark phase. In previous feeding 
studies, 0.03nmol NDP-MSH was established as the lowest effective dose which elicited a reduction 
in food intake when administered at the onset of the dark phase in ad libitum fed rats, and thus 
0.03nmol NDP-MSH was selected for this study. For mice, 0.02nmol NDP-MSH was established as an 
effective dose which elicited a reduction in food intake when administered at the onset of the dark 
phase in ad libitum fed mice, and thus 0.02nmol NDP-MSH was selected for this study. 
 
Rats fed ad libitum during the light phase (09:00 – 19:00) were randomised into treatment groups by 
body weight and received an intra-VTA injection of saline or 0.03nmol NDP-MSH (n= 9-11) at the 
onset of the early dark phase (19:00 – 20:00). Mice fed ad libitum during the light phase (09:00 – 
19:00) were randomised into treatment groups by body weight and received an intra-VTA injection 
of saline or 0.02nmol NDP-MSH (n= 3) at the onset of the early dark phase (19:00 – 20:00). All 
rodents were immediately returned to their cages following intra-VTA administration with no access 
to RM3 diet and free access to water. Rodents were euthanased at 90 minutes following intra-VTA 
administration of saline or NDP-MSH.   
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Table 3.1 Range of co-ordinate sets used to identify the parabrachial pigmented nucleus of the 
VTA, amygdala, lateral septal nuclei, nucleus accumbens, ventral pallidum, prelimbic cortex and 
the paraventricular nucleus in brain sections from rats and mice following intra-VTA NDP-MSH 
administration. Co-ordinates were established using ‘The Rat Brain in Stereotaxic co-ordinates’ 
(Paxinos and Watson 2006) for rats and ‘The Mouse Brain in Stereotaxic co-ordinates’ (Franklin and 
Paxinos 2007) for mice. 
 
 
 
 
 
 
 
 
 
Brain nuclei 
Range of co-ordinates considered 
in rats (mm) 
Range of co-ordinates considered 
in mice  (mm caudal from bregma) 
Parabrachial pigmented 
nucleus of the VTA 
>5.16 and <6.24 caudal from 
bregma 
>3.08 and <3.88 caudal from 
bregma 
Amygdala 
>1.72 and <3.60 caudal from 
bregma 
>0.94 and <2.18 caudal from 
bregma 
Septal nuclei 
<0.60 caudal from bregma and 
<2.04 rostral from bregma 
<0.46 caudal from bregma and 
<1.42 rostral from bregma 
Nucleus accumbens 
<3.00 and >0.72 rostral from 
bregma 
<1.98 and >0.74 rostral from 
bregma 
Ventral pallidum 
<0.84 caudal from bregma and 
<1.42 rostral from bregma 
<0.46 caudal from bregma and 
<0.74 rostral from bregma 
Prelimbic cortex of the 
prefrontal cortex 
<6.24 and >5.16 rostral from 
bregma 
<2.18 and >1.54 rostral from 
bregma 
Paraventricular nucleus 
>1.08 and <2.04 caudal from 
bregma 
>0.22 and <1.22 caudal from 
bregma 
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cFLI was investigated in the PBP of the VTA, as the majority of the cell bodies of dopaminergic 
neurons which signal within the mesocorticolimbic system are located in the PBP, and it may thus be 
a target for melanocortin signalling, in the amygdala, as it signals to affect reward memory and is a 
major efferent target for both the VTA and the NAcb,  in the septal nuclei due to their involvement 
in regulating behavioural response to rewarding stimuli, in the NAcb as it receives the majority of 
efferent neuronal projections from the VTA and has a well characterised role in mediating reward 
processing, in the VP due to the role of the VP in influencing motivational processing of voluntary 
motor behaviour and the large proportion of efferent neuronal projections received from the NAcb, 
in the PRL as it is a prominent cortical region contained within the PFC of the mesocorticolimbic 
system which receives afferent neuronal projections from a number of mesocorticolimbic areas and 
signals to affect behavioural execution, and also in the PVN of the hypothalamus to confirm that 
intra-VTA administration of NDP-MSH did not activate the most sensitive melanocortin-responsive 
hypothalamic circuits (Balthasar, Dalgaard et al. 2005).  
 
3.2.12 Statistics 
 
All cFLI data is presented as the median, inter-quartile and total range. cFLI data was analysed using 
a Mann Whitney U test (GraphPad Prism Version 5.01, GraphPad Software, CA, USA). In all data 
analyses P values were defined as the following: p<0.05, *, p<0.01, **, p<0.001, ***.  
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3.3 Results 
 
 
3.3.1 Verification of intra-VTA co-ordinates in rats 
 
The accuracy of the co-ordinates targeting the PBP of the VTA was confirmed with intra-nuclear ink 
injection in rats as described in section 2.3.1.  
 
 
3.3.2 Verification of intra-VTA co-ordinates in mice 
 
The accuracy of the co-ordinates targeting the PBP of the VTA was confirmed with intra-nuclear ink 
injection in mice as described in section 2.3.3.  
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3.3.3 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos like 
immunoreactivity in the brains of ad libitum fed rats and ad libitum fed mice  
 
Intra-VTA administration of 0.03nmol NDP-MSH to ad libitum fed rats at the onset of the early dark 
phase significantly increased cFLI in the VTA (saline: 9.63 ± 1.75 vs. NDP-MSH: 195.3 ± 44.69, 
p<0.001) (Figure 3.2), amygdala (saline: 3.92 ± 0.86 vs. NDP-MSH: 63.82 ± 11.94, p<0.001) (Figure 
3.3), septal nuclei (saline: 4.13 ± 1.03 vs. NDP-MSH: 50.29 ± 7.55, p<0.001) (Figure 3.4), nucleus 
accumbens (saline: 4.33 ± 0.88 vs. NDP-MSH: 65.13 ± 11.51, p<0.001) (Figure 3.5), ventral pallidum 
(saline: 2.61 ± 0.53 vs. NDP-MSH: 20.98 ± 4.70, p<0.001) (Figure 3.6) and prefrontal cortex (saline: 
4.88 ± 0.90 vs. NDP-MSH: 70.13 ± 16.37, p<0.001) (Figure 3.7) compared to saline injected controls. 
There was no significant effect on cFLI in the PVN (Figure 3.8).  Representative bright field 
microphotographs are shown in Figures 3.2 to 3.8.  
 
Intra-VTA administration of 0.02nmol NDP-MSH to ad libitum fed mice at the onset of the early dark 
phase had no significant effect on cFLI in any of the regions examined, though there was a trend for 
an effect in the VTA (saline: 100.7 ± 5.35 vs. NDP-MSH: 382.6 ± 64.44, p<0.1) (Figure 3.2), amygdala 
(saline: 74.4 ± 30.47 vs. NDP-MSH: 157.4 ± 7.77, p<0.1), (Figure 3.3) septal nuclei (saline: 45.39 ± 
0.86 vs. NDP-MSH: 172.1 ± 8.56, p<0.1) (Figure 3.4), nucleus accumbens (saline: 75.33 ± 4.53 vs. 
NDP-MSH: 290.6 ± 20.40, p<0.1) (Figure 3.5), ventral pallidum (saline: 41.33 ± 3.43 vs. NDP-MSH: 
161.3 ± 27.92, p<0.1) (Figure 3.6) and prefrontal cortex (saline: 52.76 ± 5.91 vs. NDP-MSH: 319.90 ± 
40.99, p<0.1) (Figure 3.7) compared to saline injected controls. There was no significant effect on 
cFLI in the PVN (Figure 3.8). Representative bright field microphotographs are shown in Figures 3.2 
to 3.8.  
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Figure 3.2 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the VTA in rats and mice. Abbreviations: PBP, parabrachial pigmented 
nucleus of the VTA. A) The effect of intra-VTA saline or 0.03nmol NDP-MSH administration on c-Fos-
like immunoreactivity (cFLI) positive cell counts in the ventral tegmental area (VTA) in rats. 
Representative rat brain sections located 6.0mm caudal from bregma following B) saline or C) 
0.03nmol NDP-MSH intra-VTA administration. D) Representative brain map located at 6.0mm caudal 
from bregma adapted from ‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). 
Scale bar represents 0.5mm. (n=9-11) E) The effect of intra-VTA saline or 0.02nmol NDP-MSH 
administration on cFLI positive cell counts in the VTA in mice. Representative mouse brain sections 
located 3.2mm caudal from bregma following F) saline or G) 0.03nmol NDP-MSH intra-VTA 
administration. H) Representative brain map located at 3.16mm caudal from bregma adapted from 
‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 
0.20mm. (n=3). All data is expressed as the median and interquartile range of the number of 
bilateral cFLI counts per brain area. ***p<0.001.  
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Figure 3.3 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the amygdala in rats and mice. Abbreviations: MeAD, medial amygdaloid 
nucleus anteroventral part; CeM, central amygdaloid nucleus medial division. A) The effect of intra-
VTA saline or 0.03nmol NDP-MSH administration on c-Fos-like immunoreactivity (cFLI) positive cell 
counts in the amygdala in rats. Representative rat brain sections located 2.2mm caudal from bregma 
following B) saline or C) 0.03nmol NDP-MSH intra-VTA administration. D) Representative brain map 
located at 2.28mm caudal from bregma adapted from ‘The Rat Brain in Stereotaxic Co-ordinates’ 
(Paxinos and Watson 2006). Scale bar represents 0.30mm. (n=9-11) E) The effect of intra-VTA saline 
or 0.02nmol NDP-MSH administration on cFLI positive cell counts in the amygdala in mice. 
Representative mouse brain sections located 1.0mm caudal from bregma following F) saline or G) 
0.02nmol NDP-MSH intra-VTA administration. H) Representative brain map located at 1.06mm 
caudal from bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and 
Paxinos 2007). Scale bar represents 0.20mm. (n=3). All data is expressed as the median and 
interquartile range of the number of bilateral cFLI counts per brain area. ***p<0.001.  
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Figure 3.4 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the septal nuclei in rats and mice. Abbreviations: LSD, lateral septal 
nucleus dorsal part; LSI, lateral septal nucleus intermediate part; LSV, lateral septal nucleus ventral 
part. A) The effect of intra-VTA saline or 0.03nmol NDP-MSH administration on c-Fos-like 
immunoreactivity (cFLI) positive cell counts in the septal nuclei in rats. Representative rat brain 
sections located 1.20mm caudal from bregma following B) saline or C) 0.03nmol NDP-MSH intra-VTA 
administration. D) Representative brain map located at 1.20mm caudal from bregma adapted from 
‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). Scale bar represents 
0.20mm. (n=9-11) E) The effect of intra-VTA saline or 0.02nmol NDP-MSH administration on cFLI 
positive cell counts in the septal nuclei in mice. Representative mouse brain sections located 
0.20mm rostral from bregma following F) saline or G) 0.02nmol NDP-MSH intra-VTA administration. 
H) Representative brain map located at 0.26mm rostralal from bregma adapted from ‘The Mouse 
Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.20mm. (n=3). 
All data is expressed as the median and interquartile range of the number of bilateral cFLI counts per 
brain area. ***p<0.001.   
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Figure 3.5 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the nucleus accumbens in rats and mice. Abbreviations: AcbSh, nucleus 
accumbens shell. A) The effect of intra-VTA saline or 0.03nmol NDP-MSH administration on c-Fos-
like immunoreactivity (cFLI) positive cell counts in the NAcb in rats. Representative rat brain sections 
located 1.50mm  rostral from bregma following B) saline or C) 0.03nmol NDP-MSH intra-VTA 
administration. D) Representative brain map located at 1.56mm rostral from bregma adapted from 
‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). Scale bar represents 
0.20mm. (n=9-11) E) The effect of intra-VTA saline or 0.02nmol NDP-MSH administration on cFLI 
positive cell counts in the NAcb in mice. Representative mouse brain sections located 1.2mm rostral 
from bregma following F) saline or G) 0.02nmol NDP-MSH intra-VTA administration. H) 
Representative brain map located at 1.18mm rostral from bregma adapted from ‘The Mouse Brain in 
Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.15mm. (n=3). All data 
is expressed as the median and interquartile range of the number of bilateral cFLI counts per brain 
area. ***p<0.001.   
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Figure 3.6 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the ventral pallidum in rats and mice. Abbreviations: VP, ventral pallidum. 
A) The effect of intra-VTA saline or 0.03nmol NDP-MSH administration on c-Fos-like 
immunoreactivity (cFLI) positive cell counts in the VP in rats. Representative rat brain sections 
located 0.24mm rostral from bregma following B) saline or C) 0.03nmol NDP-MSH intra-VTA 
administration. D) Representative brain map located at 6.0mm caudal from bregma adapted from 
‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). Scale bar represents 
0.25mm. (n=9-11) E) The effect of intra-VTA saline or 0.02nmol NDP-MSH administration on cFLI 
positive cell counts in the VP in mice. Representative mouse brain sections located 0.0mm from 
bregma following F) saline or G) 0.02nmol NDP-MSH intra-VTA administration. H) Representative 
brain map located at 0.02mm rostral from bregma adapted from ‘The Mouse Brain in Stereotaxic Co-
ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.25mm. (n=3). All data is expressed as 
the median and interquartile range of the number of bilateral cFLI counts per brain area. 
***p<0.001.  
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Figure 3.7 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the prefrontal cortex in rats and mice. Abbreviations: PrL, prelimbic 
cortex. A) The effect of intra-VTA saline or 0.03nmol NDP-MSH administration on c-Fos-like 
immunoreactivity (cFLI) positive cell counts in the PrL in rats. Representative rat brain sections 
located 3.70mm rostral from bregma following B) saline or C) 0.03nmol NDP-MSH intra-VTA 
administration. D) Representative brain map located at 3.72mm rostral from bregma adapted from 
‘The Rat Brain in Stereotaxic Co-ordinates’ (Paxinos and Watson 2006). Scale bar represents 
0.30mm. (n=9-11) E) The effect of intra-VTA saline or 0.02nmol NDP-MSH administration on cFLI 
positive cell counts in the PrL) in mice. Representative mouse brain sections located 1.70mm rostral 
from bregma following F) saline or G) 0.02nmol NDP-MSH intra-VTA administration. H) 
Representative brain map located at 1.70mm rostral from bregma adapted from ‘The Mouse Brain in 
Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.20mm. (n=3). All data 
is expressed as the median and interquartile range of the number of bilateral cFLI counts per brain 
area. ***p<0.001.   
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Figure 3.8 The effect of intra-VTA administration of the MC3R/MC4R agonist NDP-MSH on c-Fos 
like immunoreactivity in the paraventricular nucleus of the hypothalamus in rats and mice. 
Abbreviations: PaAP, paraventricular hypothalamic nucleus anterior parvic. A) The effect of intra-
VTA saline or 0.03nmol NDP-MSH administration on c-Fos-like immunoreactivity (cFLI) positive cell 
counts in the PVN in rats. Representative rat brain sections located 1.40mm caudal from bregma 
following B) saline or C) 0.03nmol NDP-MSH intra-VTA administration. D) Representative brain map 
located at 1.44mm caudal from bregma adapted from ‘The Rat Brain in Stereotaxic Co-ordinates’ 
(Paxinos and Watson 2006). Scale bar represents 0.20mm. (n=9-11) E) The effect of intra-VTA saline 
or 0.02nmol NDP-MSH administration on cFLI positive cell counts in the PVN in mice. Representative 
mouse brain sections located 0.60mm caudal from bregma following F) saline or G) 0.02nmol NDP-
MSH intra-VTA administration. H) Representative brain map located at 0.58mm caudal from bregma 
adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar 
represents 0.15mm. (n=3). All data is expressed as the median and interquartile range of the number 
of bilateral cFLI counts per brain area. ***p<0.001.  
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Figure 3.9 Summary of c-Fos like-immunoreactivity detected in downstream brain areas in coronal 
rat brain sections following intra-VTA administration of NDP-MSH. Abbreviations: AcbSh, nucleus 
accumbens shell; AD, amygdala; LS, lateral septal nuclei; PBP, parabrachial pigmented nucleus of the 
VTA; PrL, prelimbic cortex of the prefrontal cortex; PVN, paraventricular nucleus of the 
hypothalamus; VP, ventral pallidum. CFLI is indicated by (+), ns = non-significant.  +++p<0.001. 
Adapted from ‘The Rat Brain in Stereotaxic co-ordinates’ (Paxinos and Watson 2006). 
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3.4 Discussion 
 
Chapter 2 described the acute effects of intra-VTA melanocortin administration on food intake and 
behaviour. In order to investigate how melanocortins signal in order to affect these acute 
behaviours, it is important to understand the neuronal circuitry and brain areas involved. Observing 
cFLI following intra-VTA NDP-MSH administration allows for the identification of downstream 
mesocorticolimbic brain areas which are activated in response to melanocortin signalling in the VTA.  
 
Intra-VTA administration of NDP-MSH to rats significantly increased cFLI in the VTA itself. Intra-VTA 
administration of NDP-MSH to mice showed a strong trend towards increased cFLI in the VTA. As 
NDP-MSH is an MC3R/MC4R agonist, this suggests the presence of MC3R and/or MC4R in the VTA. 
Indeed, MC3R expression is high within the VTA (Gantz, Miwa et al. 1993, Roselli-Rehfuss, Mountjoy 
et al. 1993), whilst MC4R expression is widely debated (Gantz, Miwa et al. 1993, Kishi, Aschkenasi et 
al. 2003, Liu, Kishi et al. 2003). The acute feeding effects observed after administration of an MC4R 
specific agonist THIQ, as described in Chapter 2, suggest that MC4R is present in the VTA. The 
identity of the MC4R-expressing neurons remains unknown without further neuronal phenotyping. 
ICV administration of AgRP has been shown to increase cFLI in the VTA, likely through activation of 
LH neurons and the subsequent projections to the VTA (Davis, Choi et al. 2011). The neurons 
activated in the VTA were identified as tyrosine hydroxylase (TH) containing neurons, a metabolite 
involved in dopamine synthesis. However, Intra-VTA pre-treatment with bicuculline, a GABA 
antagonist, results in an increase in grooming behaviour immediately after subsequent α-MSH 
administration (De Barioglio, Lezcano et al. 1991), suggesting melanocortins are also able to interact 
with GABAergic signalling in the VTA to affect behaviour. Thus, it appears that the VTA contains 
neurons which are sensitive to melanocortin agonists and antagonists, and it is likely that these 
neurons are dopaminergic or GABAergic.  
 
Intra-VTA administration of NDP-MSH to rats significantly increased cFLI in the amygdala and intra-
VTA NDP-MSH administration to mice showed a strong trend towards increased cFLI in the 
amygdala. cFLI was observed in the MeA and the CeA in both rats and mice. This suggests that first 
order neurons originating in the VTA are activated by melanocortins which project to the amygdala, 
where they synapse with and activate local neurons. MC4R expression is also high in the amygdala, 
though it seems unlikely that the NDP diffused this far to directly influence neurons, particularly 
given the lack of activation in the PVN. POMC has been reported to be present in the VTA (King and 
Hentges 2011), suggesting the possibility of  VTA neurons projecting to the amygdala to release 
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melanocortins locally. However, the presence of POMC in the VTA has been widely discredited 
(Civelli, Birnberg et al. 1982, Kishi, Aschkenasi et al. 2003), and it is likely other POMC containing 
regions such as the hypothalamus send discrete projections to the amygdala. Furthermore, it has 
been demonstrated that presynaptic MC4R is able to inhibit presynaptic calcium channels in 
amygdala neurons, and that these neurons are likely to be GABAergic (Agosti, Lopez Soto et al. 
2014). Therefore, it is possible that amygdala neurons which are responsive to melanocortin 
administration upstream may well be GABAergic. Interestingly, acute stress has been shown to 
activate neurons in the MeA, whilst blockade of MC4R signalling by administration of SHU9119 
attenuates this effect (Liu, Garza et al. 2013). Thus, MC4R appears to be required to mediate an 
acute stress response in the amygdala. This finding is important to consider when observing 
neuronal activation in the amygdala during an experiment which requires restraint, which will 
inevitably stress an animal. Despite this, administration of NDP-MSH to the VTA significantly 
increased cFLI in the amygdala compared to saline injected rodents. This suggests neurons within 
the amygdala are activated in response to stimuli other than stress. It is possible that a melanocortin 
responsive neuronal circuit in the VTA may mediate its effects on food intake via the amygdala.  
 
Intra-VTA administration of NDP-MSH to rats significantly increased cFLI in the LS, but not in other 
septal nuclei. Intra-VTA administration of NDP-MSH to mice showed a similar trend towards 
increased cFLI in the LS. Given that the LS has a well established role in reward signalling and 
receives many neuronal projections from the VTA and NAcb, it is likely that robust activation of 
neurons in the VTA would result in the activation of downstream neurons in the LS. The LS consists 
primarily of GABAergic neurons which fire tonically (Castañeda, Sanabria et al. 2005). These results 
suggest that melanocortin signalling in the VTA activates specific pathways involving the LS, and it is 
likely that this involves activation of LS GABAergic neurons.  
 
Intra-VTA administration of NDP-MSH to rats also significantly increased cFLI in the NAcbSh, but not 
the NAcbC. Intra-VTA administration of NDP-MSH to mice also showed a strong trend towards 
increased cFLI in the NAcbSh, but not the NAcbC core. The role of the NAcbSh is chiefly concerned 
with negatively regulating the response to stimuli which do not predict reward, versus the NAcbC 
which positively regulates the response to stimuli which do predict reward. This is in accord with 
VTA melanocortin signalling resulting in an inhibitory response to reward mediated through the 
NAcbSh. This appears to fit with the anorectic signalling properties of melanocortins, which inhibit 
food intake independently via the hypothalamus and the mesocorticolimbic system. As the NAcb is a 
direct downstream target of the VTA, it is likely that melanocortin signalling in the VTA activates 
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specific dopaminergic neurons in the VTA which project to the NAcb where they release dopamine 
to influence neuronal activity specifically in the NAcbSh. The expression of MC4R in the NAcb again 
suggests a melanocortin projection to the NAcb, but the upstream origin of these putative POMC 
projections remains unknown. It has been shown that pre-treatment with a D1-receptor antagonist 
in brain slices containing the NAcb attenuates cAMP levels after application of NDP-MSH, suggesting 
melanocortins are able to activate NAcb neurons which express D1 (Florijn, Mulder et al. 1993). The 
vast majority of neurons in the NAcb are GABAergic, though there is also a significantly smaller 
population of cholinergic neurons (Sesack and Pickel 1990). Given the tendency of melanocortins to 
affect GABAergic transmission in the amygdala (Agosti, Lopez Soto et al. 2014) and the importance 
of GABAergic inhibitory control of reward mediated by dopamine signalling, it is likely that the 
neurons activated in the NAcbSh are GABAergic.  
 
Intra-VTA administration of NDP-MSH to rats also significantly increased cFLI in the VP, and intra-
VTA administration of NDP-MSH to mice also showed a strong trend towards increased cFLI in the 
VP. The VP is a mesocorticolimbic area closely linked with areas of the basal ganglia which are 
responsible for motor execution. This suggests that melanocortin signalling via the VTA is able to 
activate neurons in the VP, and that this may represent a neuronal circuit which is responsible for 
the initiation of feeding behaviour. The VP also receives a large number of reciprocal projections 
from many areas of the mesocorticolimbic system including the VTA, the NAcb and the amygdala. 
The neuronal activation observed in the VP thus likely represents indirect activation from the VTA. 
The neuronal populations in the VP consist of GABAergic and glutamatergic neurons (Kupchik and 
Kalivas 2013), but it is unclear which of these populations are activated in this study.  
 
Finally, intra-VTA administration of NDP-MSH to rats significantly increased cFLI in the PRL of the 
PFC, as did intra-VTA administration of NDP-MSH to mice which showed a strong trend towards 
increased cFLI in the PRL of the PFC. These findings suggest that melanocortin signalling via the VTA 
induces a robust activation of cortical regions associated with executive reward processing. This is 
likely to be via dopaminergic neurons which originate in the VTA and project directly to the PFC  
where they locally release dopamine. The identity of the neurons which are activated in the PRL are 
likely to be GABAergic or glutamatergic, as they comprise the majority of the neurons in the PFC. 
GABAergic neurons in the PFC have been shown to primarily express D1 receptors (Santana, Mengod 
et al. 2009). Therefore, melanocortin signalling in the VTA may activate dopaminergic neurons which 
project to the PFC and cause the local release of dopamine, activating GABAergic neurons expressing 
D1. 
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Importantly, there was no significant difference in cFLI in the PVN of the hypothalamus in rats or 
mice following intra-VTA administration of NDP-MSH. This suggests that the reduction in food intake 
following intra-VTA administration of melanocortins is not mediated by hypothalamic circuits, and 
that the NDP administered into the VTA does not spread to nearby brain regions.  
 
The precise identity of the neurons activated following intra-VTA administration of melanocortins 
remains to be elucidated. As with all cFLI observations, the phenotype of the neuron which is 
activated is not usually discriminated. The only information offered by observing cFLI is that a 
neuron has been activated, but it does not indicate if this is an excitatory glutamatergic neuron or a 
GABAergic inhibitory neuron, or if the action potential which influenced the neuron is excitatory or 
inhibitory. Neuronal phenotyping using immunohistochemistry or in situ hybdridisation can be used 
in conjunction with cFLI to observe the co-localisation of markers denoting particular neurons. It 
would be thus be beneficial to undertake these studies in order to better define the mechanism of 
action of the melanocortins within mesocorticolimbic neuronal circuits.  
 
Increased cFLI has been observed in the VTA, PRL, mPFC, MeA and NAcbSh and NAcbC in rats fed 
corn oil, whilst glucose and fructose intake only resulted in increased cFLI in the NAcbC and MeA 
(Dela Cruz, Coke et al. 2014). This study also demonstrated that when significant cFLI was observed, 
there was a strong correlation between each activated brain area, which is also observed in the 
studies described in this chapter. Therefore, it is likely that experiencing the same food reward 
habitually activates the same brain areas each time. It may also be that certain macronutrients 
activate specific reward circuits, as demonstrated by the findings that intra-amygdala administration 
of Melanotan II was only able to decrease intake of a HF but not a standard chow diet (Boghossian, 
Park et al. 2010). Therefore, it may also be important to consider nutrient content of the food being 
administered when investigating the effects of food intake on cFLI. It would also be interesting to 
observe the pattern of neuronal activation following intra-VTA administration of melanocortins in 
fasted animals. The rodents used in these studies were ad libitum fed at the time of melanocortin 
administration, as this is when the VTA appears to be sensitive to their anorectic effects. If the 
sensitivity of the VTA does indeed alter with nutritional status, we might expect a lower level of 
neuronal activation in these regions in fasted animals.  
 
It would be useful to repeat this study using a larger number of mice. Due to time and facility 
restraints, the mouse study was statistically underpowered.  Additionally, the location of the VTA 
cannulae in both rats and mice could not be precisely estimated with a post-mortem ink injection in 
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this procedure as the c-Fos tissue processing steps do not allow for this.  However, ink injections in 
previous cohorts of intra-VTA cannulated rats indicate a VTA cannulation accuracy rate of 
approximately 95 – 100% (Data not shown, K. A. Banks (2011) MRes thesis), and observation of the 
brains during sectioning revealed slight tissue damage in the VTA, as would be expected from the 
cannulation and injection procedure, but not in nearby regions.   
 
It is important to consider the limitations of using cFLI as a measure of neuronal activation. c-Fos is a 
protein which is constantly produced at a basal level within the nucleus (Dragunow and Faull 1989), 
but requires a robust increase in expression in order to produce detectable changes in expression 
levels. This may be difficult to achieve with treatments which are chronic and prolonged (Dragunow 
and Faull 1989). c-Fos may also be induced if a neuron is injured. The procedure of intranuclear 
cannulation undoubtedly results in some local tissue injury, but the acute effects of this damage 
should have subsided by the time of NDP-MSH administration in this study. Administration of a 
volume of liquid into brain tissue during the experimental procedure will increase pressure within 
the tissue, and this pressure may induce c-Fos protein as neurons directly within the injection site 
may be injured. However, using a saline control should allow the separation of such effects from 
those caused specifically by melanocortin signalling.  
 
Finally, areas of the mesocorticolimbic system, such as the amygdala, are acutely responsive to 
stressors, such as restraint or noise. Basal c-Fos expression may be reduced with regular handling 
and sham injecting animals prior to the experimental procedure.  However the mice needed to be 
restrained during the injection procedure, while the rats did not, and this restraint is likely 
responsible for the higher baseline activation observed with the control saline injections in mice. 
Even with this raised baseline, there was a clear trend in the mice for increased activation in 
mesocorticolimbic regions following NDP-MSH administration.  
  
In conclusion, it is likely that melanocortin signalling in the VTA is sufficient to activate local neurons 
in the VTA. This confirms that there are melanocortin-sensitive neurons in the VTA, and that these 
neurons are able to influence neuronal activation in other areas in the mesocorticolimbic system. It 
is likely that these first order VTA neurons are dopaminergic, although further phenotyping is 
required to confirm this. These studies have thus identified brain areas in rats and mice which may 
be involved in central melanocortin signalling via the VTA in the control of food intake.   
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4.1 Introduction 
 
 
4.1.1 Adeno-associated virus and cre recombinase 
 
Transgenic mouse models of perturbed neuronal signalling are able to provide phenotypic evidence 
pertaining to the function of particular proteins, circuits and brain areas. KO mice are traditionally 
created by in vitro manipulation of native DNA sequences, embryonic stem cell transfer and back-
crossing of the offspring. This results in a transgenic mouse which possesses a genetic mutation 
throughout development, which is often deleterious to the function of a particular protein. There 
are obvious disadvantages to using transgenic mice which lack normal gene function throughout 
development. Developmental compensation can arise, whereby other proteins become upregulated 
in order to compensate for the gene product which has been knocked-out. This may result in an 
adult mouse model which does not accurately reflect the loss of the targeted gene function. In order 
to overcome developmental compensation, conditional expression transgenic mouse models are 
increasingly used. These allow post-developmental manipulation of gene function to occur, thereby 
avoiding developmental compensation. One of the methods used to manipulate gene function post-
development is the use of viruses to insert genetic material into the existing genome. Adeno-
associated virus (AAV) is a non-pathogenic helper dependent parvovirus which comprises a single 
stranded linear DNA sequence (Deyle and Russell 2009). AAV is unable to undergo the normal post-
infection life cycle of a virus without adenovirus, making it ideal for latent infection of targeted cells. 
AAV exists in many different serotypes, AAV2 being most suitable for neuronal cell integration. AAV 
integrates into the genome in a site-specific manner, on human chromosome 19 or mouse 
chromosome 7 (Dutheil, Yoon-Robarts et al. 2004). This insertional mutagenesis allows for the 
introduction of genetic sequences carried by the AAV into the host genome, enabling endogenous 
transcription of that sequence.  
 
Conditional mouse models can utilise AAV in order to insert regulatory genetic sequences into DNA 
at specific sites, to upregulate or downregulate protein expression. AAV can also be used to re-
express proteins which may have been previously knocked-out.   This can be achieved with the use 
of a cre recombinase strategy. Cre recombinase is a Type 1 topoisomerase from the bacteriophage 
P1. It is an enzyme which is able to catalyse site-specific recombination at loxP sites, DNA elements 
which are the targets for cre recombinase. When cre recombinase binds to loxP sites which flank a 
stretch of DNA, the loxP sites are brought together allowing cre recombinase to cleave the DNA 
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sequence at each loxP site. This causes the excision, or floxing, of the DNA sequence flanked by the 
loxP sites and rejoining of the cleaved sequence left behind (Lee and Sadowski 2003). Typically, gene 
regulatory elements such as promoters or stop codons are engineered to be targeted by AAV, 
therefore transgenic mouse models are engineered to express loxP sites which flank the targeted 
DNA element. AAV can then used to introduce cre recombinase into the nucleus where it catalyses 
site-specific recombination. This often results in the conditional silencing or re-expression of a 
particular protein, such as MC4R.   
 
Another advantage of AAV is that it allows for location-specific genetic manipulation. The stereotaxic 
administration of AAV to the brain will result in AAV integration into cells in that specific area 
determined by the volume and spread of the AAV. This means that brain nuclei of particular interest 
can be targeted in order to deduce more about how a certain protein may function there. Cre 
recombinase strategies can also be used to target specific tissues. This can be achieved by crossing a 
transgenic mouse which expresses cre recombinase under the control of a tissue specific promoter, 
with a mouse which has loxP sites flanking a regulatory element of the protein of interest. Thus, 
when these mice are crossed, the expression of cre recombinase will flox out the targeted sequence 
only in those specific tissues. This can also be achieved with AAV alone, wherein the AAV can be 
under the control of specific promoters (Gray, Foti et al. 2011). This allows for both location and 
tissue specific manipulation of protein expression.  
 
An obvious disadvantage of using AAV to affect protein expression is the lack of control over virus 
spread and integration. When administering AAV into brain tissue, the volume injected and the 
spread throughout the tissue is often difficult to assess in vivo. Fluorescent markers such as GFP are 
often part of an AAV construct and are thus integrated into the DNA, but they cannot be fully 
assessed until post-mortem, especially in deeper regions of the brain. Optimisation of AAV 
administration is therefore important before conducting an experiment where a change in a 
phenotype is expected. However, it is unlikely that AAV will be successfully targeted to integrate into 
a high percentage of the cells contained within a specific area or tissue. Additionally, transgenic 
mouse models which express cre recombinase under the control of a promoter will not always result 
in 100% of those cells successfully undergoing targeted recombination due to cellular energy 
inefficiencies, the length of the DNA to be excised or the type of promoter (Heffner, Herbert Pratt et 
al. 2012).  
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4.1.2 The physiological role of MC4R in energy homeostasis 
 
As discussed previously, the phenotypes of the relevant KO mice suggest that MC4R signalling is 
critical in the control of food intake and MC3R signalling is more important in energy expenditure. 
Initial studies using a global MC4R KO mouse also reported the intermediate phenotype observed in 
heterozygous mice which possess one null copy of the MC4R allele (Huszar, Lynch et al. 1997, Chen, 
Metzger et al. 2000). This suggests a gene dosage effect of MC4R, whereby a linear relationship is 
observed between the phenotype and number of faulty alleles.  
 
When MC4R KO mice are exposed to a HFD they become increasingly hyperphagic. Weight gain is 
accelerated as they also exhibit a blunted thermogenic response to the increasing caloric content of 
food. Additionally, unlike WT mice, MC4R KO mice do not increase activity in response to increased 
caloric intake, further demonstrating deficits in energy expenditure (Butler, Marks et al. 2001, 
Sutton, Trevaskis et al. 2006). Uncoupling protein 1 (UCP1) expression is also unaltered by central 
and peripheral leptin administration in these mice, suggesting MC4R is necessary in driving the 
thermogenic response to leptin. However, food intake is decreased after central and peripheral 
leptin administration in obese MC4R KO mice only, suggesting that the anorectic effects of leptin are 
not fully dependent on MC4R (Marsh, Hollopeter et al. 1999, Zhang, Kilroy et al. 2005). Furthermore, 
oxygen consumption is approximately 20% lower in MC4R KO mice compared to body weight 
matched WT mice, thus MC4R deletion results in perturbations in energy expenditure, contributing 
to the obese phenotype (Ste. Marie, Miura et al. 2000).  
 
These initial characterisations of the global MC4R mouse were followed by a landmark study using 
conditional re-expression of MC4R in a global MC4R KO mouse which aimed to identify the key brain 
areas important in melanocortin signalling (Balthasar, Dalgaard et al. 2005). In these mice, a 
transcriptional blocking (TB) sequence was inserted upstream of the MC4R gene and was flanked by 
cre recombinase sensitive loxP sites. Thus, when cre recombinase is introduced into the nucleus of 
loxTB MC4R cells, the transcriptional blocking sequence is removed and the endogenous re-
expression of MC4R is enabled. Firstly, loxTB MC4R mice were crossed with nestin-cre recombinase 
(Nes-Cre) transgenic mice, which express cre recombinase in all neuronal cells. Nestin is a neuronal 
cytoskeletal protein expressed in all neurons. Therefore, the resulting offspring had MC4R specific 
re-expression in MC4R containing neurons only. The obesity and increased body length observed in 
loxTB MC4R mice was completely attenuated in Nes-Cre, loxTB MC4R mice, thus proving that the 
energy homeostasis phenotype could be solely attributed to neuronal MC4R signalling. Furthermore, 
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specific re-expression of MC4R in the hypothalamus was achieved by crossing loxTB MC4R mice with 
transgenic mice which express cre recombinase under the promoter of single-minded homolog 1 
(Sim1), also known as Sim1-Cre mice. Sim1 is a transcription factor which is expressed in discrete 
brain areas, including the hypothalamus. Therefore, the resulting offspring had MC4R specific re-
expression in hypothalamic neurons. It was observed that the resultant mice, Sim1-Cre, loxTB MC4R, 
gained less weight than their loxTB MC4R counterparts, but were still shown to exhibit around 37-
46% of the obesity of loxTB MC4R mice. This suggests that melanocortin signalling in the control of 
energy homeostasis is mediated via other brain areas distinct from the hypothalamus. However, a 
decrease in food intake was observed comparable to that of WT mice. This was reflected by acute 
administration of Melanotan II which did not affect food intake in loxTB MC4R mice but decreased 
food intake in Sim1-Cre, loxTB MC4R mice, which has also been observed by others (Chen, Metzger 
et al. 2000). This would also fit with the observation that the orexigenic effects of AgRP are 
completely ablated in MC4R KO mice (Fekete, Marks et al. 2004).   
 
Collectively, this suggests that MC4R signalling in the control of food intake is predominantly 
mediated via the hypothalamus, and MC4R signalling governing energy expenditure is partially 
mediated via the hypothalamus.  It is noted that endogenous MC4R expression is detected in many 
brain areas, including the amygdala. In these studies, it was observed that Sim1 is expressed in the 
amygdala. Therefore, the Sim1-Cre, loxTB MC4R mouse also had MC4R re-expressed in the 
amygdala. The amygdala is an area of the mesocorticolimbic system which is known to be involved in 
melanocortin signalling and food intake (Kask and Schiöth 2000, Boghossian, Park et al. 2010). It is 
therefore possible that the re-expression of MC4R in the amygdala may also have contributed to the 
correction in food intake observed in these mice. It is unclear what percentage of total food intake 
the amygdala is responsible for, but it remains unlikely that the hypothalamus is the only brain area 
which mediates food intake via the MC4R.  
 
Interestingly, AAV administration of cre recombinase to the PVN was attempted in these studies, but 
did not yield the same profound phenotypic effects as observed in Sim1-Cre, loxTB MC4R mice. 
Unilateral injection of an AAV-Cre construct into the PVN in loxTB MC4R mice caused a decrease in 
body weight and food intake when compared with loxTB MC4R mice, but they were still 
approximately 80% as heavy as these mice (as compared to wild types, which were approximately 
50% as heavy). The hit rate for the PVN for AAV administration was estimated to be too low, and 
these studies were replaced with the Sim1-Cre studies outlined above. However, these findings may 
suggest that the amygdala plays a more important role in food intake than previously thought. It is 
156 
 
also important to note that these studies focused on unilateral, not bilateral re-expression, although 
it was found that the more accurate the hit rate of the injection, the more profound the loss of body 
weight.  
 
The observations from this study which suggest that food intake is controlled predominantly by 
MC4R hypothalamic signalling may also be due to developmental compensation in hypothalamic 
circuits. These transgenic mice were generated to have MC4R disruption from birth, thus potentially 
being subjected to developmental compensation resulting from a lack of anorectic signalling in the 
hypothalamus. It may be that other anorectic signalling pathways were upregulated during 
development in order to compensate for the loss of MC4R pathways, and therefore when MC4R is 
reintroduced into the hypothalamus, it may appear to contribute significantly more to the reversal 
of the obese phenotype.  
 
Another key study investigating the contribution of MC4R signalling in food intake focuses on the 
extra-hypothalamic expression of MC4R in cholinergic neurons. A transgenic mouse model was 
created wherein MC4R was re-expressed in cholinergic neurons using a cre recombinase strategy 
(Rossi, Balthasar et al. 2011). These mice showed a slight decrease in body weight gain compared to 
their global MC4R KO counterparts and an attenuation of hyperglycemia and hyperinsulinemia, 
although food intake was unaffected. This suggests that MC4R signalling via cholinergic neurons is 
more important in energy expenditure and glucose homeostasis than in food intake. Thus, it is likely 
that MC4R signalling from cholinergic neurons located in the mesocorticolimbic system is not 
involved in the control of food intake.  
 
4.1.3 MC4R in reward related aspects of feeding 
 
As the VTA represents the upstream mediator of dopaminergic signalling within the 
mesocorticolimbic system, it seems obvious to assess the physiological role of melanocortin 
signalling by first focusing on the VTA. Indeed, the effect of ectopically over-expressing POMC in the 
VTA using AAV transfection in rats has been investigated in order to assess the effects of chronic VTA 
melanocortin signalling on energy homeostasis (Andino, Ryder et al. 2011). It was found that 
increased VTA POMC signalling was sufficient to attenuate diet-induced obesity, comparable with 
POMC over expression in the Arc. However, caloric intake was unaltered. UCP-1 expression was 
significantly increased in the VTA POMC treatment group, suggesting that melanocortin signalling in 
the VTA may have effects on energy expenditure. The LH and the Arc both project to the VTA, thus 
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the ectopic expression of POMC may have amplified the signalling effects of these hypothalamic 
projections.  
 
Evidence suggests that some of the deficits in the control of food intake in MC4R KO mice may be 
mediated by the reward system.  When presented with a choice between a high-fat and a high-
sucrose food alongside normal chow, heterozygous MC4R KO mice do not exhibit preference 
behaviour different from that of a WT mouse (Panaro and Cone 2013). However, homozygous MC4R 
KO mice show a decreased preference for the high-fat and high-sucrose foods. Both heterozygous 
and homozygous MC4R KO mice exhibited increased food intake irrespective of the food type. 
Therefore, it appears that a deficit in MC4R signalling results in hyperphagia which is not dependent 
on palatability but may be dependent on variety. Interestingly, MC4R KO mice are less motivated to 
work for a food reward in an operant chamber experiment when compared to WT and MC3R KO 
mice (Vaughan, Moore et al. 2005). Additionally, re-expression of MC4R in D1-receptor containing 
neurons in global MC4R KO mice is not able to rescue the deficit in motivational behaviour to attain 
a high fat reward (Cui, Mason et al. 2012). Subsequent stringent investigation of food seeking 
behaviour in MC4R KO mice revealed they are more likely to consume an increased amount of food 
in one meal and once they begin to consume food they exhibit an increased motivation to continue 
eating (Vaughan, Moore et al. 2006). MC4R KO mice have also been described as hyperphagic in 
times of low cost to attain a food reward, but as soon as the cost to attain the food reward 
increases, they become hypophagic (Atalayer, Robertson et al. 2010). Collectively, these findings 
show that deficits in MC4R signalling result in defective reward processing and suggest that MC4R 
signalling in this system may only be required during distinct phases of food seeking behaviour, or 
may be upregulated when a novel or palatable foodstuff is encountered.  
 
The phenotype of the MC4R KO mouse suggests that a melanocortin tone is required for anorectic 
signalling in the control of both energy intake and energy expenditure. This appears to be mediated 
predominantly via the hypothalamus but may also be reliant on extra hypothalamic melanocortin 
signalling from mesocorticolimbic regions. The data regarding MC4R expression in the VTA is 
ambiguous (Roselli-Rehfuss, Mountjoy et al. 1993, Mountjoy, Mortrud et al. 1994, Alvaro, Tatro et al. 
1996, Kishi, Aschkenasi et al. 2003, Liu, Kishi et al. 2003, Lippert, Ellacott et al. 2014), though the VTA 
does respond pharmacologically to melanocortins and MC4R specific agonists and antagonists, as 
demonstrated in Chapters 2 and 3. Following attempts to re-express MC4R in the VTA, I therefore 
surmised that MC4R may be present presynaptically in the VTA, originating in neurons which are 
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located in distinct locations separate from the VTA. I therefore also investigated the effects of re-
expression of the MC4R in brain regions that provide neuronal input into the VTA.  
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4.1.4 Hypothesis 
 
I hypothesise that the re-expression of MC4R in the mesocorticolimbic system of MC4R KO mice will 
result in altered energy homeostasis.  
 
4.1.5 Aims 
 
To investigate the physiological role of MC4R in the mesocorticolimbic system in the control of 
energy homeostasis, I will determine:- 
 
- The effect of MC4R signalling in the ventral tegmental area (VTA), the medial amygdala 
(MeA), the lateral septal nuclei (LS), the nucleus accumbens shell (NAcbSh) and the ventral 
pallidum (VP) on chronic food intake and body weight in male MC4R KO mice using AAV 
mediated conditional re-expression of MC4R.  
- The effect of MC4R signalling in the VTA, MeA, LS, NAcbSh and VP on behaviour and food 
seeking behaviour in male MC4R KO mice using AAV mediated conditional re-expression of 
MC4R.  
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4.2 Methods 
 
 
4.2.1 Materials  
 
Recombinant adeno-associated viral constructs (serotype 2) expressing cre recombinase and green-
fluorescent protein (AAV-Cre-GFP) or GFP (AAV-GFP) with a mean titre of 1x1013 genome copies 
(GC)/ml were purchased from Vector Biolabs, Philadelphia, USA. Primary polyclonal anti-MC4R 
rabbit antibody (extracellular) was purchased from Alomone Laboratories, UK. Secondary donkey-
anti rabbit fluorescent Alexa-Fluor 594 antibody was purchased from Life Technologies, Paisley, UK.  
 
4.2.2 Animals  
 
Four heterozygous breeding pairs of B6;12934-Mc4rtmLowl/J mice (Balthasar, Dalgaard et al. 2005) 
were purchased from The Jackson Laboratory (Maine, USA). All breeding mice were group housed 
and maintained in individually ventilated cages under controlled temperatures (21-23°C) and a 12 
hour light/dark cycle with ad libitum access to Rat and Mouse 3 diet (RM3) or 60% kcals from fat 
HFD (Special Diet Services, UK) and water. All mice post-surgery were singly housed and maintained 
in individually ventilated cages under the same conditions as breeding mice.  
 
All animal procedures undertaken were approved by the British Home Office and carried out under 
the British Home Office Animals (Scientific Procedures) Act 1986 (Project licences 70/7096, 70/7229 
and 70/7236).  
 
4.2.3 Generation of B6;12934-Mc4rtmLowl/J mice  
 
Global conditional MC4R knockout mice purchased from The Jackson Laboratory were generated as 
described in Figure 4.1. Mice were bred for eight generations using a heterozygote breeding 
strategy.  
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Figure 4.1 Molecular strategy for global conditional MC4R transcriptional blocking. Abbreviations: 
WT, wildtype; Mc4r, melanocortin receptor four; TB, transcriptional blocking sequence; HinDIII, 
Haemophilus influenzae deoxyribonuclease restriction enzyme III; ATG, ATG start codon. A loxP-
flanked transcriptional blocker (loxTB) was inserted between the site of transcription initiation (+1) 
and the ATG sequence of MC4R. Endogenous global expression of MC4R is thus prevented. Adapted 
from Balthasar et al (Balthasar, Dalgaard et al. 2005).  
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4.2.4 Genotyping of B6;12934-Mc4rtmLowl/J mice 
 
Materials 
 
Phire Animal Tissue Direct polymerase chain reaction (PCR) kit: Dilution Buffer, DNARelease Additive, 
2x Animal Tissue PCR Buffer, Phire Hot Start II DNA Polymerase  (New England Biolabs, USA) 
20µM oligonucleotide primers (Table 4.1) (Invitrogen, UK) 
DNA loading buffer (Appendix 1) 
Tris-acetate-EDTA (TAE) 1.5% agarose gel (Appendix 1) 
50 x TAE buffer (Appendix 1) 
1µg/µl 1kb Plus DNA ladder (New England Biolabs, USA) 
 
Methods 
 
Ear tissue biopsies (approximately 1mm2) were retrieved using sterile scissors and DNA was 
extracted to determine the genotype of each mouse. In order to extract DNA, biopsies were digested 
in 20µl of Dilution Buffer and 0.5µl of DNARelease Additive and mixed by vortexing. This solution 
was briefly spun down using a microcentrifuge (Model Mini-spin Plus, Eppendorf, UK) before 
incubating for 3 minutes at RTP. After incubation, the solutions were placed into a pre-heated PCR 
block (Peltier Thermal Cycler PTC-200, MJ Research, Quebec, Canada) at 98°C for 2 minutes to 
prevent further digestion then briefly spun down and stored at 20°C if not used immediately.  
 
Discrimination between wild type (MC4R+/+), homozygous (MC4R-/-) and heterozygous (MC4R+/-) 
genotypes required one primer which detects the wild type endogenous sequence in a forward 
direction, one primer which detects the wild type endogenous sequence in a reverse direction and 
one primer which detects the modified loxP allele (Table 4.1). One µl of each primer, 10µl of 2x Phire 
Animal Tissue PCR Buffer, 0.4µl of Hot Start II DNA Polymerase and 6.6µl of GDW were mixed 
together by vortexing before finally adding 1µl of DNA sample. Initial denaturation took place at 
94°C for 3 minutes and the reactions were subsequently cycled 35 times at 94°C (30 seconds), 65°C 
(30 seconds) and 72°C (1 minute) followed by incubation at 4°C until removal. Four µl of 6 x DNA 
loading buffer was added to each PCR product to enable size fractionation using electrophoresis on a 
1.5% (w/v) agarose Type-II A gel. Agarose was dissolved in 1 x TAE using a microwave and ethidium  
bromide added to achieve a final concentration of 0.5µg/ml. 1 x TAE running buffer containing 
0.5µg/ml ethidium bromide was added to the electrophoresis chamber before the gel was 
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Table 4.1 Primers used to genotype B6;12934-Mc4rtmLowl/J and WT mice targeting the wild type 
melanocortin receptor 4 (MC4R) allele and the modified loxP allele.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Representative photograph of 1.5% agarose gel visualised with ultraviolet (UV) light 
showing separated amplified DNA fragments for genotyping B6;12934-Mc4rtmLowl/J mice. 
Abbreviations: MC4R, melanocortin receptor 4. From left to right: 1kb Plus DNA ladder, 500bp DNA 
band indicating MC4R+-+, 400bp DNA band indicating MC4R-/- and 400bp and 500bp DNA bands 
indicating MC4R+/-.  
 
 
 
 
 
 
Wild type forward primer GCA GTA CAG CGA GTC TCA GG 
Wild type reverse primer CTC CAA CAG GCT TAT GAC ACC 
Mutant GTG CAA GTG CAG GTGCCA G 
164 
 
electrophoresed for 45 minutes at 120mV. Ultra violet (UV) illumination was used to visualise DNA 
fragment bands and a 1kb Plus DNA ladder was used for comparison. One band at 500bp signified 
MC4R+/+, one band at 400bp signified MC4R-/- and bands at both 400bp and 500bp signified MC4R+/- 
(Figure 4.2).   
 
4.2.5 Verification of intra-nuclear injection site  
 
4.2.5.1   Intra-nuclear ink injections  
 
The co-ordinates for intra-nuclear AAV administration were optimised by prior intra-nuclear 
injection of 0.5µl 1:40 v/v Indian ink (Stephens, UK) in 0.01M PBS (Appendix 1) into the targeted 
brain area, as described for the PBP of the VTA in section 2.2.3.2.  
 
4.2.5.2   Cresyl violet staining of intra-nuclear ink injected brain tissue  
 
Tissue preparation and cresyl violet staining of intra-nuclear ink injected mouse brain tissue was 
carried out as described in section 2.2.3.3. Stereotaxic co-ordinates which resulted in observed ink 
spread 2mm outside the boundary of the target brain nucleus were discounted. Verification of  
injection site was undertaken using ‘The Mouse Brain in Stereotaxic co-ordinates’ (Franklin and 
Paxinos 2007). 
 
4.2.6 Bilateral intra-nuclear administration of adeno-associated viral constructs  
 
Mice were anaesthetised with 2l/min O2 and 4% isofluorane within an anaesthetic induction 
chamber until loss of the pedal reflex was observed. Fur covering the dorsal cranial area caudal from 
the eyes was removed using fur clippers. Prophylactic antibiotics (Appendix 2) were administered IP 
to prevent post-operative bacterial infection and carprofen (Appendix 2) was administered SC to 
provide long-term analgesia. Mice were supported on an insulated platform and fixed on a 
stereotaxic frame (Model 900, David Kopf Instruments, USA) with non-rupture ear bars and the 
incisor bar positioned 2mm below the interaural line. A mouse anaesthetic mask (Model 907, David 
Kopf Instruments, USA) was adjusted to fit the frame and initially delivered 1l/min O2 and 2.5% 
isofluorane. Isofluorane percentage was adjusted to deliver an appropriate depth of anaesthesia 
according to observation of mouse respiratory rate and pedal reflex throughout the procedure. 
Lacrilube (Allergan, UK) was applied to the eyes to prevent keratitis and the cranial area was 
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swabbed with 1:10 v/v iodine (Ecolabs Ltd, UK) and sterile water (B.Braun, UK) to promote sterility. A 
1cm longitudinal incision was made on the dorsal cranial surface and the periosteum was cleared to 
expose the cranium. Bregma was identified to guide placement of the required stereotaxic co-
ordinates determined from ink injection studies. Bilateral holes with a diameter of 0.7mm were 
drilled in the cranium surface above each identified brain nucleus using a stereotaxically mounted 
electric drill. A stainless steel 28 gauge cannula (Plastics One, USA) was positioned over each hole 
using a stereotaxically mounted clamp which acted as a guide cannula for a stainless steel 32 gauge 
injector which was inserted to project 1mm beyond the tip of the cannula. An electrical infusion 
pump (Model A55-1111, Harvard Apparatus, USA) was calibrated to deliver a flow rate of 12µl/hr via 
the injector. The infusion pump used a closed water system via a polythene tube (Plastics One, USA) 
and a 10µl Hamilton syringe (Fisher Scientific, UK) which was separated from the injectable 
substance by the formation of an air bubble. The guide cannula and injector were inserted into the 
right drilled hole first to the required depth and 0.5µl of either AAV-Cre-GFP or AAV-GFP was 
delivered over 2.5 minutes. The guide cannula and injector remained in situ for a further 5 minutes 
before removal to prevent injector backflow. Sterile 0.9% sodium chloride solution (B.Braun, UK) 
was administered to the exposed dermis to prevent drying and AAV delivery was repeated for the 
left drilled hole. After bilateral injection was complete, the incision site was sutured using Prolene 6-
0 (Ethicon, UK) interrupted stitches. Mice were placed in a warming chamber to recover post-
surgery at 32°C and 0.2ml of warmed 0.9% sodium chloride solution was administered IP to 
counteract dehydration. Buprenorphine (Appendix 2) was administered SC upon visible 
improvement of respiratory rate. Mice were housed individually and given access to liquid RM3 diet 
for 24 hours post-surgery. Sutures were removed 10 days post-surgery.  
 
4.2.7 Transcardial perfusion of mice and tissue preparation  
 
Transcardial perfusion surgery was carried out as described in section 3.2.8.  
 
For GFP fluorescence analysis, brains were rapidly frozen in isopentane over dry ice and sliced at 
40µm on a sliding microtome (Model AS200 Shandon, Thermo Fisher Scientific, UK) and stored in 
antifreeze at 20°C.  
 
For immunohistochemical analysis, brains were dissected into 3mm coronal sections and placed in 
tissue cassettes in 100% ethanol prior to wax embedding. Wax embedding was undertaken by the 
Histopathology Department (Hammersmith Hospital, Imperial College Healthcare NHS Trust, UK). 
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Wax embedded tissue was sliced in 7µm coronal sections using a microtome (Model 1512, Leica 
Leitz, UK), and sections were floated on a water bath heated to 37°C before mounting onto 
polylysine coated microscope slides.  
 
4.2.8 Confirmation of GFP fluorescence in AAV-targeted nuclei  
 
Materials 
 
1 x PBS (Appendix 1) 
GDW 
Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, UK) 
 
Method 
 
Slices were washed in 1 x PBS followed by GDW to remove residual antifreeze before mounting on 
polylysine coated microscope slides. Slides were allowed to dry for 4 hours in the dark at RTP before 
glass coverslips were applied using Vectashield mounting medium with DAPI. Slides were stored at 
4°C and GFP fluorescence visualised using a fluorescence microscope (Model DM4000B, Leica 
Microsystems, UK).  
 
4.2.9 Confirmation of MC4R re-expression in AAV-targeted nuclei using immunohistochemistry  
 
Materials 
 
Xylene (VWR, UK) 
Ethanol absolute (VWR, UK) 
GDW 
Antigen retrieval solution (Appendix 1)  
1 x Tris-buffered saline (TBS) (Appendix 1) 
Antibody diluent solution (Appendix 1) 
Blocking solution for MC4R immunohistochemistry (Appendix 1) 
Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, UK) 
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Method 
 
Slides were first deparaffinised in xylene for 2 x 3 minutes followed by dehydration for 3 minutes in 
1:1 v/v xylene and 100% ethanol, 2 x 3 minutes in 100% ethanol, 95% ethanol for 3 minutes, 70% 
ethanol for 3 minutes, 50% ethanol for 3 minutes and 5 minutes in GDW. Antigen retrieval was 
undertaken to unmask epitope regions by boiling antigen retrieval solution in a microwave oven 
before adding the slides and further heating in the microwave oven for 20 minutes. Upon removal 
the slides were washed in GDW for 10 minutes. A wax pen was used to draw round the periphery of 
each microscope slide and slides were washed 2 x 5 minutes in 1 x TBS. Thirty µl of blocking solution 
was applied to each slide before leaving for 2 hours at RTP to minimise non-specific binding. Slides 
were drained and placed in a humidified chamber prior to primary antibody incubation. MC4R 
antibody was diluted 1:400 v/v in antibody diluent solution and 30µl applied to the slides before 
incubation at 4°C in the humidified chamber in the dark for 12 hours. The following day, slides were 
washed 2 x 5 minutes in 1 x TBS followed by application of 30µl of secondary donkey-anti rabbit 
Alexa-Fluor 594 antibody (Life Technologies, UK) and incubated for 1 hour at RTP in the dark. Slides 
were washed 3 x 5 minutes in 1 x TBS before glass coverslips were applied using Vectashield 
mounting medium with DAPI. Slides were stored at 4°C and fluorescence visualised using a 
fluorescence microscope (Model DM4000B, Leica Microsystems, UK). Brain sections containing the 
PVN from MC4R-/- mice were used as a negative control for MC4R immunoreactivity.  
 
4.2.10 The effect of MC4R-/-, MC4R+/-, and MC4R+/+  genotype on body weight in male and female 
B6;12934-Mc4rtmLowl/J mice 
 
The effect of MC4R-/- and MC4R+/- in B6;12934-Mc4rtmLowl/J on body weight has been established 
elsewhere (Balthasar, Dalgaard et al. 2005). To confirm the effect of MC4R-/- and MC4R+/- on body 
weight in the current breeding cohort, body weight was measured at the same time of day (10:00) 
three times a week from 3 to 20 weeks of age (n=5-9).  
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4.2.11 Intra-VTA administration of AAV-GFP or AAV-Cre-GFP in MC4R+/+ and MC4R-/- mice 
 
4.2.11.1 GFP expression and MC4R immunoreactivity in the PBP following intra-VTA 
administration of AAV-Cre-GFP in MC4R-/- mice 
 
As described previously in section 4.1.1, cre recombinase Type 1 topoisomerase is able to catalyse 
site-specific recombination at loxP sites within DNA. The introduction of cre-recombinase via AAV 
was used to remove the loxP flanked stop codon inserted upstream of MC4R. Removal of this stop 
codon allows endogenous re-expression of MC4R in targeted brain areas. Successful transfection 
with AAV-Cre-GFP and AAV-GFP constructs should result in GFP expression, allowing post-mortem 
visualisation of AAV transfection location and spread. GFP expression was investigated post-intra-
VTA administration of AAV-GFP-Cre to confirm accurate targeting and the ability of the AAV to drive 
gene expression. MC4R immunoreactivity was assessed in the VTA post-intra-VTA administration of 
AAV-GFP-Cre to investigate MC4R re-expression.  
 
Male 22 week old MC4R-/- mice which had previously undergone bilateral intra-VTA administration of 
AAV-Cre-GFP or AAV-GFP constructs were transcardially perfused for analysis of GFP expression 
(n=3) and MC4R immunoreactivity (n=4) at 80 days post-administration.  
 
4.2.11.2 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R+/+ and MC4R-/- mice 
 
The effect of intra-VTA melanocortin administration on acute food intake in ad libitum fed rodents 
has been established in chapter 2. Conditional re-expression of MC4R in the VTA was investigated to 
characterise the effect of endogenous VTA melanocortin signalling on chronic food intake and body 
weight.  
 
Male 8 week old MC4R+/+ and MC4R-/- mice were randomised into treatment groups by body weight 
and received intra-VTA bilateral administration of either control AAV-GFP construct or AAV-Cre-GFP 
(n=6-11). Mice were individually housed following surgery for bilateral administration of AAV. Body 
weight and cumulative food weight was measured at the same time of day (10:00) three times a 
week immediately following administration for 80 days.  
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4.2.11.3 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on general 
behaviour in MC4R-/- and MC4R+/+ mice 
 
The effect of acute intra-VTA melanocortin administration on acute food intake in ad libitum fed 
rodents has been established in chapter 2. To establish the behavioural effects of intra-VTA AAV-Cre-
GFP administration in MC4R-/- and MC4R+/+ mice, general behaviour was monitored post-AAV 
administration using an adapted observational protocol as described in section 2.2.13.  
 
Male 14 week old MC4R-/- and MC4R+/+ mice which had previously undergone bilateral intra-VTA 
administration of AAV-Cre-GFP or AAV-GFP constructs at 8 weeks (n=6-11) were fed ad libitum and 
monitored at the onset of the light phase (09:00 – 10:00) and at the onset of the dark phase (19:00 – 
20:00). General behaviour monitoring was undertaken between 4 – 6 weeks post-AAV 
administration. Behaviour was monitored for 1 hour in 5 minute intervals by two observers blinded 
to the treatment groups. The beginning of each 5 minute interval was divided into three five second 
intervals and the behaviour of the mouse was observed on each 5 second interval. Mouse behaviour 
was categorised as feeding, drinking, locomotion, rearing, climbing, stationary, sleeping, bed-
making, burrowing and grooming (Table 2.1).  
 
4.2.12 Intra-medial amygdala (MeA) administration of AAV-Cre-GFP in MC4R-/-mice 
 
4.2.12.1 GFP expression and MC4R immunoreactivity in the medial amygdala (MeA) following 
intra-MeA administration of AAV-Cre-GFP in MC4R-/- mice 
 
GFP expression was investigated post-intra-MeA administration of AAV-GFP-Cre to confirm accurate 
targeting and the ability of the AAV to drive gene expression. MC4R immunoreactivity was assessed 
in the MeA post-intra-MeA administration of AAV-GFP-Cre to investigate MC4R re-expression. MC4R 
immunoreactivity was also investigated in the VTA to determine whether there was any presynaptic 
re-expression in the VTA.  
 
Male 22 week old MC4R-/- mice which had previously undergone bilateral intra-MeA administration 
of AAV-Cre-GFP or AAV-GFP constructs were transcardially perfused for analysis of GFP expression 
(n=3) and MC4R immunoreactivity (n=3) at 100 days post-administration. 
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4.2.12.2 The effect of bilateral intra-medial amygdala (MeA) administration of AAV-GFP or AAV-
Cre-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
It was hypothesised that MC4R may signal pre-synaptically within the VTA. The MeA is a nucleus 
within the mesocorticolimbic system which expresses MC4R and sends afferent projections to the 
VTA. The MeA was thus proposed as a putative source of presynaptic MC4R projections into the 
VTA. The effect of expression of cre recombinase in the MeA to drive endogenous MC4R re-
expression on chronic food intake and body weight was thus investigated. Mice were fed a 60% HFD 
after administration of Cre-recombinase into the MeA as it was hypothesised that a highly palatable 
diet would be more likely to reveal any effect on chronic food intake and body weight in these mice.  
 
Male 8 week old MC4R-/- mice were randomised into treatment groups by body weight and received 
intra-MeA bilateral administration of either AAV-Cre-GFP or a control AAV-GFP construct (n=8). Mice 
were individually housed following bilateral administration surgery and fed ad libitum RM3 diet with 
free access to water. At day 20 all mice were switched to an ad libitum 60% HFD with free access to 
water. Body weight and cumulative food weight was measured at the same time of day (10:00) three 
times a week immediately following administration for 100 days. A fasting re-feeding study was 
conducted on day 70 in these mice but was not fully completed.  
 
4.2.12.3 The effect of bilateral intra-medial amygdala (MeA) administration of AAV-GFP or AAV-
Cre-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
The effect of acute intra-VTA melanocortin signalling on acute food intake in ad libitum fed rodents 
was investigated in studies described in chapter 2. Conditional re-expression of MC4R in the MeA 
was investigated to determine whether the MeA was the source of presynaptic MC4R in the VTA, 
and the role of MeA MC4R signalling in chronic food intake and body weight. To establish the 
behavioural effects of intra-MeA AAV-Cre-GFP administration in MC4R-/- mice, general behaviour 
was monitored post-AAV administration using an adapted observational protocol as described in 
section 2.2.13.  
 
To establish the specific effects of intra-MeA AAV-Cre-GFP administration on feeding behaviour in 
MC4R-/- mice, breakpoint to commence seeking and total duration spent seeking a palatable 
foodstuff was observed post-AAV administration using an adapted observational protocol as 
described in section 2.2.14.  
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Male 14 week old MC4R-/- mice which had previously undergone bilateral intra-MeA administration 
of AAV-Cre-GFP or AAV-GFP constructs (n=8) were fed ad libitum and monitored at the onset of the 
light phase (09:00 – 10:00) and at the onset of the dark phase (19:00 – 20:00). Behaviour was 
recorded as described in section 4.2.11.3. 
 
Male 15 week old MC4R-/- mice which had previously undergone bilateral intra-MeA administration 
of AAV-Cre-GFP or AAV-GFP constructs (n=8) were fed ad libitum and monitored at the onset of the 
light phase (09:00) and at the onset of the dark phase (19:00). Food-seeking behaviour monitoring 
was undertaken between 4 – 6 weeks post-AAV administration. Mice were consistently placed in the 
same quadrant of the open field chamber and the peanut butter filled eppendorf consistently placed 
in an opposite quadrant at time zero. Breakpoint to initiate food seeking behaviour was defined as 
the time at which sniffing, licking or touching the eppendorf with the front paws commenced. Total 
time spent food seeking was defined as the total time recorded sniffing, licking or touching the 
eppendorf with the front paws during 10 minutes. Mice were returned to their cages following 
behavioural observation completion.  
 
4.2.13 Results following intra-lateral septal (LS) administration of AAV-GFP or AAV-Cre-GFP in 
MC4R-/- mice 
 
4.2.13.1 GFP expression and MC4R immunoreactivity in the lateral septal nuclei (LS) following 
intra-LS administration of AAV-Cre-GFP in MC4R-/- mice 
 
GFP expression was investigated post-intra-LS administration of AAV-Cre-GFP to confirm accurate 
targeting and the ability of the AAV to drive gene expression. MC4R immunoreactivity was assessed 
in the LS post-intra-LS administration of AAV-Cre-GFP to investigate MC4R re-expression. MC4R 
immunoreactivity was also investigated in the VTA to determine whether there was any presynaptic 
re-expression in the VTA.  
 
Male 22 week old MC4R-/- mice which had previously undergone bilateral intra-LS administration of 
AAV-Cre-GFP or AAV-GFP constructs were transcardially perfused for analysis of GFP expression 
(n=2) and MC4R immunoreactivity (n=2) at 90 days post-administration. 
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4.2.13.2 The effect of bilateral intra-lateral septal nuclei (LS) administration of AAV-Cre-GFP or 
AAV-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
The LS are a set of nuclei within the mesocorticolimbic system which express MC4R and sends 
reciprocal projections to the VTA. The LS were thus hypothesised as a possible source of presynaptic 
MC4R projections into the VTA. The effect of expression of cre recombinase into the LS, to drive 
endogenous MC4R re-expression, on chronic food intake and body weight was thus investigated. 
Mice were fed a 60% HFD after administration of cre recombinase into the LS as it was hypothesised 
that a highly palatable diet would be more likely to reveal any effect on chronic food intake and 
body weight in these mice. 
 
Male 8 week old MC4R-/- mice were randomised into treatment groups by body weight and received 
intra-LS bilateral administration of either a control AAV-GFP construct or AAV-Cre-GFP (n=3). Mice 
were individually housed following bilateral administration surgery and fed ad libitum RM3 diet with 
free access to water. At day 70 all mice were switched to an ad libitum 60% HFD with free access to 
water. Body weight and cumulative food weight was measured at the same time of day (10:00) three 
times a week immediately following administration for 90 days.  
 
 
4.2.13.3 The effect of bilateral intra-lateral septal nuclei (LS) administration of AAV-Cre-GFP or 
AAV-GFP on general behaviour in MC4R-/- mice 
 
To establish the behavioural effects of intra-LS AAV-Cre-GFP administration in MC4R-/- mice, general 
behaviour was monitored post-AAV administration using an adapted observational protocol as 
described in section 2.2.13.  
 
Male 14 week old MC4R-/- mice which had previously undergone bilateral intra-LS administration of 
AAV-GFP or AAV-Cre-GFP constructs (n=3) were fed ad libitum and monitored at the onset of the 
light phase (09:00 – 10:00) and at the onset of the dark phase (19:00 – 20:00). Behaviour was 
monitored as described in section 4.2.11.3.  
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4.2.14 Intra-nucleus accumbens shell (NAcbSh) administration of AAV-GFP or AAV-Cre-GFP in 
MC4R-/- mice 
 
4.2.14.1 GFP expression and MC4R immunoreactivity in the nucleus accumbens shell (NAcbSh) 
following intra-NAcbSh administration of AAV-Cre-GFP in MC4R-/- mice 
 
GFP expression was investigated post-intra-NAcbSh administration of AAV-GFP-Cre to confirm 
accurate targeting and the ability of the AAV to drive gene expression. MC4R immunoreactivity was 
assessed in the NAcbSh post-intra-NAcbSh administration of AAV-GFP-Cre to investigate MC4R re-
expression. MC4R immunoreactivity was also investigated in the VTA to determine whether there 
was any presynaptic re-expression in the VTA.  
 
Male 22 week old MC4R-/- mice which had previously undergone bilateral intra-NAcbSh 
administration of AAV-Cre-GFP or AAV-GFP constructs were transcardially perfused for analysis of 
GFP expression (n=2) and MC4R immunoreactivity (n=2) at 100 days post-administration. 
 
4.2.14.2 The effect of bilateral intra-nucleus accumbens shell (NAcbSh) administration of AAV-
Cre-GFP or AAV-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
The NAcbSh is a nucleus within the mesocorticolimbic system which expresses MC4R and sends 
afferent projections to the VTA. The NAcbSh was thus hypothesised as a possible source of 
presynaptic MC4R projections into the VTA. The effect of expression of cre recombinase into the 
NAcbSh, to drive endogenous MC4R re-expression, on chronic food intake and body weight was thus 
investigated. Mice were fed a 60% HFD after administration of cre recombinase into the NAcbSh as it 
was hypothesised that a highly palatable diet would be more likely to reveal any effect on chronic 
food intake and body weight in these mice.  
 
Male 8 week old MC4R-/- mice were randomised into treatment groups by body weight and received 
intra-NAcbSh bilateral administration of either a control AAV-GFP construct or AAV-Cre-GFP (n=3). 
Mice were individually housed following bilateral administration surgery and fed ad libitum RM3 diet 
with free access to water. At day 20 all mice were switched to an ad libitum 60% HFD with free 
access to water. Body weight and cumulative food weight was measured at the same time of day 
(10:00) three times a week immediately following administration for 90 days.  
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4.2.14.3 The effect of bilateral intra-nucleus accumbens shell (NAcbSh)  administration of AAV-
Cre-GFP or AAV-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
To establish the behavioural effects of intra-NAcbSh AAV-Cre-GFP administration in MC4R-/- mice, 
general behaviour was monitored post-AAV administration using an adapted observational protocol 
as described in section 2.2.13. To establish the specific effects of intra-NAcbSh AAV-Cre-GFP 
administration on feeding behaviour in MC4R-/- mice, breakpoint to commence seeking and total 
duration spent seeking a palatable foodstuff was observed post-AAV administration using an 
adapted observational protocol as described in section 2.2.14.  
 
Male 14 week old MC4R-/- mice which had previously undergone bilateral intra-NAcbSh 
administration of AAV-GFP or AAV-Cre-GFP constructs (n=3) were fed ad libitum and monitored at 
the onset of the light phase (09:00 – 10:00) and at the onset of the dark phase (19:00 – 20:00). 
Behaviour was monitored as described in section 4.2.11.3. Male 15 week old MC4R-/- mice which had 
previously undergone bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP constructs 
(n=3) were fed ad libitum and monitored at the onset of the light phase (09:00) and at the onset of 
the dark phase (19:00). Food seeking behaviour was monitored as described in section 4.2.12.3.  
 
4.2.15 Intra-ventral pallidum (VP) administration of AAV-GFP or AAV-Cre-GFP in MC4R-/- mice 
 
4.2.15.1 GFP expression and MC4R immunoreactivity in the ventral pallidum (VP) following 
intra-VP administration of AAV-Cre-GFP in MC4R-/- mice 
 
GFP expression was investigated in the VP post-intra-VP administration of AAV-GFP-Cre to confirm 
accurate targeting and the ability of the AAV to drive gene expression. MC4R immunoreactivity was 
assessed in the VP post-intra-VP administration of AAV-GFP-Cre to investigate MC4R re-expression. 
MC4R immunoreactivity was also investigated in the VTA to determine whether there was any 
presynaptic re-expression in the VTA.  
 
Male 22 week old MC4R-/- mice which had previously undergone bilateral intra-VP administration of 
AAV-GFP or AAV-Cre-GFP constructs were transcardially perfused for analysis of GFP expression 
(n=3) and MC4R immunoreactivity (n=3) at 90 days post-administration. 
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4.2.15.2 The effect of bilateral intra-ventral pallidum (VP) administration of AAV-Cre-GFP or 
AAV-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
The VP is a nucleus within the mesocorticolimbic system which expresses MC4R and sends efferent 
projections to the VTA. The VP was thus hypothesised as a possible source of presynaptic MC4R 
projections into the VTA. The effect of expression of cre recombinase into the VP, to drive 
endogenous MC4R re-expression, on chronic food intake and body weight was thus investigated. 
Mice were fed a 60% HFD after administration of cre recombinase into the VP as it was hypothesised 
that a highly palatable diet would be more likely to reveal any effect on chronic food intake and 
body weight in these mice.  
 
Male 8 week old MC4R-/- mice were randomised into treatment groups by body weight and received 
intra-VP bilateral administration of either a control AAV-GFP construct or AAV-Cre-GFP (n=6). Mice 
were individually housed following bilateral administration surgery and fed ad libitum RM3 diet with 
free access to water. At day 70 all mice were switched to an ad libitum 60% HFD with free access to 
water. Body weight and cumulative food weight was measured at the same time of day (10:00) three 
times a week immediately following administration for 90 days.  
 
4.2.15.3 The effect of bilateral intra-ventral pallidum (VP) administration of AAV-Cre-GFP or 
AAV-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
To establish the behavioural effects of intra-VP AAV-Cre-GFP administration in MC4R-/- mice, general 
behaviour was monitored post-AAV administration using an adapted observational protocol as 
described in section 2.2.13. To establish the specific effects of intra-VP AAV-Cre-GFP administration 
on feeding behaviour in MC4R-/- mice, breakpoint to commence seeking and total duration spent 
seeking a palatable foodstuff was observed post-AAV administration using an adapted observational 
protocol as described in section 2.2.14.  
 
Male 14 week old MC4R-/- mice which had previously undergone bilateral intra-VP administration of 
AAV-GFP or AAV-Cre-GFP constructs (n=6) were fed ad libitum and monitored at the onset of the 
light phase (09:00 – 10:00) and at the onset of the dark phase (19:00 – 20:00). Behaviour was 
monitored as described in section 4.2.11.3. Male 15 week old MC4R-/- mice which had previously 
undergone bilateral intra-VP administration of AAV-Cre-GFP or AAV-GFP constructs (n=6) were fed 
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ad libitum and monitored at the onset of the light phase (09:00) and at the onset of the dark phase 
(19:00). Food seeking behaviour was monitored as described in section 4.2.12.3. 
 
4.2.16 Statistics 
 
All body weight and cumulative food intake data (in grams and kcal) is presented as mean ± standard 
error of the mean (SEM). General behavioural and food seeking behavioural observational data is 
presented as the median, inter-quartile and total range. Chronic body weight and cumulative food 
intake data was analysed using the Generalised Estimating Equation (GEE) (Stata Version 9, TX, USA). 
General behavioural and food seeking behavioural observational data was analysed using a Mann-
Whitney test, or if repeated values were observed, data was analysed using a Wilcoxon signed rank 
test (GraphPad Prism Version 5.01, GraphPad Software, CA, USA). In all data analyses P values were 
defined as the following: p<0.05, *, p<0.01, **, p<0.001, ***.  
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4.3 Results 
 
 
4.3.1 Verification of accurate intra-VTA ink injection for AAV administration  
 
Co-ordinates targeting the PBP of the VTA were located and confirmed with intra-nuclear ink 
injection in mice as described in section 2.2.4.  
 
4.3.2 Verification of accurate intra-medial amygdala (MeA) ink injection for AAV administration  
 
Co-ordinates targeting the MeA were located and confirmed with intra-nuclear ink injection. Ink 
staining was observed unilaterally in the right MeA in 100% of mice (n=2) with limited spread to 
surrounding brain areas. A representative bright field microphotograph is shown in Figure 4.3A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Verification of accurate ink injection targeting the medial amygdala (MeA) in mice. 
Abbreviations: MeAD, medial amygdaloid nucleus anterodorsal part; MeAV, medial amygdaloid 
nucleus anteroventral part. Mice received a unilateral injection of 0.5µl 1:40 v/v Indian ink in 0.01M 
PBS into the right MeA. MeA co-ordinates were located at 1.0mm caudal from bregma, 1.7mm 
lateral from bregma and 5.2mm ventral from the surface of the brain. Brain tissue was 
counterstained with cresyl violet solution. A) Mouse brain section located at 1.00mm caudal to 
bregma. B) Representative brain map located at 1.06mm caudal to bregma adapted from ‘The 
Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.15mm.  
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4.3.3 Verification of accurate intra-lateral septal nuclei (LS) ink injection for AAV administration  
 
Co-ordinates targeting the LS were located and confirmed with intra-nuclear ink injection. Ink 
staining was observed unilaterally in the right LS in 100% of mice (n=2) with limited spread to 
surrounding brain areas. A representative bright field microphotograph is shown in Figure 4.4A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Verification of accurate ink injection targeting the lateral septal nuclei (LS) in mice. 
Abbreviations: LSD, lateral septal nucleus dorsal part; LSI, lateral septal nucleus intermediate part. 
Mice received a unilateral injection of 0.5µl 1:40 v/v Indian ink in 0.01M PBS into the right LS. LS co-
ordinates were located at 0.2mm rostral from bregma, 0.25mm lateral from bregma and 3mm 
ventral from the surface of the brain. Brain tissue was counterstained with cresyl violet solution. A) 
Mouse brain section located at 0.2mm rostral to bregma. B) Representative brain map located at 
0.26mm caudal to bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and 
Paxinos 2007). Scale bar represents 0.25mm.  
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4.3.4 Verification of accurate intra-nucleus accumbens shell (NAcbSh) ink injection for AAV 
administration  
 
Co-ordinates targeting the NAcbSh were located and confirmed with intra-nuclear ink injection. Ink 
staining was observed unilaterally in the right NAcbSh in 100% of mice (n=2) with limited spread to 
surrounding brain areas. A representative bright field microphotograph is shown in Figure 4.5A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Verification of accurate ink injection targeting the nucleus accumbens shell (NAcbSh) in 
mice. Abbreviations: AcbSh, nucleus accumbens shell. Mice received a unilateral injection of 0.5µl 
1:40 v/v Indian ink in 0.01M PBS into the right NAcbSh. NAcbSh co-ordinates were located at 1.5mm 
rostral from bregma, 0.6mm lateral from bregma and 4mm ventral from the surface of the brain. 
Brain tissue was counterstained with cresyl violet solution. A) Mouse brain section located at mm 
caudal to bregma. B) Representative brain map located at 1.54mm rostral from bregma adapted 
from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 
0.25mm.  
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4.3.5 Verification of accurate intra-ventral pallidum (VP) ink injection for AAV administration  
 
Co-ordinates targeting the VP were located and confirmed with intra-nuclear ink injection. Ink 
staining was observed unilaterally in the right VP in 100% of mice (n=2) with limited spread to 
surrounding brain areas. A representative bright field microphotograph is shown in Figure 4.6A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Verification of accurate ink injection targeting the ventral pallidum (VP) in mice. 
Abbreviations: VP, ventral pallidum. Mice received a unilateral injection of 0.5µl 1:40 v/v Indian ink 
in 0.01M PBS into the right VP. VP co-ordinates were located at 0.0mm caudal from bregma, 2.0mm 
lateral from bregma and 4.5mm ventral from the surface of the brain. Brain tissue was 
counterstained with cresyl violet solution. A) Mouse brain section located at 0mm caudal to bregma. 
B) Representative brain map located at 0.02mm caudal to bregma adapted from ‘The Mouse Brain in 
Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 0.25mm.  
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4.3.6 The effect of MC4R-/-, MC4R+/-, and MC4R+/+  genotype on body weight in male and female 
B6;12934-Mc4rtmLowl/J mice 
 
The body weight of male MC4R-/-mice was increased compared to male MC4R+/-and male 
MC4R+/+mice at day 140 (MC4R+/+: 34.64 ± 1.12 vs. MC4R+/-: 40.14 ± 2.66 and MC4R-/-: 49.57 ± 2.42). 
The body weight of male MC4R-/-mice was increased over the total 140 days compared to male 
MC4R+/-and male MC4R+/+mice according to GEE analysis (MC4R-/- vs. MC4R+/+: p<0.001, MC4R-/- vs.  
MC4R+/-: p<0.01). The body weight of female MC4R-/-mice was increased compared to female 
MC4R+/-and female MC4R+/+mice at day 140 (MC4R+/+: 28.41 ± 1.01 vs. MC4R+/-: 35.69 ± 1.11 and 
MC4R-/-: 46.49 ± 1.83). The body weight of female MC4R-/-mice was increased over the total 140 days 
compared to female MC4R+/-and female MC4R+/+mice according to GEE analysis (MC4R-/- vs.  
MC4R+/+: p<0.001, MC4R-/- vs.  MC4R+/-: p<0.001) (Figure 4.7).  
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Figure 4.7 Body weight of MC4R-/-, MC4R+/- and MC4R+/+ male and female B6;12934-Mc4rtmLowl/J 
mice. Male and female mice were weighed from 3 to 20 weeks of age. Body weight is expressed as 
mean grams of body weight ± SEM and analysed using GEE. (n=5-9). *p<0.5, **p<0.01, ***p<0.001.   
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4.3.7 GFP expression and MC4R immunoreactivity in the PBP following intra-VTA administration 
of AAV-Cre-GFP in MC4R-/- mice 
 
Intra-VTA administration of AAV-Cre-GFP in MC4R-/- mice resulted in bilateral expression of GFP 
fluorescence localised to the VTA in 100% of mice examined (n=3), with limited spread to 
surrounding brain areas. However, intra-VTA administration of AAV-Cre-GFP in MC4R-/- mice did not 
result in visible MC4R immunoreactivity in the VTA or any other brain region (n=4). Representative 
fluorescence pictures are shown in Figure 4.8.  
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Figure 4.8 The effect of intra-VTA administration of AAV-Cre-GFP on GFP expression and MC4R 
immunoreactivity in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations: PBP, parabrachial 
pigmented nucleus of the VTA; MC4R, melanocortin receptor 4; AAV, adeno-associated virus; GFP, 
green fluorescent protein; Cre, cre-recombinase. Male MC4R-/- mice received bilateral injection of 
0.5µl AAV-Cre-GFP into the PBP of the VTA.  Mice were culled 14 weeks post AAV-Cre-GFP 
administration. PBP co-ordinates were located at 3.2mm caudal from bregma, 0.5mm lateral from 
bregma and 4.8mm ventral from the surface of the brain. A) AAV-Cre-GFP administered MC4R-/- 
mouse brain section located at 3.52mm caudal to bregma. B) Representative brain map located at 
3.52mm caudal to bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and 
Paxinos 2007). Scale bar represents 250µmmm. C) AAV-GFP administered MC4R-/- mouse brain 
section located at 3.2mm caudal to bregma. D) AAV-Cre-GFP administered MC4R-/- mouse brain 
section located at 3.2mm caudal to bregma. Scale bar represents 20µm.  
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4.3.8 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R+/+ and MC4R-/- mice 
 
The body weight of male MC4R-/- mice administered intra-VTA AAV-Cre-GFP was not significantly 
different to male MC4R-/- mice administered intra-VTA AAV-GFP, at day 80 post-administration or for 
the total duration of the experiment. The body weight of male WT controls administered intra-VTA 
AAV-Cre-GFP was not significantly different to male WT controls administered intra-VTA AAV-GFP, at 
day 90 post-administration or for the total duration of the experiment. Cumulative food intake of 
male MC4R-/- mice administered intra-VTA AAV-Cre-GFP was not significantly different to male 
MC4R-/- mice administered intra-VTA AAV-GFP at day 80 post-administration or for the total duration 
of the experiment. Cumulative food intake of male WT controls administered intra-VTA AAV-Cre-GFP 
was not significantly different to male WT controls administered intra-VTA AAV-GFP at day 80 post-
administration or for the total duration of the experiment (Figure 4.9). 
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Figure 4.9 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R+/+ and MC4R-/- mice on body weight in male B6;12934-
Mc4rtmLowl/J mice. A) Male MC4R+/+ and MC4R-/- mice were weighed from 0 to 80 days post AAV 
administration. Body weight is expressed as mean grams of body weight ± SEM and analysed using 
GEE. (n=6-11). B) Food intake is expressed as mean grams of RM3 diet ± SEM and analysed using 
GEE. (n=6-11).  
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4.3.9 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on general 
behaviour in MC4R-/- and MC4R+/+ mice 
 
Bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R+/+ mice 
resulted in a difference in bed-making behaviour only during the 0-1 hour time interval at the onset 
of the early dark phase (MC4R+/+ AAV-GFP: 7.83 ± 1.74 vs. MC4R+/+ AAV-Cre-GFP: 2.00 ± 1.67, p<0.05) 
(Figure 4.10B). Bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed 
MC4R+/+ mice did not result in any significant difference in general behaviour during the 0-1 hour 
time interval at the onset of the early light phase (Figure 4.10A).  
 
Bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not 
result in any significant difference in general behaviour during the 0-1 hour time interval at the onset 
of the early light phase or at the onset of the early dark phase (Figure 4.11).  
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Figure 4.10 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R+/+  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R+/+ mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=6-11). 
*p<0.05. 
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Figure 4.11 The effect of bilateral intra-VTA administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R-/- mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=6-11).  
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4.3.10 GFP expression and MC4R immunoreactivity in the medial amygdala (MeA) following 
intra-MeA administration of AAV-Cre-GFP in MC4R-/- mice 
 
Intra-MeA administration of AAV-Cre-GFP in MC4R-/- mice resulted in bilateral expression of GFP 
fluorescence partially localised to the MeA in 100% of mice examined (n=3), with moderate spread 
to surrounding brain areas. Intra-MeA administration of AAV-Cre-GFP in MC4R-/- mice resulted in 
visible MC4R immunoreactivity in the MeA with limited spread to surrounding brain areas (n=3). 
Representative fluorescence pictures are shown in Figure 4.12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 The effect of intra-MeA administration of AAV-Cre-GFP on GFP expression and MC4R 
immunoreactivity in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations: MeAD, medial 
amygdaloid nucleus anterodorsal part; MeAV, medial amygdaloid nucleus anteroventral part; MC4R, 
melanocortin receptor 4; AAV, adeno-associated virus; GFP, green fluorescent protein; Cre, cre-
recombinase. Male MC4R-/- mice received bilateral injection of 0.5µl AAV-Cre-GFP into the MeA.  
Mice were culled 14 weeks post AAV-Cre-GFP administration. MeA co-ordinates were located at 
1.0mm caudal from bregma, 1.7mm lateral from bregma and 5.2mm ventral from the surface of the 
brain. A) AAV-Cre-GFP administered MC4R-/- mouse brain section located at 1.0mm caudal to 
bregma. B) Representative brain map located at 1.0mm caudal to bregma adapted from ‘The Mouse 
Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 200µm. C) AAV-
GFP administered MC4R-/- mouse brain section located at 1.0mm caudal to bregma. D) AAV-Cre-GFP 
administered MC4R-/- mouse brain section located at 1.0mm caudal to bregma. Scale bar represents 
5µm.  
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4.3.11 The effect of bilateral intra-medial amygdala (MeA) administration of AAV-GFP or AAV-
Cre-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
Mice were given a HFD from day 20 as it was hypothesised that this might exacerbate any 
differences in energy homeostasis caused by re-expression of MC4R in the MeA. The body weight of 
male MC4R-/- mice administered intra-MeA AAV-Cre-GFP was not significantly different to male 
MC4R-/- mice administered intra-MeA AAV-GFP at day 90 post-administration or for the total 
duration of the experiment. Cumulative food intake of male MC4R-/- mice administered intra-MeA 
AAV-Cre-GFP was not significantly different to male MC4R-/- mice administered intra-MeA AAV-GFP 
at day 100 post-administration or for the total duration of the experiment (Figure 4.13). 
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Figure 4.13 The effect of bilateral intra-MeA administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R-/- B6;12934-Mc4rtmLowl/J mice. A) Male MC4R-/- mice 
were weighed from 0 to 100 days post AAV administration. Body weight is expressed as mean grams 
of body weight ± SEM and analysed using GEE. (n=8). B) Food intake is expressed as mean grams of 
RM3 diet or 60% HFD ± SEM and analysed using GEE. (n=8). A fasting re-feeding study was 
conducted on day 70 in these mice (data not shown due to incompletion of study).  
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4.3.12 The effect of bilateral intra-medial amygdala (MeA) administration of AAV-GFP or AAV-
Cre-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
Bilateral intra-MeA administration of AAV-Cre-GFP in ad libitum fed MC4R-/- mice resulted in a 
difference in bed-making behaviour only during the 0-1 hour time interval at the onset of the early 
light phase (MC4R-/- AAV-GFP: 1.62 ± 0.59 vs. MC4R-/- AAV-Cre-GFP: 4.75 ± 1.14, p<0.05). Bilateral 
intra-MeA administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not result in 
any significant difference in general behaviour during the 0-1 hour time interval at the onset of the 
early dark phase (Figure 4.14).  
 
Bilateral intra-MeA administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not 
result in any significant difference in food seeking duration or food seeking breakpoint behaviour at 
the onset of the light phase or dark phase between groups (Figure 4.15).  
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Figure 4.14 The effect of bilateral intra-MeA administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R-/- mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=8). *p<0.05. 
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Figure 4.15 The effect of bilateral intra-MeA administration of AAV- GFP or AAV-Cre-GFP on food 
seeking behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase 
and early dark phase. Food seeking behaviour was monitored in MC4R-/- mice at the onset of the 
light phase (09:00) and at the onset of the dark phase (19:00). A) Food seeking duration and B) food 
seeking breakpoint in the light phase, and C) Food seeking duration and D) food seeking breakpoint 
in the dark phase is expressed as the median and interquartile range of the number of seconds 
observed during a 0-10 minute time interval (n=8).  
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4.3.13 GFP expression and MC4R immunoreactivity in the lateral septal nuclei (LS) following intra-
LS administration of AAV-Cre-GFP in MC4R-/- mice 
 
Intra-LS administration of AAV-Cre-GFP in MC4R-/- mice resulted in bilateral expression of GFP 
fluorescence localised to the LS in 100% of mice examined (n=2), with limited spread to surrounding 
brain areas. Intra-LS administration of AAV-Cre-GFP in MC4R-/- mice resulted in visible MC4R 
immunoreactivity in the LS with limited spread to surrounding brain area (n=2). Representative 
fluorescence pictures are shown in Figure 4.16.  
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Figure 4.16 The effect of intra-LS administration of AAV-Cre-GFP on GFP expression and MC4R 
immunoreactivity in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations: LSI, lateral septal 
nucleus intermediate part; MC4R, melanocortin receptor 4; AAV, adeno-associated virus; GFP, green 
fluorescent protein; Cre, cre-recombinase. Male MC4R-/- mice received bilateral injection of 0.5µl 
AAV-Cre-GFP into the LS.  Mice were culled 14 weeks post AAV-Cre-GFP administration. LS co-
ordinates were located at 0.2mm rostral from bregma, 0.25mm lateral from bregma and 3.0mm 
ventral from the surface of the brain. A) AAV-Cre-GFP administered MC4R-/- mouse brain section 
located at 0.2mm caudal to bregma. B) Representative brain map located at 0.26mm caudal to 
bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). 
Scale bar represents 200µm. C) AAV-GFP administered MC4R-/- mouse brain section located at 
0.2mm caudal to bregma. D) AAV-Cre-GFP administered MC4R-/- mouse brain section located at 
0.2mm caudal to bregma. Scale bar represents 20µm.  
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4.3.14 The effect of bilateral intra-lateral septal nuclei (LS) administration of AAV-GFP or AAV-
Cre-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
Only three mice in each group were injected as a pilot study to identify whether the MC4R in the LS 
might be important in energy homeostasis. The body weight of male MC4R-/- mice administered 
intra-LS AAV-Cre-GFP was not significantly different to male MC4R-/- mice administered intra-LS AAV-
GFP at day 90 post-administration or for the total duration of the experiment. Cumulative food 
intake of male MC4R-/- mice administered intra-LS AAV-Cre-GFP was not significantly different to 
male MC4R-/- mice administered intra-LS AAV-GFP at day 90 post-administration or for the total 
duration of the experiment (Figure 4.17). 
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Figure 4.17 The effect of bilateral intra-LS administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R-/- B6;12934-Mc4rtmLowl/J mice. A) Male MC4R-/- mice 
were weighed from 0 to 90 days post AAV administration. Body weight is expressed as mean grams 
of body weight ± SEM and analysed using GEE. (n=3). B) Food intake is expressed as mean grams of 
RM3 diet or 60% HFD ± SEM and analysed using GEE. (n=3).  
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4.3.15 The effect of bilateral intra-lateral septal nuclei (LS) administration of AAV-GFP or AAV-
Cre-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
Bilateral intra-LS administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not 
result in any significant difference in general behaviour at the onset of the light phase and at the 
onset of the dark phase (Figure 4.18).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 The effect of bilateral intra-LS administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R-/- mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=3).  
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4.3.16 GFP expression and MC4R immunoreactivity in the nucleus accumbens shell (NAcbSh) 
following intra-NAcbSh administration of AAV-Cre-GFP in MC4R-/- mice 
 
Intra-NAcbSh administration of AAV-Cre-GFP in MC4R-/- mice resulted in bilateral expression of GFP 
fluorescence localised to the NAcbSh in 100% of mice (n=2) with limited spread to surrounding brain 
areas. Intra-NAcbSh administration of AAV-Cre-GFP in MC4R-/- mice did not result in visible MC4R 
immunoreactivity in the NAcbSh or any other brain region (n=2). Representative fluorescence 
pictures are observed in Figure 4.19.  
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Figure 4.19 The effect of intra-NAcbSh administration of AAV-Cre-GFP on GFP expression and 
MC4R immunoreactivity in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations: AcbSh, nucleus 
accumbens shell; MC4R, melanocortin receptor 4; AAV, adeno-associated virus; GFP, green 
fluorescent protein; Cre, cre-recombinase. Male MC4R-/- mice received bilateral injection of 0.5µl 
AAV-Cre-GFP into the NAcbSh.  Mice were culled 14 weeks post AAV-Cre-GFP administration. 
NAcbSh co-ordinates were located at 1.5mm rostral from bregma, 0.6mm lateral from bregma and 
4.0mm ventral from the surface of the brain. A) AAV-Cre-GFP administered MC4R-/- mouse brain 
section located at 1.5mm rostral to bregma. B) Representative brain map located at 1.54mm rostral 
to bregma adapted from ‘The Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). 
Scale bar represents 300µm. C) AAV-GFP administered MC4R-/- mouse brain section located at 
1.5mm caudal to bregma. D) AAV-Cre-GFP administered MC4R-/- mouse brain section located at 
1.5mm caudal to bregma. Scale bar represents 30µm.  
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4.3.17 The effect of bilateral intra-nucleus accumbens shell (NAcbSh) administration of AAV-GFP 
or AAV-Cre-GFP on body weight and cumulative food intake in MC4R-/- mice 
 
Only three mice in each group were injected as a pilot study to identify whether the MC4R in the 
NAcbSh might be important in energy homeostasis. The body weight of male MC4R-/- mice 
administered intra-NAcbSh AAV-Cre-GFP was not significantly different to male MC4R-/- mice 
administered intra-NAcbSh AAV-GFP at day 90 post-administration or for the total duration of the 
experiment. Cumulative food intake of male MC4R-/- mice administered intra-NAcbSh AAV-Cre-GFP 
was not significantly different to male MC4R-/- mice administered intra-NAcbSh AAV-GFP at day 90 
post-administration or for the total duration of the experiment (Figure 4.20). 
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Figure 4.20 The effect of bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP on 
body weight and cumulative food intake in MC4R-/- B6;12934-Mc4rtmLowl/J mice. A) Male MC4R-/- 
mice were weighed from 0 to 90 days post AAV administration. Body weight is expressed as mean 
grams of body weight ± SEM and analysed using GEE. (n=3). B) Food intake is expressed as mean 
grams of RM3 diet or 60% HFD ± SEM and analysed using GEE. (n=3).  
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4.3.18 The effect of bilateral intra-nucleus accumbens shell (NAcbSh) administration of AAV-GFP 
or AAV-Cre-GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
Bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did 
not result in any significant difference in general behaviour at the onset of the light phase and at the 
onset of the dark phase (Figure 4.21).   
 
Bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did 
not result in any significant difference in food seeking duration or food seeking breakpoint behaviour 
at the onset of the light phase or dark phase between groups (Figure 4.22) 
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Figure 4.21 The effect of bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R-/- mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=3).  
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Figure 4.22 The effect of bilateral intra-NAcbSh administration of AAV-GFP or AAV-Cre-GFP on 
food seeking behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light 
phase and early dark phase. Food seeking behaviour was monitored in MC4R-/- mice at the onset of 
the light phase (09:00) and at the onset of the dark phase (19:00). A) Food seeking duration and B) 
food seeking breakpoint in the light phase, and C) Food seeking duration and D) food seeking 
breakpoint in the dark phase is expressed as the median and interquartile range of the number of 
seconds observed during a 0-10 minute time interval (n=3).  
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4.3.19 GFP expression and MC4R immunoreactivity in the ventral pallidum (VP) following intra-
VP administration of AAV-Cre-GFP in MC4R-/- mice 
 
Intra-VP administration of AAV-Cre-GFP in MC4R-/- mice resulted in bilateral expression of GFP 
fluorescence localised to the VP in 100% of mice (n=3) with limited spread to surrounding brain 
areas. Intra-VP administration of AAV-Cre-GFP in MC4R-/- mice resulted in visible MC4R 
immunoreactivity in the VP with limited spread to surrounding brain area. Intra-VP administration of 
AAV-Cre-GFP in MC4R-/- mice did not result in visible MC4R immunoreactivity in the PBP of the VTA 
(n=3). Representative fluorescence pictures are observed in Figure 4.23 and Figure 4.24.  
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Figure 4.23 The effect of intra-VP administration of AAV-Cre-GFP on GFP expression and MC4R 
immunoreactivity in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations: VP, ventral pallidum; 
MC4R, melanocortin receptor 4; AAV, adeno-associated virus; GFP, green fluorescent protein; Cre, 
cre-recombinase. Male MC4R-/- mice received bilateral injection of 0.5µl AAV-Cre-GFP into the VP. 
Mice were culled 14 weeks post AAV-Cre-GFP administration. VP co-ordinates were located at 
0.0mm from bregma, 2.0mm lateral from bregma and 4.5mm ventral from the surface of the brain. 
A) AAV-Cre-GFP administered MC4R-/- mouse brain section located at 0.0mm caudal to bregma. B) 
Representative brain map located at 0.02mm caudal to bregma adapted from ‘The Mouse Brain in 
Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007). Scale bar represents 250µm. C) AAV-GFP 
administered MC4R-/- mouse brain section located at 0.2mm caudal to bregma. D) AAV-Cre-GFP 
administered MC4R-/- mouse brain section located at 0.2mm caudal to bregma. Scale bar represents 
5µm. 
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Figure 4.24 The effect of intra-VP administration of AAV-Cre-GFP on MC4R immunoreactivity in the 
PBP of the VTA in male MC4R-/- B6;12934-Mc4rtmLowl/J mice. Abbreviations:VTA, ventral tegmental 
area; MC4R, melanocortin receptor 4; AAV, adeno-associated virus; Cre, cre-recombinase; PBP, 
parabrachial pigmented nucleus. Male MC4R-/- mice received bilateral injection of 0.5µl AAV-Cre-GFP 
into the VP. Mice were culled 14 weeks post AAV-Cre-GFP administration. VP co-ordinates were 
located at 0.0mm from bregma, 2.0mm lateral from bregma and 4.5mm ventral from the surface of 
the brain. A) AAV-GFP administered MC4R-/- mouse brain section located at 3.2mm caudal to 
bregma. B) AAV-Cre-GFP administered MC4R-/- mouse brain section located at 3.2mm caudal to 
bregma. Scale bar represents 25µm.  
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4.3.20 The effect of bilateral intra-ventral pallidum (VP) administration of AAV-GFP or AAV-Cre-
GFP on body weight and cumulative food intake in MC4R-/- mice 
 
The body weight of male MC4R-/- mice administered intra-VP AAV-Cre-GFP was not significantly 
different to male MC4R-/- mice administered intra-VP AAV-GFP at day 90 post-administration or for 
the total duration of the experiment. Cumulative food intake of male MC4R-/- mice administered 
intra-VP AAV-Cre-GFP was significantly decreased compared to male MC4R-/- mice administered 
intra-VP AAV-GFP at day 90 post-administration (MC4R-/- AAV-GFP: 246.1 ± 21.58 vs. MC4R-/- AAV-
Cre-GFP: 209.8 ± 17.56). The cumulative food intake of male MC4R-/- mice administered intra-VP 
AAV-Cre-GFP was significantly decreased over the total 90 days compared to male MC4R-/- mice 
administered intra-VP AAV-GFP according to GEE analysis (MC4R-/- AAV-GFP vs MC4R-/- AAV-Cre-GFP: 
p<0.001) (Figure 4.25). 
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Figure 4.25 The effect of bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP on body 
weight and cumulative food intake in MC4R-/- B6;12934-Mc4rtmLowl/J mice. A) Male MC4R-/- mice 
were weighed from 0 to 90 days post AAV administration. Body weight is expressed as mean grams 
of body weight ± SEM and analysed using GEE. (n=6). B) Food intake is expressed as mean grams of 
RM3 diet or 60% HFD ± SEM and analysed using GEE. (n=6). ***p<0.001.  
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4.3.21 The effect of bilateral intra-ventral pallidum (VP) administration of AAV-GFP or AAV-Cre-
GFP on general behaviour and food seeking behaviour in MC4R-/- mice 
 
Bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice resulted 
in a significant decrease in locomotion behaviour (MC4R-/- AAV-GFP: 4.50 ± 0.76 vs. MC4R-/- AAV-Cre-
GFP: 1.50 ± 0.71, p<0.05), rearing behaviour (MC4R-/- AAV-GFP: 4.50 ± 0.84 vs. MC4R-/- AAV-Cre-GFP: 
2.00 ± 0.57, p<0.05) and burrowing behaviour (MC4R-/- AAV-GFP: 5.50 ± 0.92 vs. MC4R-/- AAV-Cre-
GFP: 0.83 ± 0.30, p<0.01) during the 0-1 hour time interval at the onset of the early dark phase.  
Bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not 
result in any significant difference in general behaviour during the 0-1 hour time interval at the onset 
of the early light phase (Figure 4.26).  
 
Bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP in ad libitum fed MC4R-/- mice did not 
result in any significant difference in food seeking duration or food seeking breakpoint behaviour at 
the onset of the light phase or dark phase between groups (Figure 4.27).  
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Figure 4.26 The effect of bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP on 
behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase and early 
dark phase. Male MC4R-/- mice were monitored A) at the onset of the early light phase (09:00) or B) 
at the onset of the early dark phase (19:00). Behaviour is expressed as the median and interquartile 
range of the number of behavioural observations between a 0-1 hour time interval (n=6). *p<0.05, 
**p<0.01.  
 
 
A 
B 
217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 The effect of bilateral intra-VP administration of AAV-GFP or AAV-Cre-GFP on food 
seeking behaviour in ad libitum fed MC4R-/-  B6;12934-Mc4rtmLowl/J mice in the early light phase 
and early dark phase. Food seeking behaviour was monitored in MC4R-/- mice at the onset of the 
light phase (09:00) and at the onset of the dark phase (19:00). A) Food seeking duration and B) food 
seeking breakpoint in the light phase, and C) Food seeking duration and D) food seeking breakpoint 
in the dark phase is expressed as the median and interquartile range of the number of seconds 
observed during a 0-10 minute time interval (n=6).  
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4.4 Discussion 
 
The studies described in Chapter 2 investigated the acute effects of intra-VTA melanocortin 
administration on food intake, whilst those described in Chapter 3 investigated the effects of intra-
VTA melanocortin administration on neuronal activation in both the VTA and areas of the 
mesocorticolimbic system downstream of the VTA.  The acute effects of melanocortins on feeding 
and neuronal activation have thus been well described in these chapters; however, the physiological 
role of melanocortin signalling via the mesocorticolimbic system has yet to be studied. The 
restoration of melanocortin signalling, via MC4R, in a global KO mouse model is a useful approach 
for the initial characterisation of the physiological role of melanocortin signalling in the 
mesocorticolimbic system in the chronic control of food intake, energy expenditure and feeding 
behaviour.  
 
The conditional MC4R KO mouse model used in these experiments was first developed and 
characterised elsewhere (Balthasar, Dalgaard et al. 2005). The observations made in these previous 
studies reflect those reported here regarding the progression of body weight increase and food 
intake. Adult male MC4R-/- mice are approximately 60% heavier than their WT counterparts, whereas 
adult female MC4R-/- are approximately 90% heavier than their WT counterparts. Both male and 
female MC4R-/+ mice exhibit an intermediate phenotype as a result of the gene dosage effect of 
MC4R.  
 
Intra-VTA administration of AAV-GFP or AAV-Cre-GFP in order to restore MC4R signalling in the VTA 
had no effect on chronic food intake or body weight. Furthermore, there were no significant 
alterations in general behaviour, except a small decrease in bed-making activity in the dark phase, 
which is likely to represent a type I error. This lack of an energy homeostasis phenotype was 
unexpected, as the administration of a specific MC4R agonist, THIQ, to the VTA caused an acute 
reduction in food intake, suggesting the presence of MC4R in the VTA (Chapter 2). It may be that 
MC4R only signals to reduce food intake in times of acute overfeeding, and is thus not important in 
the long term control of food intake as normal physiological bouts of feeding and fasting may mask 
any acute anorectic feeding effects. Thus, MC4R in the VTA may not be important in the chronic 
control of food intake and body weight. However, it has been shown that chronic administration of 
melanocortins into the VTA is able to suppress food intake and reduce body weight (Roseberry 
2013). It would be interesting to observe the effects of intra-VTA administration of AAV-GFP-Cre on 
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acute food-seeking behaviour, as this is a specific feeding behaviour that might be affected by acute 
melanocortin signalling if the animal is ad libitum fed as a baseline.  
 
During the course of these studies, I identified an antibody that appeared to allow specific 
immunohistochemistry to be performed for the MC4R. Using this antibody, I was unable to detect 
MC4R immunoreactivity in any subdivision of the VTA. It can often be difficult to identify protein 
expression in areas of the brain, particularly GPCRs, which require extensive tissue processing 
optimisation.  The VTA is a dense structure containing a large number of cell bodies, and which many 
axon bundles pass through and synapse within. Our data suggest that if MC4R is present in the VTA, 
then this is likely to be at low levels. In accord with this, previous studies suggest that MC4R mRNA is 
either present at extremely low levels in the VTA, or is not expressed there (Kishi, Aschkenasi et al. 
2003, Liu, Kishi et al. 2003, Lippert, Ellacott et al. 2014). Protein immunoreactivity within the brain 
reflects protein expression and is likely to reveal the anatomical position of axon terminal 
projections. MRNA expression within the brain is likely to be detected in the cell body of the neuron 
which expresses the respective protein at its axon terminals. The pattern of protein and mRNA 
expression within the brain can aid in identifying both areas containing the cell bodies of neurons 
expressing the protein of interest, and the areas innervated by those neurons. Considering the 
pharmacological data suggesting the presence of MC4R in the VTA, the difficulty in detecting MC4R 
protein in the VTA, and the lack of MC4R mRNA expression, it is possible that MC4R is present on 
presynaptic terminals in the VTA.  
 
Presynaptic receptors, also known as autoreceptors, often function to inhibit the signalling activity of 
the presynaptic neuron as part of a regulatory negative feedback loop. The presence of presynaptic 
MC4R has been reported in other areas of the brain, including the NTS (Wan, Browning et al. 2008) 
and the PVN (Cowley, Pronchuk et al. 1999). In these studies, activation of MC4R was demonstrated 
to increase the GABAergic inhibitory postsynaptic response. Previous studies in our group found that 
the anorectic effects of NDP-MSH in the rat VTA were blocked by a GABA antagonist.   
 
It was thus hypothesised that the presence of MC4R protein in the VTA may exist on the presynaptic 
membrane of a neuron, rather than the postsynaptic membrane, and that these neurons were likely 
to be GABAergic. Therefore, the presynaptic neuron would project from an area of the brain distinct 
from the VTA, and synapse within the VTA. In this scenario, targeting the VTA with AAV-Cre-GFP 
would not induce the re-expression of presynaptic MC4R, as AAV-Cre-GFP is unlikely to be 
successfully be taken up into the terminals of these neurons and transported back to the cell body 
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where it must integrate in order to re-express MC4R. In order to enable the re-expression of MC4R, 
AAV-Cre-GFP must be targeted to the cell body of a neuron where it can easily gain access to the 
nucleus. My experiments following the VTA MC4R re-expression study thus targeted areas of the 
mesocorticolimbic system which have well known GABAergic neuronal projections to the VTA, and 
are known to express relatively high levels of MC4R mRNA. A comprehensive examination of the 
existing literature resulted in the selection of the MeA, LS, NAcbSh and the VP as promising targets.  
 
The MeA of the amygdala was selected based on the established high expression of MC4R and the 
known neuronal projections to and from the VTA (Sah, Faber et al. 2003). Intra-MeA administration 
of AAV-Cre-GFP had no effect on chronic food intake, body weight, general behaviour or feeding 
behaviour, despite the confirmation of MC4R immunoreactivity in the MeA. There was a slight 
increase in bed-making behaviour during the light phase in the AAV-Cre-GFP group, which again may 
reflect a type I error. Additionally, when the mice were placed on a HFD feeding regime, this did not 
affect body weight or food intake significantly between groups. This suggests that the MeA is 
unlikely to be the source of presynaptic MC4R in the VTA, and that MC4R signalling in the MeA does 
not play an important role in the chronic control of energy homeostasis. Considering that the re-
expression of MC4R in the PVN and amygdala had a profound effect on the obese phenotype of the 
global MC4R KO mouse (Balthasar, Dalgaard et al. 2005), my data suggests that the PVN is likely 
more important than the amygdala in MC4R signalling in energy homeostasis. Interestingly, the 
Balthasar et al study highlights problems with fully targeting a whole brain nucleus with AAV. 
Stereotaxic delivery of AAV to the PVN was abandoned due to the low hit rate in this study. It is 
possible that inaccuracies occurred during the studies reported here. In addition, such injections are 
unlikely to reach all neurons in a brain region, particularly as many of the targeted nuclei are made 
up of multiple subdivisions, with asymmetrical architecture that extends significantly beyond the 
area of diffusion. As shown in Figure 4.12, the GFP expression from integration of the AAV-Cre-GFP 
construct suggests that MC4R was only re-expressed in approximately 30% of the MeA. Thus while 
my results suggest melanocortin signalling in the MeA does not have a significant physiological role 
in energy homeostasis, it is possible that the relatively low number of neurons transfected explain 
the lack of a detectable phenotype. 
 
The LS was selected as a possible source of MC4R producing neurons which project to the VTA. The 
LS is known to express a moderate level of MC4R and projects extensively to the VTA (Meibach and 
Siegel 1977). Intra-LS administration of AAV-Cre-GFP had no effect on body weight, food intake, 
general behaviour or food seeking behaviour despite confirmation of MC4R immunoreactivity in the 
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LS. Again, placing the mice on a HFD regime had no effect on body weight between treatment 
groups. GFP expression appeared to encompass most of the LS, with minimal diffusion beyond its 
boundaries. As this was a pilot study to determine if there were any profound effects on energy 
homeostasis after AAV-Cre-GFP treatment, the data sets are not adequately statistically powered, 
and may not have detected a relatively subtle role of melanocortin signalling in the LS. However, 
they do suggest that MC4R in the LS does not play a major role in energy homeostasis.  
 
The NAcbSh was selected based on the established expression of MC4R and the reciprocal 
projections to the VTA, as the VTA and the NAcbSh exhibit the highest number of reciprocal 
projections of any brain regions studied here (Heimer, Zahm et al. 1991). Intra-NAcbSh 
administration of AAV-Cre-GFP did not affect body weight, food intake, general behaviour or food-
seeking behaviour. Additionally, placing the mice on a HFD regime did not result in a difference in 
body weight or food intake between the treatment groups. Again, the architecture of the NAcbSh 
makes it difficult to accurately target the whole nucleus. The GFP expression analysis in Figure 4.19 
suggests that around a quarter of the NAcbSh was successfully targeted. However, MC4R 
immunoreactivity was not detected in the NAcbSh following administration of AAV-Cre-GFP. Like the 
LS study, the NAcbSh was under powered, but aimed to examine whether MC4R in this region had a 
profound effect on energy homeostasis. However, the lack of MC4R re-expression makes it difficult 
to draw conclusions regarding the role of the MC4R in the NAcbSh in energy homeostasis.   
 
Finally, the VP was selected to receive AAV-Cre-GFP in order to restore the expression of MC4R, 
which has been reported at moderate to high levels in this region. GFP expression confirmed that 
the VP had been successfully targeted with limited diffusion beyond the boundaries of the region, 
and MC4R immunoreactivity was detectable in those animals examined following injection of AAV-
Cre-GFP. Interestingly, those animals administered AAV-Cre-GFP had significantly reduced food 
intake compared to AAV-GFP controls, but their body weight was not significantly different. This 
finding suggests that AAV-Cre-GFP mice are likely to have reduced energy expenditure. When 
general behaviour was monitored in these mice, it was found that locomotion, rearing and 
burrowing behaviour in the dark phase was significantly decreased in those mice which received 
AAV-Cre-GFP. There were no significant differences in food seeking behaviour between any of the 
groups analysed. This reduced activity could occur as the result of a number of possible processes. 
MC4R signalling in the VP may reduce arousal, which would result in a decrease in food intake and 
activity. However, it would also suggest reduced wakefulness, which was not observed to be 
significantly increased. Another possibility is that MC4R signalling in the VP may decrease general 
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motor activity, which would encompass both general and feeding related behaviours. It is also 
possible that MC4R signalling via the VP reduces the efificency of energy utilisation, which in turn 
may negatively feedback to reduce activity. The decrease in food intake may subsequently be driven 
by the reduced energy expenditure, which reflects reduced activity.  
 
It is therefore likely that MC4R signalling in the VP plays a direct or indirect role in energy 
homeostasis. It would be beneficial to measure the expression of a marker indicative of 
thermogenesis, such as UCP-1, which may provide evidence of decreased energy efficiency. 
Complementary to this would be the assessment of the oxygen consumption and respiratory 
quotient (RQ) in a comprehensive laboratory animal monitoring system (CLAMS) that can also assess 
locomotor activity, in order to try and separate out the effects of perturbed energy expenditure 
from reduced arousal. It would be also interesting to see if this same phenotype is observed when 
the mice are fed on a standard chow diet for the full 90 days. It may be that a HFD regime may have 
further exacerbated the need to increase/decrease energy expenditure. However, a divergence in 
food intake between groups was observed well before introduction of the HFD.  
 
Despite the interesting energy homeostasis phenotype observed following re-expression of the 
MC4R in the VP, it seems unlikely that the VP is the source of presynaptic MC4R in the VTA. The 
acute feeding studies described in Chapter 2 describe melanocortin signalling in the VTA as being 
sufficient to reduce food seeking behaviours in ad libitum fed animals. However, the restoration of 
MC4R signalling in the VP had no effect on these parameters. In addition, injection of AAV-Cre-GFP 
into the VP did not result in detectable MC4R expression in the VTA. However, given the difficulty of 
picking up the putative presence of MC4R in the VTA of wild-type animals, this does not necessarily 
demonstrate that injection of AAV-Cre-GFP into the VP does not cause some slight pre-synaptic 
expression of MC4R in the VTA. However, on balance it seems unlikely that the MC4R made in VP 
cell bodies signals in the VTA to influence food intake.  
 
In all mice injected with AAV-GFP or AAV-Cre-GFP, scattered GFP expression was visualised 
throughout the brain, reflecting the projection profiles of neurons in these brain areas. In particular, 
the LS received relatively dense projections from all areas injected. The hypothalamus exhibited low 
GFP expression in VTA injected animals, most likely reflecting projections to the LH. However, it is 
clear that AAV-Cre-GFP administration did not result in the detectable re-expression of MC4R in the 
VTA. A preliminary experiment was undertaken to confirm the re-expression of MC4R and the 
attenuation of the obese phenotype of the MC4R KO mouse, whereby AAV-Cre-GFP was directed to 
223 
 
the PVN (n=1, data not shown). It was confirmed that this resulted in a significant decrease in body 
weight and food intake, although not as profound as that reported for in Sim1-Cre, loxTB MC4R mice 
(Balthasar, Dalgaard et al. 2005), perhaps owing to the contribution of other brain areas such as the 
amygdala to melanocortin signalling, or to the fact that a lower proportion of PVN neurons re-
expressed MC4R. This study confirmed that the AAV-Cre-GFP used was able to drive functional re-
expression of MC4R in the conditional MC4R KO mouse model used. Combining 
immunohistochemical staining of cre recombinase and MC4R which would confirm the percentage 
of neurons which MC4R expression has been successfully restored in, and would provide a more 
accurate reflection of phenotype according to the degree of MC4R re-expression. Additionally, it is 
important to consider that the spread of AAV is influenced by the density of the tissue and the 
proximity of the ventricular system. Assessing the expression of GFP suggested that AAV did not 
spread significantly into other tissues via the ventricular system.  
 
The use of cre-driver mouse lines in neuroscientific investigation has been questioned in terms of 
reliability (Smith 2011, Harno, Cottrell et al. 2013, Stuber, Stamatakis et al. 2015). As described in 
section 4.0.1, the use of cre-dependent mouse models to manipulate the expression of specific 
proteins in specific tissues offers a level of control unavailable with conventional KO models. 
However, a recent report has shown that cre recombinase transgenes under the control of the TH 
promoter and the DAT promoter do not exhibit an identical expression profile, as they would be 
expected to (Lammel, Steinberg et al.). It appears that cre recombinase is being expressed in off-
target cells. This may result from a phenotypic change during neuronal development, whereby the 
neuron has since lost the ability to produce dopamine but retains some of the regulatory DNA 
elements (Stuber, Stamatakis et al. 2015). This is a common problem with cre-expressing 
dopaminergic neurons. These potential limitations should be kept in mind, and future studies 
involving the use of conditional dopaminergic KO models to investigate VTA melanocortin signalling 
should be evaluated carefully.   
 
It is important to consider the effects of MC4R signalling on energy expenditure. Recently, it has 
been shown that the restoration of MC4R in the LH of global MC4R KO mice causes increased 
sympathetic activation of brown fat and increased glucose uptake, whilst having no effect on body 
weight (Morgan, McDaniel et al. 2015). It is possible that the decrease in activity and food intake 
observed in the AAV-Cre-GFP VP injected mice might be offset by the lack of MC4R signalling in the 
LH. Recently, it has been proposed that adenosine may signal antagonistically with dopamine to 
affect GABA signalling in the VP to affect food seeking behaviour (Wydra, Suder et al. 2014). 
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Increased dopaminergic signalling caused by adenosine receptor blockade resulted in increased food 
seeking. This is interesting because it concerns dopaminergic neuronal signalling at the interface of 
locomotor behaviour and food intake behaviour. The VP is highly implicated in the execution of 
these motivated behaviours. It is possible that melanocortins may affect food seeking behaviour by 
altering dopaminergic signalling via GABA neurons in the VP, though our preliminary studies did not 
find an effect on food seeking behaviours.  
 
If there is presynaptic MC4R in the VTA, the source and identity of the putative neurons remains 
unknown. The majority of afferent projections of the VTA are glutamatergic, and so such neurons 
may be glutamatergic. However, previous data from our group suggests in rats that GABA signalling 
is implicated in the anorectic effects of melanocortins in the VTA. It is entirely possible that MC4R is 
postsynaptic in the VTA, but expressed at extremely low levels. The studies described herein have 
not fully characterised the role of MC4R in the VTA, but they have revealed a novel role for MC4R 
signalling in the control of energy homeostasis in the VP. Further studies are now required to 
characterise the precise neuronal circuits involved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
225 
 
Chapter 5: Discussion 
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5.1 Introduction  
 
An estimated 1.4 billion people worldwide are classed as overweight with 500 million of these being 
clinically obese (World Health Organisation 2013). The increasing worldwide incidence of obesity 
may be partially due to the increased consumption of highly palatable foods, driven by a number of 
changing socio-economic factors. Current treatments for obesity include gastric restrictive or bypass 
surgeries, which successfully produce sustained weight loss but can be expensive and invasive 
procedures. Pharmacological interventions have been met with varying degrees of success, however, 
it remains that current pharmacological therapies are not sufficiently efficacious for producing 
sustained long term weight loss without significant side effects. Considering the increasing incidence 
of obesity and the prominent links between obesity and chronic diseases such as heart disease and 
cancer, the development of an effective anti-obesity therapy is urgently required.  
 
Despite extensive clinical investigation into reward driven feeding behaviour in humans, there is a 
lack of understanding between the presentation of feeding patterns and the physiological 
mechanisms driving those feeding behaviours. The highly complex signalling within the 
mesocorticolimbic system is reflective of the extremely varied environment and behavioural cues 
that a person may encounter. Humans are very heterogeneous in their perception of the 
environment and reaction to stimuli, which makes investigating the physiology of the 
mesocorticolimbic system difficult.  
 
The central control of energy homeostasis is determined by neuronal signalling within both the 
hypothalamus and extra-hypothalamic brain areas, such as the brain stem and the 
mesocorticolimbic system. Melanocortins are known to play an important role in energy 
homeostasis via the hypothalamus and brain stem, but the role of melanocortin signalling in the 
mesocorticolimbic system in the control of energy homeostasis remains to be fully elucidated.  
 
The investigations described in this thesis provide further characterisation of the role of 
melanocortin signalling via MC4R in the mesocorticolimbic system in both acute energy intake and in 
the long term control of energy homeostasis.  
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5.2 Investigating the acute feeding effects of the melanocortins in 
the ventral tegmental area  
 
The initial investigations describing the effects of intra-VTA melanocortin administration on acute 
food intake were first described elsewhere (Kylie. E. Beale (2011) PhD thesis) and confirmed shortly 
afterwards (K. A. Banks (2011) MRes thesis). Intra-VTA administration of NDP-MSH, an MC3R/MC4R 
agonist, results in decreased food intake during the 0 – 1 hour duration post-administration in ad 
libitum fed animals only. Animals which have been fasted are not sensitive to the anorectic effects of 
intra-VTA melanocortin administration. This suggests that the VTA of recently fed animals is more 
sensitive to melanocortin input, and thus the existence of a neuronal circuit in the VTA which uses 
melanocortin signalling to reduce food intake, and which is influenced by current nutritional status. 
Initially, it was hypothesised that leptin, levels of which are dependent on acute nutritional status, 
might act as a permissive signalling factor which increases the sensitivity of VTA melanocortin 
circuits. In studies described elsewhere (K. A. Banks (2011) MRes thesis), leptin was administered 
peripherally to fasted animals 4 hours prior to intra-VTA administration of melanocortins, in order to 
recapitulate the effect of acute feeding on leptin levels. However, the acute food intake of animals 
receiving both leptin and intra-VTA NDP-MSH did not differ significantly from those animals 
receiving saline and intra-VTA NDP-MSH. Thus, it appears unlikely that leptin is responsible for 
sensitising the VTA circuits to the anorectic effects of the melanocortins.  
 
The studies described in Chapter 2 further characterised the pharmacological profile of melanocortin 
signalling in the VTA and the effects on acute feeding behaviour. Intra-VTA administration of THIQ, 
an MC4R specific agonist, was sufficient to reduce food intake in ad libitum fed rats, suggesting that 
the anorectic effects of melanocortins in the VTA are mediated via MC4R. Acute administration of 
melanocortins to intra-VTA cannulated MC4R KO mice would provide further confirmation of the 
role of MC4R in mediating the response to intra-VTA melanocortins, and these studies are currently 
underway.  
 
Intra-VTA administration of NDP-MSH in mice resulted in the a similar nutritional state-dependent 
response to that observed in rats, wherein ad libitum fed mice exhibit reduced acute food intake 
compared to fasted mice following intra-VTA melanocortin administration. Acute food-seeking 
duration in ad libitum fed mice was also shown to be reduced after intra-VTA administration, further 
characterising the anorectic signalling role of melanocortins in the VTA. These studies suggest that 
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melanocortin signalling in the VTA works in a similar fashion between species, though further work is 
required to determine whether this is true in humans.  
 
Diurnal variation was also shown to be an important variable in VTA melanocortin signalling in the 
control of food intake. Satiated animals appear to be sensitive to VTA melanocortin signalling 
independent of the diurnal phase, whereas fasted animals show differential sensitivity to VTA 
melanocortin signalling which is likely dependent on the diurnal phase. This suggests that 
melanocortin signalling in the VTA is sensitive to both the arousal state of the animal and nutritional 
status, and may reflect a diurnal pattern of neuronal signalling in the VTA which can be overridden if 
excessive food intake occurs. A differential sensitivity of the VTA to melanocortin signalling in 
feeding and fasting might be beneficial, as anorectic signalling in a state of nutritional deficit could 
be harmful.  These experiments suggest that melanocortin signalling in the VTA may be helpful in 
reducing food intake in times of nutrient excess, and may therefore be relevant in reducing over 
consumption of food.  
 
Although all rodents used in these studies were male, it is important to recognise there is sexual 
dimorphism in VTA melanocortin signalling. Global deletion of MC3R causes a 42% reduction of 
dopamine in the VTA, and decreases sucrose intake and preference in female but not male mice 
(Lippert, Ellacott et al. 2014). There may be significant cross-talk in oestrogen and melanocortin 
signalling, oestrogen perhaps acting as a permissive factor in food intake. It would therefore be 
interesting to investigate sexual dimorphism in VTA MC4R signalling in both male and female 
rodents.  
 
It would also be interesting to observe the acute effects of melanocortins on pathological eating 
patterns such as binge eating. Rodent models of binge eating (Hagan, Wauford et al. 2002, Avena, 
Rada et al. 2006, Corwin and Wojnicki 2006) are increasingly used to study the effects of obesity 
therapeutics (Di Segni, Patrono et al. 2014). However, if a parallel is to be drawn between 
investigating overeating in animals and treating overeating in humans, it is important to model food 
intake behaviour as closely as possible on human feeding patterns. Pathological food intake patterns 
have complex psychosomatic factors which cannot be recapitulated accurately in rodents. This is 
manifested clearly in anatomical brain differences between rodents and humans. Rodents are 
lissencephalic and do not have the same higher functioning capabilities that cortically developed 
human brains possess. Therefore, it is important to consider the validity of modelling rodent food 
intake patterns when investigating potential clinical therapies at the preclinical stage.  
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The identity of the neurons which signal to reduce food intake in the VTA post melanocortin 
administration remains unknown. MC4R may be expressed on a number of neuronal phenotypes 
within the VTA. Additional pharmacological investigation using specific inhibitors of dopaminergic, 
glutamatergic or GABAergic signalling before administration of melanocortins to the VTA may 
provide further information regarding which neurons are involved in the anorectic response.  
 
I have reported here that the VTA is acutely sensitive to anorectic melanocortin signalling, which 
may be dependent on both nutritional status and diurnal phase. I have also provided evidence that 
these anorectic feeding effects are mediated via MC4R, and that they apply to both rats and mice.  
 
 
5.3 The effect of melanocortins on neuronal activation via the 
ventral tegmental area 
 
Chapter 2 described studies investigating the pharmacological effect of intra-VTA melanocortin 
administration on acute food intake behaviour. In order to further dissect the neuronal circuits in 
the mesocorticolimbic system which may be responsible for mediating these effects, the effect of 
intra-VTA melanocortin administration on neuronal activation in the brain areas downstream of the 
VTA was investigated. It is well known that the mesocorticolimbic system recruits multiple brain 
areas in reward processing, and it was hypothesised that melanocortin administration would be 
sufficient to activate multiple mesocorticolimbic brain areas to reduce food intake.  
 
Increased neuronal activation was observed in the VTA itself, NAcbSh, amygdala, VP, LS and the PFC 
in both ad libitum fed rats and mice following intra-VTA melanocortin administration. This confirms 
that melanocortins are able to initiate neuronal activity in the VTA, which results in the downstream 
activation of neurons in areas of the mesocorticolimbic system. The collective neuronal activation 
observed in all areas may be a result of both direct activation of neurons which receive input from 
VTA neurons, and of indirect activation from interneurons which receive input from VTA neurons 
themselves. As discussed in Chapter 3, all of these brain areas have been extensively studied and are 
heavily implicated in reward processing. Thus, it is unsurprising that pharmacological activation of 
neurons in the VTA will result in the activation of neurons in these brain areas. Furthermore, the 
PVN of the hypothalamus did not show increased neuronal activation following intra-VTA 
melanocortin administration. This demonstrates that the injections into the VTA did not activate 
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hypothalamic circuits to cause their effects, and suggests that melanocortin signalling in the VTA is 
sufficient to activate areas of the mesocorticolimbic system in order to reduce acute food intake.  
 
Again, the phenotypes of the neurons which are activated by intra-VTA melanocortin administration 
were not identified. Neuronal activation does not necessarily reflect an increase in excitatory 
neuronal signalling, as inhibitory neurons are also capable of being activated. Thus, no conclusions 
can be drawn up from these experiments as to the identity of these neurons. It is likely that the 
activation observed collectively from all the areas of the mesocorticolimbic system investigated here 
is a mixture of both excitatory and inhibitory neurons. Each brain area identified exhibits a different 
neuronal population and proportion of neuronal phenotypes. Furthermore, MC4R receptors have 
been shown to be expressed on both dopaminergic and glutamatergic neurons (Hsu, Taylor et al. 
2005, Cui, Mason et al. 2012, Lim, Huang et al. 2012, Shah, Vong et al. 2014). Further 
immunohistochemical co-localisation studies are therefore required to fully elucidate the identity of 
the circuits activated by intra-VTA melanocortin signalling. Additionally, it would interesting to see if 
the administration of a specific MC4R agonist, such as THIQ, is sufficient to cause the same pattern 
and degree of activation in those brain areas identified in these studies.  
 
Within the VTA, there exist subset populations of GABAergic neurons which are differentially 
activated in order to suppress dopaminergic neuronal firing, resulting in differential behavioural 
outcomes. Thus the VTA contains separate circuits which are responsible for distinct aspects of 
behaviour (van Zessen, Phillips et al. 2012). Activation of unspecified neuronal circuits within the 
VTA may result in differential phenotypes according to which GABA population has been targeted. 
This makes interpretation of behaviour difficult, as the architecture of the VTA may be dissected into 
smaller functional components, each responsible for mediating a different aspect of reward. Thus, 
pharmacological administration is a relatively unsophisticated approach, activating different pools of 
neurons which might not be activated together by endogenous melanocortins, but one which 
provides the initial proof-of-concept. Precise electrophysiological characterisation would be able to 
identify the signalling profile of particular neurons in selected brain areas in response to 
pharmacological administration. Electrophysiological investigation would therefore help identify the 
precise circuits in the VTA which are responsive to acute melanocortin signalling. Use of specific cre-
lox lines and tools such as designer receptors exclusively activated by designer drugs (DREADD) or 
optogenetics might allow the separation of the effects of specific melanocortin responsive neuronal 
populations in vivo. Neuronal tracing studies would also help to elucidate whether neuronal 
activation of neurons within the VTA is directly contacting particular brain areas, or whether MC4R 
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containing neurons are able to activate a network of neurons which spread diffusely and contact 
other brain areas via second order neurons. These second order neurons need not be sensitive to 
melanocortins, and may represent part of an important signalling pathway which begins with 
melanocortin activation and finishes with exclusively GABA or glutamatergic neuronal activation. 
This signalling cascade may play an important role in synaptic plasticity and the production of 
behaviour, such as feeding behaviour.  
 
The measurement of dopamine metabolites in these downstream areas following intra-VTA 
melanocortin administration would also help characterise the effect on dopamine release, a key 
signalling mediator in communicating reward. Amylin, an anorectic peptide, has been shown to 
signal within the VTA to reduce food intake. The activation of amylin receptors on VTA dopaminergic 
neurons reduces phasic firing in those neurons, suppressing dopamine release in the NAcb core 
(Mietlicki-Baase, Reiner et al. 2015). Intra-NAcb administration of a D1/D2 receptor agonist 
attenuated the resulting hypophagia. Melanocortins may signal in a similar fashion to affect VTA 
signalling, influencing the release of dopamine in downstream brain areas such as the NAcb. It is also 
likely that these effects are mediated via D1 and/or D2 receptors, which are the key dopamine 
receptors expressed within the mesocorticolimbic system.  
 
I have demonstrated here that melanocortin signalling in the VTA results in the activation of neurons 
in the VTA, NAcbSh, amygdala, VP, LS and the PFC in both rats and mice. These studies highlight the 
connectivity of neuronal circuits which are sensitive to melanocortin input which originate in the 
VTA, and have identified the brain areas likely involved in mediating the response to intra-VTA 
melanocortins, either by direct or indirect neuronal communication. In summary, melanocortin 
administration into the VTA is sufficient to activate neurons in downstream areas of the 
mesocorticolimbic system.  
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5.4 The physiological role of the melanocortin 4 receptor in the 
mesocorticolimbic system in the control of energy 
homeostasis 
 
Chapters 2 and 3 have characterised the signalling effects of intra-VTA melanocortin signalling on 
acute food intake behaviour and neuronal activation in the mesocorticolimbic system. Feeding 
behaviour appears to be mediated via the MC4R in the VTA, and this behaviour is likely mediated by 
neuronal signalling within the VTA, NAcbSh, amygdala, VP, LS and the PFC. To investigate the 
physiological role of VTA melanocortin signalling in energy homeostasis, studies aimed at restoration 
of MC4R expression in the VTA in a global MC4R KO mouse were carried out and the resulting 
phenotype assessed.  
 
The administration of AAV-Cre-GFP into the VTA did not affect chronic energy intake or energy 
expenditure. During the course of these studies, an antibody that enables what appears to be 
relatively specific MC4R immunohistochemistry became available, and allowed the investigation of 
the effects of AAV-Cre-GFP on MC4R expression to be determined. MC4R immunoreactivity was 
undetectable following the administration of AAV-Cre-GFP into the VTA, although given that the use 
of the antibody suggested detecting endogenous MC4R in the VTA was problematic, it is difficult to 
determine whether this represents a lack of an effect, or a small effect that is undetectable.  Due to 
the ambiguity concerning MC4R expression in the VTA from the literature, it is likely that MC4R is 
expressed at very low levels in the VTA. Following these observations, it was hypothesised that the 
neurons which express MC4R in the VTA may have their cell bodies located in a brain area distinct 
from the VTA, and may project into the VTA in order to mediate melanocortin signalling in the VTA. 
Therefore, MC4R may be present presynaptically in the VTA. Thus, targeted injection of AAV-Cre-GFP 
in the VTA would be unlikely to restore MC4R signalling in the VTA, as the cell bodies of the neurons 
which express MC4R would need to be targeted. The NAcbSh, MeA, VP and LS were identified as 
areas of the mesocorticolimbic system which express MC4R and have established projections to the 
VTA. Therefore, it was hypothesised that these brain areas could be the source of the putative 
presynaptic MC4R in the VTA.  
 
Administration of AAV-Cre-GFP to the NAcbSh, MeA and LS had no effect on energy intake or energy 
expenditure and food seeking behaviour. MC4R immunoreactivity was not detected in the NAcbSh 
following administration of AAV-Cre-GFP, therefore the hypothesis that the NAcbSh is not the source 
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of presynaptic MC4R in the VTA has not been tested. However, administration of AAV-Cre-GFP into 
the VP resulted in the re-expression of MC4R in the VP, and was associated with a reduction in food 
intake. However, body weight was unaffected, and general behaviours indicating activity were 
reduced in these mice. Therefore, it appeared that the restoration of MC4R signalling in the VP had 
resulted in the activation of a circuit which signals to conserve energy, either by reducing all energy 
consuming activity including feeding, or by reducing energy expenditure which in turn may 
negatively feed back to reduce activity in order to conserve energy. These findings may also reflect a 
reduced arousal state of the animal, in which case all activity would be reduced, resulting in the 
phenotype observed. The lack of MC4R immunoreactivity in the VTA in these mice does not 
necessarily demonstrate that they do not re-express MC4R in presynpatic terminals in this region, as 
even endogenous levels cannot be detected easily. However, VTA administration of melanocortins 
did not cause profound effects on general behaviour, suggesting that the VP is unlikely to be the 
major source of presynaptic MC4R in the VTA.  However, a novel role for melanocortin signalling in 
the VP has been identified. The VP is an area of the mesocorticolimbic system known to mediate 
food reward (Morgane 1961), and has been described as a key brain area which integrates input 
from areas of the mesocorticolimbic system in order to produce a final behavioural outcome, such as 
feeding (Smith, Tindell et al. 2009). This likely involves cross talk with the adjacent GP, which plays 
an important role in motor execution (Maurice, Deniau et al. 1997).  
 
It is entirely possible that in this model of conditional MC4R restoration, MC4R signalling in the VP is 
exaggerated to compensate for the lack of MC4R signalling elsewhere. However, this does suggest 
the existence of a circuit in the VP which expresses MC4R and may affect energy homeostasis, or 
arousal. In order to investigate the basis of the phenotype observed here, it would be interesting to 
measure indicators of energy expenditure such as UCP-1 expression or RQ in these mice to confirm 
the effects of MC4R restoration in the VP. Additionally, it would be interesting to observe the acute 
effect of transient neuronal activation in vivo of neurons which express MC4R in the VP. This could 
be achieved with the use of DREADD technology (Alexander, Rogan et al. 2009). DREADD is applied 
using AAV administration of a construct which is cre-dependent, and will thus be expressed only in a 
targeted neuronal population which expresses cre, such as MC4R Cre expressing neurons. This could 
be achieved with the use of an MC4R Cre driver mouse line (The Jackson Laboratory 2005). The 
construct also contains an insertional sequence coding for a modified human muscarinic (hM) 
receptor which is exclusively activated by the designer drug clozapine-N-oxide (CNO). Thus, the 
resulting mouse will express the modified hM on the surface of MC4R expressing neurons only. 
Depending on the G protein which is coupled to the hM receptor, which may be Gs, Gi or Gq, the 
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resultant activation of the hM receptor will either selectively activate or inhibit the firing of that 
neuron. Activation of the receptor is achieved with peripheral administration of CNO to these mice, 
which will result in acute transient activation of MC4R neurons in the targeted brain area, such as 
the VP. This could provide further evidence for the acute role of melanocortin signalling in the VP in 
the control of feeding behaviour and activity. These studies are currently planned in order to 
advance the findings reported in this thesis.  
 
I have reported here that the administration of AAV-Cre-GFP to the VTA of MC4R KO mice did not 
result in an energy homeostasis phenotype, suggesting that targeting the VTA in order to restore 
MC4R expression may be insufficient to influence this system. Therefore, it was hypothesised that 
MC4R may be presynaptic in the VTA. I have shown that the the MeA and LS are unlikely to be the 
source of presynaptic MC4R in the VTA. Furthermore, this demonstrates that AAV-Cre-GFP 
administration to these brain areas in order to restore MC4R expression did not result in an easily 
observable phenotype, suggesting that these brain areas are not significantly important in chronic 
melanocortin signalling in the control of energy homeostasis. Finally, I have established a new role 
for the VP in melanocortin signalling in the control of energy homeostasis. Further experiments are 
required to elucidate the specific effect of melanocortin signalling in the VP on energy expenditure. 
It is entirely possible that MC4R is presynaptic in the VTA, therefore further investigation of other 
areas of the mesocorticolimbic system is required.  
 
 
5.5 Final summary  
 
In humans, mutations in MC4R have been implicated in affecting eating behaviour. Mealtime 
hyperphagia (Farooqi, Yeo et al. 2000, Farooqi, Keogh et al. 2003, Stutzmann, Tan et al. 2008), binge 
eating disorder (Branson, Potoczna et al. 2003) and increased snacking outside of mealtimes 
(Stutzmann, Tan et al. 2008, Stutzmann, Cauchi et al. 2009) commonly manifest in humans with 
MC4R mutations. Lower satiety responsiveness following food intake in children with MC4R 
mutations (Valladares, Dominguez-Vasquez et al. 2010) and a preference for high fat and high 
protein foods in women with MC4R mutations (Qi, Kraft et al. 2008) have also been reported, 
although these aspects of feeding have not been reported in other populations with MC4R 
mutations (Hebebrand, Geller et al. 2004, Lubrano-Berthelier, Dubern et al. 2006). This may reflect 
specificity in MC4R mutations in affecting distinct aspects of feeding behaviour, or an age or sex 
specific effect of MC4R signalling on feeding behaviour. Despite the inconclusiveness of specific 
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effects of MC4R signalling on feeding behaviour in humans, it does appear that MC4R exerts an 
inhibitory control over feeding behaviour and the loss of a central melanocortin tone may contribute 
significantly to hyperphagia and obesity. The full contribution of mesocorticolimbic melanocortin 
signalling in energy homeostasis remains to be fully defined, but it appears that perturbing MC4R 
signalling within distinct areas of the mesocorticolimbic system, such as the VTA and VP, results in 
significant effects on energy homeostasis. Thus, it is highly likely that melanocortin signalling from 
widespread brain areas signals collaboratively to affect specific components of feeding behaviour 
and energy expenditure.  
 
There are obvious problems with the chronic administration of MC4R agonists, including many 
unwanted side effects such as increased blood pressure, but recent studies have reported the use of 
MC4R agonists which are able to reduce food intake and increase energy expenditure acutely (Chen, 
Muniyappa et al. 2015) and reduce obesity and improve glucose tolerance chronically (Kievit, Halem 
et al. 2013), without increasing blood pressure, in non-human primates. This shows promise for the 
development of melanocortin therapeutics in the treatment of obesity. Recent developments 
demonstrating melanocortin receptor signalling in enteroendocrine L cells (Panaro, Tough et al. 
2014) suggest that peripheral melanocortin receptors may also represent a possible therapeutic 
target, though their ability to chronically modulate energy homeostasis has not yet been 
demonstrated. Melanocortin signalling undoubtedly affects both energy intake and energy 
expenditure, and it is therefore important to fully elucidate the central effects of melanocortins in 
order to develop new, safe therapeutics for the treatment of obesity. Interestingly, the ability of 
MC4R to couple to different signalling mechanisms in neurons also suggests that it might be possible 
to design MC4R agonists that are biased towards particular intracellullar signalling pathways, 
potentially allowing specific side effects to be avoided (Ghamari-Langroudi, Digby et al. 2015).The 
current obesity epidemic is partially driven by the over consumption of highly palatable, energy 
dense foods. The mesocorticolimbic system is responsible for assigning a reward value to and for 
mediating the hedonic aspects of these types of foods, thus the increased activation of this brain 
system may be responsible for increased consumption of these foods, resulting in obesity. This 
thesis describes a role for melanocortins in affecting the intake of food, a rewarding substrate, via 
MC4R signalling in the VTA which is dependent on nutritional status. This is particularly relevant in 
times of starvation when a reduction in food intake may be detrimental. Finally, this thesis has 
identified a new role for MC4R signalling in the VP wherein melanocortin signalling may affect 
energy homeostasis. In conclusion, this thesis has helped to partially elucidate the role of 
melanocortin signalling in the mesocorticolimbic system, particularly the VTA and the VP, in the 
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control of energy homeostasis. It is hoped that these observations will contribute to the growing 
knowledge of how melanocortin signalling may be exploited in order to treat obesity and metabolic 
disease.  
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Figure 5.1 Schematic diagram summarising investigations in this thesis. Abbreviations: MC4R, 
melanocortin 4 receptor; VP, ventral pallidum; VTA, ventral tegmental area; AAV, adeno-associated 
virus. Acute administration of melanocortins to the VTA of fed rodents results in a reduction in acute 
food intake and food seeking behaviour. This reduction in food intake is mediated partially via 
MC4R. MC4R is likely to be presynaptic in the VTA, although these studies have not identified the 
extra-VTA brain area which may be the source of MC4R. MC4R expression in the VTA was not 
confirmed, likely due to the low expression of MC4R. The restoration of MC4R expression in the VP 
resulted in a chronic reduction in food intake, a decrease in dark phase activity but had no effect on 
body weight. It is unlikely that neurons originating in the VP and extending to the VTA are the source 
of presynaptic MC4R in the VTA, owing to the phenotypic differences observed upon acute 
administration or restoration of melanocortin signalling in these brain areas. The role of 
melanocortin signalling in the VP in energy homeostasis remains to be elucidated, but it is likely that 
melanocortin signalling in the VP is important in energy expenditure or arousal. Adapted from ‘The 
Mouse Brain in Stereotaxic Co-ordinates’ (Franklin and Paxinos 2007).  
238 
 
References  
 
 
Abbott, C. R., M. Rossi, M.-S. Kim, S. H. AlAhmed, G. M. Taylor, M. A. Ghatei, D. M. Smith and S. R. 
Bloom (2000). "Investigation of the melanocyte stimulating hormones on food intake: Lack of 
evidence to support a role for the melanocortin-3-receptor." Brain Research 869(1–2): 203-210. 
Abdel-Malek, Z. A. (2010). "Development of alpha-melanocortin analogs for melanoma prevention 
and targeting." Adv Exp Med Biol 681: 126-132. 
Abizaid, A., Z. W. Liu, Z. B. Andrews, M. Shanabrough, E. Borok, J. D. Elsworth, R. H. Roth, M. W. 
Sleeman, M. R. Picciotto, M. H. Tschop, X. B. Gao and T. L. Horvath (2006). "Ghrelin modulates the 
activity and synaptic input organization of midbrain dopamine neurons while promoting appetite." J 
Clin Invest 116(12): 3229-3239. 
Adan, R. A., R. D. Cone, J. P. Burbach and W. H. Gispen (1994). "Differential effects of melanocortin 
peptides on neural melanocortin receptors." Mol Pharmacol 46(6): 1182-1190. 
Adan, R. H. (2000). Effects of Melanocortins in the Nervous System. The Melanocortin Receptors. R. 
Cone, Humana Press: 109-141. 
Agosti, F., E. J. Lopez Soto, A. Cabral, D. Castrogiovanni, H. B. Schioth, M. Perello and J. Raingo 
(2014). "Melanocortin 4 receptor activation inhibits presynaptic N-type calcium channels in 
amygdaloid complex neurons." Eur J Neurosci 40(5): 2755-2765. 
Albanese, A. and D. Minciacchi (1983). "Organization of the ascending projections from the ventral 
tegmental area: a multiple fluorescent retrograde tracer study in the rat." J Comp Neurol 216(4): 
406-420. 
Alexander, G. M., S. C. Rogan, A. I. Abbas, B. N. Armbruster, Y. Pei, J. A. Allen, R. J. Nonneman, J. 
Hartmann, S. S. Moy, M. A. Nicolelis, J. O. McNamara and B. L. Roth (2009). "Remote control of 
neuronal activity in transgenic mice expressing evolved G protein-coupled receptors." Neuron 63(1): 
27-39. 
Alhadeff, A. L., L. E. Rupprecht and M. R. Hayes (2012). "GLP-1 neurons in the nucleus of the solitary 
tract project directly to the ventral tegmental area and nucleus accumbens to control for food 
intake." Endocrinology 153(2): 647-658. 
Allen, B. M. (1916). "The results of extirpation of the anterior lobe of the hypophysis and of the 
thyroid of rana pipiens larvae." Science 44(1143): 755-758. 
Alvaro, J. D., J. B. Tatro, J. M. Quillan, M. Fogliano, M. Eisenhard, M. R. Lerner, E. J. Nestler and R. S. 
Duman (1996). "Morphine down-regulates melanocortin-4 receptor expression in brain regions that 
mediate opiate addiction." Mol Pharmacol 50(3): 583-591. 
Ambroggi, F., A. Ghazizadeh, S. M. Nicola and H. L. Fields (2011). "Roles of nucleus accumbens core 
and shell in incentive-cue responding and behavioral inhibition." J Neurosci 31(18): 6820-6830. 
Anand, B. K. and J. R. Brobeck (1951). "Hypothalamic control of food intake in rats and cats." Yale J 
Biol Med 24(2): 123-140. 
Andersen, G. N., M. Hagglund, O. Nagaeva, L. Frangsmyr, R. Petrovska, L. Mincheva-Nilsson and J. E. 
Wikberg (2005). "Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 
and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood 
leucocytes." Scand J Immunol 61(3): 279-284. 
Andino, L. M., D. J. Ryder, A. Shapiro, M. K. Matheny, Y. Zhang, M. K. Judge, K. Y. Cheng, N. Tumer 
and P. J. Scarpace (2011). "POMC overexpression in the ventral tegmental area ameliorates dietary 
obesity." J Endocrinol 210(2): 199-207. 
Aponte, Y., D. Atasoy and S. M. Sternson (2011). "AGRP neurons are sufficient to orchestrate feeding 
behavior rapidly and without training." Nat Neurosci 14(3): 351-355. 
239 
 
Arase, K., D. A. York, H. Shimizu, N. Shargill and G. A. Bray (1988). "Effects of corticotropin-releasing 
factor on food intake and brown adipose tissue thermogenesis in rats." Am J Physiol 255(3 Pt 1): 
E255-259. 
Argiolas, A., M. R. Melis, S. Murgia and H. B. Schioth (2000). "ACTH- and alpha-MSH-induced 
grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of 
melanocortin receptors." Brain Res Bull 51(5): 425-431. 
Ariano, M. A., J. Wang, K. L. Noblett, E. R. Larson and D. R. Sibley (1997). "Cellular distribution of the 
rat D4 dopamine receptor protein in the CNS using anti-receptor antisera." Brain Research 752(1–2): 
26-34. 
Artuc, M., A. Grutzkau, T. Luger and B. M. Henz (1999). "Expression of MC1- and MC5-receptors on 
the human mast cell line HMC-1." Ann N Y Acad Sci 885: 364-367. 
Asai, M., S. Ramachandrappa, M. Joachim, Y. Shen, R. Zhang, N. Nuthalapati, V. Ramanathan, D. E. 
Strochlic, P. Ferket, K. Linhart, C. Ho, T. V. Novoselova, S. Garg, M. Ridderstråle, C. Marcus, J. N. 
Hirschhorn, J. M. Keogh, S. O’Rahilly, L. F. Chan, A. J. Clark, I. S. Farooqi and J. A. Majzoub (2013). 
"Loss of Function of the Melanocortin 2 Receptor Accessory Protein 2 Is Associated with Mammalian 
Obesity." Science 341(6143): 275-278. 
Atalayer, D., K. L. Robertson, C. Haskell-Luevano, A. Andreasen and N. E. Rowland (2010). "Food 
demand and meal size in mice with single or combined disruption of melanocortin type 3 and 4 
receptors." Am J Physiol Regul Integr Comp Physiol 298(6): R1667-1674. 
Avena, N. M., P. Rada and B. G. Hoebel (2006). "Sugar bingeing in rats." Curr Protoc Neurosci 
Chapter 9: Unit9.23C. 
Azam, L., U. H. Winzer-Serhan, Y. Chen and F. M. Leslie (2002). "Expression of neuronal nicotinic 
acetylcholine receptor subunit mRNAs within midbrain dopamine neurons." The Journal of 
Comparative Neurology 444(3): 260-274. 
Azevedo, F. A. C., L. R. B. Carvalho, L. T. Grinberg, J. M. Farfel, R. E. L. Ferretti, R. E. P. Leite, W. J. 
Filho, R. Lent and S. Herculano-Houzel (2009). "Equal numbers of neuronal and nonneuronal cells 
make the human brain an isometrically scaled-up primate brain." The Journal of Comparative 
Neurology 513(5): 532-541. 
Badrinarayan, A., S. A. Wescott, C. M. Vander Weele, B. T. Saunders, B. E. Couturier, S. Maren and B. 
J. Aragona (2012). "Aversive stimuli differentially modulate real-time dopamine transmission 
dynamics within the nucleus accumbens core and shell." J Neurosci 32(45): 15779-15790. 
Bagnol, D., X. Y. Lu, C. B. Kaelin, H. E. Day, M. Ollmann, I. Gantz, H. Akil, G. S. Barsh and S. J. Watson 
(1999). "Anatomy of an endogenous antagonist: relationship between Agouti-related protein and 
proopiomelanocortin in brain." J Neurosci 19(18): Rc26. 
Bai, F., M. A. Sozen, W. J. Lukiw and G. Argyropoulos (2005). "Expression of AgRP, NPY, POMC and 
CART in human fetal and adult hippocampus." Neuropeptides 39(4): 439-443. 
Baker, R. A. and M. Herkenham (1995). "Arcuate nucleus neurons that project to the hypothalamic 
paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA 
levels in the rat." J Comp Neurol 358(4): 518-530. 
Balcita-Pedicino, J. J. and S. R. Sesack (2007). "Orexin axons in the rat ventral tegmental area synapse 
infrequently onto dopamine and gamma-aminobutyric acid neurons." J Comp Neurol 503(5): 668-
684. 
Balthasar, N., L. T. Dalgaard, C. E. Lee, J. Yu, H. Funahashi, T. Williams, M. Ferreira, V. Tang, R. A. 
McGovern, C. D. Kenny, L. M. Christiansen, E. Edelstein, B. Choi, O. Boss, C. Aschkenasi, C. Y. Zhang, 
K. Mountjoy, T. Kishi, J. K. Elmquist and B. B. Lowell (2005). "Divergence of melanocortin pathways in 
the control of food intake and energy expenditure." Cell 123(3): 493-505. 
Barberini, C. L., S. E. Morrison, A. Saez, B. Lau and C. D. Salzman (2012). "Complexity and competition 
in appetitive and aversive neural circuits." Front Neurosci 6: 170. 
Barone, F. C., M. J. Wayner, S. L. Scharoun, R. Guevara-Aguilar and H. U. Aguilar-Baturoni (1981). 
"Afferent connections to the lateral hypothalamus: a horseradish peroxidase study in the rat." Brain 
Res Bull 7(1): 75-88. 
240 
 
Baxter, M. G. and E. A. Murray (2002). "The amygdala and reward." Nat Rev Neurosci 3(7): 563-573. 
Bayer, H. M. and P. W. Glimcher (2005). "Midbrain dopamine neurons encode a quantitative reward 
prediction error signal." Neuron 47(1): 129-141. 
Bayer, V. E. and V. M. Pickel (1991). "GABA-labeled terminals form proportionally more synapses 
with dopaminergic neurons containing low densities of tyrosine hydroxylase-immunoreactivity in rat 
ventral tegmental area." Brain Res 559(1): 44-55. 
Beaulieu, J. M. and R. R. Gainetdinov (2011). "The physiology, signaling, and pharmacology of 
dopamine receptors." Pharmacol Rev 63(1): 182-217. 
Bell, M. E., S. Bhatnagar, S. F. Akana, S. Choi and M. F. Dallman (2000). "Disruption of 
arcuate/paraventricular nucleus connections changes body energy balance and response to acute 
stress." J Neurosci 20(17): 6707-6713. 
Berk, M. L. and J. A. Finkelstein (1981). "Afferent projections to the preoptic area and hypothalamic 
regions in the rat brain." Neuroscience 6(8): 1601-1624. 
Bernardis, L. (1970). "Participation of the dorsomedial hypothalamic nucleus in the “feeding center” 
and water intake circuitry of the weanling rat." Journal of Neuro-Visceral Relations 31(4): 387-398. 
Bernheimer, H. and O. Hornykiewicz (1965). "Herabgesetzte Konzentration der Homovanillinsäure 
im Gehirn von parkinsonkranken Menschen als Ausdruck der Störung des zentralen 
Dopaminstoffwechsels." Klinische Wochenschrift 43(13): 711-715. 
Berridge, K. and M. Kringelbach (2011). "Building a neuroscience of pleasure and well-being." 
Psychology of Well-Being 1(1): 1-26. 
Berridge, K. C. (2007). "The debate over dopamine's role in reward: the case for incentive salience." 
Psychopharmacology (Berl) 191(3): 391-431. 
Berridge, K. C., C.-Y. Ho, J. M. Richard and A. G. DiFeliceantonio (2010). "The tempted brain eats: 
Pleasure and desire circuits in obesity and eating disorders." Brain Research 1350(0): 43-64. 
Berridge, K. C., T. E. Robinson and J. W. Aldridge (2009). "Dissecting components of reward: 'liking', 
'wanting', and learning." Curr Opin Pharmacol 9(1): 65-73. 
Bertolini, A., R. Poggioli and W. Ferrari (1979). "ACTH-induced hyperalgesia in rats." Experientia 
35(9): 1216-1217. 
Bertolini, A., R. Poggioli and A. V. Vergoni (1988). "Cross-species comparison of the ACTH-induced 
behavioral syndrome." Ann N Y Acad Sci 525: 114-129. 
Biebermann, H., H. Krude, A. Elsner, V. Chubanov, T. Gudermann and A. Grüters (2003). "Autosomal-
Dominant Mode of Inheritance of a Melanocortin-4 Receptor Mutation in a Patient with Severe 
Early-Onset Obesity Is Due to a Dominant-Negative Effect Caused by Receptor Dimerization." 
Diabetes 52(12): 2984-2988. 
Bird, C. M. and N. Burgess (2008). "The hippocampus and memory: insights from spatial processing." 
Nat Rev Neurosci 9(3): 182-194. 
Björklund, A. and S. B. Dunnett (2007). "Dopamine neuron systems in the brain: an update." Trends 
in Neurosciences 30(5): 194-202. 
Boghossian, S., M. Park and D. A. York (2010). Melanocortin activity in the amygdala controls 
appetite for dietary fat. 
Bohm, M., T. Brzoska, U. Schulte, M. Schiller, U. Kubitscheck and T. A. Luger (1999). 
"Characterization of a polyclonal antibody raised against the human melanocortin-1 receptor." Ann 
N Y Acad Sci 885: 372-382. 
Borgland, S. L., E. Storm and A. Bonci (2008). "Orexin B/hypocretin 2 increases glutamatergic 
transmission to ventral tegmental area neurons." Eur J Neurosci 28(8): 1545-1556. 
Bozarth, M. A. and R. A. Wise (1981). "Intracranial self-administration of morphine into the ventral 
tegmental area in rats." Life Sci 28(5): 551-555. 
Branson, R., N. Potoczna, J. G. Kral, K.-U. Lentes, M. R. Hoehe and F. F. Horber (2003). "Binge Eating 
as a Major Phenotype of Melanocortin 4 Receptor Gene Mutations." New England Journal of 
Medicine 348(12): 1096-1103. 
241 
 
Broberger, C., J. Johansen, C. Johansson, M. Schalling and T. Hökfelt (1998). "The neuropeptide 
Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium 
glutamate-treated mice." Proceedings of the National Academy of Sciences 95(25): 15043-15048. 
Broberger, C., M. Landry, H. Wong, J. N. Walsh and T. Hokfelt (1997). "Subtypes Y1 and Y2 of the 
neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-
containing neurons of the rat hypothalamic arcuate nucleus." Neuroendocrinology 66(6): 393-408. 
Bronstein, D. M., M. K. Schafer, S. J. Watson and H. Akil (1992). "Evidence that beta-endorphin is 
synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA." Brain Res 587(2): 
269-275. 
Bronstein, D. M., M. K. H. Schafer, S. J. Watson and H. Akil (1992). "Evidence that β-endorphin is 
synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA." Brain Research 
587(2): 269-275. 
Brown, J. H. and M. H. Makman (1972). "Stimulation by dopamine of adenylate cyclase in retinal 
homogenates and of adenosine-3':5'-cyclic monophosphate formation in intact retina." Proc Natl 
Acad Sci U S A 69(3): 539-543. 
Bruijnzeel, A. W., X. Qi and L. W. Corrie (2013). "Anorexic effects of intra-VTA leptin are similar in 
low-fat and high-fat-fed rats but attenuated in a subgroup of high-fat-fed obese rats." Pharmacol 
Biochem Behav 103(3): 573-581. 
Bunzow, J. R., H. H. Van Tol, D. K. Grandy, P. Albert, J. Salon, M. Christie, C. A. Machida, K. A. Neve 
and O. Civelli (1988). "Cloning and expression of a rat D2 dopamine receptor cDNA." Nature 
336(6201): 783-787. 
Butler, A. A. (2006). "The melanocortin system and energy balance." Peptides 27(2): 281-290. 
Butler, A. A., D. L. Marks, W. Fan, C. M. Kuhn, M. Bartolome and R. D. Cone (2001). "Melanocortin-4 
receptor is required for acute homeostatic responses to increased dietary fat." Nat Neurosci 4(6): 
605-611. 
Calver, A. R., A. D. Medhurst, M. J. Robbins, K. J. Charles, M. L. Evans, D. C. Harrison, M. Stammers, S. 
A. Hughes, G. Hervieu, A. Couve, S. J. Moss, D. N. Middlemiss and M. N. Pangalos (2000). "The 
expression of GABAB1 and GABAB2 receptor subunits in the cNS differs from that in peripheral 
tissues." Neuroscience 100(1): 155-170. 
Cardinal, R. N., D. R. Pennicott, C. Lakmali , Sugathapala, T. W. Robbins and B. J. Everitt (2001). 
"Impulsive Choice Induced in Rats by Lesions of the Nucleus Accumbens Core." Science 292(5526): 
2499-2501. 
Carlson, J. M., D. Foti, L. R. Mujica-Parodi, E. Harmon-Jones and G. Hajcak (2011). "Ventral striatal 
and medial prefrontal BOLD activation is correlated with reward-related electrocortical activity: A 
combined ERP and fMRI study." NeuroImage 57(4): 1608-1616. 
Carlson, N. A. (1992). "Foundations of Physiological Psychology." Needham Heights, Massachusetts: 
Simon & Schuster: 53. 
Carlsson, A., M. Lindqvist, T. Magnusson and B. Waldeck (1958). "On the presence of 3-
hydroxytyramine in brain." Science 127(3296): 471. 
Carlsson, A., M. Lindqvist and T. O. R. Magnusson (1957). "3,4-Dihydroxyphenylalanine and 5-
Hydroxytryptophan as Reserpine Antagonists." Nature 180(4596): 1200-1200. 
Carter, M. E., M. E. Soden, L. S. Zweifel and R. D. Palmiter (2013). "Genetic identification of a neural 
circuit that suppresses appetite." Nature 503(7474): 111-114. 
Caruso, V., M. C. Lagerstrom, P. K. Olszewski, R. Fredriksson and H. B. Schioth (2014). "Synaptic 
changes induced by melanocortin signalling." Nat Rev Neurosci 15(2): 98-110. 
Castañeda, M. T., E. R. G. Sanabria, S. Hernandez, A. Ayala, T. A. Reyna, J.-Y. Wu and L. V. Colom 
(2005). "Glutamic acid decarboxylase isoforms are differentially distributed in the septal region of 
the rat." Neuroscience Research 52(1): 107-119. 
Castrucci, A. M., M. E. Hadley, T. K. Sawyer, B. C. Wilkes, F. al-Obeidi, D. J. Staples, A. E. de Vaux, O. 
Dym, M. F. Hintz, J. P. Riehm and et al. (1989). "Alpha-melanotropin: the minimal active sequence in 
the lizard skin bioassay." Gen Comp Endocrinol 73(1): 157-163. 
242 
 
Catania, A., C. Lonati, A. Sordi, A. Carlin, P. Leonardi and S. Gatti (2010). "The melanocortin system in 
control of inflammation." ScientificWorldJournal 10: 1840-1853. 
Chaki, S., S.-i. Ogawa, Y. Toda, T. Funakoshi and S. Okuyama (2003). "Involvement of the 
melanocortin MC4 receptor in stress-related behavior in rodents." European Journal of 
Pharmacology 474(1): 95-101. 
Chemelli, R. M., J. T. Willie, C. M. Sinton, J. K. Elmquist, T. Scammell, C. Lee, J. A. Richardson, S. C. 
Williams, Y. Xiong, Y. Kisanuki, T. E. Fitch, M. Nakazato, R. E. Hammer, C. B. Saper and M. Yanagisawa 
(1999). "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation." Cell 98(4): 437-
451. 
Chen, A. S., D. J. Marsh, M. E. Trumbauer, E. G. Frazier, X. M. Guan, H. Yu, C. I. Rosenblum, A. Vongs, 
Y. Feng, L. Cao, J. M. Metzger, A. M. Strack, R. E. Camacho, T. N. Mellin, C. N. Nunes, W. Min, J. 
Fisher, S. Gopal-Truter, D. E. MacIntyre, H. Y. Chen and L. H. Van der Ploeg (2000). "Inactivation of 
the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass." Nat 
Genet 26(1): 97-102. 
Chen, A. S., J. M. Metzger, M. E. Trumbauer, X. M. Guan, H. Yu, E. G. Frazier, D. J. Marsh, M. J. 
Forrest, S. Gopal-Truter, J. Fisher, R. E. Camacho, A. M. Strack, T. N. Mellin, D. E. MacIntyre, H. Y. 
Chen and L. H. Van der Ploeg (2000). "Role of the melanocortin-4 receptor in metabolic rate and 
food intake in mice." Transgenic Res 9(2): 145-154. 
Chen, K. Y., R. Muniyappa, B. S. Abel, K. P. Mullins, P. Staker, R. J. Brychta, X. Zhao, M. Ring, T. L. 
Psota, R. D. Cone, B. L. Panaro, K. Gottesdiener, L. Van der Ploeg, M. L. Reitman and M. C. Skarulis 
(2015). "RM-493, a Melanocortin-4 Receptor (MC4R) Agonist Increases Resting Energy Expenditure 
in Obese Individuals." J Clin Endocrinol Metab: jc20144024. 
Chen, W., M. A. Kelly, X. Opitz-Araya, R. E. Thomas, M. J. Low and R. D. Cone (1997). "Exocrine gland 
dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function 
by melanocortin peptides." Cell 91(6): 789-798. 
Chergui, K., P. J. Charlety, H. Akaoka, C. F. Saunier, J. L. Brunet, M. Buda, T. H. Svensson and G. 
Chouvet (1993). "Tonic activation of NMDA receptors causes spontaneous burst discharge of rat 
midbrain dopamine neurons in vivo." Eur J Neurosci 5(2): 137-144. 
Cheung, C. C., D. K. Clifton and R. A. Steiner (1997). "Proopiomelanocortin neurons are direct targets 
for leptin in the hypothalamus." Endocrinology 138(10): 4489-4492. 
Chida, D., S. Nakagawa, S. Nagai, H. Sagara, H. Katsumata, T. Imaki, H. Suzuki, F. Mitani, T. Ogishima, 
C. Shimizu, H. Kotaki, S. Kakuta, K. Sudo, T. Koike, M. Kubo and Y. Iwakura (2007). "Melanocortin 2 
receptor is required for adrenal gland development, steroidogenesis, and neonatal 
gluconeogenesis." Proc Natl Acad Sci U S A 104(46): 18205-18210. 
Chuhma, N., H. Zhang, J. Masson, X. Zhuang, D. Sulzer, R. Hen and S. Rayport (2004). "Dopamine 
Neurons Mediate a Fast Excitatory Signal via Their Glutamatergic Synapses." The Journal of 
Neuroscience 24(4): 972-981. 
Civelli, O., N. Birnberg and E. Herbert (1982). "Detection and quantitation of pro-opiomelanocortin 
mRNA in pituitary and brain tissues from different species." J Biol Chem 257(12): 6783-6787. 
Clifton, P. G., I. N. Rusk and S. J. Cooper (1991). "Effects of dopamine D1 and dopamine D2 
antagonists on the free feeding and drinking patterns of rats." Behav Neurosci 105(2): 272-281. 
Cone, J. J., J. E. McCutcheon and M. F. Roitman (2014). "Ghrelin Acts as an Interface between 
Physiological State and Phasic Dopamine Signaling." The Journal of Neuroscience 34(14): 4905-4913. 
Cone, R. D. (2005). "Anatomy and regulation of the central melanocortin system." Nat Neurosci 8(5): 
571-578. 
Considine, R. V., M. K. Sinha, M. L. Heiman, A. Kriauciunas, T. W. Stephens, M. R. Nyce, J. P. 
Ohannesian, C. C. Marco, L. J. McKee, T. L. Bauer and J. F. Caro (1996). "Serum Immunoreactive-
Leptin Concentrations in Normal-Weight and Obese Humans." New England Journal of Medicine 
334(5): 292-295. 
243 
 
Cools, A. R. and J. M. Van Rossum (1976). "Excitation-mediating and inhibition-mediating dopamine-
receptors: a new concept towards a better understanding of electrophysiological, biochemical, 
pharmacological, functional and clinical data." Psychopharmacologia 45(3): 243-254. 
Cornea-Hebert, V., M. Riad, C. Wu, S. K. Singh and L. Descarries (1999). "Cellular and subcellular 
distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat." J Comp 
Neurol 409(2): 187-209. 
Corwin, R. L. and F. H. Wojnicki (2006). "Binge eating in rats with limited access to vegetable 
shortening." Curr Protoc Neurosci Chapter 9: Unit9.23B. 
Covelo, I. R., Z. I. Patel, J. A. Luviano, T. R. Stratford and D. Wirtshafter (2014). "Manipulation of 
GABA in the ventral pallidum, but not the nucleus accumbens, induces intense, preferential, fat 
consumption in rats." Behav Brain Res 270: 316-325. 
Cowley, M. A., N. Pronchuk, W. Fan, D. M. Dinulescu, W. F. Colmers and R. D. Cone (1999). 
"Integration of NPY, AGRP, and Melanocortin Signals in the Hypothalamic Paraventricular Nucleus: 
Evidence of a Cellular Basis for the Adipostat." Neuron 24(1): 155-163. 
Cowley, M. A., J. L. Smart, M. Rubinstein, M. G. Cerdan, S. Diano, T. L. Horvath, R. D. Cone and M. J. 
Low (2001). "Leptin activates anorexigenic POMC neurons through a neural network in the arcuate 
nucleus." Nature 411(6836): 480-484. 
Cowley, M. A., R. G. Smith, S. Diano, M. Tschöp, N. Pronchuk, K. L. Grove, C. J. Strasburger, M. 
Bidlingmaier, M. Esterman, M. L. Heiman, L. M. Garcia-Segura, E. A. Nillni, P. Mendez, M. J. Low, P. 
Sotonyi, J. M. Friedman, H. Liu, S. Pinto, W. F. Colmers, R. D. Cone and T. L. Horvath (2003). "The 
Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic 
Circuit Regulating Energy Homeostasis." Neuron 37(4): 649-661. 
Crimmins, E. M., S. H. Preston and B. Cohen (2011). Explaining Divergent Levels of Longevity in High-
Income Countries, The National Academies Press. 
Cromwell, H. C. and K. C. Berridge (1993). "Where does damage lead to enhanced food aversion: the 
ventral pallidum/substantia innominata or lateral hypothalamus?" Brain Res 624(1-2): 1-10. 
Csiffáry, A., T. J. Görcs and M. Palkovits (1990). "Neuropeptide Y innervation of ACTH-
immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic 
double immunolabeling study." Brain Research 506(2): 215-222. 
Cui, H., B. L. Mason, C. Lee, A. Nishi, J. K. Elmquist and M. Lutter (2012). "Melanocortin 4 receptor 
signaling in dopamine 1 receptor neurons is required for procedural memory learning." Physiology & 
Behavior 106(2): 201-210. 
da Silva, A. A., J. J. Kuo, L. S. Tallam, J. Liu and J. E. Hall (2006). "Does Obesity Induce Resistance to 
the Long-Term Cardiovascular and Metabolic Actions of Melanocortin 3/4 Receptor Activation?" 
Hypertension 47(2): 259-264. 
Date, Y., N. Murakami, K. Toshinai, S. Matsukura, A. Niijima, H. Matsuo, K. Kangawa and M. Nakazato 
(2002). "The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone 
secretion in rats." Gastroenterology 123(4): 1120-1128. 
Davis, J. F., D. L. Choi and S. C. Benoit (2010). "Insulin, leptin and reward." Trends Endocrinol Metab 
21(2): 68-74. 
Davis, J. F., D. L. Choi, J. D. Shurdak, E. G. Krause, M. F. Fitzgerald, J. W. Lipton, R. R. Sakai and S. C. 
Benoit (2011). "Central melanocortins modulate mesocorticolimbic activity and food seeking 
behavior in the rat." Physiol Behav 102(5): 491-495. 
Davis, M. (1992). "The Role of the Amygdala in Fear and Anxiety." Annual Review of Neuroscience 
15(1): 353-375. 
Daw, N. D., Y. Niv and P. Dayan (2005). "Uncertainty-based competition between prefrontal and 
dorsolateral striatal systems for behavioral control." Nat Neurosci 8(12): 1704-1711. 
de Araujo, I. E. and S. A. Simon (2009). "The gustatory cortex and multisensory integration." Int J 
Obes (Lond) 33 Suppl 2: S34-43. 
De Barioglio, S. R., N. Lezcano and M. E. Celis (1991). "Alpha MSH-induced excessive grooming 
behavior involves a GABAergic mechanism." Peptides 12(1): 203-205. 
244 
 
de Lecea, L., T. S. Kilduff, C. Peyron, X.-B. Gao, P. E. Foye, P. E. Danielson, C. Fukuhara, E. L. F. 
Battenberg, V. T. Gautvik, F. S. Bartlett, W. N. Frankel, A. N. van den Pol, F. E. Bloom, K. M. Gautvik 
and J. G. Sutcliffe (1998). "The hypocretins: Hypothalamus-specific peptides with 
neuroexcitatory activity." Proceedings of the National Academy of Sciences 95(1): 322-327. 
De Luca, M., W. Siegrist, S. Bondanza, M. Mathor, R. Cancedda and A. N. Eberle (1993). "Alpha 
melanocyte stimulating hormone (alpha MSH) stimulates normal human melanocyte growth by 
binding to high-affinity receptors." J Cell Sci 105 ( Pt 4): 1079-1084. 
Dela Cruz, J. A., T. Coke, T. Karagiorgis, C. Sampson, D. Icaza-Cukali, K. Kest, R. Ranaldi and R. J. 
Bodnar (2014). "c-Fos induction in mesotelencephalic dopamine pathway projection targets and 
dorsal striatum following oral intake of sugars and fats in rats." Brain Res Bull 111c: 9-19. 
Department of Health, G. O. f. S. (2007). "Tackling obesities: future choices." 
Deyle, D. R. and D. W. Russell (2009). "Adeno-associated virus vector integration." Current opinion in 
molecular therapeutics 11(4): 442-447. 
Di Chiara, G. (2002). "Nucleus accumbens shell and core dopamine: differential role in behavior and 
addiction." Behav Brain Res 137(1-2): 75-114. 
Di Segni, M., E. Patrono, L. Patella, S. Puglisi-Allegra and R. Ventura (2014). "Animal models of 
compulsive eating behavior." Nutrients 6(10): 4591-4609. 
Dickson, S. L. and S. M. Luckman (1997). "Induction of c-fos Messenger Ribonucleic Acid in 
Neuropeptide Y and Growth Hormone (GH)-Releasing Factor Neurons in the Rat Arcuate Nucleus 
Following Systemic Injection of the GH Secretagogue, GH-Releasing Peptide-6." Endocrinology 
138(2): 771-777. 
Dickson, S. L., R. H. Shirazi, C. Hansson, F. Bergquist, H. Nissbrandt and K. P. Skibicka (2012). "The 
glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new 
role for mesolimbic GLP-1 receptors." J Neurosci 32(14): 4812-4820. 
Dietrich, M. O., J. Bober, J. G. Ferreira, L. A. Tellez, Y. S. Mineur, D. O. Souza, X.-B. Gao, M. R. 
Picciotto, I. Araujo, Z.-W. Liu and T. L. Horvath (2012). "AgRP neurons regulate development of 
dopamine neuronal plasticity and nonfood-associated behaviors." Nat Neurosci 15(8): 1108-1110. 
Dominguez-Lopez, S., R. D. Howell, M. G. Lopez-Canul, M. Leyton and G. Gobbi (2014). 
"Electrophysiological characterization of dopamine neuronal activity in the ventral tegmental area 
across the light-dark cycle." Synapse. 
Dores, R. M. (2009). "Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the 
melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective." Ann N Y 
Acad Sci 1163: 93-100. 
Dragunow, M. and R. Faull (1989). "The use of c-fos as a metabolic marker in neuronal pathway 
tracing." Journal of Neuroscience Methods 29(3): 261-265. 
Drewnowski, A. and M. R. Greenwood (1983). "Cream and sugar: human preferences for high-fat 
foods." Physiol Behav 30(4): 629-633. 
Dutheil, N., M. Yoon-Robarts, P. Ward, E. Henckaerts, L. Skrabanek, K. I. Berns, F. Campagne and R. 
M. Linden (2004). "Characterization of the Mouse Adeno-Associated Virus AAVS1 Ortholog." Journal 
of Virology 78(16): 8917-8921. 
Duva, M. A., E. M. Tomkins, L. M. Moranda, R. Kaplan, A. Sukhaseum and B. G. Stanley (2005). 
"Origins of lateral hypothalamic afferents associated with N-methyl-d-aspartic acid-elicited eating 
studied using reverse microdialysis of NMDA and Fluorogold." Neurosci Res 52(1): 95-106. 
Egecioglu, E., E. Jerlhag, N. Salome, K. P. Skibicka, D. Haage, Y. M. Bohlooly, D. Andersson, M. 
Bjursell, D. Perrissoud, J. A. Engel and S. L. Dickson (2010). "Ghrelin increases intake of rewarding 
food in rodents." Addict Biol 15(3): 304-311. 
Elias, C. F., C. Lee, J. Kelly, C. Aschkenasi, R. S. Ahima, P. R. Couceyro, M. J. Kuhar, C. B. Saper and J. K. 
Elmquist (1998). "Leptin Activates Hypothalamic CART Neurons Projecting to the Spinal Cord." 
Neuron 21(6): 1375-1385. 
Ellacott, K. L., G. J. Morton, S. C. Woods, P. Tso and M. W. Schwartz (2010). "Assessment of feeding 
behavior in laboratory mice." Cell Metab 12(1): 10-17. 
245 
 
Elmquist, J. K., C. Bjorbaek, R. S. Ahima, J. S. Flier and C. B. Saper (1998). "Distributions of leptin 
receptor mRNA isoforms in the rat brain." J Comp Neurol 395(4): 535-547. 
Eskay, R. L., P. Giraud, C. Oliver and M. J. Brown-Stein (1979). "Distribution of alpha-melanocyte-
stimulating hormone in the rat brain: evidence that alpha-MSH-containing cells in the arcuate region 
send projections to extrahypothalamic areas." Brain Res 178(1): 55-67. 
Espana, R. A., J. R. Melchior, D. C. Roberts and S. R. Jones (2011). "Hypocretin 1/orexin A in the 
ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-
administration." Psychopharmacology (Berl) 214(2): 415-426. 
Espana, R. A., E. B. Oleson, J. L. Locke, B. R. Brookshire, D. C. Roberts and S. R. Jones (2010). "The 
hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic 
dopamine system." Eur J Neurosci 31(2): 336-348. 
Fahrbach, S. E., J. I. Morrell and D. W. Pfaff (1989). "Studies of ventromedial hypothalamic afferents 
in the rat using three methods of HRP application." Experimental Brain Research 77(2): 221-233. 
Fallon, J. H. (1981). "Collateralization of monoamine neurons: mesotelencephalic dopamine 
projections to caudate, septum, and frontal cortex." J Neurosci 1(12): 1361-1368. 
Fan, W., B. A. Boston, R. A. Kesterson, V. J. Hruby and R. D. Cone (1997). "Role of melanocortinergic 
neurons in feeding and the agouti obesity syndrome." Nature 385(6612): 165-168. 
Fani, L., S. Bak, P. Delhanty, E. F. C. van Rossum and E. L. T. van den Akker (2014). "The melanocortin-
4 receptor as target for obesity treatment: a systematic review of emerging pharmacological 
therapeutic options." Int J Obes 38(2): 163-169. 
Farooqi, I. S., J. M. Keogh, G. S. Yeo, E. J. Lank, T. Cheetham and S. O'Rahilly (2003). "Clinical 
spectrum of obesity and mutations in the melanocortin 4 receptor gene." N Engl J Med 348(12): 
1085-1095. 
Farooqi, I. S., J. M. Keogh, G. S. H. Yeo, E. J. Lank, T. Cheetham and S. O'Rahilly (2003). "Clinical 
Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene." New England Journal of 
Medicine 348(12): 1085-1095. 
Farooqi, I. S., G. S. Yeo, J. M. Keogh, S. Aminian, S. A. Jebb, G. Butler, T. Cheetham and S. O'Rahilly 
(2000). "Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 
receptor deficiency." J Clin Invest 106(2): 271-279. 
Fehm, H. L., R. Smolnik, W. Kern, G. P. McGregor, U. Bickel and J. Born (2001). "The Melanocortin 
Melanocyte-Stimulating Hormone/Adrenocorticotropin4–10 Decreases Body Fat in Humans." The 
Journal of Clinical Endocrinology & Metabolism 86(3): 1144-1148. 
Fekete, C., G. Legradi, E. Mihaly, Q. H. Huang, J. B. Tatro, W. M. Rand, C. H. Emerson and R. M. 
Lechan (2000). "alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating 
thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus 
and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression." J 
Neurosci 20(4): 1550-1558. 
Fekete, C., D. L. Marks, S. Sarkar, C. H. Emerson, W. M. Rand, R. D. Cone and R. M. Lechan (2004). 
"Effect of Agouti-related protein in regulation of the hypothalamic-pituitary-thyroid axis in the 
melanocortin 4 receptor knockout mouse." Endocrinology 145(11): 4816-4821. 
Ferrari, W. (1958). "Behavioural Changes in Animals after Intracisternal Injection with 
Adrenocorticotrophic Hormone and Melanocyte-Stimulating Hormone." Nature 181(4613): 925-926. 
Fields, H. L., G. O. Hjelmstad, E. B. Margolis and S. M. Nicola (2007). "Ventral tegmental area neurons 
in learned appetitive behavior and positive reinforcement." Annu Rev Neurosci 30: 289-316. 
Figlewicz, D., P. Szot, M. Chavez, S. Woods and R. Veith (1994). "Intraventricular insulin increases 
dopamine transporter mRNA in rat VTA/substantia nigra." Brain Research 644(2): 331-334. 
Figlewicz, D. P., J. L. Bennett, S. Aliakbari, A. Zavosh and A. J. Sipols (2008). "Insulin acts at different 
CNS sites to decrease acute sucrose intake and sucrose self-administration in rats." Am J Physiol 
Regul Integr Comp Physiol 295(2): R388-394. 
246 
 
Figlewicz, D. P., S. B. Evans, J. Murphy, M. Hoen and D. G. Baskin (2003). "Expression of receptors for 
insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat." Brain Res 
964(1): 107-115. 
Figlewicz, D. P., J. L. Jay, M. A. Acheson, I. J. Magrisso, C. H. West, A. Zavosh, S. C. Benoit and J. F. 
Davis (2013). "Moderate high fat diet increases sucrose self-administration in young rats." Appetite 
61(1): 19-29. 
Figlewicz, D. P., T. A. Patterson, L. B. Johnson, A. Zavosh, P. A. Israel and P. Szot (1998). "Dopamine 
transporter mRNA is increased in the CNS of Zucker fatty (fa/fa) rats." Brain Res Bull 46(3): 199-202. 
Fitzgerald, L. W., J. Ortiz, A. G. Hamedani and E. J. Nestler (1996). "Drugs of abuse and stress increase 
the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: 
common adaptations among cross-sensitizing agents." J Neurosci 16(1): 274-282. 
Florijn, W. J., A. H. Mulder, D. H. Versteeg and W. H. Gispen (1993). "Adrenocorticotropin/alpha-
melanocyte-stimulating hormone (ACTH/MSH)-like peptides modulate adenylate cyclase activity in 
rat brain slices: evidence for an ACTH/MSH receptor-coupled mechanism." J Neurochem 60(6): 2204-
2211. 
Franklin, K. B. J. and G. Paxinos (2007). "The Mouse Brain in Stereotaxic Co-ordinates " Elsevier. 
Fukushima, M., K. Tokunaga, J. Lupien, J. W. Kemnitz and G. A. Bray (1987). "Dynamic and static 
phases of obesity following lesions in PVN and VMH." Am J Physiol 253(3 Pt 2): R523-529. 
Fuxe, K. (1965). "Evidence for the existence of monoamine neurons in the central nervous system." 
Zeitschrift für Zellforschung und Mikroskopische Anatomie 65(4): 573-596. 
Gantz, I., Y. Konda, T. Tashiro, Y. Shimoto, H. Miwa, G. Munzert, S. J. Watson, J. DelValle and T. 
Yamada (1993). "Molecular cloning of a novel melanocortin receptor." J Biol Chem 268(11): 8246-
8250. 
Gantz, I., H. Miwa, Y. Konda, Y. Shimoto, T. Tashiro, S. J. Watson, J. DelValle and T. Yamada (1993). 
"Molecular cloning, expression, and gene localization of a fourth melanocortin receptor." J Biol 
Chem 268(20): 15174-15179. 
Garcin, G., L. Le Gallic, P. E. Stoebner, A. Guezennec, J. Guesnet, T. Lavabre-Bertrand, J. Martinez and 
L. Meunier (2009). "Constitutive expression of MC1R in HaCaT keratinocytes inhibits basal and UVB-
induced TNF-alpha production." Photochem Photobiol 85(6): 1440-1450. 
Gatto, G. J., W. J. McBride, J. M. Murphy, L. Lumeng and T. K. Li (1994). "Ethanol self-infusion into 
the ventral tegmental area by alcohol-preferring rats." Alcohol 11(6): 557-564. 
Geerling, J. C., J. W. Shin, P. C. Chimenti and A. D. Loewy (2010). "Paraventricular hypothalamic 
nucleus: axonal projections to the brainstem." J Comp Neurol 518(9): 1460-1499. 
Geiger, B. M., G. G. Behr, L. E. Frank, A. D. Caldera-Siu, M. C. Beinfeld, E. G. Kokkotou and E. N. 
Pothos (2008). "Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats." 
Faseb j 22(8): 2740-2746. 
Geiger, B. M., M. Haburcak, N. M. Avena, M. C. Moyer, B. G. Hoebel and E. N. Pothos (2009). 
"Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity." Neuroscience 159(4): 
1193-1199. 
Geisler, S. and D. S. Zahm (2005). "Afferents of the ventral tegmental area in the rat-anatomical 
substratum for integrative functions." J Comp Neurol 490(3): 270-294. 
Getting, S. J., M. Kaneva, Y. Bhadresa, D. Renshaw, G. Leoni, H. B. Patel, M. J. Kerrigan and I. C. Locke 
(2009). "Melanocortin peptide therapy for the treatment of arthritic pathologies." 
ScientificWorldJournal 9: 1394-1414. 
Getting, S. J., C. W. Lam, G. Leoni, F. N. Gavins, P. Grieco and M. Perretti (2006). "[D-Trp8]-gamma-
melanocyte-stimulating hormone exhibits anti-inflammatory efficacy in mice bearing a nonfunctional 
MC1R (recessive yellow e/e mouse)." Mol Pharmacol 70(6): 1850-1855. 
Ghamari-Langroudi, M., G. J. Digby, J. A. Sebag, G. L. Millhauser, R. Palomino, R. Matthews, T. 
Gillyard, B. L. Panaro, I. R. Tough, H. M. Cox, J. S. Denton and R. D. Cone (2015). "G-protein-
independent coupling of MC4R to Kir7.1 in hypothalamic neurons." Nature 520(7545): 94-98. 
247 
 
Ghamari-Langroudi, M., G. J. Digby, J. A. Sebag, G. L. Millhauser, R. Palomino, R. Matthews, T. 
Gillyard, B. L. Panaro, I. R. Tough, H. M. Cox, J. S. Denton and R. D. Cone (2015). "G-protein-
independent coupling of MC4R to Kir7.1 in hypothalamic neurons." Nature advance online 
publication. 
Giraudo, S. Q., C. J. Billington and A. S. Levine (1998). "Feeding effects of hypothalamic injection of 
melanocortin 4 receptor ligands." Brain Res 809(2): 302-306. 
Godar, R., Y. Dai, H. Bainter, C. Billington, C. M. Kotz and C. F. Wang (2011). "Reduction of high-fat 
diet-induced obesity after chronic administration of brain-derived neurotrophic factor in the 
hypothalamic ventromedial nucleus." Neuroscience 194: 36-52. 
Gold, R. M. (1973). "Hypothalamic Obesity: The Myth of the Ventromedial Nucleus." Science 
182(4111): 488-490. 
Goldstein, R. Z., P. A. Woicik, S. J. Moeller, F. Telang, M. Jayne, C. Wong, G. J. Wang, J. S. Fowler and 
N. D. Volkow (2010). "Liking and wanting of drug and non-drug rewards in active cocaine users: the 
STRAP-R questionnaire." J Psychopharmacol 24(2): 257-266. 
Grace, A. A. and B. S. Bunney (1983). "Intracellular and extracellular electrophysiology of nigral 
dopaminergic neurons--1. Identification and characterization." Neuroscience 10(2): 301-315. 
Grace, A. A. and B. S. Bunney (1985). "Opposing effects of striatonigral feedback pathways on 
midbrain dopamine cell activity." Brain Res 333(2): 271-284. 
Gray, S. J., S. B. Foti, J. W. Schwartz, L. Bachaboina, B. Taylor-Blake, J. Coleman, M. D. Ehlers, M. J. 
Zylka, T. J. McCown and R. J. Samulski (2011). "Optimizing Promoters for Recombinant Adeno-
Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using 
Self-Complementary Vectors." Human Gene Therapy 22(9): 1143-1153. 
Greenfield, J. R., J. W. Miller, J. M. Keogh, E. Henning, J. H. Satterwhite, G. S. Cameron, B. Astruc, J. P. 
Mayer, S. Brage, T. C. See, D. J. Lomas, S. O'Rahilly and I. S. Farooqi (2009). "Modulation of Blood 
Pressure by Central Melanocortinergic Pathways." New England Journal of Medicine 360(1): 44-52. 
Greig, L. C., M. B. Woodworth, M. J. Galazo, H. Padmanabhan and J. D. Macklis (2013). "Molecular 
logic of neocortical projection neuron specification, development and diversity." Nat Rev Neurosci 
14(11): 755-769. 
Griffon, N., V. Mignon, P. Facchinetti, J. Diaz, J. C. Schwartz and P. Sokoloff (1994). "Molecular 
Cloning and Characterisation of the Rat Fifth Melanocortin Receptor." Biochemical and Biophysical 
Research Communications 200(2): 1007-1014. 
Grill, H. J. (1980). "Production and regulation of ingestive consummatory behavior in the chronic 
decerebrate rat." Brain Research Bulletin 5, Supplement 4(0): 79-87. 
Grill, H. J., A. B. Ginsberg, R. J. Seeley and J. M. Kaplan (1998). "Brainstem application of 
melanocortin receptor ligands produces long-lasting effects on feeding and body weight." J Neurosci 
18(23): 10128-10135. 
Grill, H. J. and R. Norgren (1978). "Chronically decerebrate rats demonstrate satiation but not bait 
shyness." Science 201(4352): 267-269. 
Grill, H. J., M. W. Schwartz, J. M. Kaplan, J. S. Foxhall, J. Breininger and D. G. Baskin (2002). "Evidence 
That the Caudal Brainstem Is a Target for the Inhibitory Effect of Leptin on Food Intake." 
Endocrinology 143(1): 239-246. 
Grove, K. L., R. S. Brogan and M. S. Smith (2001). "Novel expression of neuropeptide Y (NPY) mRNA 
in hypothalamic regions during development: region-specific effects of maternal deprivation on NPY 
and Agouti-related protein mRNA." Endocrinology 142(11): 4771-4776. 
Guan, X. M., H. Yu, O. C. Palyha, K. K. McKee, S. D. Feighner, D. J. Sirinathsinghji, R. G. Smith, L. H. 
Van der Ploeg and A. D. Howard (1997). "Distribution of mRNA encoding the growth hormone 
secretagogue receptor in brain and peripheral tissues." Brain Res Mol Brain Res 48(1): 23-29. 
Guan, X. M., H. Yu, M. Trumbauer, E. Frazier, L. H. Van der Ploeg and H. Chen (1998). "Induction of 
neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice." Neuroreport 
9(15): 3415-3419. 
248 
 
Guillery, R. W. and S. M. Sherman (2002). "Thalamic relay functions and their role in corticocortical 
communication: generalizations from the visual system." Neuron 33(2): 163-175. 
Haber, S. N., H. J. Groenewegen, E. A. Grove and W. J. Nauta (1985). "Efferent connections of the 
ventral pallidum: evidence of a dual striato pallidofugal pathway." J Comp Neurol 235(3): 322-335. 
Hagan, M. M., S. C. Benoit, P. A. Rushing, L. M. Pritchard, S. C. Woods and R. J. Seeley (2001). 
"Immediate and prolonged patterns of Agouti-related peptide-(83--132)-induced c-Fos activation in 
hypothalamic and extrahypothalamic sites." Endocrinology 142(3): 1050-1056. 
Hagan, M. M., P. K. Wauford, P. C. Chandler, L. A. Jarrett, R. J. Rybak and K. Blackburn (2002). "A new 
animal model of binge eating: key synergistic role of past caloric restriction and stress." Physiol 
Behav 77(1): 45-54. 
Hahn, T. M., J. F. Breininger, D. G. Baskin and M. W. Schwartz (1998). "Coexpression of Agrp and NPY 
in fasting-activated hypothalamic neurons." Nat Neurosci 1(4): 271-272. 
Hajnal, A., G. P. Smith and R. Norgren (2004). "Oral sucrose stimulation increases accumbens 
dopamine in the rat." Am J Physiol Regul Integr Comp Physiol 286(1): R31-37. 
Halliday, G. M. and I. Tork (1986). "Comparative anatomy of the ventromedial mesencephalic 
tegmentum in the rat, cat, monkey and human." J Comp Neurol 252(4): 423-445. 
Hansen, M. J., H. B. Schioth and M. J. Morris (2005). "Feeding responses to a melanocortin agonist 
and antagonist in obesity induced by a palatable high-fat diet." Brain Res 1039(1-2): 137-145. 
Harno, E., Elizabeth C. Cottrell and A. White (2013). "Metabolic Pitfalls of CNS Cre-Based 
Technology." Cell Metabolism 18(1): 21-28. 
Harris, G. C. and G. Aston-Jones (2003). "Critical role for ventral tegmental glutamate in preference 
for a cocaine-conditioned environment." Neuropsychopharmacology 28(1): 73-76. 
Harris, G. C., M. Wimmer, R. Byrne and G. Aston-Jones (2004). "Glutamate-associated plasticity in 
the ventral tegmental area is necessary for conditioning environmental stimuli with morphine." 
Neuroscience 129(3): 841-847. 
Haskell-Luevano, C., R. D. Cone, E. K. Monck and Y. P. Wan (2001). "Structure activity studies of the 
melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), 
melanocortin agonist and synthetic peptide antagonist interaction determinants." Biochemistry 
40(20): 6164-6179. 
Hatfield, T., J.-S. Han, M. Conley, M. Gallagher and P. Holland (1996). "Neurotoxic Lesions of 
Basolateral, But Not Central, Amygdala Interfere with Pavlovian Second-Order Conditioning and 
Reinforcer Devaluation Effects." The Journal of Neuroscience 16(16): 5256-5265. 
He, S., Z. Ye, P. H. Dobbelaar, R. K. Bakshi, Q. Hong, J. P. Dellureficio, I. K. Sebhat, L. Guo, J. Liu, T. 
Jian, Y. Lai, C. L. Franklin, M. Reibarkh, M. A. Holmes, D. H. Weinberg, T. MacNeil, R. Tang, C. 
Tamvakopoulos, Q. Peng, R. R. Miller, R. A. Stearns, H. Y. Chen, A. S. Chen, A. M. Strack, T. M. Fong, 
M. J. Wyvratt, Jr. and R. P. Nargund (2010). "Discovery of highly potent and efficacious MC4R 
agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity." 
Bioorg Med Chem Lett 20(22): 6524-6532. 
He, S., Z. Ye, P. H. Dobbelaar, I. K. Sebhat, L. Guo, J. Liu, T. Jian, Y. Lai, C. L. Franklin, R. K. Bakshi, J. P. 
Dellureficio, Q. Hong, D. H. Weinberg, T. MacNeil, R. Tang, A. M. Strack, C. Tamvakopoulos, Q. Peng, 
R. R. Miller, R. A. Stearns, H. Y. Chen, A. S. Chen, T. M. Fong, M. J. Wyvratt Jr and R. P. Nargund 
(2010). "Spiroindane based amides as potent and selective MC4R agonists for the treatment of 
obesity." Bioorganic & Medicinal Chemistry Letters 20(15): 4399-4405. 
Headley, P. M. and S. Grillner (1990). "Excitatory amino acids and synaptic transmission: the 
evidence for a physiological function." Trends in Pharmacological Sciences 11(5): 205-211. 
Hebebrand, J., F. Geller, A. Dempfle, M. Heinzel-Gutenbrunner, M. Raab, G. Gerber, A. K. Wermter, 
F. F. Horro, J. Blundell, H. Schafer, H. Remschmidt, S. Herpertz and A. Hinney (2004). "Binge-eating 
episodes are not characteristic of carriers of melanocortin-4 receptor gene mutations." Mol 
Psychiatry 9(8): 796-800. 
249 
 
Heffner, C. S., C. Herbert Pratt, R. P. Babiuk, Y. Sharma, S. F. Rockwood, L. R. Donahue, J. T. Eppig and 
S. A. Murray (2012). "Supporting conditional mouse mutagenesis with a comprehensive cre 
characterization resource." Nat Commun 3: 1218. 
Heimer, L. and R. D. Wilson (1975). "The subcortical projections of the allocortex: similarities in the 
neural associations of the hippocampus, the piriform cortex, and the neocortex. ." Golgi Centennial 
Symposium Proceedings, Raven Press, New York: 177 - 193. 
Heimer, L., D. S. Zahm, L. Churchill, P. W. Kalivas and C. Wohltmann (1991). "Specificity in the 
projection patterns of accumbal core and shell in the rat." Neuroscience 41(1): 89-125. 
Hernandez, L. and B. G. Hoebel (1988). "Feeding and hypothalamic stimulation increase dopamine 
turnover in the accumbens." Physiol Behav 44(4-5): 599-606. 
Hess, S., Y. Linde, O. Ovadia, E. Safrai, D. E. Shalev, A. Swed, E. Halbfinger, T. Lapidot, I. Winkler, Y. 
Gabinet, A. Faier, D. Yarden, Z. Xiang, F. P. Portillo, C. Haskell-Luevano, C. Gilon and A. Hoffman 
(2008). "Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally 
administrated drug lead for treating obesity." J Med Chem 51(4): 1026-1034. 
Hoebel, B. G., A. P. Monaco, L. Hernandez, E. F. Aulisi, B. G. Stanley and L. Lenard (1983). "Self-
injection of amphetamine directly into the brain." Psychopharmacology 81(2): 158-163. 
Hoffman, G. E., M. S. Smith and J. G. Verbalis (1993). "c-Fos and Related Immediate Early Gene 
Products as Markers of Activity in Neuroendocrine Systems." Frontiers in Neuroendocrinology 14(3): 
173-213. 
Holdeman, M. and J. M. Lipton (1985). "Antipyretic activity of a potent alpha-MSH analog." Peptides 
6(2): 273-275. 
Hollerman, J. R. and W. Schultz (1998). "Dopamine neurons report an error in the temporal 
prediction of reward during learning." Nat Neurosci 1(4): 304-309. 
Hollmann, M., A. O'Shea-Greenfield, S. W. Rogers and S. Heinemann (1989). "Cloning by functional 
expression of a member of the glutamate receptor family." Nature 342(6250): 643-648. 
Holloway, P. M., H. K. Smith, D. Renshaw, R. J. Flower, S. J. Getting and F. N. Gavins (2011). 
"Targeting the melanocortin receptor system for anti-stroke therapy." Trends Pharmacol Sci 32(2): 
90-98. 
Holst, J. J. (2007). "The physiology of glucagon-like peptide 1." Physiol Rev 87(4): 1409-1439. 
Hommel, J. D., R. Trinko, R. M. Sears, D. Georgescu, Z. W. Liu, X. B. Gao, J. J. Thurmon, M. Marinelli 
and R. J. DiLeone (2006). "Leptin receptor signaling in midbrain dopamine neurons regulates 
feeding." Neuron 51(6): 801-810. 
Hong, Q., R. K. Bakshi, B. L. Palucki, M. K. Park, Z. Ye, S. He, P. G. Pollard, I. K. Sebhat, J. Liu, L. Guo, D. 
E. Cashen, W. J. Martin, D. H. Weinberg, T. MacNeil, R. Tang, C. Tamvakopoulos, Q. Peng, R. R. Miller, 
R. A. Stearns, H. Y. Chen, A. S. Chen, A. M. Strack, T. M. Fong, D. E. MacIntyre, M. J. Wyvratt and R. P. 
Nargund (2011). "Discovery of a piperazine urea based compound as a potent, selective, orally 
bioavailable melanocortin subtype-4 receptor partial agonist." Bioorg Med Chem Lett 21(8): 2330-
2334. 
Hoover, W. and R. Vertes (2007). "Anatomical analysis of afferent projections to the medial 
prefrontal cortex in the rat." Brain Structure and Function 212(2): 149-179. 
Howard, A. D., S. D. Feighner, D. F. Cully, J. P. Arena, P. A. Liberator, C. I. Rosenblum, M. Hamelin, D. 
L. Hreniuk, O. C. Palyha, J. Anderson, P. S. Paress, C. Diaz, M. Chou, K. K. Liu, K. K. McKee, S. S. Pong, 
L. Y. Chaung, A. Elbrecht, M. Dashkevicz, R. Heavens, M. Rigby, D. J. Sirinathsinghji, D. C. Dean, D. G. 
Melillo, A. A. Patchett, R. Nargund, P. R. Griffin, J. A. DeMartino, S. K. Gupta, J. M. Schaeffer, R. G. 
Smith and L. H. Van der Ploeg (1996). "A receptor in pituitary and hypothalamus that functions in 
growth hormone release." Science 273(5277): 974-977. 
Hruby, V. J., B. C. Wilkes, M. E. Hadley, F. Al-Obeidi, T. K. Sawyer, D. J. Staples, A. E. de Vaux, O. Dym, 
A. M. Castrucci, M. F. Hintz and et al. (1987). "alpha-Melanotropin: the minimal active sequence in 
the frog skin bioassay." J Med Chem 30(11): 2126-2130. 
250 
 
Hsu, R., J. R. Taylor, S. S. Newton, J. D. Alvaro, C. Haile, G. Han, V. J. Hruby, E. J. Nestler and R. S. 
Duman (2005). "Blockade of melanocortin transmission inhibits cocaine reward." Eur J Neurosci 
21(8): 2233-2242. 
Hunt, G., S. Kyne, K. Wakamatsu, S. Ito and A. J. Thody (1995). "Nle4DPhe7 alpha-melanocyte-
stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes." 
J Invest Dermatol 104(1): 83-85. 
Hunt, G., C. Todd, S. Kyne and A. J. Thody (1994). "ACTH stimulates melanogenesis in cultured 
human melanocytes." J Endocrinol 140(1): R1-3. 
Hur, E. E. and L. Zaborszky (2005). "Vglut2 afferents to the medial prefrontal and primary 
somatosensory cortices: A combined retrograde tracing in situ hybridization." The Journal of 
Comparative Neurology 483(3): 351-373. 
Huszar, D., C. A. Lynch, V. Fairchild-Huntress, J. H. Dunmore, Q. Fang, L. R. Berkemeier, W. Gu, R. A. 
Kesterson, B. A. Boston, R. D. Cone, F. J. Smith, L. A. Campfield, P. Burn and F. Lee (1997). "Targeted 
disruption of the melanocortin-4 receptor results in obesity in mice." Cell 88(1): 131-141. 
Hyde, T. M. and R. R. Miselis (1983). "Effects of area postrema/caudal medial nucleus of solitary tract 
lesions on food intake and body weight." Am J Physiol 244(4): R577-587. 
Hyman, S. E., R. C. Malenka and E. J. Nestler (2006). "Neural mechanisms of addiction: the role of 
reward-related learning and memory." Annu Rev Neurosci 29: 565-598. 
Ikemoto, S. and J. Panksepp (1999). "The role of nucleus accumbens dopamine in motivated 
behavior: a unifying interpretation with special reference to reward-seeking." Brain Res Brain Res 
Rev 31(1): 6-41. 
Jackson, R. S., S. O’Rahilly, C. Brain and S. S. Nussey (1999). "Proopiomelanocortin Products and 
Human Early-Onset Obesity." The Journal of Clinical Endocrinology & Metabolism 84(2): 819-820. 
Jacobowitz, D. M. and T. L. O'Donohue (1978). "alpha-Melanocyte stimulating hormone: 
immunohistochemical identification and mapping in neurons of rat brain." Proc Natl Acad Sci U S A 
75(12): 6300-6304. 
Jansone, B., L. Bergstrom, S. Svirskis, J. Lindblom, V. Klusa and J. E. Wikberg (2004). "Opposite effects 
of gamma(1)- and gamma(2)-melanocyte stimulating hormone on regulation of the dopaminergic 
mesolimbic system in rats." Neurosci Lett 361(1-3): 68-71. 
Jégou, S., I. Boutelet and H. Vaudry (2000). "Melanocortin-3 Receptor mRNA Expression in Pro-
Opiomelanocortin Neurones of the Rat Arcuate Nucleus." Journal of Neuroendocrinology 12(6): 501-
505. 
Jennings, J. H., G. Rizzi, A. M. Stamatakis, R. L. Ung and G. D. Stuber (2013). "The Inhibitory Circuit 
Architecture of the Lateral Hypothalamus Orchestrates Feeding." Science 341(6153): 1517-1521. 
Jeong, J. K. and S. Diano (2014). "Prolyl carboxypeptidase mRNA expression in the mouse brain." 
Brain Res 1542: 85-92. 
Jerlhag, E., E. Egecioglu, S. L. Dickson, A. Douhan, L. Svensson and J. A. Engel (2007). "PRECLINICAL 
STUDY: Ghrelin administration into tegmental areas stimulates locomotor activity and increases 
extracellular concentration of dopamine in the nucleus accumbens." Addiction Biology 12(1): 6-16. 
Johnson, P. I., J. R. Stellar and A. D. Paul (1993). "Regional reward differences within the ventral 
pallidum are revealed by microinjections of a mu opiate receptor agonist." Neuropharmacology 
32(12): 1305-1314. 
Johnson, S., V. Seutin and R. North (1992). "Burst firing in dopamine neurons induced by N-methyl-
D-aspartate: role of electrogenic sodium pump." Science 258(5082): 665-667. 
Johnson, S. W. and R. A. North (1992). "Opioids excite dopamine neurons by hyperpolarization of 
local interneurons." J Neurosci 12(2): 483-488. 
Joseph, S. A. and G. J. Michael (1988). "Efferent ACTH-ir opiocortin projections from nucleus tractus 
solitarius: A hypothalamic deafferentation study." Peptides 9(1): 193-201. 
Joseph, S. A., W. H. Pilcher and C. Bennett-Clarke (1983). "Immunocytochemical localization of ACTH 
perikarya in nucleus tractus solitarius: evidence for a second opiocortin neuronal system." Neurosci 
Lett 38(3): 221-225. 
251 
 
Kask, A., F. Mutulis, R. Muceniece, R. Pahkla, I. Mutule, J. E. Wikberg, L. Rago and H. B. Schioth 
(1998). "Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): 
evaluation in vitro and in vivo." Endocrinology 139(12): 5006-5014. 
Kask, A., L. Rago, F. Mutulis, R. Pahkla, J. E. Wikberg and H. B. Schioth (1998). "Selective antagonist 
for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats." Biochem 
Biophys Res Commun 245(1): 90-93. 
Kask, A. and H. B. Schiöth (2000). "Tonic inhibition of food intake during inactive phase is reversed by 
the injection of the melanocortin receptor antagonist into the paraventricular nucleus of the 
hypothalamus and central amygdala of the rat." Brain Research 887(2): 460-464. 
Katz, D. B., M. A. Nicolelis and S. A. Simon (2000). "Nutrient tasting and signaling mechanisms in the 
gut. IV. There is more to taste than meets the tongue." Am J Physiol Gastrointest Liver Physiol 
278(1): G6-9. 
Kawamoto, Y., S. Nakamura, S. Nakano, N. Oka, I. Akiguchi and J. Kimura (1996). 
"Immunohistochemical localization of brain-derived neurotrophic factor in adult rat brain." 
Neuroscience 74(4): 1209-1226. 
Keinanen, K., W. Wisden, B. Sommer, P. Werner, A. Herb, T. A. Verdoorn, B. Sakmann and P. H. 
Seeburg (1990). "A family of AMPA-selective glutamate receptors." Science 249(4968): 556-560. 
Kelley, A. E. and K. C. Berridge (2002). "The Neuroscience of Natural Rewards: Relevance to Addictive 
Drugs." The Journal of Neuroscience 22(9): 3306-3311. 
Kievit, P., H. Halem, D. L. Marks, J. Z. Dong, M. M. Glavas, P. Sinnayah, L. Pranger, M. A. Cowley, K. L. 
Grove and M. D. Culler (2013). "Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes 
Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced 
Obese Rhesus Macaques." Diabetes 62(2): 490-497. 
Kim, E. M., M. K. Grace, E. O'Hare, C. J. Billington and A. S. Levine (2002). "Injection of alpha-MSH, 
but not beta-endorphin, into the PVN decreases POMC gene expression in the ARC." Neuroreport 
13(4): 497-500. 
Kim, M. S., M. Rossi, S. Abusnana, D. Sunter, D. G. Morgan, C. J. Small, C. M. Edwards, M. M. Heath, 
S. A. Stanley, L. J. Seal, J. R. Bhatti, D. M. Smith, M. A. Ghatei and S. R. Bloom (2000). "Hypothalamic 
localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating 
hormone." Diabetes 49(2): 177-182. 
King, C. M. and S. T. Hentges (2011). "Relative number and distribution of murine hypothalamic 
proopiomelanocortin neurons innervating distinct target sites." PLoS One 6(10): e25864. 
Kishi, T., C. J. Aschkenasi, C. E. Lee, K. G. Mountjoy, C. B. Saper and J. K. Elmquist (2003). "Expression 
of melanocortin 4 receptor mRNA in the central nervous system of the rat." The Journal of 
Comparative Neurology 457(3): 213-235. 
Kishi, T., C. J. Aschkenasi, C. E. Lee, K. G. Mountjoy, C. B. Saper and J. K. Elmquist (2003). "Expression 
of melanocortin 4 receptor mRNA in the central nervous system of the rat." J Comp Neurol 457(3): 
213-235. 
Klebig, M. L., J. E. Wilkinson, J. G. Geisler and R. P. Woychik (1995). "Ectopic expression of the agouti 
gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur." Proc Natl Acad 
Sci U S A 92(11): 4728-4732. 
Klein, T. A., J. Neumann, M. Reuter, J. Hennig, D. Y. von Cramon and M. Ullsperger (2007). 
"Genetically determined differences in learning from errors." Science 318(5856): 1642-1645. 
Klitenick, M. A., A. Y. Deutch, L. Churchill and P. W. Kalivas (1992). "Topography and functional role 
of dopaminergic projections from the ventral mesencephalic tegmentum to the ventral pallidum." 
Neuroscience 50(2): 371-386. 
Klusa, V., S. Svirskis, B. Opmane, R. Muceniece, A. Skujins, F. Mutulis, J. E. Wikberg and H. B. Schioth 
(1998). "Evaluation of behavioural effects of neural melanocortin receptor antagonists injected ICV 
and in VTA in rats." Neuropeptides 32(6): 573-580. 
252 
 
Kolaczynski, J. W., R. V. Considine, J. Ohannesian, C. Marco, I. Opentanova, M. R. Nyce, M. Myint and 
J. F. Caro (1996). "Responses of leptin to short-term fasting and refeeding in humans: a link with 
ketogenesis but not ketones themselves." Diabetes 45(11): 1511-1515. 
Kolaczynski, J. W., J. P. Ohannesian, R. V. Considine, C. C. Marco and J. F. Caro (1996). "Response of 
leptin to short-term and prolonged overfeeding in humans." J Clin Endocrinol Metab 81(11): 4162-
4165. 
Komura, Y., R. Tamura, T. Uwano, H. Nishijo, K. Kaga and T. Ono (2001). "Retrospective and 
prospective coding for predicted reward in the sensory thalamus." Nature 412(6846): 546-549. 
Konda, Y., I. Gantz, J. DelValle, Y. Shimoto, H. Miwa and T. Yamada (1994). "Interaction of dual 
intracellular signaling pathways activated by the melanocortin-3 receptor." Journal of Biological 
Chemistry 269(18): 13162-13166. 
Koylu, E. O., P. R. Couceyro, P. D. Lambert and M. J. Kuhar (1998). "Cocaine- and amphetamine-
regulated transcript peptide immunohistochemical localization in the rat brain." The Journal of 
Comparative Neurology 391(1): 115-132. 
Krahn, D. D., B. A. Gosnell, A. S. Levine and J. E. Morley (1988). "Behavioral effects of corticotropin-
releasing factor: localization and characterization of central effects." Brain Res 443(1-2): 63-69. 
Krishna, R., B. Gumbiner, C. Stevens, B. Musser, M. Mallick, S. Suryawanshi, L. Maganti, H. Zhu, T. H. 
Han, L. Scherer, B. Simpson, D. Cosgrove, K. Gottesdiener, J. Amatruda, B. J. Rolls, J. Blundell, G. A. 
Bray, K. Fujioka, S. B. Heymsfield, J. A. Wagner and G. A. Herman (2009). "Potent and selective 
agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human 
subjects: energy intake predicts lack of weight loss efficacy." Clin Pharmacol Ther 86(6): 659-666. 
Krude, H., H. Biebermann, W. Luck, R. Horn, G. Brabant and A. Gruters (1998). "Severe early-onset 
obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans." Nat 
Genet 19(2): 155-157. 
Kupchik, Y. M. and P. W. Kalivas (2013). "The rostral subcommissural ventral pallidum is a mix of 
ventral pallidal neurons and neurons from adjacent areas: an electrophysiological study." Brain 
Struct Funct 218(6): 1487-1500. 
Labbe, O., F. Desarnaud, D. Eggerickx, G. Vassart and M. Parmentier (1994). "Molecular cloning of a 
mouse melanocortin 5 receptor gene widely expressed in peripheral tissues." Biochemistry 33(15): 
4543-4549. 
Labouebe, G., S. Liu, C. Dias, H. Zou, J. C. Y. Wong, S. Karunakaran, S. M. Clee, A. G. Phillips, B. Boutrel 
and S. L. Borgland (2013). "Insulin induces long-term depression of ventral tegmental area dopamine 
neurons via endocannabinoids." Nat Neurosci 16(3): 300-308. 
Lammel, S., Elizabeth E. Steinberg, C. Földy, Nicholas R. Wall, K. Beier, L. Luo and Robert C. Malenka 
(2015). "Diversity of Transgenic Mouse Models for Selective Targeting of Midbrain Dopamine 
Neurons." Neuron 85(2): 429-438. 
Landwehrmeyer, B., G. Mengod and J. M. Palacios (1993). "Dopamine D3 receptor mRNA and 
binding sites in human brain." Molecular Brain Research 18(1–2): 187-192. 
Lapchak, P. A. and F. Hefti (1992). "BDNF and NGF treatment in lesioned rats: effects on cholinergic 
function and weight gain." Neuroreport 3(5): 405-408. 
Larsen, L. H., S. M. Echwald, T. I. Sorensen, T. Andersen, B. S. Wulff and O. Pedersen (2005). 
"Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified 
among 750 men with juvenile-onset obesity." J Clin Endocrinol Metab 90(1): 219-224. 
Larsen, P. J. and S. E. Mau (1994). "Effect of acute stress on the expression of hypothalamic 
messenger ribonucleic acids encoding the endogenous opioid precursors preproenkephalin A and 
proopiomelanocortin." Peptides 15(5): 783-790. 
Lee, H. J., A. H. Macbeth, J. H. Pagani and W. S. Young, 3rd (2009). "Oxytocin: the great facilitator of 
life." Prog Neurobiol 88(2): 127-151. 
Lee, L. and P. D. Sadowski (2003). "Sequence of the loxP Site Determines the Order of Strand 
Exchange by the Cre Recombinase." Journal of Molecular Biology 326(2): 397-412. 
253 
 
Leinninger, G. M., Y. H. Jo, R. L. Leshan, G. W. Louis, H. Yang, J. G. Barrera, H. Wilson, D. M. Opland, 
M. A. Faouzi, Y. Gong, J. C. Jones, C. J. Rhodes, S. Chua, Jr., S. Diano, T. L. Horvath, R. J. Seeley, J. B. 
Becker, H. Munzberg and M. G. Myers, Jr. (2009). "Leptin acts via leptin receptor-expressing lateral 
hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding." Cell 
Metab 10(2): 89-98. 
Lemaire, J.-J., H. Nezzar, L. Sakka, Y. Boirie, D. Fontaine, A. Coste, G. Coll, A. Sontheimer, C. Sarret, J. 
Gabrillargues and A. D. Salles (2013). "Maps of the adult human hypothalamus." Surgical Neurology 
International 4(156): S156–S163. 
Leonard, W., J. J. Snodgrass and M. Robertson (2011). Diet and Brain Evolution: Nutritional 
Implications of Large Human Brain Size. Handbook of Behavior, Food and Nutrition. V. R. Preedy, R. 
R. Watson and C. R. Martin, Springer New York: 3-15. 
Leriche, M., A. Cote-Velez and M. Mendez (2007). "Presence of pro-opiomelanocortin mRNA in the 
rat medial prefrontal cortex, nucleus accumbens and ventral tegmental area: studies by RT-PCR and 
in situ hybridization techniques." Neuropeptides 41(6): 421-431. 
Lerma-Cabrera, J. M., F. Carvajal, L. de la Torre, L. de la Fuente, M. Navarro, T. E. Thiele and I. Cubero 
(2012). "Control of food intake by MC4-R signaling in the lateral hypothalamus, nucleus accumbens 
shell and ventral tegmental area: interactions with ethanol." Behav Brain Res 234(1): 51-60. 
Levey, A. I., S. M. Hersch, D. B. Rye, R. K. Sunahara, H. B. Niznik, C. A. Kitt, D. L. Price, R. Maggio, M. R. 
Brann and B. J. Ciliax (1993). "Localization of D1 and D2 dopamine receptors in brain with subtype-
specific antibodies." Proc Natl Acad Sci U S A 90(19): 8861-8865. 
Lim, B. K., K. W. Huang, B. A. Grueter, P. E. Rothwell and R. C. Malenka (2012). "Anhedonia requires 
MC4R-mediated synaptic adaptations in nucleus accumbens." Nature 487(7406): 183-189. 
Lindblom, J., B. Opmane, F. Mutulis, I. Mutule, R. Petrovska, V. Klusa, L. Bergstrom and J. E. Wikberg 
(2001). "The MC4 receptor mediates alpha-MSH induced release of nucleus accumbens dopamine." 
Neuroreport 12(10): 2155-2158. 
Lindefors, N. (1993). "Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and 
GABA release in the striatum: a review." Prog Neuropsychopharmacol Biol Psychiatry 17(6): 887-903. 
Lippert, R. N., K. L. Ellacott and R. D. Cone (2014). "Gender-specific roles for the melanocortin-3 
receptor in the regulation of the mesolimbic dopamine system in mice." Endocrinology 155(5): 1718-
1727. 
Lippert, R. N., K. L. J. Ellacott and R. D. Cone (2014). "Gender-Specific Roles for the Melanocortin-3 
Receptor in the Regulation of the Mesolimbic Dopamine System in Mice." Endocrinology 155(5): 
1718-1727. 
Liu, H., T. Kishi, A. G. Roseberry, X. Cai, C. E. Lee, J. M. Montez, J. M. Friedman and J. K. Elmquist 
(2003). "Transgenic Mice Expressing Green Fluorescent Protein under the Control of the 
Melanocortin-4 Receptor Promoter." The Journal of Neuroscience 23(18): 7143-7154. 
Liu, J., J. C. Garza, W. Li and X.-Y. Lu (2013). "Melanocortin-4 receptor in the medial amygdala 
regulates emotional stress-induced anxiety-like behaviour, anorexia and corticosterone secretion." 
The international journal of neuropsychopharmacology / official scientific journal of the Collegium 
Internationale Neuropsychopharmacologicum (CINP) 16(1): 105-120. 
Liu, J., J. C. Garza, W. Li and X. Y. Lu (2013). "Melanocortin-4 receptor in the medial amygdala 
regulates emotional stress-induced anxiety-like behaviour, anorexia and corticosterone secretion." 
Int J Neuropsychopharmacol 16(1): 105-120. 
Ljungberg, T., P. Apicella and W. Schultz (1992). "Responses of monkey dopamine neurons during 
learning of behavioral reactions." J Neurophysiol 67(1): 145-163. 
Llewellyn, C. H., M. Trzaskowski, C. M. van Jaarsveld, R. Plomin and J. Wardle (2014). "Satiety 
mechanisms in genetic risk of obesity." JAMA Pediatrics 168(4): 338-344. 
Llinas, R. R. (1988). "The intrinsic electrophysiological properties of mammalian neurons: insights 
into central nervous system function." Science 242(4886): 1654-1664. 
Lobb, C. J., C. J. Wilson and C. A. Paladini (2010). "A dynamic role for GABA receptors on the firing 
pattern of midbrain dopaminergic neurons." J Neurophysiol 104(1): 403-413. 
254 
 
Lorens, S. A. and C. Y. Kondo (1969). "Effects of septal lesions on food and water intake and operant 
responding for food." Physiology & Behavior 4(5): 729-732. 
Lu, D., D. Willard, I. R. Patel, S. Kadwell, L. Overton, T. Kost, M. Luther, W. Chen, R. P. Woychik, W. O. 
Wilkison and et al. (1994). "Agouti protein is an antagonist of the melanocyte-stimulating-hormone 
receptor." Nature 371(6500): 799-802. 
Lu, L., J. W. Grimm, Y. Shaham and B. T. Hope (2003). "Molecular neuroadaptations in the 
accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine 
self-administration in rats." J Neurochem 85(6): 1604-1613. 
Lu, X. Y., D. Bagnol, S. Burke, H. Akil and S. J. Watson (2000). "Differential distribution and regulation 
of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting." Horm Behav 
37(4): 335-344. 
Lubrano-Berthelier, C., B. Dubern, J. M. Lacorte, F. Picard, A. Shapiro, S. Zhang, S. Bertrais, S. 
Hercberg, A. Basdevant, K. Clement and C. Vaisse (2006). "Melanocortin 4 receptor mutations in a 
large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype 
relationship, and lack of association with binge eating." J Clin Endocrinol Metab 91(5): 1811-1818. 
Lubrano-Berthelier, C., E. Durand, B. Dubern, A. Shapiro, P. Dazin, J. Weill, C. Ferron, P. Froguel and 
C. Vaisse (2003). "Intracellular retention is a common characteristic of childhood obesity-associated 
MC4R mutations." Hum Mol Genet 12(2): 145-153. 
Ludwig, M. and G. Leng (2006). "Dendritic peptide release and peptide-dependent behaviours." Nat 
Rev Neurosci 7(2): 126-136. 
Luo, A. H., P. Tahsili-Fahadan, R. A. Wise, C. R. Lupica and G. Aston-Jones (2011). "Linking context 
with reward: a functional circuit from hippocampal CA3 to ventral tegmental area." Science 
333(6040): 353-357. 
Macaluso, A., D. McCoy, G. Ceriani, T. Watanabe, J. Biltz, A. Catania and J. M. Lipton (1994). 
"Antiinflammatory influences of alpha-MSH molecules: central neurogenic and peripheral actions." J 
Neurosci 14(4): 2377-2382. 
Macdonald, R. and J. L. Barker (1978). "Benzodiazepines specifically modulate GABA-mediated 
postsynaptic inhibition in cultured mammalian neurones." Nature 271(5645): 563-564. 
Maffei, M., J. Halaas, E. Ravussin, R. E. Pratley, G. H. Lee, Y. Zhang, H. Fei, S. Kim, R. Lallone, S. 
Ranganathan and et al. (1995). "Leptin levels in human and rodent: measurement of plasma leptin 
and ob RNA in obese and weight-reduced subjects." Nat Med 1(11): 1155-1161. 
Maliszewska-Scislo, M. and W. Trojniar (1999). "Augmentation of ventral tegmental area 
stimulation-induced feeding by both stimulation and lesion of the contralateral ventral tegmental 
area in the rat." Acta Neurobiol Exp (Wars) 59(4): 287-293. 
Mandrika, I., R. Petrovska and J. Wikberg (2005). "Melanocortin receptors form constitutive homo- 
and heterodimers." Biochem Biophys Res Commun 326(2): 349-354. 
Manna, S. K. and B. B. Aggarwal (1998). "Alpha-melanocyte-stimulating hormone inhibits the nuclear 
transcription factor NF-kappa B activation induced by various inflammatory agents." J Immunol 
161(6): 2873-2880. 
Marcus, J. N., C. J. Aschkenasi, C. E. Lee, R. M. Chemelli, C. B. Saper, M. Yanagisawa and J. K. Elmquist 
(2001). "Differential expression of orexin receptors 1 and 2 in the rat brain." The Journal of 
Comparative Neurology 435(1): 6-25. 
Marder, E. (2012). "Neuromodulation of Neuronal Circuits: Back to the Future." Neuron 76(1): 1-11. 
Margolis, E. B., H. Lock, V. I. Chefer, T. S. Shippenberg, G. O. Hjelmstad and H. L. Fields (2006). 
"Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex." Proc 
Natl Acad Sci U S A 103(8): 2938-2942. 
Marín, F., M.-T. Herrero, S. Vyas and L. Puelles (2005). "Ontogeny of tyrosine hydroxylase mRNA 
expression in mid- and forebrain: Neuromeric pattern and novel positive regions." Developmental 
Dynamics 234(3): 709-717. 
255 
 
Marsh, D. J., G. Hollopeter, D. Huszar, R. Laufer, K. A. Yagaloff, S. L. Fisher, P. Burn and R. D. Palmiter 
(1999). "Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides." 
Nat Genet 21(1): 119-122. 
Martire, S. I., N. Holmes, R. F. Westbrook and M. J. Morris (2013). "Altered Feeding Patterns in Rats 
Exposed to a Palatable Cafeteria Diet: Increased Snacking and Its Implications for Development of 
Obesity." PLoS ONE 8(4): e60407. 
Mathon, D. S., H. M. B. Lesscher, M. A. F. M. Gerrits, A. Kamal, J. E. Pintar, A. G. P. Schuller, B. M. 
Spruijt, J. P. H. Burbach, M. P. Smidt, J. M. van Ree and G. M. J. Ramakers (2005). "Increased 
gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine 
reinforcement in μ-opioid receptor knockout mice." Neuroscience 130(2): 359-367. 
Matthews, G., G. Ayoub and R. Heidelberger (1994). "Presynaptic inhibition by GABA is mediated via 
two distinct GABA receptors with novel pharmacology." The Journal of Neuroscience 14(3): 1079-
1090. 
Maurice, N., J. M. Deniau, A. Menetrey, J. Glowinski and A. M. Thierry (1997). "Position of the ventral 
pallidum in the rat prefrontal cortex-basal ganglia circuit." Neuroscience 80(2): 523-534. 
McDonald, A. J. (1992). "Projection neurons of the basolateral amygdala: A correlative Golgi and 
retrograde tract tracing study." Brain Research Bulletin 28(2): 179-185. 
McGavigan, A. K., H. C. O'Hara, A. Amin, J. Kinsey-Jones, E. Spreckley, A. Alamshah, A. Agahi, K. 
Banks, R. France, G. Hyberg, C. Wong, G. A. Bewick, J. V. Gardiner, A. Lehmann, N. M. Martin, M. A. 
Ghatei, S. R. Bloom and K. G. Murphy (2015). "l-cysteine suppresses ghrelin and reduces appetite in 
rodents and humans." Int J Obes (Lond) 39(3): 447-455. 
McMinn, J. E., C. W. Wilkinson, P. J. Havel, S. C. Woods and M. W. Schwartz (2000). Effect of 
intracerebroventricular α-MSH on food intake, adiposity, c-Fos induction, and neuropeptide 
expression. 
Meador-Woodruff, J. H., A. Mansour, D. K. Grandy, S. P. Damask, O. Civelli and S. J. Watson, Jr. 
(1992). "Distribution of D5 dopamine receptor mRNA in rat brain." Neurosci Lett 145(2): 209-212. 
Meador-Woodruff, J. H., A. Mansour, D. J. Healy, R. Kuehn, Q. Y. Zhou, J. R. Bunzow, H. Akil, O. Civelli 
and S. J. Watson, Jr. (1991). "Comparison of the distributions of D1 and D2 dopamine receptor 
mRNAs in rat brain." Neuropsychopharmacology 5(4): 231-242. 
Mebel, D. M., J. C. Y. Wong, Y. J. Dong and S. L. Borgland (2012). "Insulin in the ventral tegmental 
area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake." 
European Journal of Neuroscience 36(3): 2336-2346. 
Mechanick, J. I., N. Levin, J. L. Roberts and D. J. Autelitano (1992). "Proopiomelanocortin gene 
expression in a distinct population of rat spleen and lung leukocytes." Endocrinology 131(1): 518-
525. 
Meibach, R. C. and A. Siegel (1977). "Efferent connections of the septal area in the rat: An analysis 
utilizing retrograde and anterograde transport methods." Brain Research 119(1): 1-20. 
Mercer, J. G. and S. P. Bird (2012). "NeuroFAST – the Integrated Neurobiology of Food Intake, 
Addiction and Stress." Obesity Facts 5(2): 293-297. 
Mercer, J. G., N. Hoggard, L. M. Williams, C. B. Lawrence, L. T. Hannah, P. J. Morgan and P. Trayhurn 
(1996). "Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of 
mouse hypothalamus." J Neuroendocrinol 8(10): 733-735. 
Merchenthaler, I., M. Lane and P. Shughrue (1999). "Distribution of pre-pro-glucagon and glucagon-
like peptide-1 receptor messenger RNAs in the rat central nervous system." The Journal of 
Comparative Neurology 403(2): 261-280. 
Mezey, E., G. Eisenhofer, G. Harta, S. Hansson, L. Gould, B. Hunyady and B. J. Hoffman (1996). "A 
novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases 
dopamine." Proceedings of the National Academy of Sciences of the United States of America 
93(19): 10377-10382. 
Mietlicki-Baase, E. G., P. I. Ortinski, L. E. Rupprecht, D. R. Olivos, A. L. Alhadeff, R. C. Pierce and M. R. 
Hayes (2013). "The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in 
256 
 
the ventral tegmental area are mediated by AMPA/kainate receptors." Am J Physiol Endocrinol 
Metab 305(11): E1367-1374. 
Mietlicki-Baase, E. G., D. J. Reiner, J. J. Cone, D. R. Olivos, L. E. McGrath, D. J. Zimmer, M. F. Roitman 
and M. R. Hayes (2015). "Amylin Modulates the Mesolimbic Dopamine System to Control Energy 
Balance." Neuropsychopharmacology 40(2): 372-385. 
Miller, J. M., S. R. Vorel, A. J. Tranguch, E. T. Kenny, P. Mazzoni, W. G. van Gorp and H. D. Kleber 
(2006). "Anhedonia after a selective bilateral lesion of the globus pallidus." Am J Psychiatry 163(5): 
786-788. 
Miller, L. G., D. J. Greenblatt, J. G. Barnhill and R. I. Shader (1988). "Chronic benzodiazepine 
administration. I. Tolerance is associated with benzodiazepine receptor downregulation and 
decreased gamma-aminobutyric acidA receptor function." J Pharmacol Exp Ther 246(1): 170-176. 
Moga, M. M. and C. B. Saper (1994). "Neuropeptide-immunoreactive neurons projecting to the 
paraventricular hypothalamic nucleus in the rat." The Journal of Comparative Neurology 346(1): 137-
150. 
Mogenson, G. J., D. L. Jones and C. Y. Yim (1980). "From motivation to action: functional interface 
between the limbic system and the motor system." Prog Neurobiol 14(2-3): 69-97. 
Monyer, H., N. Burnashev, D. J. Laurie, B. Sakmann and P. H. Seeburg (1994). "Developmental and 
regional expression in the rat brain and functional properties of four NMDA receptors." Neuron 
12(3): 529-540. 
Morecraft, R. J., C. Geula and M. M. Mesulam (1992). "Cytoarchitecture and neural afferents of 
orbitofrontal cortex in the brain of the monkey." The Journal of Comparative Neurology 323(3): 341-
358. 
Morgan, D. A., L. N. McDaniel, T. Yin, M. Khan, J. Jiang, M. R. Acevedo, S. A. Walsh, L. L. Boles Ponto, 
A. W. Norris, M. Lutter, K. Rahmouni and H. Cui (2015). "Regulation of Glucose Tolerance and 
Sympathetic Activity by MC4R Signaling in the Lateral Hypothalamus." Diabetes. 
Morgane, P. J. (1961). "Alterations in feeding and drinking behavior of rats with lesions in globi 
pallidi." Am J Physiol 201: 420-428. 
Morris, D. G., B. Kola, N. Borboli, G. A. Kaltsas, M. Gueorguiev, A. M. McNicol, R. Ferrier, T. H. Jones, 
S. Baldeweg, M. Powell, S. Czirjak, Z. Hanzely, J. O. Johansson, M. Korbonits and A. B. Grossman 
(2003). "Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human 
pituitary and its loss of expression in pituitary adenomas." J Clin Endocrinol Metab 88(12): 6080-
6087. 
Mounien, L., P. Bizet, I. Boutelet, H. Vaudry and S. Jégou (2005). "Expression of Melanocortin MC3 
and MC4 Receptor mRNAs by Neuropeptide Y Neurons in the Rat Arcuate Nucleus." 
Neuroendocrinology 82(3-4): 164-170. 
Mountjoy, K. G., C. S. Jenny Wu, L. M. Dumont and J. M. Wild (2003). "Melanocortin-4 receptor 
messenger ribonucleic acid expression in rat cardiorespiratory, musculoskeletal, and integumentary 
systems." Endocrinology 144(12): 5488-5496. 
Mountjoy, K. G., M. T. Mortrud, M. J. Low, R. B. Simerly and R. D. Cone (1994). "Localization of the 
melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain." 
Mol Endocrinol 8(10): 1298-1308. 
Mountjoy, K. G., L. S. Robbins, M. T. Mortrud and R. D. Cone (1992). "The cloning of a family of genes 
that encode the melanocortin receptors." Science 257(5074): 1248-1251. 
Muceniece, R., L. Zvejniece, O. Kirjanova, E. Liepinsh, L. Krigere, R. Vilskersts, L. Baumane, V. 
Gordjusina, I. Kalvinsh, J. E. Wikberg and M. Dambrova (2005). "Beta-MSH inhibits brain 
inflammation via MC(3)/(4) receptors and impaired NF-kappaB signaling." J Neuroimmunol 169(1-2): 
13-19. 
Murray, E. A., E. A. Gaffan and R. W. Flint, Jr. (1996). "Anterior rhinal cortex and amygdala: 
dissociation of their contributions to memory and food preference in rhesus monkeys." Behav 
Neurosci 110(1): 30-42. 
257 
 
Mutch, D. M. and K. Clément (2006). "Unraveling the Genetics of Human Obesity." PLoS Genet 2(12): 
e188. 
Naim, M., J. G. Brand, M. R. Kare and R. G. Carpenter (1985). "Energy intake, weight gain and fat 
deposition in rats fed flavored, nutritionally controlled diets in a multichoice ("cafeteria") design." J 
Nutr 115(11): 1447-1458. 
Nair-Roberts, R. G., S. D. Chatelain-Badie, E. Benson, H. White-Cooper, J. P. Bolam and M. A. Ungless 
(2008). "Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the 
ventral tegmental area, substantia nigra and retrorubral field in the rat." Neuroscience 152(4): 1024-
1031. 
Nakamura, T., K. Uramura, T. Nambu, T. Yada, K. Goto, M. Yanagisawa and T. Sakurai (2000). 
"Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system." Brain 
Res 873(1): 181-187. 
Ni, X. P., A. A. Butler, R. D. Cone and M. H. Humphreys (2006). "Central receptors mediating the 
cardiovascular actions of melanocyte stimulating hormones." J Hypertens 24(11): 2239-2246. 
Noble, E. P. (1998). "The D2 dopamine receptor gene: a review of association studies in alcoholism 
and phenotypes." Alcohol 16(1): 33-45. 
Norgren, R. and C. M. Leonard (1971). "Taste pathways in rat brainstem." Science 173(4002): 1136-
1139. 
O'Rahilly, S., H. Gray, P. J. Humphreys, A. Krook, K. S. Polonsky, A. White, S. Gibson, K. Taylor and C. 
Carr (1995). "Brief report: impaired processing of prohormones associated with abnormalities of 
glucose homeostasis and adrenal function." N Engl J Med 333(21): 1386-1390. 
O’Rourke, R. W., J. Andrus, B. S. Diggs, M. Scholz, D. B. McConnell and C. W. Deveney (2006). 
"Perioperative morbidity associated with bariatric surgery: An academic center experience." 
Archives of Surgery 141(3): 262-268. 
Oades, R. D. and G. M. Halliday (1987). "Ventral tegmental (A10) system: neurobiology. 1. Anatomy 
and connectivity." Brain Research Reviews 12(2): 117-165. 
Oh, S. W., J. A. Harris, L. Ng, B. Winslow, N. Cain, S. Mihalas, Q. Wang, C. Lau, L. Kuan, A. M. Henry, 
M. T. Mortrud, B. Ouellette, T. N. Nguyen, S. A. Sorensen, C. R. Slaughterbeck, W. Wakeman, Y. Li, D. 
Feng, A. Ho, E. Nicholas, K. E. Hirokawa, P. Bohn, K. M. Joines, H. Peng, M. J. Hawrylycz, J. W. Phillips, 
J. G. Hohmann, P. Wohnoutka, C. R. Gerfen, C. Koch, A. Bernard, C. Dang, A. R. Jones and H. Zeng 
(2014). "A mesoscale connectome of the mouse brain." Nature 508(7495): 207-214. 
Okada, H., N. Matsushita, K. Kobayashi and K. Kobayashi (2004). "Identification of GABAA receptor 
subunit variants in midbrain dopaminergic neurons." J Neurochem 89(1): 7-14. 
Olds, J. and P. Milner (1954). "Positive reinforcement produced by electrical stimulation of septal 
area and other regions of rat brain." J Comp Physiol Psychol 47(6): 419-427. 
Ollmann, M. M., M. L. Lamoreux, B. D. Wilson and G. S. Barsh (1998). "Interaction of Agouti protein 
with the melanocortin 1 receptor in vitro and in vivo." Genes Dev 12(3): 316-330. 
Ollmann, M. M., B. D. Wilson, Y. K. Yang, J. A. Kerns, Y. Chen, I. Gantz and G. S. Barsh (1997). 
"Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein." 
Science 278(5335): 135-138. 
Omelchenko, N. and S. R. Sesack (2009). "Ultrastructural analysis of local collaterals of rat ventral 
tegmental area neurons: GABA phenotype and synapses onto dopamine and GABA cells." Synapse 
63(10): 895-906. 
Opland, D., A. Sutton, H. Woodworth, J. Brown, R. Bugescu, A. Garcia, L. Christensen, C. Rhodes, M. 
Myers, Jr. and G. Leinninger (2013). "Loss of neurotensin receptor-1 disrupts the control of the 
mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity." Mol Metab 2(4): 
423-434. 
Ortiz, J., L. W. Fitzgerald, M. Charlton, S. Lane, L. Trevisan, X. Guitart, W. Shoemaker, R. S. Duman 
and E. J. Nestler (1995). "Biochemical actions of chronic ethanol exposure in the mesolimbic 
dopamine system." Synapse 21(4): 289-298. 
258 
 
Padilla, S. L., D. Reef and L. M. Zeltser (2012). "Defining POMC neurons using transgenic reagents: 
impact of transient Pomc expression in diverse immature neuronal populations." Endocrinology 
153(3): 1219-1231. 
Page, K. A., D. Seo, R. Belfort-DeAguiar, C. Lacadie, J. Dzuira, S. Naik, S. Amarnath, R. T. Constable, R. 
S. Sherwin and R. Sinha (2011). "Circulating glucose levels modulate neural control of desire for high-
calorie foods in humans." The Journal of Clinical Investigation 121(10): 4161-4169. 
Panaro, B. L. and R. D. Cone (2013). "Melanocortin-4 receptor mutations paradoxically reduce 
preference for palatable foods." Proceedings of the National Academy of Sciences 110(17): 7050-
7055. 
Panaro, B. L., I. R. Tough, M. S. Engelstoft, R. T. Matthews, G. J. Digby, C. L. Moller, B. Svendsen, F. 
Gribble, F. Reimann, J. J. Holst, B. Holst, T. W. Schwartz, H. M. Cox and R. D. Cone (2014). "The 
melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide 
YY and glucagon-like peptide 1 in vivo." Cell Metab 20(6): 1018-1029. 
Pandit, R., S. E. la Fleur and R. A. Adan (2013). "The role of melanocortins and Neuropeptide Y in 
food reward." Eur J Pharmacol 719(1-3): 208-214. 
Pape, H. C. and D. Pare (2010). "Plastic synaptic networks of the amygdala for the acquisition, 
expression, and extinction of conditioned fear." Physiol Rev 90(2): 419-463. 
Pardridge, W. M. (1986). "Receptor-Mediated Peptide Transport through the Blood-Brain Barrier." 
Endocrine Reviews 7(3): 314-330. 
Paxinos, G. and C. Watson (2006). "The Rat Brain in Stereotaxic Co-ordinates " Elsevier(6th edition ). 
Pedersen, R. C., N. Ling and A. C. Brownie (1982). "Immunoreactive gamma-melanotropin in rat 
pituitary and plasma: a partial characterization." Endocrinology 110(3): 825-834. 
Pelchat, M. L. (2002). "Of human bondage: Food craving, obsession, compulsion, and addiction." 
Physiology & Behavior 76(3): 347-352. 
Pelleymounter, M., M. Cullen, M. Baker, R. Hecht, D. Winters, T. Boone and F. Collins (1995). "Effects 
of the obese gene product on body weight regulation in ob/ob mice." Science 269(5223): 540-543. 
Pelleymounter, M. A., M. J. Cullen and C. L. Wellman (1995). "Characteristics of BDNF-induced 
weight loss." Exp Neurol 131(2): 229-238. 
Phillipson, O. T. (1979). "Afferent projections to the ventral tegmental area of Tsai and interfascicular 
nucleus: a horseradish peroxidase study in the rat." J Comp Neurol 187(1): 117-143. 
Pierroz, D. D., M. Ziotopoulou, L. Ungsunan, S. Moschos, J. S. Flier and C. S. Mantzoros (2002). 
"Effects of Acute and Chronic Administration of the Melanocortin Agonist MTII in Mice With Diet-
Induced Obesity." Diabetes 51(5): 1337-1345. 
Pinheiro, P. S. and C. Mulle (2008). "Presynaptic glutamate receptors: physiological functions and 
mechanisms of action." Nat Rev Neurosci 9(6): 423-436. 
PitkÄNen, A., M. Pikkarainen, N. Nurminen and A. Ylinen (2000). "Reciprocal Connections between 
the Amygdala and the Hippocampal Formation, Perirhinal Cortex, and Postrhinal Cortex in Rat: A 
Review." Annals of the New York Academy of Sciences 911(1): 369-391. 
Poggioli, R., A. V. Vergoni and A. Bertolini (1986). "ACTH-(1–24) and α-MSH antagonize feeding 
behavior stimulated by kappa opiate agonists." Peptides 7(5): 843-848. 
Prentice, A. M. (1998). "Manipulation of dietary fat and energy density and subsequent effects on 
substrate flux and food intake." The American Journal of Clinical Nutrition 67(3): 535S-541S. 
Prus, A. J., J. R. James and J. A. Rosecrans (2009). "Conditioned Place Preference " Methods of 
Behavior Analysis in Neuroscience. 2nd edition. Chapter 4. 
Qi, L., P. Kraft, D. J. Hunter and F. B. Hu (2008). "The common obesity variant near MC4R gene is 
associated with higher intakes of total energy and dietary fat, weight change and diabetes risk in 
women." Hum Mol Genet 17(22): 3502-3508. 
Qian, S., H. Chen, D. Weingarth, M. E. Trumbauer, D. E. Novi, X. Guan, H. Yu, Z. Shen, Y. Feng, E. 
Frazier, A. Chen, R. E. Camacho, L. P. Shearman, S. Gopal-Truter, D. J. MacNeil, L. H. T. Van der Ploeg 
and D. J. Marsh (2002). "Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for 
the Regulation of Energy Homeostasis in Mice." Molecular and Cellular Biology 22(14): 5027-5035. 
259 
 
Qu, D., D. S. Ludwig, S. Gammeltoft, M. Piper, M. A. Pelleymounter, M. J. Cullen, W. F. Mathes, R. 
Przypek, R. Kanarek and E. Maratos-Flier (1996). "A role for melanin-concentrating hormone in the 
central regulation of feeding behaviour." Nature 380(6571): 243-247. 
Raynor, H. A. and L. H. Epstein (2001). "Dietary variety, energy regulation, and obesity." Psychol Bull 
127(3): 325-341. 
René, P., C. Le Gouill, I. D. Pogozheva, G. Lee, H. I. Mosberg, I. S. Farooqi, K. J. Valenzano and M. 
Bouvier (2010). "Pharmacological Chaperones Restore Function to MC4R Mutants Responsible for 
Severe Early-Onset Obesity." Journal of Pharmacology and Experimental Therapeutics 335(3): 520-
532. 
Revitsky, A. R. and L. C. Klein (2013). "Role of ghrelin in drug abuse and reward-relevant behaviors: a 
burgeoning field and gaps in the literature." Curr Drug Abuse Rev 6(3): 231-244. 
Richardson, K. A. and G. Aston-Jones (2012). "Lateral hypothalamic orexin/hypocretin neurons that 
project to ventral tegmental area are differentially activated with morphine preference." J Neurosci 
32(11): 3809-3817. 
Risold, P. Y. and L. W. Swanson (1997). "Connections of the rat lateral septal complex." Brain 
Research Reviews 24(2–3): 115-195. 
Robbins, L. S., J. H. Nadeau, K. R. Johnson, M. A. Kelly, L. Roselli-Rehfuss, E. Baack, K. G. Mountjoy 
and R. D. Cone (1993). "Pigmentation phenotypes of variant extension locus alleles result from point 
mutations that alter MSH receptor function." Cell 72(6): 827-834. 
Roberts, D. C. and G. F. Koob (1982). "Disruption of cocaine self-administration following 6-
hydroxydopamine lesions of the ventral tegmental area in rats." Pharmacol Biochem Behav 17(5): 
901-904. 
Rodd-Henricks, Z. A., D. L. McKinzie, T. K. Li, J. M. Murphy and W. J. McBride (2002). "Cocaine is self-
administered into the shell but not the core of the nucleus accumbens of Wistar rats." J Pharmacol 
Exp Ther 303(3): 1216-1226. 
Rodd, Z. A., R. I. Melendez, R. L. Bell, K. A. Kuc, Y. Zhang, J. M. Murphy and W. J. McBride (2004). 
"Intracranial Self-Administration of Ethanol within the Ventral Tegmental Area of Male Wistar Rats: 
Evidence for Involvement of Dopamine Neurons." The Journal of Neuroscience 24(5): 1050-1057. 
Rogers, D. C., E. M. C. Fisher, S. D. M. Brown, J. Peters, A. J. Hunter and J. E. Martin (1997). 
"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for 
comprehensive phenotype assessment." Mammalian Genome 8(10): 711-713. 
Rogers, R. D., A. M. Owen, H. C. Middleton, E. J. Williams, J. D. Pickard, B. J. Sahakian and T. W. 
Robbins (1999). "Choosing between small, likely rewards and large, unlikely rewards activates 
inferior and orbital prefrontal cortex." J Neurosci 19(20): 9029-9038. 
Rogers, R. D., N. Ramnani, C. Mackay, J. L. Wilson, P. Jezzard, C. S. Carter and S. M. Smith (2004). 
"Distinct portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward 
processing in separable phases of decision-making cognition." Biol Psychiatry 55(6): 594-602. 
Rolls, B. J., E. A. Rowe, E. T. Rolls, B. Kingston, A. Megson and R. Gunary (1981). "Variety in a meal 
enhances food intake in man." Physiology & Behavior 26(2): 215-221. 
Rolls, B. J., P. M. Van Duijvenvoorde and E. A. Rowe (1983). "Variety in the diet enhances intake in a 
meal and contributes to the development of obesity in the rat." Physiol Behav 31(1): 21-27. 
Roseberry, A. G. (2013). "Altered feeding and body weight following melanocortin administration to 
the ventral tegmental area in adult rats." Psychopharmacology (Berl) 226(1): 25-34. 
Roselli-Rehfuss, L., K. G. Mountjoy, L. S. Robbins, M. T. Mortrud, M. J. Low, J. B. Tatro, M. L. 
Entwistle, R. B. Simerly and R. D. Cone (1993). "Identification of a receptor for gamma melanotropin 
and other proopiomelanocortin peptides in the hypothalamus and limbic system." Proc Natl Acad Sci 
U S A 90(19): 8856-8860. 
Rossi, J., N. Balthasar, D. Olson, M. Scott, E. Berglund, C. E. Lee, M. J. Choi, D. Lauzon, B. B. Lowell 
and J. K. Elmquist (2011). "Melanocortin-4-receptors Expressed by Cholinergic Neurons Regulate 
Energy Balance and Glucose Homeostasis." Cell metabolism 13(2): 195-204. 
260 
 
Rowland, N. E., J. W. Schaub, K. L. Robertson, A. Andreasen and C. Haskell-Luevano (2010). "Effect of 
MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 
receptor knockout mice." Peptides 31(12): 2314-2317. 
Rucker, D., R. Padwal, S. K. Li, C. Curioni and D. C. W. Lau (2007). "Long term pharmacotherapy for 
obesity and overweight: updated meta-analysis." BMJ 335(7631): 1194-1199. 
Rushworth, Matthew F. S., MaryAnn P. Noonan, Erie D. Boorman, Mark E. Walton and Timothy E. 
Behrens (2011). "Frontal Cortex and Reward-Guided Learning and Decision-Making." Neuron 70(6): 
1054-1069. 
Sah, P., E. S. Faber, M. Lopez De Armentia and J. Power (2003). "The amygdaloid complex: anatomy 
and physiology." Physiol Rev 83(3): 803-834. 
Saito, Y., M. Cheng, F. M. Leslie and O. Civelli (2001). "Expression of the melanin-concentrating 
hormone (MCH) receptor mRNA in the rat brain." J Comp Neurol 435(1): 26-40. 
Saito, Y., H.-P. Nothacker, Z. Wang, S. H. S. Lin, F. Leslie and O. Civelli (1999). "Molecular 
characterization of the melanin-concentrating-hormone receptor." Nature 400(6741): 265-269. 
Sakurai, T., A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams, J. A. 
Richardson, G. P. Kozlowski, S. Wilson, J. R. Arch, R. E. Buckingham, A. C. Haynes, S. A. Carr, R. S. 
Annan, D. E. McNulty, W. S. Liu, J. A. Terrett, N. A. Elshourbagy, D. J. Bergsma and M. Yanagisawa 
(1998). "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-
coupled receptors that regulate feeding behavior." Cell 92(4): 573-585. 
Sandman, C. A. and A. J. Kastin (1981). "Intraventricular administration of MSH induces hyperalgesia 
in rats." Peptides 2(2): 231-233. 
Santana, N., G. Mengod and F. Artigas (2009). "Quantitative analysis of the expression of dopamine 
D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex." Cereb Cortex 
19(4): 849-860. 
Saper, C. B., T. C. Chou and J. K. Elmquist (2002). "The need to feed: homeostatic and hedonic 
control of eating." Neuron 36(2): 199-211. 
Saper, C. B., A. D. Loewy, L. W. Swanson and W. M. Cowan (1976). "Direct hypothalamo-autonomic 
connections." Brain Res 117(2): 305-312. 
Saper, C. B., L. W. Swanson and W. M. Cowan (1976). "The efferent connections of the ventromedial 
nucleus of the hypothalamus of the rat." The Journal of Comparative Neurology 169(4): 409-442. 
Sawyer, T. K., P. J. Sanfilippo, V. J. Hruby, M. H. Engel, C. B. Heward, J. B. Burnett and M. E. Hadley 
(1980). "4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent 
alpha-melanotropin with ultralong biological activity." Proc Natl Acad Sci U S A 77(10): 5754-5758. 
Schauer, E., F. Trautinger, A. Kock, A. Schwarz, R. Bhardwaj, M. Simon, J. C. Ansel, T. Schwarz and T. 
A. Luger (1994). "Proopiomelanocortin-derived peptides are synthesized and released by human 
keratinocytes." J Clin Invest 93(5): 2258-2262. 
Schiöth, H. B., R. Muceniece, J. E. S. Wikberg and V. Chhajlani (1995). "Characterisation of 
melanocortin receptor subtypes by radioligand binding analysis." European Journal of Pharmacology: 
Molecular Pharmacology 288(3): 311-317. 
Schultz, W., P. Apicella and T. Ljungberg (1993). "Responses of monkey dopamine neurons to reward 
and conditioned stimuli during successive steps of learning a delayed response task." The Journal of 
Neuroscience 13(3): 900-913. 
Schultz, W., P. Dayan and P. R. Montague (1997). "A Neural Substrate of Prediction and Reward." 
Science 275(5306): 1593-1599. 
Schwartz, G. J. (2000). "The role of gastrointestinal vagal afferents in the control of food intake: 
current prospects." Nutrition 16(10): 866-873. 
Scott, V., N. Kimura, J. A. Stark and S. M. Luckman (2005). "Intravenous Peptide YY3-36 and Y2 
Receptor Antagonism in the Rat: Effects on Feeding Behaviour." Journal of Neuroendocrinology 
17(7): 452-457. 
Sebag, J. A. and P. M. Hinkle (2007). "Melanocortin-2 receptor accessory protein MRAP forms 
antiparallel homodimers." Proceedings of the National Academy of Sciences 104(51): 20244-20249. 
261 
 
Sebag, J. A. and P. M. Hinkle (2009). "Opposite Effects of the Melanocortin-2 (MC2) Receptor 
Accessory Protein MRAP on MC2 and MC5 Receptor Dimerization and Trafficking." Journal of 
Biological Chemistry 284(34): 22641-22648. 
Sebag, J. A., C. Zhang, P. M. Hinkle, A. M. Bradshaw and R. D. Cone (2013). "Developmental Control 
of the Melanocortin-4 Receptor by MRAP2 Proteins in Zebrafish." Science 341(6143): 278-281. 
Sesack, S. R., A. Y. Deutch, R. H. Roth and B. S. Bunney (1989). "Topographical organization of the 
efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study 
with Phaseolus vulgaris leucoagglutinin." J Comp Neurol 290(2): 213-242. 
Sesack, S. R. and V. M. Pickel (1990). "In the rat medial nucleus accumbens, hippocampal and 
catecholaminergic terminals converge on spiny neurons and are in apposition to each other." Brain 
Res 527(2): 266-279. 
Setlow, B., G. Schoenbaum and M. Gallagher (2003). "Neural encoding in ventral striatum during 
olfactory discrimination learning." Neuron 38(4): 625-636. 
Shadiack, A. M., S. D. Sharma, D. C. Earle, C. Spana and T. J. Hallam (2007). "Melanocortins in the 
treatment of male and female sexual dysfunction." Curr Top Med Chem 7(11): 1137-1144. 
Shah, B. P., L. Vong, D. P. Olson, S. Koda, M. J. Krashes, C. Ye, Z. Yang, P. M. Fuller, J. K. Elmquist and 
B. B. Lowell (2014). "MC4R-expressing glutamatergic neurons in the paraventricular hypothalamus 
regulate feeding and are synaptically connected to the parabrachial nucleus." Proc Natl Acad Sci U S 
A 111(36): 13193-13198. 
Shelkar, G. P., A. D. Kale, U. Singh, P. S. Singru, N. K. Subhedar and D. M. Kokare (2015). "Alpha-
melanocyte stimulating hormone modulates ethanol self-administration in posterior ventral 
tegmental area through melanocortin-4 receptors." Addiction Biology 20(2): 302-315. 
Shen, C. L. (1983). "Efferent projections from the lateral hypothalamus in the guinea pig: an 
autoradiographic study." Brain Res Bull 11(3): 335-347. 
Shen, Y., W. Y. Fu, E. Y. Cheng, A. K. Fu and N. Y. Ip (2013). "Melanocortin-4 receptor regulates 
hippocampal synaptic plasticity through a protein kinase A-dependent mechanism." J Neurosci 33(2): 
464-472. 
Shimada, M., N. A. Tritos, B. B. Lowell, J. S. Flier and E. Maratos-Flier (1998). "Mice lacking melanin-
concentrating hormone are hypophagic and lean." Nature 396(6712): 670-674. 
Shipp, S. (2007). "Structure and function of the cerebral cortex." Current Biology 17(12): R443-R449. 
Shoaib, M. and I. P. Stolerman (1992). "MK801 attenuates behavioural adaptation to chronic 
nicotine administration in rats." British Journal of Pharmacology 105(3): 514-515. 
Shutter, J. R., M. Graham, A. C. Kinsey, S. Scully, R. Luthy and K. L. Stark (1997). "Hypothalamic 
expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant 
mice." Genes Dev 11(5): 593-602. 
Siegel, G. J. and B. W. Agranoff (1999). Basic Neurochemistry: Molecular, Cellular, and Medical 
Aspects, Lippincott Williams & Wilkins. 
Siljee, J. E., U. A. Unmehopa, A. Kalsbeek, D. F. Swaab, E. Fliers and A. Alkemade (2013). 
"Melanocortin 4 receptor distribution in the human hypothalamus." European Journal of 
Endocrinology 168(3): 361-369. 
Silverman, A. J., D. L. Hoffman and E. A. Zimmerman (1981). "The descending afferent connections of 
the paraventricular nucleus of the hypothalamus (PVN)." Brain Res Bull 6(1): 47-61. 
Silvers, W. K. and E. S. Russell (1955). "An experimental approach to action of genes at the agouti 
locus in the mouse." Journal of Experimental Zoology 130(2): 199-220. 
Siragy, H. M., R. A. Felder, N. L. Howell, R. L. Chevalier, M. J. Peach and R. M. Carey (1989). "Evidence 
that intrarenal dopamine acts as a paracrine substance at the renal tubule." Am J Physiol 257(3 Pt 2): 
F469-477. 
Sjöström, L., A.-K. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, S. Dahlgren, B. 
Larsson, K. Narbro, C. D. Sjöström, M. Sullivan and H. Wedel (2004). "Lifestyle, Diabetes, and 
Cardiovascular Risk Factors 10 Years after Bariatric Surgery." New England Journal of Medicine 
351(26): 2683-2693. 
262 
 
Sjöström, P. J., E. A. Rancz, A. Roth and M. Häusser (2008). Dendritic Excitability and Synaptic 
Plasticity. 
Skibicka, K. P. (2013). "The central GLP-1: implications for food and drug reward." Front Neurosci 7: 
181. 
Skibicka, K. P., C. Hansson, M. Alvarez-Crespo, P. A. Friberg and S. L. Dickson (2011). "Ghrelin directly 
targets the ventral tegmental area to increase food motivation." Neuroscience 180: 129-137. 
Skibicka, K. P., R. H. Shirazi, C. Rabasa-Papio, M. Alvarez-Crespo, C. Neuber, H. Vogel and S. L. 
Dickson (2013). "Divergent circuitry underlying food reward and intake effects of ghrelin: 
Dopaminergic VTA-accumbens projection mediates ghrelin's effect on food reward but not food 
intake." Neuropharmacology 73(0): 274-283. 
Skofitsch, G., D. M. Jacobowitz and N. Zamir (1985). "Immunohistochemical localization of a melanin 
concentrating hormone-like peptide in the rat brain." Brain Res Bull 15(6): 635-649. 
Skuladottir, G. V., L. Jonsson, J. O. Skarphedinsson, F. Mutulis, R. Muceniece, A. Raine, I. Mutule, J. 
Helgason, P. Prusis, J. E. Wikberg and H. B. Schioth (1999). "Long term orexigenic effect of a novel 
melanocortin 4 receptor selective antagonist." Br J Pharmacol 126(1): 27-34. 
Slominski, A., G. Ermak and M. Mihm (1996). "ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes 
are expressed in skin." J Clin Endocrinol Metab 81(7): 2746-2749. 
Smith, G. P., C. Jerome, B. J. Cushin, R. Eterno and K. J. Simansky (1981). "Abdominal vagotomy 
blocks the satiety effect of cholecystokinin in the rat." Science 213(4511): 1036-1037. 
Smith, K. S., A. J. Tindell, J. W. Aldridge and K. C. Berridge (2009). "Ventral pallidum roles in reward 
and motivation." Behavioural Brain Research 196(2): 155-167. 
Smith, L. (2011). "Good planning and serendipity: exploiting the Cre/Lox system in the testis." 
Reproduction 141(2): 151-161. 
Smith, M. L., N. A. Kohart, B. A. Newmyer and M. A. Cline (2009). "Gamma(2)-melanocyte stimulating 
hormone decreases food intake in chicks." Neuroscience Letters 465(3): 210-213. 
Smith, P. E. (1916). "Experimental ablation of the hypophesis in the frog embryo " Science 44(1130): 
280-282. 
Snowdon, C. T. and A. N. Epstein (1970). "Oral and intragastric feeding in vagotomized rats." J Comp 
Physiol Psychol 71(1): 59-67. 
Soderpalm, A. H. and K. C. Berridge (2000). "The hedonic impact and intake of food are increased by 
midazolam microinjection in the parabrachial nucleus." Brain Res 877(2): 288-297. 
Spencer, J. D. and K. U. Schallreuter (2009). "Regulation of pigmentation in human epidermal 
melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/melanocortin-4 
receptor signaling." Endocrinology 150(3): 1250-1258. 
Staiger, J. F. and F. G. Wouterlood (1990). "Efferent projections from the lateral septal nucleus to the 
anterior hypothalamus in the rat: A study combining Phaseolus vulgaris-leucoagglutinin tracing with 
vasopressin immunocytochemistry." Cell and Tissue Research 261(1): 17-23. 
Stanley, B. G. and S. F. Leibowitz (1985). "Neuropeptide Y injected in the paraventricular 
hypothalamus: a powerful stimulant of feeding behavior." Proc Natl Acad Sci U S A 82(11): 3940-
3943. 
Stanley, S. A., C. J. Small, K. G. Murphy, E. Rayes, C. R. Abbott, L. J. Seal, D. G. Morgan, D. Sunter, C. L. 
Dakin, M. S. Kim, R. Hunter, M. Kuhar, M. A. Ghatei and S. R. Bloom (2001). "Actions of cocaine- and 
amphetamine-regulated transcript (CART) peptide on regulation of appetite and hypothalamo-
pituitary axes in vitro and in vivo in male rats." Brain Res 893(1-2): 186-194. 
Ste. Marie, L., G. I. Miura, D. J. Marsh, K. Yagaloff and R. D. Palmiter (2000). "A metabolic defect 
promotes obesity in mice lacking melanocortin-4 receptors." Proceedings of the National Academy 
of Sciences 97(22): 12339-12344. 
Stuber, G. D., T. S. Hnasko, J. P. Britt, R. H. Edwards and A. Bonci (2010). "Dopaminergic Terminals in 
the Nucleus Accumbens But Not the Dorsal Striatum Corelease Glutamate." The Journal of 
Neuroscience 30(24): 8229-8233. 
263 
 
Stuber, Garret D., Alice M. Stamatakis and Pranish A. Kantak (2015). "Considerations When Using 
Cre-Driver Rodent Lines for Studying Ventral Tegmental Area Circuitry." Neuron 85(2): 439-445. 
Stutzmann, F., S. Cauchi, E. Durand, C. Calvacanti-Proenca, M. Pigeyre, A. L. Hartikainen, U. Sovio, J. 
Tichet, M. Marre, J. Weill, B. Balkau, N. Potoczna, J. Laitinen, P. Elliott, M. R. Jarvelin, F. Horber, D. 
Meyre and P. Froguel (2009). "Common genetic variation near MC4R is associated with eating 
behaviour patterns in European populations." Int J Obes (Lond) 33(3): 373-378. 
Stutzmann, F., K. Tan, V. Vatin, C. Dina, B. Jouret, J. Tichet, B. Balkau, N. Potoczna, F. Horber, S. 
O'Rahilly, I. S. Farooqi, P. Froguel and D. Meyre (2008). "Prevalence of melanocortin-4 receptor 
deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees." 
Diabetes 57(9): 2511-2518. 
Südhof, T. C. and J. Rizo (2011). "Synaptic Vesicle Exocytosis." Cold Spring Harbor Perspectives in 
Biology 3(12). 
Sulzer, D., M. P. Joyce, L. Lin, D. Geldwert, S. N. Haber, T. Hattori and S. Rayport (1998). "Dopamine 
Neurons Make Glutamatergic Synapses In Vitro." The Journal of Neuroscience 18(12): 4588-4602. 
Sun, Y., P. Wang, H. Zheng and R. G. Smith (2004). "Ghrelin stimulation of growth hormone release 
and appetite is mediated through the growth hormone secretagogue receptor." Proceedings of the 
National Academy of Sciences of the United States of America 101(13): 4679-4684. 
Sutton, G. M., J. L. Trevaskis, M. W. Hulver, R. P. McMillan, N. J. Markward, M. J. Babin, E. A. Meyer 
and A. A. Butler (2006). "Diet-genotype interactions in the development of the obese, insulin-
resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors." Endocrinology 147(5): 
2183-2196. 
Swanson, L. W. (1977). "Immunohistochemical evidence for a neurophysin-containing autonomic 
pathway arising in the paraventricular nucleus of the hypothalamus." Brain Res 128(2): 346-353. 
Swanson, L. W. (1982). "The projections of the ventral tegmental area and adjacent regions: a 
combined fluorescent retrograde tracer and immunofluorescence study in the rat." Brain Res Bull 
9(1-6): 321-353. 
Swanson, L. W. and H. G. Kuypers (1980). "The paraventricular nucleus of the hypothalamus: 
cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, 
and spinal cord as demonstrated by retrograde fluorescence double-labeling methods." J Comp 
Neurol 194(3): 555-570. 
Swarbrick, M. M. and C. Vaisse (2003). "Emerging trends in the search for genetic variants 
predisposing to human obesity." Current Opinion in Clinical Nutrition & Metabolic Care 6(4): 369-376 
310.1097/1001.mco.0000078997.0000096795.0000078903. 
Swords, F. M., L. A. Noon, P. J. King and A. J. Clark (2004). "Constitutive activation of the human 
ACTH receptor resulting from a synergistic interaction between two naturally occurring missense 
mutations in the MC2R gene." Mol Cell Endocrinol 213(2): 149-154. 
Tao, Y. X., H. Huang, Z. Q. Wang, F. Yang, J. N. Williams and G. V. Nikiforovich (2010). "Constitutive 
activity of neural melanocortin receptors." Methods Enzymol 484: 267-279. 
Tartaglia, L. A., M. Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards, L. A. Campfield, 
F. T. Clark, J. Deeds, C. Muir, S. Sanker, A. Moriarty, K. J. Moore, J. S. Smutko, G. G. Mays, E. A. Wool, 
C. A. Monroe and R. I. Tepper (1995). "Identification and expression cloning of a leptin receptor, OB-
R." Cell 83(7): 1263-1271. 
Tatro, J. B. (1996). "Receptor biology of the melanocortins, a family of neuroimmunomodulatory 
peptides." Neuroimmunomodulation 3(5): 259-284. 
Tecuapetla, F., J. C. Patel, H. Xenias, D. English, I. Tadros, F. Shah, J. Berlin, K. Deisseroth, M. E. Rice, J. 
M. Tepper and T. Koos (2010). "Glutamatergic Signaling by Mesolimbic Dopamine Neurons in the 
Nucleus Accumbens." The Journal of Neuroscience 30(20): 7105-7110. 
Tepper, J. M. and C. R. Lee (2007). GABAergic control of substantia nigra dopaminergic neurons. 
Progress in Brain Research. E. D. A. James M. Tepper and J. P. Bolam, Elsevier. Volume 160: 189-208. 
Ter Horst, G. J. and P. G. Luiten (1986). "The projections of the dorsomedial hypothalamic nucleus in 
the rat." Brain Res Bull 16(2): 231-248. 
264 
 
Ter Horst, G. J. and P. G. Luiten (1987). "Phaseolus vulgaris leuco-agglutinin tracing of 
intrahypothalamic connections of the lateral, ventromedial, dorsomedial and paraventricular 
hypothalamic nuclei in the rat." Brain Res Bull 18(2): 191-203. 
The Jackson Laboratory, T. (2005). "Tg(Mc4r-cre)25Rck related." Information obtained from The 
Jackson Laboratory, Bar Harbor, ME Unpublished. 
Thiele, T. E., G. Van Dijk, K. A. Yagaloff, S. L. Fisher, M. Schwartz, P. Burn and R. J. Seeley (1998). 
Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste 
aversion. 
Thompson, J. L. and S. L. Borgland (2013). "Presynaptic leptin action suppresses excitatory synaptic 
transmission onto ventral tegmental area dopamine neurons." Biol Psychiatry 73(9): 860-868. 
Tobler, P. N., C. D. Fiorillo and W. Schultz (2005). "Adaptive Coding of Reward Value by Dopamine 
Neurons." Science 307(5715): 1642-1645. 
Torre, E. and M. E. Celis (1986). "Alpha-MSH injected into the substantia nigra or intraventricularly 
alters behavior and the striatal dopaminergic activity." Neurochem Int 9(1): 85-89. 
Tracy, A. L., D. J. Clegg, J. D. Johnson, T. L. Davidson and S. C. Benoit (2008). "The melanocortin 
antagonist AgRP (83-132) increases appetitive responding for a fat, but not a carbohydrate, 
reinforcer." Pharmacol Biochem Behav 89(3): 263-271. 
Tritsch, N. X., J. B. Ding and B. L. Sabatini (2012). "Dopaminergic neurons inhibit striatal output 
through non-canonical release of GABA." Nature 490(7419): 262-266. 
Trivedi, P., H. Yu, D. J. MacNeil, L. H. Van der Ploeg and X. M. Guan (1998). "Distribution of orexin 
receptor mRNA in the rat brain." FEBS Lett 438(1-2): 71-75. 
Trojniar, W. and M. Staszewska (1994). "Unilateral damage to the ventral tegmental area facilitates 
feeding induced by stimulation of the contralateral ventral tegmental area." Brain Res 641(2): 333-
340. 
Tsai, C. (1925). "The optic tracts and centers of the opossum. Didelphis virginiana." The Journal of 
Comparative Neurology 39(2): 173-216. 
Ulrich-Lai, Y. M. and J. P. Herman (2009). "Neural regulation of endocrine and autonomic stress 
responses." Nat Rev Neurosci 10(6): 397-409. 
Unger, T. J., G. A. Calderon, L. C. Bradley, M. Sena-Esteves and M. Rios (2007). "Selective Deletion of 
Bdnf in the Ventromedial and Dorsomedial Hypothalamus of Adult Mice Results in Hyperphagic 
Behavior and Obesity." The Journal of Neuroscience 27(52): 14265-14274. 
Ungerstedt, U. (1971). "Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the 
nigro-striatal dopamine system." Acta Physiol Scand Suppl 367: 95-122. 
Ungless, M. A. and A. A. Grace (2012). "Are you or aren't you? Challenges associated with 
physiologically identifying dopamine neurons." Trends Neurosci 35(7): 422-430. 
Ungless, M. A., J. L. Whistler, R. C. Malenka and A. Bonci (2001). "Single cocaine exposure in vivo 
induces long-term potentiation in dopamine neurons." Nature 411(6837): 583-587. 
Vaisse, C., K. Clement, B. Guy-Grand and P. Froguel (1998). "A frameshift mutation in human MC4R is 
associated with a dominant form of obesity." Nat Genet 20(2): 113-114. 
Valdivia, S., A. Patrone, M. Reynaldo and M. Perello (2014). "Acute High Fat Diet Consumption 
Activates the Mesolimbic Circuit and Requires Orexin Signaling in a Mouse Model." PLoS ONE 9(1): 
e87478. 
Valladares, M., P. Dominguez-Vasquez, A. M. Obregon, G. Weisstaub, R. Burrows, A. Maiz and J. L. 
Santos (2010). "Melanocortin-4 receptor gene variants in Chilean families: association with 
childhood obesity and eating behavior." Nutr Neurosci 13(2): 71-78. 
Vallone, D., R. Picetti and E. Borrelli (2000). "Structure and function of dopamine receptors." 
Neuroscience & Biobehavioral Reviews 24(1): 125-132. 
Van Den Pol, A. N. (1982). "The magnocellular and parvocellular paraventricular nucleus of rat: 
Intrinsic organization." The Journal of Comparative Neurology 206(4): 317-345. 
265 
 
van der Kooy, D., L. Y. Koda, J. F. McGinty, C. R. Gerfen and F. E. Bloom (1984). "The organization of 
projections from the cortex, amygdala, and hypothalamus to the nucleus of the solitary tract in rat." 
J Comp Neurol 224(1): 1-24. 
Van der Ploeg, L. H. T., W. J. Martin, A. D. Howard, R. P. Nargund, C. P. Austin, X. Guan, J. Drisko, D. 
Cashen, I. Sebhat, A. A. Patchett, D. J. Figueroa, A. G. DiLella, B. M. Connolly, D. H. Weinberg, C. P. 
Tan, O. C. Palyha, S.-S. Pong, T. MacNeil, C. Rosenblum, A. Vongs, R. Tang, H. Yu, A. W. Sailer, T. M. 
Fong, C. Huang, M. R. Tota, R. S. Chang, R. Stearns, C. Tamvakopoulos, G. Christ, D. L. Drazen, B. D. 
Spar, R. J. Nelson and D. E. MacIntyre (2002). "A role for the melanocortin 4 receptor in sexual 
function." Proceedings of the National Academy of Sciences 99(17): 11381-11386. 
van Zessen, R., J. L. Phillips, E. A. Budygin and G. D. Stuber (2012). "Activation of VTA GABA neurons 
disrupts reward consumption." Neuron 73(6): 1184-1194. 
Vaughan, C., M. Moore, C. Haskell-Luevano and N. E. Rowland (2006). "Food motivated behavior of 
melanocortin-4 receptor knockout mice under a progressive ratio schedule." Peptides 27(11): 2829-
2835. 
Vaughan, C. H., M. C. Moore, C. Haskell-Luevano and N. E. Rowland (2005). "Meal patterns and 
foraging in melanocortin receptor knockout mice." Physiol Behav 84(1): 129-133. 
Vergoni, A., A. Bertolini, J. Wikberg and H. Schiöth (1999). "Selective melanocortin MC4 receptor 
blockage reduces immobilization stress-induced anorexia in rats." European Journal of 
Pharmacology: Molecular Pharmacology 369 (1): 11-15. 
Vergoni, A. V., A. Bertolini, F. Mutulis, J. E. Wikberg and H. B. Schioth (1998). "Differential influence 
of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral 
effects in rats." Eur J Pharmacol 362(2-3): 95-101. 
Vittoz, N. M. and C. W. Berridge (2006). "Hypocretin/orexin selectively increases dopamine efflux 
within the prefrontal cortex: involvement of the ventral tegmental area." 
Neuropsychopharmacology 31(2): 384-395. 
Volkow, N. D., G. J. Wang, L. Maynard, M. Jayne, J. S. Fowler, W. Zhu, J. Logan, S. J. Gatley, Y. S. Ding, 
C. Wong and N. Pappas (2003). "Brain dopamine is associated with eating behaviors in humans." Int J 
Eat Disord 33(2): 136-142. 
Volkow, N. D., G. J. Wang, F. Telang, J. S. Fowler, P. K. Thanos, J. Logan, D. Alexoff, Y. S. Ding, C. 
Wong, Y. Ma and K. Pradhan (2008). "Low dopamine striatal D2 receptors are associated with 
prefrontal metabolism in obese subjects: possible contributing factors." Neuroimage 42(4): 1537-
1543. 
Wakamatsu, K., A. Graham, D. Cook and A. J. Thody (1997). "Characterisation of ACTH peptides in 
human skin and their activation of the melanocortin-1 receptor." Pigment Cell Res 10(5): 288-297. 
Waldbillig, R. J. (1975). "Attack, eating, drinking, and gnawing elicited by electrical stimulation of rat 
mesencephalon and pons." J Comp Physiol Psychol 89(3): 200-212. 
Wallingford, N., B. Perroud, Q. Gao, A. Coppola, E. Gyengesi, Z. W. Liu, X. B. Gao, A. Diament, K. A. 
Haus, Z. Shariat-Madar, F. Mahdi, S. L. Wardlaw, A. H. Schmaier, C. H. Warden and S. Diano (2009). 
"Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents." J Clin Invest 
119(8): 2291-2303. 
Wan, S., K. N. Browning, F. H. Coleman, G. Sutton, H. Zheng, A. Butler, H.-R. Berthoud and R. A. 
Travagli (2008). "Presynaptic Melanocortin-4 receptors on vagal afferent fibers modulate the 
excitability of rat nucleus tractus solitarius neurons." The Journal of neuroscience : the official 
journal of the Society for Neuroscience 28(19): 4957-4966. 
Wang, C., E. Bomberg, C. Billington, A. Levine and C. M. Kotz (2007). "Brain-derived neurotrophic 
factor in the hypothalamic paraventricular nucleus increases energy expenditure by elevating 
metabolic rate." Am J Physiol Regul Integr Comp Physiol 293(3): R992-1002. 
Wang, G. J., N. D. Volkow, F. Telang, M. Jayne, J. Ma, M. Rao, W. Zhu, C. T. Wong, N. R. Pappas, A. 
Geliebter and J. S. Fowler (2004). "Exposure to appetitive food stimuli markedly activates the human 
brain." Neuroimage 21(4): 1790-1797. 
266 
 
Watson, S. J., H. Akil, C. W. Richard and J. D. Barchas (1978). "Evidence for two separate opiate 
peptide neuronal systems." Nature 275(5677): 226-228. 
Wessells, H., N. Levine, M. E. Hadley, R. Dorr and V. Hruby (2000). "Melanocortin receptor agonists, 
penile erection, and sexual motivation: human studies with Melanotan II." Int J Impot Res 12 Suppl 
4: S74-79. 
Wisden, W., D. J. Laurie, H. Monyer and P. H. Seeburg (1992). "The distribution of 13 GABAA 
receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon." J 
Neurosci 12(3): 1040-1062. 
Wise, R. A. (1982). "Neuroleptics and operant behavior: The anhedonia hypothesis." Behavioral and 
Brain Sciences 5(01): 39-53. 
World Health Organisation, W. (2013). "Obesity and overweight: Fact sheet N°311." 
World Health Organization, W. (2008). "Health topics: Obesity ": 
http://www.who.int/topics/obesity/en/  
Wydra, K., A. Suder, D. O. Borroto-Escuela, M. Filip and K. Fuxe (2014). "On the role of A and D 
receptors in control of cocaine and food-seeking behaviors in rats." Psychopharmacology (Berl). 
Xia, Y. and J. E. S. Wikberg (1996). "Localization of ACTH receptor mRNA by in situ hybridization in 
mouse adrenal gland." Cell and Tissue Research 286(1): 63-68. 
Xu, B., E. H. Goulding, K. Zang, D. Cepoi, R. D. Cone, K. R. Jones, L. H. Tecott and L. F. Reichardt 
(2003). "Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 
receptor." Nat Neurosci 6(7): 736-742. 
Yamaguchi, T., H.-L. Wang, X. Li, T. H. Ng and M. Morales (2011). "Mesocorticolimbic Glutamatergic 
Pathway." The Journal of Neuroscience 31(23): 8476-8490. 
Yamamoto, T., Y. Fujimoto, T. Shimura and N. Sakai (1995). "Conditioned taste aversion in rats with 
excitotoxic brain lesions." Neuroscience Research 22(1): 31-49. 
Yamazaki, M., K. Araki, A. Shibata and M. Mishina (1992). "Molecular cloning of a cDNA encoding a 
novel member of the mouse glutamate receptor channel family." Biochem Biophys Res Commun 
183(2): 886-892. 
Yang, L., K. A. Scott, J. Hyun, K. L. Tamashiro, N. Tray, T. H. Moran and S. Bi (2009). "Role of 
Dorsomedial Hypothalamic Neuropeptide Y in Modulating Food Intake and Energy Balance." The 
Journal of Neuroscience 29(1): 179-190. 
Yang, Y. (2011). "Structure, function and regulation of the melanocortin receptors." Eur J Pharmacol 
660(1): 125-130. 
Yaswen, L., N. Diehl, M. B. Brennan and U. Hochgeschwender (1999). "Obesity in the mouse model 
of pro-opiomelanocortin deficiency responds to peripheral melanocortin." Nat Med 5(9): 1066-1070. 
Ye, Z., T. MacNeil, D. H. Weinberg, R. N. Kalyani, R. Tang, A. M. Strack, B. A. Murphy, R. T. Mosley, D. 
Euan MacIntyre, L. H. T. Van der Ploeg, A. A. Patchett, M. J. Wyvratt and R. P. Nargund (2005). 
"Structure–activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human 
melanocortin-4 receptor and effects on feeding behaviors in rat." Peptides 26(10): 2017-2025. 
Yen, H.-H. and A. Roseberry (2014). "Decreased consumption of rewarding sucrose solutions after 
injection of melanocortins into the ventral tegmental area of rats." Psychopharmacology: 1-10. 
Yeo, G. S., I. S. Farooqi, S. Aminian, D. J. Halsall, R. G. Stanhope and S. O'Rahilly (1998). "A frameshift 
mutation in MC4R associated with dominantly inherited human obesity." Nat Genet 20(2): 111-112. 
Young, P. T. (1940). "Reversal of Food Preferences of the White Rat Through Controlled Pre-
Feeding." The Journal of General Psychology 22(1): 33-66. 
Zahm, D. S., E. Williams and C. Wohltmann (1996). "Ventral striatopallidothalamic projection: IV. 
Relative involvements of neurochemically distinct subterritories in the ventral pallidum and adjacent 
parts of the rostroventral forebrain." J Comp Neurol 364(2): 340-362. 
Zhang, Y., G. E. Kilroy, T. M. Henagan, V. Prpic-Uhing, W. G. Richards, A. W. Bannon, R. L. Mynatt and 
T. W. Gettys (2005). "Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, 
alters nutrient partitioning and compromises behavioral and metabolic responses to leptin." The 
FASEB Journal 19(11): 1482-1491. 
267 
 
Zhi, J., A. T. Melia, H. Eggers, R. Joly and I. H. Patel (1995). "Review of Limited Systemic Absorption of 
Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers." The Journal of Clinical Pharmacology 
35(11): 1103-1108. 
Zigman, J. M., J. E. Jones, C. E. Lee, C. B. Saper and J. K. Elmquist (2006). "Expression of ghrelin 
receptor mRNA in the rat and the mouse brain." J Comp Neurol 494(3): 528-548. 
Zigman, J. M., Y. Nakano, R. Coppari, N. Balthasar, J. N. Marcus, C. E. Lee, J. E. Jones, A. E. Deysher, A. 
R. Waxman, R. D. White, T. D. Williams, J. L. Lachey, R. J. Seeley, B. B. Lowell and J. K. Elmquist 
(2005). "Mice lacking ghrelin receptors resist the development of diet-induced obesity." J Clin Invest 
115(12): 3564-3572. 
Zoeller, R. T., S. W. Tan and R. W. Tyl (2007). "General Background on the Hypothalamic-Pituitary-
Thyroid (HPT) Axis." Critical Reviews in Toxicology 37(1-2): 11-53. 
Zweifel, L. S., E. Argilli, A. Bonci and R. D. Palmiter (2008). "Role of NMDA receptors in dopamine 
neurons for plasticity and addictive behaviors." Neuron 59(3): 486-496. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
268 
 
Appendix 1: Solutions  
 
 
Antibody diluent solution for MC4R immunohistochemistry  
 
Add 870mg of NaCl (sodium chloride) (VWR, UK), 50µl of Proclin 300 (Sigma-Aldrich, UK) and 1g of 
bovine albumin serum (BSA) (Sigma-Aldrich, UK) to 5ml 1M Tris-HCl (Tris-hydrochloride) and invert  
to dissolve. pH to 7.6 and adjust volume to 100ml. Store at -20°C.  
 
Anti-freeze 
 
Add 200ml HOCH₂CH(OH)CH₂OH (glycerol) (VWR, UK), 300ml HOCH₂CH₂OH (ethylene glycol) (VWR, 
UK), 400ml 2 x phosphate buffered saline (PBS) and 100ml GDW and stir to mix.  
 
Avidin-biotin complex (ABC) solution  
 
Dilute both avidin and biotin from the Vectastain Elite avidin-biotin-complex kit (Vector Laboratories, 
UK) to 0.5% (v/v) in 0.05M TrisHCl and invert to mix.   
 
Blocking solution for c-Fos immunohistochemistry  
 
Dilute Triton-X 100 (Sigma-Aldrich, UK) solution to 0.25% (w/v) in 0.01M PBS and add goat serum 
(Generon, UK) to 3% (v/v).  Invert to mix.  
 
Blocking solution for MC4R immunohistochemistry  
 
Dilute donkey serum (Sigma-Aldrich, UK) to 20% (v/v) in 1 x TBS and add 1% BSA (w/v). Invert to mix.  
 
Cresyl violet solution 
 
Add 5g C18H15N3O3 (cresyl violet acetate) (Sigma-Aldrich, UK), 60ml of 1M sodium acetate solution 
and 340ml CH₃COOH (glacial acetic acid) (Sigma-Aldrich, UK) to 600ml of GDW. Stir to mix for seven 
days and filter through 11µm pore diameter filter paper (Whatman, UK).  
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6 x DNA loading buffer 
 
Add 2.5g Ficoll Type 400 (Pharmacia Biotech, Sweden), 400µl of 0.5M EDTA solution and 18µl 10% 
(w/v) CH3(CH2)11OSO3Na (sodium dodecyl sulphate, SDS) (Sigma-Aldrich, UK) to 5ml GDW. Adjust 
volume to 10ml and add C16H10N2Na2O7S2 (Orange G) (Merck Millipore, USA) to desired colour 
intensity and mix by inverting.  
 
50mg/ml 3,3′-Diaminobenzidine (DAB) solution 
 
Add 1g of (NH2)2C6H3C6H3(NH2)2 (DAB) (Sigma-Aldrich, UK) to 20ml GDW. Stir in the dark to dissolve 
for 20 minutes and filter through 11µm pore diameter filter paper. Store at -20°C.  
 
0.5M ethylenediaminetetraacetic acid (EDTA) solution 
 
Add 186.1g of C10H14H2ONa2.2H2O (EDTA) (Sigma-Aldrich, UK) to 900ml of GDW and stir to mix. pH to 
8.0 using NaCl pellets and stir to aid dissolution of EDTA and adjust volume to 1l.  
 
4% formaldehyde solution 
 
Add 100ml of 37% HCHO (formaldehyde) solution (VWR, UK) to 900ml of 1 x PBS and invert to mix. 
Store at 4°C for a maximum of 24 hours.  
 
10 x phosphate buffered saline (PBS) 
 
Add 80g of NaCl (sodium chloride) (VWR, UK), 2.0g of KCl (potassium chloride) (VWR, UK), 14.4g of 
Na2HPO4 (sodium phosphate) (VWR, UK), 2.4g of KH2PO4 (potassium phosphate) (VWR, UK) to 800ml 
GDW and stir to dissolve. pH to 7.4 and adjust volume to 1l.  
 
Secondary antibody diluent for c-fos immunohistochemistry  
 
Dissolve BSA to 0.3% (w/v) in 0.25% (v/v) 10% (w/v) Triton-X 100 solution in GDW. Invert to dissolve.  
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1M sodium acetate solution 
 
Add 82.03g CH3COONa (sodium acetate) (Sigma-Aldrich, UK) to 900ml GDW and stir to dissolve. 
Adjust volume to 1l.  
 
40% sucrose solution 
 
Add 400g C12H22O11 (sucrose) (Tate & Lyle, UK) to 500ml of GDW and stir to dissolve. Adjust volume 
to 1l.  
 
Tris-acetate-EDTA 1.5% agarose gel  
 
 Add 2.25g agarose Type II-A (Sigma-Aldrich, UK) to 150ml GDW and heat in the microwave until the 
agarose has dissolved. Add 3ml of 50 x TAE and 7.5µl of 10mg/ml ethidium bromide (VWR, UK) and 
leave to cool for 10 minutes before decanting into gel chamber. Leave to set for 45 minutes at RTP.  
 
50 x Tris-acetate-EDTA (TAE) buffer 
 
Add 242g NH2C(CH2OH)3 (Trizma base) (Sigma-Aldrich, UK), 57.1ml of glacial acetic acid and 100ml 
0.5M C10H14H2ONa2.2H2O (EDTA) to 600ml of GDW and stir to mix. pH to 8.0 and adjust volume to 1l. 
 
10 x Tris-buffered saline (TBS) 
 
Add 24.23g Trizma base and 80.06g NaCl to 800ml GDW and stir to dissolve. pH to 7.6 and adjust 
volume to 1l.  
 
1M Tris-HCl (Tris-hydrochloride) 
 
Add 121.14g Trizma base to 800ml GDW and stir to mix. pH to 7.0 and adjust volume to 1l.  
 
10 x Tris-Tween-buffered saline (TTBS) 
 
Add 100ml of 10 x TBS, 10ml of C₅₈H₁₁₄O₂₆ (Tween 20) (VWR, UK) to 890ml GDW and stir to mix.  
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10% (w/v) Triton-X 100 solution  
 
Add 100ml C14H22O(C2H4O)9-10 (Triton-X 100) to cooled 900ml GDW. Stir to mix at 4°C for 12 hours.  
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Appendix 2: Drug regimens  
 
 
Prophylactic antibiotics 
 
For rat stereotaxic surgery: 1:1 v/v 37.5mg/kg amoxicillin (GlaxoSmithKline, UK) and 37.5mg/kg 
flucloxacillin (CP Pharmaceuticals, UK) reconstituted in sterile water (B.Braun, UK). After 
reconstitution, store at 4°C and discard after 24 hours. 
 
For mouse stereotaxic surgery: 1:1 v/v 25mg/kg amoxicillin and 25mg/kg flucloxacillin reconstituted 
in sterile water. After reconstitution, store at 4°C and discard after 24 hours. 
 
Carprofen analgesic 
 
For mouse stereotaxic surgery: 4mg/kg carprofen (Pfizer, UK) diluted in sterile water. After dilution, 
store at RTP and discard after 2 weeks.  
 
Buprenorphine analgesic 
 
For rat stereotaxic surgery: 1.2mg/kg buprenorphine (Schering-Plough Corporation, UK).  
For mouse stereotaxic surgery: 0.12mg/kg buprenorphine diluted in sterile water.  After dilution, 
store at RTP and discard after 1 month. 
 
 
